CA2447212A1 - Secretory molecules - Google Patents

Abstract

The invention provides purified secretory polynucleotides (sptm). Also encompassed are the polypeptides (SPTM) encoded by sptm. The invention also provides for the use of sptm, or complements, oligonucleotides, or fragments thereof in diagnostic assays. The invention further provides for vectors and host cells containing sptm for the expression of SPTM. The invention additionally provides for the use of isolated and purified SPTMto induce antibodies and to screen libraries of compounds and the use of anti-SPTM antibodies in diagnostic assays. Also provided are microarrays containing sp tm and methods of use.

Description

DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

NOTE : Pour les tomes additionels, veuillez contacter 1e Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME
NOTE POUR LE TOME / VOLUME NOTE:

SECRETORY MOLECULES
TECHNICAL FIELD
The present invention relates to secretory molecules and to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases associated with, as well as effects of exogenous compounds on, the expression of secretory molecules.
BACKGROUND OF THE INVENTION
so Both protein transport and secretion are involved in cellular function.
Protein transport is mediated by a signal peptide located at the amino terminus of the protein to be transported or secreted.
The signal peptide is comprised of about ten to twenty hydrophobic amino acids which target the nascent protein from the ribosome to a particular membrane bound compartment such as the endoplasrnic reticulum (ER). Proteins targeted to the ER may either proceed through the secretory 15 pathway or remain in. any of the secretory organelles such as the ER, Golgi apparatus, or lysosomes.
Proteins that transit through the secretory pathway are either secreted into the extracellular space or retained in the plasma membrane. Proteins that are retained in the plasma membrane contain one or more transmembrane domains, each comprised of about 20 hydrophobic amino acid residues. Proteins that are secreted from the cell are generally synthesized as inactive precursors that are activated by 2o post-translational processing events during transit through the secretory pathway. Such events include glycosylation, proteolysis, and removal of the signal peptide by a signal peptidase. Other events that may occur during protein transport include chaperone-dependent unfolding and folding of the nascent protein and interaction of the protein with a receptor or pore complex.
Examples of secretory proteins with amino terminal signal peptides are discussed below and include proteins with important roles in 25 cell-to-cell signaling. Such proteins include transmembrane receptors and cell surface markers, extracellular matrix molecules, cytokines, hormones, growth and differentiation factors, neuropeptides, vasomediators, ion channels, transporters/pumps, and proteases. (Reviewed in Alberts, B. et al.
(1994) Molecular Biology of The Cell, Garland Publishing, New York NY, pp. 557-560, 582-592.) G-protein coupled receptors (GPCRs) comprise a superfamily of integral membrane proteins 3 o which transduce extracellular signals. Not all GPCRs contain N-terminal signal peptides. GPCRs include receptors for biogenic amines such as dopamine, epinephrine, histamine, glutamate (metabotropic-type), acetylcholine (muscarinic-type), and serotonin; for lipid mediators of inflammation such as prostaglandins, platelet activating factor, and leukotrienes; for peptide hormones such as calcitonin, CSa anaphylatoxin, follicle stimulating hormone, gonadotropin releasing hormone, neurokinin, 3 s oxytocin, and thrombin; and for sensory signal mediators such as retinal photopigments and olfactory stimulatory molecules. The structure of these highly conserved receptors consists of seven hydrophobic transmembrane xegions, cysteine disulfide bridges between the second and third extracellular loops, an extracellular N-terminus, and a cytoplasmic C-terminus. The N-terminus interacts with ligands, the disulfide bridges interact with agonists and antagonists, and the large third intracellular loop interacts with G proteins to activate second messengers such as cyclic AMP, phospholipase C, inositol triphosphate, or ion channels. (Reviewed in Watson, S. and Arkinstall, S.
(1994) The G-protein Linked Receptor Facts Book, Academic Press, San Diego CA, pp. 2-6; and Bolander, F.F. (1994) Molecular Endocrinology, Academic Press, San Diego CA, pp. 162-176.) Other types of receptors include cell surface antigens identified on leukocytic cells of the 2 o immune system. These antigens have been identified using systematic, monoclonal antibody (mAb)-based "shot gun" techniques. These techniques have resulted in the production of hundreds of mAbs directed against unknown cell surface leukocytic antigens. These antigens have been grouped into "clusters of differentiation" based on common immunocytochemical localization patterns in various differentiated and undifferentiated leukocytic cell types. Antigens in a given cluster are presumed to is identify a single cell surface protein and are assigned a "cluster of differentiation" or "CD"
designation. Some of the genes encoding proteins identified by CD antigens have been cloned and verified by standard molecular biology techniques. CD antigens have been characterized as both transmembrane proteins and cell surface proteins anchored to the plasma membrane via covalent attachment to fatty acid-containing glycolipids such as glycosylphosphatidylinositol (GPI). (Reviewed 2 o in Barclay, A.N. et al. (1995) The Leucocyte Antigen Facts Book, Academic Press, San Diego CA, pp. 17-20.) Matrix proteins (Ml's) are transmembrane and extracellular proteins which function in formation, growth, remodeling, and maintenance of tissues and as important mediators and regulators of the inflammatory response. The expression and balance of MPs may be perturbed by biochemical 2 s changes that result from congenital, epigenetic, or infectious diseases.
In addition, MPs affect leukocyte migration, proliferation, differentiation, and activation in the immune response. MPs are frequently characterized by the presence of one or more domains which may include collagen-like domains, EGF-like domains, immunoglobulin-like domains, and fibronectin-like domains. In addition, MPs may be heavily glycosylated and may contain an Arginine-Glycine-Aspartate (RGD) tripeptide 3 o motif which may play a role in adhesive interactions. MPs include extracellular proteins such as fibxonectin, collagen, galectin, vitronectin and its proteolytic derivative somatomedin B; and cell adhesion receptors such as cell adhesion molecules (CAMS), cadherins, and integrins. (Reviewed in Ayad, S. et al. (1994) The Extracellular Matrix Facts Book, Academic Press, San Diego CA, pp. 2-16; Ruoslahti, E. (1997) Kidney Int. 51:1413-1417; Sjaastad, M.D. and Nelson, W.J. (1997) BioEssays 19:47-55.) Cytokines are secreted by hematopoietic cells in response to injury or infection. Interleukins, neurotrophins, growth factors, interferons, and chemokines all define cytokine families that work in conjunction with cellular receptors to regulate cell proliferation and differentiation. In addition, s cytokiues effect activities such as leukocyte migration and function, hematopoietic cell proliferation, temperature regulation, acute response to infection, tissue remodeling, and apoptosis.
Chemokines, in particular, are small chemoattractant cytokines involved in inflammation, leukocyte proliferation and migration, angiogenesis and angiostasis, regulation of hematopoiesis, HIV
infectivity, and stimulation of cytokine secretion. Chemokiues generally contain 70-100 amino acids so and are subdivided into four subfamilies based on the presence of conserved cysteine based motifs.
(Callard, R. and Gearing, A. (1994) The Cytokine Facts Book, Academic Press, New York NY, pp.
1$1-190, 210-213, 223-227.) Growth and differentiation factors are secreted proteins which function in intercellular communication. Some factors require oligomerization or association with MPs for activity. Complex is interactions among these factors and their receptors trigger intracellular signal transduction pathways that stimulate or inhibit cell division, cell differentiation, cell signaling, and cell motility. Most growth and differentiation factors act on cells in their local environment (paracrine signaling). There are three broad classes of growth and differentiation factors. The first class includes the.large polypeptide growth factors such as epidermal growth factor, fibroblast growth factor, transforming growth factor, 2o insulin-like growth factor, and platelet-derived growth factor. The second class includes the hematopoietic growth factors such as the colony stimulating factors (CSFs).
Hematopoietic growth factors stimulate the proliferation and differentiation of blood cells such as B-lymphocytes, T-Iymphocytes, erythrocytes, platelets, eosiuophils, basophils, neutrophils, macrophages, and their stem cell precursors. The third class includes small peptide factors such as bombesin, vasopressin, 25 oxytocin, endothelia, transferrin, angiotensin II, vasoactive intestinal peptide, and bradykinin which function as hormones to regulate cellular functions other than proliferation.
Growth anal differentiation factors play critical roles in neoplastic transformation of cells in vitro and in tumor progression in vivo. Inappropriate expression of growth factors by tumor cells may contribute to vascularization and metastasis of tumors. During hematopoiesis, growth factor 3 o misregulation can result in enemies, leukemias, and lymphomas. Certain growth factors such as interferon are cytotoxic to tumor cells both in vivo and in vitro. Moreover, some growth factors and growth factor receptors are related both structurally and functionally to oncoproteins. In addition, growth factors affect transcriptional regulation of both proto-oncogenes and oncosuppressor genes.
(Reviewed in Pimentel, E. (1994) Handbook of Growth Factors, CRC Press, Ann Arbor MI, pp. 1-9.) Proteolytic enzymes or proteases either activate or deactivate proteins by hydrolyzing peptide bonds. Proteases are found in the cytosol, in membrane bound compartments, and in the extracellular space. The major families are the zinc, serine, cysteine, thiol, and carboxyl proteases.
Ion channels, ion pumps, and transport proteins mediate the transport of molecules across s cellular membranes. Transport can occur by a passive, concentration-dependent mechanism or can be linked to an energy source such as ATP hydrolysis. Symporters and antiporters transport ions and small molecules such as amino acids, glucose, and drugs. Symporters transport molecules and ions unidirectionally, and antiporters transport molecules and ions bidirectionally. Transporter superfamilies include facilitative transporters and active ATP-binding cassette transporters which are involved in to multiple-drug resistance and the targeting of antigenic peptides to MHC
Class I molecules. Theseo transporters bind to a specific ion or other molecule and undergo a conformational change in order to transfer the ion or molecule across the membrane. (Reviewed in Alberts, B. et al. (1994) Molecular Biology of The Cell, Garland Publishing, New York NY, pp. 523-546.) Ion channels are formed by transmembrane proteins which create a lined passageway across 15 the membrane through which water and ions, such as Na+, K+, Ca2+, and Cl-, enter and exit the cell.
For example, chloride channels are involved in the regulation of the membrane electric potential as well as absorption and secretion of ions across the membrane. Chloride channels also regulate the internal pH of membrane bound organelles.
Ion pumps are ATPases which actively maintain membrane .gradients. Ion pumps are 2 o classified as P, V, or F according to their structure and function. All have one or more binding sites for ATP in their cytosolic domains. The P-class ion pumps include Caa+ ATPase and Na+/K+ ATPase and function in transporting H+, Na+, K+, and Caa+ ions. P-class pumps consist of two a and two (3 transmembrane subunits. The V- and F-class ion pumps have similar structures but transport only H+.
F class H+ pumps mediate transport across the membranes of mitochondria and chloroplasts, while V-a 5 class H+ pumps regulate acidity inside lysosomes, endosomes, and plant vacuoles.
A family of structurally related intrinsic membrane proteins known as facilitative glucose transporters catalyze the movement of glucose and other selected sugars across the plasma membrane. The proteins in this family contain a highly conserved, large transmembrane domain comprised of 12 a helices, and several weakly conserved, cytoplasmic and exoplasmic domains.
so (Pessin, J.E. and Bell, G.I. (1992) Annu. Rev. Physiol. 54:911-930.) Amino acid transport is mediated by Na+ dependent amino acid transporters.
These transporters are involved in gastrointestinal and renal uptake of dietary and cellular amino acids and in neuronal reuptake of neurotransmitters. Transport of cationic amino acids is mediated by the system y+ family and the cationic amino acid transporter (CAT) family. Members of the CAT family share a high degree of sequence homology, and each contains 12-14 putative transmembrane domains. (Ito, K. and Groudine, M. (1997) J. Biol. Chem. 272:26780-26786.) Hormones are secreted molecules that travel through the circulation and bind to specific receptors on the surface of, or within, target cells. Although they have diverse biochemical s compositions and mechanisms of action, hormones can be grouped into two categories. One category includes small lipophilic hormones that diffuse through the plasma membrane of target cells, bind to cytosolic or nuclear receptors, and form a complex that alters gene expression. Examples of these molecules include retinoic acid, thyroxine, and the cholesterol-derived steroid hormones such as progesterone, estrogen, testosterone, cortisol, and aldosterone. The second category includes ~. o hydrophilic hormones that function by binding to cell surface receptors that transduce signals across the plasma membrane. Examples of such hormones include amino acid derivatives such as catecholamines and peptide hormones such as glucagon, insulin, gastrin, secxetin, cholecystokinin, adrenocorticotropic hormone, follicle stimulating hormone, Iuteinizing hormone, thyroid stimulating hormone, and vasopressin. (See, for example, Lodish et al. (1995) Molecular Cell Biolo~y, Scientific 15 American Books Inc., New York NY, pp. 856-864.) Neuropeptides and vasomediators (NP/VM) comprise a large family of endogenous signaling molecules. Included in this family are neuropeptides and neuropeptide hormones such as bombesin, neuropeptide Y, neurotensin, neuromedin N, melanocortins, opioids, galanin, somatostatin, tachykinins;
urotensin II and related peptides involved in smooth muscle stimulation, vasopressin, vasoactive 2o intestinal peptide, and circulatory system borne signaling molecules such as angiotensin, complement, calcitonin, endothelins, formyl-methionyl peptides, glucagon, cholecystokinin and gastrin. NP/VMs can transduce signals directly, modulate the activity or release of other neurotransmitters and hormones, and act as catalytic enzymes in cascades. The effects of NP/VMs range from extremely brief to long-lasting. (Reviewed in Martin, C.R. et al. (1985) Endocrine Physiolo~y, Oxford University Press, 25 New York, NY, pp. 57-62.) The discovery of new secretory molecules provide new compositions which are useful in the diagnosis, study, prevention, and treatment of diseases associated with, as well as effects of exogenous compounds on, cell signaling and the expression of secretory molecules.
3 o SUMMARY OF THE INVENTION
Embodiments of the invention relate to nucleic acid sequences comprising human polynucleotides encoding secretory polypeptides that can contain signal peptides and/or transmembrane domains. These human polynucleotides (sptm) as presented in the Sequence Listing uniquely identify partial or full length genes encoding structural, functional, and regulatory polypeptides involved in cell signaling.
An embodiment of the invention provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ m N0:1-567; b) a polynucleotide comprising a naturally occurring polynucleotide s sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ )D N0:1-567; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). In one alternative, the polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ )D N0:1-567. In another alternative, the polynucleotide comprises at least 30 contiguous so nucleotides of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ 1D N0:1-567;
b) a polynucleotide comprising a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90%
identical to a polynucleotide sequence selected from the group consisting of SEQ m N0:1-567; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the 15 polynucleotide of b); and e) an RNA equivalent of a) through d). In another alternative, the polynucleotide comprises at least 60 contiguous nucleotides of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ m N0:1-567; b) a polynucleotide comprising a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected 2 o from the group consisting of SEQ >D N0:1-567; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA
equivalent of a) through d). Another embodiment pxovides a composition for the detection of expression of secretory polynucleotides comprising at least one isolated polynucleotide comprising a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide 25 sequence selected from the group consisting of SEQ m N0:1-567; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ~ N0:1-567; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA
equivalent of a) through d); and a detectable label.
3 o An embodiment of the invention also provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a polynucleotide sequence of a polyneucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence of a polynucleotide selected from the group consisting of SEQ m NO:1-567; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90%
identical to a polynucleotide sequence selected from the group consisting of SEQ ID N0:1-567; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
Another embodiment also provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a polynucleotide sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group so consisting of SEQ 117 N0:1-567; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID N0:1-567; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide, and b) detecting the presence ox absence of said hybridization complex, and, optionally, if present, the amount thereof. In an alternative' embodiment, the invention provides a composition comprising a target polynucleotide of the method, 2o wherein said probe comprises at least 30 contiguous nucleotides. In an alternative embodiment, the invention provides a composition comprising a target polynucleotide of the method, wherein said probe comprises at least 60 contiguous nucleotides.
Another embodiment provides a recombinant polynucleotide comprising a promoter sequence operably linked to an isolated polynucleotide selected from the group consisting of a) a polynucleotide 2 s comprising a polynucleotide sequence selected from the group consisting of SEQ ID N0:1-567; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID N0:1-567;
c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). In an alternative embodiment, the invention provides a 3 o cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.
Yet another embodiment provides a method for producing a secretory polypeptide, the method comprising a) culturing a cell under conditions suitable for expression of the secretory polypeptide, wherein said cell is transformed with a recombinant polynucleotide, said recombinant polynucleotide comprising an isolated polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ
)D N0:1-567; ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID N0:1-567;
iii) a polynucleotide s complementary to the polynucleotide of i); iv) a polynucleotide complementary to the polynucleotide of ii); and v) an RNA equivalent of i) through iv), and b) recovering the secretory polypeptide so expressed. The invention additionally provides a method wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID N0:568-1146.
Still another embodiment provides an isolated secretory polypeptide (SPTM) encoded by at so least one polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID N0:1-567. The invention further provides a method of screening for a test compound that specifically binds to the polypeptide having an amino acid sequence selected from the group consisting of SEQ ID N0:568-1146. The method comprises a) combining the polypeptide having an amino acid sequence selected from the group consisting of SEQ >D N0:568-1146 with at least one test compound 15 under suitable conditions, and b) detecting binding of the polypeptide having an amino acid sequence selected from the group consisting of SEQ ID N0:568-1146 to the test compound, thereby identifying a compound that specifically binds to the polypeptide having an amino acid sequence selected from the group consisting of SEQ ID N0:568-1146.
Still yet another embodiment provides a microarray wherein at least one element of the 2 o microarray is an isolated polynucleotide comprising at least 30 contiguous nucleotides of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID N0:1-567; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ 1D N0:1-567; c) a polynucleotide complementary to the 2 s polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA
equivalent of a) through d). The invention also provides a method for generating a transcript image of a sample which contains polynucleotides. The method comprises a) labeling the polynucleotides of the sample, b} contacting the elements of the microarxay with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and c) quantifying the 3 o expression of the polynucleotides in the sample.
Still yet another embodiment provides a method fox screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ll~ N0:1-567; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ m N0:1-567; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA
equivalent of a) through d). The method comprises a) exposing a sample comprising the target s polynucleotide to a compound, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.
Another embodiment provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) s o hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ
m N0:1-567; ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ll~ N0:1-567; iii) a polynucleotide 15 complementary to the polynucleotide of i); iv) a polynucleotide complementary to the polynucleotide of ii); and v) an RNA equivalent of i) through iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence 2o selected from the group consisting of SEQ )D N0:1-567; ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ m N0:1-567; iii) a polynucleotide complementary to the polynucleotide of i); iv) a polynucleotide complementary to the polynucleotide of ii); and v) an RNA equivalent of i) through iv), and alternatively, the target polynucleotide comprises a polynucleotide sequence of a 25 fragment of a polynucleotide selected from the group consisting of i-v above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.
3 o Another embodiment provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ m N0:568-1146, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90%
identical to an amino acid sequence selected from the group consisting of SEQ
1D N0:568-1146, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID N0:568-1146, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID N0:568-1146.
In an alternative embodiment, the invention provides an isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ m N0:568-1146.
Still another embodiment provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ m N0:568-1146, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ >D N0:568-1146, c) a biologically active fragment of a polypeptide having an amino acid so sequence selected from the group consisting of SEQ 1D N0:568-1146, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ
ll~ N0:568-1146. In one alternative, the polynucleotide encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID N0:568-1146. In another alternative, the polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID
15 N0:1-567.
Another embodiment provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ 1D N0:568-1146, b) a polypeptide comprising a naturally occurring .
amino acid sequence at least 90% identical to an amino acid sequence selected from the group 2o consisting of SEQ ID N0:568-1146, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID N0:568-1146, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ
ID N0:568-1146.
Another embodiment provides a composition comprising a polypeptide selected from the group 25 consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ 117 N0:568-1146, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID N0:568-1146, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID N0:568-1146, and d) an immunogenic fragment of a polypeptide having 3 o an amino acid sequence selected from the group consisting of SEQ )D N0:568-1146, and a pharmaceutically acceptable excipient. In an embodiment, the composition comprises a polypeptide having an amino acid sequence selected from the group consisting of SEQ 1D
N0:568-1146. Another embodiment provides a method of treating a disease or condition associated with decreased expression of functional SPTM, comprising administering to a patient in need of such treatment the composition.

Another embodiment provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ m N0:568-1146, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence s selected from the group consisting of SEQ m N0:568-1146, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m N0:568-1146, and d) an ixnmunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m NO:568-1146. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In an to alternative embodiment, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative embodiment, the invention provides a method of treating a disease or condition associated with decreased expression of functional SPTM, comprising administering to a patient in need of such treatment the composition.
15 Another embodiment provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ m N0:568-1146, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ m N0:568-1146, c) a biologically active fragment of a 2 o polypeptide having an amino acid sequence selected from the group consisting of SEQ m N0:568-1146, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID N0:568-1146. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In an alternative, the invention provides a composition comprising an antagonist compound identified by the 2s method and a pharmaceutically acceptable excipient. Tn another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional SPTM, comprising administering to a patient in need of such treatment the composition.
Another embodiment provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino 3 o acid sequence selected from the group consisting of SEQ m NO:568-1146, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ~ N0:568-1146, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m NO:568-1146, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from 35 the group consisting of SEQ m N0:568-1146. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.
DESCRIPTION OF THE TABLES
Table 1 shows the sequence identification numbers (SEQ ID NOa) and template identification numbers (template IDs) corresponding to the polynucleotides of the present invention, along with the so sequence identification numbers (SEQ 117 NOa) and open reading frame identification numbers (ORF
ms) corresponding to polypeptides encoded by the template m.
Table 2 shows the sequence identification numbers (SEQ )D NOa) and template identification numbers (template B7s) corresponding to the polynucleotides of the present invention, along with polynucleotide segments of each template sequence as defined by the indicated "start" and "stop"
is nucleotide positions. The reading frames of the polynucleotide segments are shown, and the polypeptides encoded by the polynucleotide segments constitute either signal peptide (SP) or transmembrane (TM) domains, as indicated. For TM domains, the membrane topology of the encoded polypeptide sequence is indicated as being transmembrane or on the cytosolic or non-cytosolic side of the cell membrane or organelle.
2 o Table 3 shows the sequence identification numbers and template identification numbers (template )Ds) corresponding to the polynucleotides of the present invention, along with component sequence identification spans corresponding to each template. The component sequences, which were used to assemble the template sequences, are defined by the spans indicating the nucleotide positions along each template.
2 s Table 4 shows the tissue distribution profiles for the templates of the invention.
Table 5 shows the sequence identification numbers (SEQ ID NOa) corresponding to the polypeptides of the present invention, along with the reading frames used to obtain the polypeptide segments, the lengths of the polypeptide segments, the "start" and "stop"
nucleotide positions of the polynucleotide sequences used to define the encoded polypeptide segments, the GenBankhits (GI
3 o Numbers), probability scores, and functional annotations corresponding to the GenBank hits.
Table 6 summarizes the bioinformatics tools which are useful for analysis of the polynucleotides of the present invention. The first column of Table 6 lists analytical tools, programs, and algorithms, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the 3 5 fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between two sequences).
DETAILED DESCRIPTION OF THE INVENTION
s Before the nucleic acid sequences and methods are presented, it is to be understood that this invention is not limited to the particular machines, methods, and materials described. Although particulax embodiments are described, machines, methods, and materials similar or equivalent to these embodiments may be used to practice the invention. The preferred machines, methods, and materials set forth are not intended to limit the scope of the invention which is limited only by the appended to claims.
The singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. All technical and scientific terms have the meanings commonly understood by one of ordinary skill in the art. All publications are incorporated by reference for the purpose of describing and disclosing the cell lines, vectors, and methodologies which are presented and which might be used s s in connection with the invention. Nothing in the specification is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
Definitions As used herein, the lower case "sptm" refers to a nucleic acid sequence, while the upper case 2 0 "SPTM" refers to an amino acid sequence encoded by sptm. A "full-length"
sptm refers to a nucleic acid sequence containing the entire coding region of a gene endogenously expressed in human tissue.
"Adjuvants" are materials such as Freund's adjuvant, mineral gels (aluminum hydroxide), and surface active substances (lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol) which may be administered to increase a host's immunolog~ical 2 s response.
"Allele" refers to an alternative form of a nucleic acid sequence. Alleles result from a "mutation," a change or an alternative reading of the genetic code. Any given gene may have none, one, or many allelic forms. Mutations which give rise to alleles include deletions, additions, or substitutions of nucleotides. Each of these changes may occur alone, or in combination with the 3 0 others, one or more times in a given nucleic acid sequence. The present invention encompasses allelic sptm.
An "allelic variant" is an alternative form of the gene encoding SPTM. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or 3 5 many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides.
Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.
"Altered" nucleic acid sequences encoding SPTM include those sequences with deletions, s insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as SPTM or a polypeptide with at least one functional characteristic of SPTM. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding SPTM, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding SPTM. The so encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent SPTM. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological ' or immunological activity of SPTM is retained. For example, negatively charged amino acids may is include aspartic acid and glutatnic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine;
and phenylalanine and tyrosine.
20 "Amino acid sequence" refers to a peptide, a polypeptide, or a protein of either natural or synthetic origin. The amino acid sequence is not limited to the complete, endogenous amino acid sequence and may be a fragment, epitope, variant, or derivative of a protein expressed by a nucleic acid sequence.
"Amplification" refers to the production of additional copies of a sequence and is carried out 2 s using polymerase chain reaction (PCR) technologies well known in the art.
"Antibody" refers to intact molecules as well as to fragments thereof, such as Fab, F(ab')2, and Fv fragments, which are capable of binding the epitopic determinant.
Antibodies that bind SPTM
polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or peptide used to immunize an animal (e.g., a 3 o mouse, a rat, or a rabbit) can be derived from the translation of RNA, br synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLIT). The coupled peptide is then used to immunize the animal.
The term "aptamer" refers to a nucleic acid or oligonucleotide molecule that binds to a 3 s specific molecular target. Aptamers are derived from an in vitro evolutionary process (e.g., SELEX

(Systematic Evolution of Ligands by EXponential Enrichment), described in U.S.
Patent No.

5,270,163), which selects for target-specific aptamer sequences from large combinatorial libraries.
Aptamer compositions may be double-stranded or single-stranded, and may include deoxyribonucleotides, ribonucleotides, nucleotide derivatives, or other nucleotide-like molecules. The nucleotide components of an aptamer may have modified sugar groups (e.g., the 2'-OH group of a ribonucleotide may be replaced by 2'-F or 2'-NHa), which may improve a desired property, e.g., resistance to nucleases or longer lifetime in blood. Aptamers may be conjugated to other molecules, e.g., a high molecular weight carrier to slow clearance of the aptamer from the circulatory system.
Aptamers may be specifically cross-linked to their cognate ligands, e.g., by photo-activation of a so cross-linker. (See, e.g., Brody, E.N. and L. Gold (2000) J. Biotechnol.
74:5-13.) The term "intramer" refers to an aptamer which is expressed in vivo. For example, a vaccinia virus based RNA expression system has been used to express specific RNA
aptamers at high levels in the cytoplasm of leukocytes (Blind, M. et al. (1999) Proc. Natl Acad. Sci.
USA 96:3606-3610).
The term "spiegeliner" refers to an aptamer which includes L-DNA, L-RNA, or other Ieft handed nucleotide derivatives or nucleotide-like molecules. Aptamers containing left-handed nucleotides are resistant to degradation by naturally occurring enzymes, which normally act on substrates containing right-handed nucleotides.
"Antisense sequence" refers to a sequence capable of specifically hybridizing to a target sequence. The antisense sequence may include DNA, RNA, or any nucleic acid mimic or analog 2 o such as peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified base.
"Antisense technology' refers to any technology which relies on the specific hybridization of an antisense sequence to a target sequence.
A "bin" is a portion of computer memory space used by a computer program for storage of data, and bounded in such a manner that data stored in a bin may be retrieved by the program.
"Biologically active" refers to an amino acid sequence having a structural, regulatory, or biochemical function of a naturally occurring amino acid sequence.
s o "Clone joining" is a process for combining gene bins based upon the bins' containing sequence information from the same clone. The sequences may assemble into a primary gene transcript as well as one or more splice variants.
"Complementary' describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing (5'-A-G-T-3' pairs with its complement 3'-T-C-A-5').
3 5 A "component sequence" is a nucleic acid sequence selected by a computer program such as PHRED and used to assemble a consensus or template sequence from one or more component sequences.
A "consensus sequence" or "template sequence" is a nucleic acid sequence which has been assembled from overlapping sequences, using a computer program for fragment assembly such as the s GELVIEW fragment assembly system (Genetics Computer Group (GCG), Madison W1) or using a relational database management system (RDMS).
"Conservative amino acid substitutions" are those substitutions that, when made, least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino 1 o acids which may be substituted for an original amino acid in a protein and which are regarded as conservative substitutions.
Original Residue Conservative Substitution Ala Gly, Ser 15 Arg His, Lys Asn Asp, Gln, His Asp Asn, Glu Cys Ala, Ser G1n Asn, Glu, His a o Glu Asp, Gln, His Gly AIa His Asn, Arg, Gln, Glu Ile Leu, Val Leu Tle, Val 2s Lys Arg, Gln, Glu Met Leu, Ile Phe His, Met, Leu, Trp, Tyr Ser Cys, Thr Thr Ser, Val 3 o Trp Phe, Tyr Tyr His, Phe, Trp vat ne, Leu, Thr 3 ~ Conservative substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.
"Deletion" refers to a change in either a nucleic or amino acid sequence in which at least one nucleotide or amino acid residue, respectively, is absent.
40 "Derivative" refers to the chemical modification of a nucleic acid sequence, such as by replacement of hydrogen by an alkyl, acyl, amino, hydroxyl, or other group.

"Differential expression" refers to increased or upregulated; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such comparisons may be carried out between, for example, a treated and an untreated sample, or a diseased and a normal sample.
The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.
The term "modulate" refers to a change in the activity of SPTM. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of SPTM.
"E-value" refers to the statistical probability that a match between two sequences occurred by chance.
"Exon shuffling" refers to the recombination of different coding regions (exons). Since an exon may represent a structural or functional domain of the encoded protein, new proteins may be assembled through the novel reassortment of stable substructures, thus allowing acceleration of the evolution of new protein functions.
A "fragment" is a unique portion of sptm or SPTM which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 10 to 1000 contiguous amino acid residues or nucleotides. A fragment used as a probe, primer, 2 o antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous amino acid residues or nucleotides in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly 2~ these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing and the figures, may be encompassed by the present embodiments.
A fragment of sptm comprises a region of unique polynucleotide sequence that specifically identifies sptm, for example, as distinct from any other sequence in the same genome. A fragment of sptm is useful, for example, in hybridization and amplification technologies and in analogous methods s o that clistinguish sptm from related polynucleotide sequences. The precise length of a fragment of sptm and the region of sptm to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.
A fragment of SPTM is encoded by a fragment of sptm. A fragment of SPTM
comprises a region of unique amino acid sequence that specifically identifies SPTM. For example, a fragment of 35 SPTM is useful as an immunogenic peptide for the development of antibodies that specifically recognize SPTM. The precise length of a fragment of SPTM and the region of SPTM to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.
A "full length" nucleotide sequence is one containing at least a start site for translation to a protein sequence, followed by an open reading frame and a stop site, and encoding a "full length"
polypeptide.
"Hit" refers to a sequence whose annotation will be used to describe a given template.
Criteria for selecting the top hit are as follows: if the template has one or more exact nucleic acid matches, the top hit is the exact match with highest percent identity. If the template has no exact to matches but has significant protein hits, the top hit is the protein hit with the lowest E-value. If the template has no significant protein hits, but does have significant non-exact nucleotide hits, the top hit is the nucleotide hit with the lowest E-value.
"Homology' refers to sequence similarity either between a reference nucleic acid sequence and at least a fragment of an sptm or between a reference amino acid sequence and a fragment of an SPTM.
"Hybridization" refers to the process by which a strand of nucleotides anneals with a complementary strand through base pairing. Specific hybridization is an indication that two nucleic acid sequences share a high degree of identity. Specific hybridization complexes form under defined annealing conditions, and remain hybridized after the "washing" step. The defined hybridization 2o conditions include the annealing conditions and the washing step(s), the latter of which is particularly important in detern ~'Lniug the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid probes that are not, perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable and may be consistent among hybridization experiments, whereas wash conditions may 2 s be varied among experiments to achieve the desired stringency.
Generally, stringency of hybridization is expressed with reference to the temperature under which the wash step is carried out. Generally, such wash temperatures are selected to be about 5°C
to 20°C lower than the thermal melting point (T"~ for the specific sequence at a de~tned ionic strength and pH. The Tm is the temperature (under defined ionic strength and pH) at which 50% of the target 3 o sequence hybridizes to a perfectly matched probe. An equation for calculating Tm and conditions for nucleic acid hybridization is well known and can be found in Sambrook et al., 1989, Molecular Cloning:
A Laboratory Manual, 2"d ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.
High stringency conditions for hybridization between polynucleotides of the present invention 35 include wash conditions of 68°C in the presence of about 0.2 x SSC
and about 0.1% SDS, for 1 hour.

Alternatively, temperatures of about 65°C, 60°C, or 55°C
may be used. SSC concentration may be varied from about 0.2 to 2 x SSC, with SDS being present at about 0.1%.
Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, denatured salinon sperm DNA at about 100-200 ~.g/ml. Useful variations on these conditions will be readily apparent to those skilled in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their resultant proteins.
Other parameters, such as temperature, salt concentration, and detergent concentration may be varied to aclueve the desired stringency. Denaturants, such as formamide at a concentration of so about 35-50% v/v, may also be used under particular circumstances, such as RNA:DNA
hybridizations. Appropriate hybridization conditions are routinely determinable by one of ordinary skill in the art.
"hnrnunologically active" or "immunogenic" describes the potential for a natural, recombinant, or synthetic peptide, epitope, polypeptide, or protein to induce antibody production in appropriate animals, cells, or cell lines. .
"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.
2o An "immunogenic fragment" is a polypeptide or oligopeptide fragment of SPTM
which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of SPTM which is useful in any of the antibody production methods disclosed herein. or known in the art.
"Insertion" or "addition" refers to a change in either a nucleic or amino acid sequence in which at least one nucleotide or residue, respectively, is added to the sequence.
"Labeling" refers to the covalent or noncovalent joining of a polynucleotide, polypeptide, or antibody with a reporter molecule capable of producing a detectable or measurable signal.
"Microarray" is any arrangement of nucleic acids, amino acids, antibodies, etc., on a 3 o substrate. The substrate may be a solid support such as beads, glass, paper, nitrocellulose, nylon, or an appropriate membrane.
"Linkers" are short stretches of nucleotide sequence which may be added to a vector or an sptm to create restriction endonuclease sites to facilitate cloning.
"Polylinkers" are engineered to incorporate multiple restriction enzyme sites and to provide for the use of enzymes which leave 5' or 3' overhangs (e.g., BamHI, EcoRI, and HindllI) and those which provide blunt ends (e.g., EcoRV, SnaBI, and StuI).
"Naturally occurring" refers to an endogenous polynucleotide or polypeptide that may be isolated from viruses or prokaryotic or eukaryotic cells.
s "Nucleic acid sequence" refers to the specific order of nucleotides joined by phosphodiester bonds in a linear, polymeric arrangement. Depending on the number of nucleotides, the nucleic acid sequence can be considered an oligomer, oligonucleotide, or polynucleotide.
The nucleic acid can be DNA, RNA, or any nucleic acid analog, such as PNA, may be of genomic or synthetic origin, may be either double-stranded or single-stranded, and can represent either the sense or antisense s o (complementary) strand.
"Oligomer" refers to a nucleic acid sequence of at least about 6 nucleotides and as many as about 60 nucleotides, preferably about 15 to 40 nucleotides, and most preferablybetween about 20 and 30 nucleotides, that may be used, in hybridization or amplification technologies. Oligomers may be used as, e.g., primers for PCR, and are usually chemically synthesized.
15 "Operably licked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.
20 "Peptide nucleic acid" (PNA) refers to a DNA mimic in which nucleotide bases are attached to a pseudopeptide backbone to increase stability. PNAs, also designated antigene agents, can prevent gene expression by targeting complementary messenger RNA.
The phrases "percent identity" and "% identity", as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a 2 s standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.
Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN
version 3.12e s o sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and Sharp, P.M. (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS
8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequence pairs.
Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment s Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at http:l/www.ncbi.nlm.nih.gov/BLAST/. The BLAST software suite includes various sequence analysis programs including "BLASTN," that is used to determine alignment between a known polynucleotide sequence and other sequences on a variety of databases. Also available is a tool called "BLAST 2 to Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at http://www.ncbi.nlm.nih.gov/gorf/612/. °The "BLAST 2 Sequences" tool can be used for both BLASTN and BLASTP (discussed below).
BLAST programs are commonly used with gap and other parameters set to default settings. Fox example, to compare two nucleotide sequences, one may use BLASTN with the "BLAST 2 15 Sequences" tool Version 2Ø9 (May-07-1999) set at default parameters. Such default parameters may be, for example:
Matrix: BLOSUM62 Reward for match: 1 Penalty for mismatch: -2 2o Open Gap: 5 and Extension Gap: 2 penalties Gap x drop-off. 50 Expect: 10 Word Size: I1 Filter: on 2 s Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SBQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported s o by the sequences shown herein, in figures or Sequence Listings, may be used to describe a length over which percentage identity may be measured.
Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid 3 s sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity", as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, s explained in more detail above, generally preserve the hydrophobicity and acidity of the substituted residue, thus preserving the structure (and therefore function) of the folded polypeptide.
Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN
version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of so polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.
Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise 1s comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2Ø9 (May-07-1999) with BLASTP set at default parameters. Such default parameters may be, for example:
Matrix: BLOSUM62 Open Gap: 11 and Extension Gap: 1 pefaalty a o Gap x drop-off: 50 Expect: 10 Word Size: 3 Filter: on Percent identity may be measured over the length of an entire defined polypeptide sequence, 25 for example, as defined by a particular SEQ m number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown hexein, in figures or Sequence Listings, may be used to 3 o describe a length over which percentage identity may be measured.
"Post-translational modification" of an SFTM may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modi~tcations will vary by cell type depending on the enzymatic milieu and the SPTM.

"Probe" refers to sptm or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. "Primers" are short nucleic acids, usually DNA
s oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing.
The primer may then be extended along the target DNA strand by a DNA
polymerise enzyme.
Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerise chain reaction (PCR).
Probes and primers as used in the present invention typically comprise at least 15 contiguous so nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences.
Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the figures and Sequence Listing, may be used.
15 Methods for preparing and using probes and primers are described in the references, for example Sambrook et al., 1989, Molecular Cloning: A LaboratorYManual, 2"d ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel et a1.,1987, Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis et al., 1990, PCR Protocols, A
Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be z o derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).
Oligonucleotides for use as primers are selected using software known in. the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR
primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 2 s nucleotides from an input polynucleotide sequence of up to 32 kilobases.
Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU
primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer 3 o selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The 3 5 PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments s identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.
"Purified" refers to molecules, either polynucleotides or polypeptides that are isolated or so separated from their natural environment and are at least about 60% free, preferably at least about 75% free, and most preferably at least about 90% free from other compounds with which they are naturally associated.
A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence.
1 s This artificial combination is often accomplished by chemical synthesis or, more corntnonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, su ra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence.
2 o Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.
Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.
"Regulatory element" refers to a nucleic acid sequence from nontranslated regions of a gene, 2 s and includes enhancers, promoters, introns, and 3' untrauslated regions, which interact with host proteins to carry out or regulate transcription or translation.
"Reporter" molecules are chemical or biochemical moieties used for labeling a nucleic acid, an amino acid, or an antibody. They include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in s o the art.
An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

"Sample" is used in its broadest sense. Samples may contain nucleic or amino acids, antibodies, or other materials, and may be derived from any source (e.g., bodily fluids including, but not limited to, saliva, blood, and urine; chromosome(s), organelles, or membranes isolated from a cell;
genomic DNA, RNA, or cDNA in solution or bound to a substrate; and cleared cells or tissues or blots s or imprints from such cells or tissues).
"Specific binding" or "specifically binding" refers to the interaction between a protein or peptide and its agonist, antibody, antagonist, or other binding partner. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the so presence of a polypeptide containing epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A
that binds to the antibody.
"Substitution" refers to the replacement of at least one nucleotide or amino acid by a different nucleotide or amino acid.
15 "Substrate" refers to any suitable rigid or semi-rigid support including, e.g., membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubintg, plates, polymers, microparticles or capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.
A "transcript image" refers to the collective pattern of gene expression by a particular tissue 20 or cell type under given conditions at a given time.
"Transformation" refers to a process by which exogenous DNA enters a recipient cell.
Transformation may occur under natural or artificial conditions using various methods well known in the art. Transformation may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method is selected based on the host cell 2~ being transformed.
"Transformants" include stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as cells which transiently express inserted DNA or RNA.
A "transgenic organism," as used herein, is any organism, including but not limited to animals 3 o and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such'as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro 35 fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, and plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, trausfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms s are widely known and provided in references such as Sambrook et al. (1989), supra.
A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 25% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using BLASTN with the "BLAST 2 Sequences" tool Version 2Ø9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 30%, so at least 50%, at least 60%, at least 70%, at least 80%o, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain deftued length. The variant may result in "conservative"
amino acid changes which do not affect structural and/or chemical properties.
A variant may be described as, for example, an "allelic" (as defined above), "splice,"
"species," or "polymorphic"
15 Variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA
processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid 2 o identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one base.
The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.
2 s In an alternative, variants of the polynucleotides of the present invention may be generated through recombinant methods. One possible method is a DNA shuffling technique such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat.
Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve 3 o the biological properties of SPTM, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and 3 s selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.
A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using BLASTP with the "BLAST 2 Sequences" tool Version 2Ø9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, fox example, at least 50%, so at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length of one of the polypeptides.
THE INVENTION
In a particular embodiment, cDNA sequences derived from human tissues and cell lines were aligned based on nucleotide sequence identity and assembled into "consensus"
or "template"
sequences which are designated by the template identification numbers (template IDs) in column 2 of Table 2. The sequence identification numbers (SEQ ll7 NOa) corresponding to the template IDs are shown in column 1. Segments of the template sequences are defined by the "start" and "stop"
2 o nucleotide positions listed in columns 3 and 4. These segments, when translated in the reading frames indicated in column 5, have similarity to signal peptide (SP) or transmembrane (TM) domain consensus sequences, as indicated in column 6.
The invention incorporates the nucleic acid sequences of these templates as disclosed in the Sequence Listing and the use of these sequences in the diagnosis and treatment of disease states 2 s characterized by defects in cell signaling. The invention further utilizes these sequences in hybridization and amplification technologies, and in particular, in technologies which assess gene expression patterns correlated with specific cells or tissues and their responses in vivo or in vitro to pharmaceutical agents, toxins, and other treatments. In this manner, the sequences of the present invention are used to develop a transcript image fox a particular cell or tissue.
Deriyation of Nucleic Acid Sequences cDNA was isolated from libraries constructed using RNA derived from normal and diseased human tissues and cell lines. The human tissues and cell lines used for cDNA
library construction were selected from a broad range of sources to provide a diverse population of cDNAs representative 3 s of gene transcription throughout the human body. Descriptions of the human tissues and cell lines used for cDNA library construction are provided in the LIFESEQ database (Incyte Genomics, Inc.
(Incyte), Palo Alto CA). Human tissues were broadly selected from, for example, cardiovascular, dermatologic, endocrine, gastrointestinal, hematopoietic/immune system, musculoskeletal, neuxal, reproductive, and urologic sources.
Cell lines used for cDNA library construction were derived from, for example, leukemic cells, teratocarcinomas, neuroepitheliomas, cervical carcinoma, lung fibroblasts, and endothelial cells. Such cell lines include, for example, THP-1, Jurkat, HIJVEC, hNT2, WI38, HeLa, and other cell lines commonly used and available from public depositories (American Type Culture Collection, Manassas VA). Prior to mRNA isolation, cell lines were untreated, treated with a pharmaceutical agent such as so 5'-aza-2'-deoxycytidine, treated with an activating agent such as lipopolysaccharide in the case of leukocytic cell lines, or, in the case of endothelial cell lines, subjected to shear stress.
Se9uencin~ of the cDNAs Methods for DNA sequencing are well known in the art. Conventional enzymatic methods s5 employ the I~lenow fragment of DNA polymerase I, SEQUENASE DNA polymerase (U.S.
Biochemical Corporation, Cleveland OH), Taq polymerase (Applied Biosystems, Foster City CA), thermostable T7 polymerase (Amersham Pharmacia Biotech, Inc. (Amersham Pharmacia Biotech), Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies Inc. (Life Technologies), Gaithersburg 2 o MD), to extend the nucleic acid sequence from an oligonucleotide primer annealed to the DNA
template of interest. Methods have been developed for the use of both single-stranded and double-stranded templates. Chain termination reaction products may be electrophoresed on urea-polyacrylamide gels and detected either by autoradiography (for radioisotope-labeled nucleotides) or by fluorescence (for fluorophore-labeled nucleotides). Automated methods for mechanized reaction 2 s preparation, sequencing, and analysis using fluorescence detection methods have been developed.
Machines used to prepare cDNAs for sequencing can include the MICROLAB 2200 liquid transfer system (Hamilton Company (Hamilton), Reno NV), Peltier thermal cycler (PTC200;
MJ Research, Inc. (MJ Research), Watertown MA), and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing can be carried out using, for example, the ABI 373 or 377 (Applied 3 o Biosystems) or MEGABACE 1000 (Molecular Dynamics, Inc. (Molecular Dynamics), Sunnyvale CA) DNA sequencing systems, or other automated and manual sequencing systems well known in the art.
The nucleotide sequences of the Sequence Listing have been prepared by current, state-of the-art, automated methods and, as such, may contain occasional sequencing errors or unidentified s s nucleotides. Such unidentified nucleotides are designated by an N. These infrequent unidentified bases do not represent a hindrance to practicing the invention for those skilled in the art. Several methods employing standard recombinant techniques may be used to correct errors and complete the missing sequence information. (See, e.g., those described in Ausubel, F.M. et al. (1997) Short Protocols in Molecular Biolo~y, John Wiley & Sons, New York NY; and Sambrook, J. et al. (199) s Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plaiuview NY.) Assembly of eDNA Sequences Human polynucleotide sequences may be assembled using programs or algorithms well known in the art. Sequences to be assembled are related, wholly or in part, and may be derived from a single to or many different transcripts. Assembly of the sequences can be performed using such programs as PHRAP (Phils Revised Assembly Program) and the GELVIEW fragment assembly system (GCG), or other methods known in the art.
Alternatively, cDNA sequences are used as "component" sequences that are assembled into "template" or "consensus" sequences as follows. Sequence chromatograms are processed, verified, 15 and quality scores are obtained using PHRED. Raw sequences are edited using an editing pathway known as Block 1 (See, e.g., the LIFESEQ Assembled User Guide, Incyte Genomics, Palo Alto, CA).
A series of BLAST comparisons is performed and low-information segments and repetitive elements (e.g., dinucleotide repeats, Alu repeats, etc.) are replaced by "n's", or masked, to prevent spurious matches. Mitochondrial and ribosomal RNA sequences are also removed. The processed sequences o are then loaded into a relational database management system (RDMS) which assigns edited sequences to existing templates, if available. When additional sequences are added into the RDMS, a process is initiated which modifies existing templates or creates new templates from works in progress (i.e., nonfmal assembled sequences) containing queued sequences or the sequences themselves.
After the new sequences have been assigned to templates, the templates can be merged into bins. If 2 s multiple templates exist in one bin, the bin can be split and the templates reannotated.
Once gene bins have been generated based upon sequence alignments, bins are "clone joined"
based upon clone information. Clone joining occurs when the 5' sequence of one clone is present in one bin and the 3' sequence from the same clone is present in a different bin, indicating that the two bins should be merged into a single bin. Only bins which share at least two different clones are 3 o merged.
A resultant template sequence may contain either a partial or a full length open reading frame, or all or part of a genetic regulatory element. This variation is due in part to the fact that the full length cDNAs of many genes are several hundred, and sometimes several thousand, bases in length.
With current technology, cDNAs comprising the coding regions of large genes cannot be cloned 3 5 because of vector limitations, incomplete reverse transcription of the mRNA, or incomplete "second strand" synthesis. Template sequences may be extended to include additional contiguous sequences derived from the parent RNA transcript using a variety of methods known to those of skill in the art.
Extension may thus be used to achieve the full length coding sequence of a gene.
s Analysis of the cDNA Seguences The cDNA sequences are analyzed using a variety of programs and algorithms which are well known in the art. (See, e.g., Ausubel, 1997, suura, Chapter 7.7; Meyers, R.A. (Ed.) (1995) Molecular Biolo~y and Biotechuolo~y, Wiley VCH, New York NY, pp. 856-853; and Table 6.) These analyses comprise both reading frame determinations, e.g., based on triplet codon periodicity for so particular organisms (Fickett, J.W. (1982) Nucleic Acids Res. 10:5303-5318); analyses of potential start and stop codons; and homology searches.
Computer programs known to those of skill i_n the art for performing computer-assisted searches for amino acid and nucleic acid sequence similarity, include, for example, Basic Local Alignment Search Tool (BLAST; Altschul, S.F. (1993) J. Mol. Evol. 36:290-300;
Altschul, S.F. et al.
is (1990) J. Mol. Biol. 215:403-410). BLAST is especially useful in determining exact matches and comparing two sequence fragments of arbitrary but equal lengths, whose alignment is locally maximal and for which the alignment score meets or exceeds a threshold or cutoff score set by the user (Karlin, S. et al. (1988) Proc. Natl. Acad. Sci. USA 85:841-845). Using an appropriate search tool (e.g., BLAST or HMM), GenBank, SwissProt, BLOCKS, PFAM and other databases may be 2 o searched for sequences containing regions of homology to a query sptm or SPTM of the present invention.
Other approaches to the identification, assembly, storage, and display of nucleotide and polypeptide sequences are provided in "Relational Database for Storing Biomolecule Information,"
U.S.S.N. 08/947,845, filed October 9, 1997; "Project-Based Full-Length Biomolecular Sequence 2s Database," U.S. Patent Number 5,953,727; and "Relational Database and System for Storing Information Relating to Biomolecular Sequences," U.S.S.N. 09/034,807, filed March 4, 1998, all of which are incorporated by reference herein in their entirety.
Protein hierarchies can be assigned to the putative encoded polypeptide based on, e.g., motif, BLAST, or biological analysis. Methods for assigning these hierarchies are described, for example, in 3 0 "Database System Employing Protein Function Hierarchies for Viewing Biomolecular Sequence Data," U.S. Patent Number 6,023,659, incorporated herein by reference.
Human Secretory Seguences The sptm of the present invention may be used for a variety of diagnostic and therapeutic 35 purposes. For example, an sptm maybe used to diagnose a particular condition, disease, or disorder associated with cell signaling. Such conditions, diseases, and disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including s adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, a cancer of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an immune system disorder such as such as inflammation, actinic keratosis, acquired immunodeficiency syndrome to (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, arteriosclerosis, asthma, atherosclerosis, autoixnmune hemolytic anemia, autoimmune thyroiditis, bronchitis, bursitis, cholecystitis, cirrhosis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, 1s Hashimoto's thyroiditis, paroxysmal nocturnalhemoglobinuria, hepatitis, hypereosinophilia, irritable bowel syndrome, episodic lyrnphopenia with lymphocytotoxins, mixed connective tissue disease (MCTD), multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, myelofibrosis, osteoarthritis, osteoporosis, pancreatitis, polycythemia vera, polymyositis, psoriasis, Reiter's syndrome rheumatoid arthritis, scleroderma, Sjogren's syndrome,.systemic anaphylaxis, systemic lupus 2 o erythematosus, systemic sclerosis, primary thrombocythemia, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, trauma, and hematopoietic cancer including lymphoma, leukemia, and myeloma; and a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other 2 s extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prior diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker 3 o syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemaugioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorder of the central nervous system, cerebral palsy, a neuroskeletal disorder, au autonomic nervous system disorder, a cranial nerve disorder, a spinal cord disease, muscular dystrophy and other neuromuscular disorder, a peripheral nervous 3 s system disorder, dermatomyositis and polymyositas, inherited, metabolic, endocrine, and toxic myopathy, myasthenia gravis, periodic paralysis, a mental disorder including mood, anxiety, and schizophrenic disorder, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, and Tourette's disorder. The sptm can be used to detect the presence of, or to quantify the amount of, an sptm-related polynucleotide in a sample. This information is then compared to information obtained from appropriate reference samples, and a diagnosis is established. Alternatively, a polynucleotide complementary to a given sptm can inhibit or inactivate a therapeutically relevant gene related to the sptm.
to Analysis of s~tm Expression Patterns The expression of sptm may be routinely assessed by hybridization based methods to determine, for example, the tissue-specificity, disease-specificity, or developmental stage-specificity of sptm expression. For example, the level of expression of sptm may be compared among different cell types or tissues, among diseased and normal cell types or tissues, among cell types or tissues at 15 different developmental stages, or among cell types or tissues undergoing various treatments. This type of analysis is useful, for example, to assess the relative levels of sptm expression in fully or partially differentiated cells or tissues, to determine if changes in sptm expression levels are correlated with the development or progression of specific disease states, and to assess the response of a cell or tissue to a specific therapy, for example, in pharmacological or toxicological studies. Methods for the 2 o analysis of sptm expression are based on hybridization and amplification technologies and include membrane-based procedures such as northern blot analysis, high-throughput procedures that utilize, for example, microarrays, and PCR based procedures.
Hybridization and Genetic Analysis 25 The sptm, their fragments, or complementary sequences, may be used to identify the presence of and/or to determine the degree of similarity between two (or more) nucleic acid sequences. The sptm may be hybridized to naturally occurring or recombinant nucleic acid sequences under appropriately selected temperatures and salt concentrations. Hybridization with a probe based on the nucleic acid sequence of at least one of the sptm allows for the detection of nucleic acid sequences, 3 o including genomic sequences, which are identical or related to the sptm of the Sequence Listing.
Probes may be selected from non-conserved or unique regions of at least one of the polynucleotides of SEQ )17 N0:1-567 and tested for their ability to identify or amplify the target nucleic acid sequence using standard protocols.
Polynucleotide sequences that are capable of hybridizing, in particular, to those shown in SEQ
35 1D N0:1-567 and fragments thereof, can be identified using various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) Methods Enzymol. 152:399-407;
Kim_m__el, A.R. (1987) Methods Enzymol. 152:507-511.) Hybridization conditions are discussed in "Definitions."
A probe for use in Southern or northern hybridization may be derived from a fragment of an sptm sequence, or its complement, that is up to several hundred nucleotides in length and is either s single-stranded or double-stranded. Such probes may be hybridized in solution to biological materials such as plasmids, bacterial, yeast, or human artificial chromosomes, cleared or sectioned tissues, or to artificial substrates containing sptm. Microarrays are particularly suitable for identifying the presence of and detecting the level of expression for multiple genes of interest by examining gene expression correlated with, e.g., various stages of development, treatment with a drug or compound, or disease so progression. An array analogous to a dot or slot blot may be used to arrange and link polynucleotides to the surface of a substrate using one or more of the following: mechanical (vacuum), chemical, thermal, or LTV bonding procedures. Such an array may contain any number of sptm and may be produced by hand or by using available devices, materials, and machines.
Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., 15 Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al.
(1996) Proc. Natl. Acad.
Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application W095/251116; Shalon, D. et al. (1995) PCT application W095/35505; Heller, R.A. et al. (1997) Proc. Natl.
Acad. Sci. USA
94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Probes may be labeled by either PCR or enzymatic techniques using a variety of 2 o commercially available reporter molecules. For example, commercial kits are available for radioactive and chemiluminescent labeling (Amersham Pharmacia Biotech) and for alkaline phosphatase labeling (Life Technologies). Alternatively, sptm may be cloned into commercially available vectors for the production of RNA probes. Such probes may be transcribed in the presence of at least one labeled nucleotide (e.g., 32P-ATP, Amersham Pharmacia Biotech).
2 s Additionally the polynucleotides of SEQ )D NO:1-567 or suitable fragments thereof can be used to isolate full length cDNA sequences utilizing hybridization and/or amplification procedures well known in the art, e.g., cDNA library screening, PCR amplification, etc. The molecular cloning of such full length cDNA sequences may employ the method of cDNA library screening with probes using the hybridization, stringency, washing, and probing strategies described above and in Ausubel, supra, 3 o Chapters 3, 5, and 6. These procedures may also be employed with genomic libraries to isolate genomic sequences of sptm in order to analyze, e.g., regulatory elements.
Genetic Mapping Gene identification and mapping are important in the investigation and treatment of almost all 3 s conditions, diseases, and disorders. Cancer, cardiovascular disease, Alzheimer's disease, arthritis, diabetes, and mental illnesses are of particular interest. Each of these conditions is more complex than the single gene defects of sickle cell anemia or cystic fibrosis, with select groups of genes being predictive of predisposition for a particular condition, disease, or disorder.
Fox example, cardiovascular disease may result from malfunctioning receptor molecules that fail to clear cholesterol s from the bloodstream, and diabetes may result when a particular individual's immune system is activated by an infection and attacks the insulin-producing cells of the pancreas. In some studies, Alzheimer's disease has been linked to a gene on chromosome 21; other studies predict a different gene and location. Mapping of disease genes is a complex and reiterative process and generally proceeds from genetic linkage analysis to physical mapping.
so As a condition is noted among members of a family, a genetic linkage map traces parts of chromosomes that are inherited in the same pattern as the condition.
Statistics link the inheritance of particular conditions to particular regions of chromosomes, as defined by RFLP
or other markers.
(See, for example, Lander, E. S, and Botstein, D. (1986) Proc. Natl. Acad.
Sci. USA 83:7353-7357.) Occasionally, genetic markers and their locations are known from previous studies. More often, 15 however, the markers are simply stretches of DNA that differ among individuals. Examples. of genetic linkage maps can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OM1M) World Wide Web site.
In another embodiment of the invention, sptm sequences may be used to generate hybridization probes useful in chromosomal mapping of naturally occurring genomic sequences. Either 2 o coding or noncoding sequences of sptm may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of an sptm coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes 2s (HACs), yeast artificial chromosomes (PACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat.
Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J.
(1991) Trends Genet.

7:149-154.) Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome 3o mapping techniques and genetic map data. (See, e.g., Meyers, supra, pp. 965-968.) Correlation between the location of sptm on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the xegion of DNA
associated with that disorder.
The sptm sequences may also be used to detect polymorphisms that are genetically linked to the inheritance of a particular condition, disease, or disorder.
3 5 In situ hybridization of chromosomal preparations and genetic mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending existing genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of the corresponding human chromosome is not known. These new marker sequences can be mapped to human chromosomes s and may provide valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once a disease or syndrome has been crudely correlated by genetic linkage with a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation.
(See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequences of the subject so invention may also be used to detect differences in chromosomal architecture due to translocation, inversion, etc., among normal, carrier, or affected individuals.
Once a disease-associated gene is mapped to a chromosomal region, the gene is cloned in order to identify mutations or other alterations (e.g., translocations or inversions) that may be correlated with disease. This process includes a physical map of the chromosomal region containing 15 the disease-gene of interest along with associated markers. A physical map is necessary for determining the nucleotide sequence of and order of marker genes on a particular chromosomal region. Physical mapping techniques are well known in the art and involve the generation of overlapping sets of cloned DNA fragments from a particular organelle, chromosome, or genome.
These clones are analyzed to reconstruct and catalog their order. Once the position of a marker is 2 o determined, the DNA from that region is obtained by consulting the catalog and selecting clones from that region. The gene of interest is located through positional cloning techniques using hybridization or similar methods.
Diagnostic Uses 2 s In various embodiments, embodiments of sptm described herein can be configured to be used to design probes useful in diagnostic assays known to those skilled in the art. Such assays can be conftgured to be used to diagnose, detect, confirm or quantitate conditions, disorders, or diseases associated with~abnormal levels of sptm expression. Labeled probes developed from sptm sequences are added to a sample under hybridizing conditions of desired stringency. In some instances, sptm, or 3 o fragments or oligonucleotides derived from sptm, may be used as primers in amplification steps prior to hybridization. The amount of hybridization complex formed is quantified and compared with standards for a selected cell or tissue type. Indication of the presence of the condition, disorder, or disease can be determined by variation of the amount of sptm expression from the assay standard. The amount of variation indicative of the condition can be above or below the standard, can be selected by the s s medical practioner, can be determined from known patient populations and/or amounts known in the medical arts and/or associated standards organizations or regulations (e.g.
CLIA). Examples of qualitative or quantitative diagnostic assays or methods may include but are not limited to northern, dot blot, or other membrane or dip-stick based technologies or multiple-sample format technologies such as PCR, enzyme-linked immunosorbent assay (ELISA)-like, pint, chip-based assays and the like.
The probes described above may also be used to monitor the progress of conditions, disorders, or diseases associated with abnormal levels of sptm expression, or to evaluate the efficacy of a particular therapeutic treatment. The candidate probe may be identified from the sptm that are specific to a given human tissue and have not been observed in GenBank or other genome databases.
Such a probe may be used in animal studies, preclinical tests, clinical trials, or in monitoring the so treatment of an individual patient. In a typical process, standard expression is established by methods well known in the art for use as a basis of comparison, samples from patients affected by the disorder or disease are combined with the probe to evaluate any deviation from the standard profile, and a therapeutic agent is administered and effects are monitored to generate a treatment profile. Efficacy is evaluated by determining whether the expression progresses toward or returns to the standard s5 normal pattern. Treatment profiles may be generated over a period of several days or several months.
Statistical methods well known to those skilled in the art may be use to determine the significance of such therapeutic agents.
The polynucleotides are also useful for identifying individuals from minute biological samples,.
for example, by matching the RFLP pattern of a sample's DNA to that of an individual's DNA. The 2 o polynucleotides of the present invention can also be used to determine the actual base by-base DNA
sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, an individual can be identified through a unique set of DNA
sequences. Once a unique ID database is established for an individual, positive identification of that individual can be made from 2s extremely small tissue samples.
In a particular aspect, oligonucleotide primers derived from the sptm of the invention may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and s o fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from sptm are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like.
SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSCCP, the s s oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (isSNP), are capable of identifying polymorphisms by comparing the sequences of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation s of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSfLRRAY system (Sequenom, Inc., San Diego CA).
DNA-based identification techniques can be used in forensic technology. DNA
sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, so saliva, semen, etc., can be amplified using, e.g., PCR, to identify individuals. (See, e.g., Erlich, H.
(1992) PCR Technolo~y, Freeman and Co., New York, NY). Similarly, polynucleotides of the present invention can be used as polymorphic markers.
There is also a need for reagents capable of identifying the source of a particular tissue.
Appropriate reagents can comprise, for example, DNA probes or primers prepared from the 15 sequences of the present invention that are specific for particular tissues. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.
The polynucleotides of the present invention can also be used as molecular weight markers on nucleic acid gels or Southern blots, as diagnostic probes for the presence of a specific mRNA in a 2o particular cell type, in the creation of subtracted cDNA libraries which aid in the discovery of novel polynucleotides, in selection and synthesis of oligomers for attachment to an array or other support, and as an antigen to elicit an immune response.
Disease Model Systems Using sptm 2 s The polynucleotides encoding SPTM or their mammalian homologs may be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent Number 5,175,383 and U.S. Patent Number 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and s o grown in culture. The ES cells are transformed with a vector containing the gene of intterest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP
system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D.
35 (1996) Clip. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic Acids Res. 25:4323-4330).

Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.
s The polynucleotides encoding SPTM may also be manipulated in vitro in ES
cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al.
(1998) Science 282:1145-1147).
so The polynucleotides encoding SPTM of the invention can also be used to create "knockin"
humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of sptm is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential 15 pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress sptm, resulting, e.g., in.the secretion of SPTM
in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).
Screening Assays 2 o SPTM encoded by polynucleotides of the present invention may be used to screen for molecules that bind to or are bound by the encoded polypeptides. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the bound molecule. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.
2s Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a ligand or fragment thereof, a natural substrate, or a structural or functional mimetic. (See, Coligan et al., (1991) Current Protocols in Immunolo~y 1(2): Chapter 5.) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or to at least a fragment of the receptor, e.g., the active site. In either case, the molecule can be rationally designed using known techniques.
3 o Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing the polypeptide or cell membrane fractions which contain the expressed polypeptide are then contacted with a test compound and binding, stimulation, or inhibition of activity of either the polypeptide or the molecule is analyzed.
3 5 An assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. Alternatively, the assay may assess binding in the presence of a labeled competitor.
Additionally, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures.
The assay may also simply s comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.
Preferably, an ELISA assay using, e.g., a monoclonal or polyclonal antibody, can measure polypeptide level in a sample. The antibody can measure polypeptide level by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.
All of the above assays can be used in a diagnostic or prognostic context. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptide from s s suitably manipulated cells or tissues.
Transc~t Ima~in,~ and Toxicological Testing Another embodiment relates to the use of sptm to develop a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell 2 o type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a a 5 particular tissue or cell type. In an embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant trauscript image would provide a profile of gene activity pertaining to cell signaling.
Transcript images which profile sptm expression may be generated using transcripts isolated 3 o from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect sptm expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.
Transcript images which profile sptm expression may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of 3 s industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E. F. et a1. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and Anderson, N. L. (2000) Toxicol. Lett. 112-113:467-71, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known s toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families.
Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization so procedure is useful for comparison of expression data after treatment with different compounds.
While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at 15 http://www.niehs.nih.gov/oc/news/toxchip.htm.) 'Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.
In an embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present 2 o invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the 'treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.
Another particular embodiment relates to the use of SPTM encoded by polynucleotides of the 2 5 present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by 3 o separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by 35 staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the s spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.
so A proteomic profile may also be generated using antibodies specific for SPTM to quantify the levels of SPTM expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem. 270:103-11; Mendoze, L. G. et al. (1999) Biotechniques 27:778-88). Detection may be performed by a variety is of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.
Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor 2 o correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N. L. and Seilhamer, J. (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.
2s In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample.
A difference in the amount of protein between the two samples is indicative of a toxic response to the 3 o test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the SPTM encoded by polynucleotides of the present invention.
In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated 3 s with antibodies specific to the SPTM encoded by polynucleotides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.
s Transcript images may be used to profile sptm expression in distinct tissue types. This process can be used to determine cell signaling activity in a particular tissue type relative to this activity in a different tissue type. Transcript images rnay be used to generate a profile of sptm expression characteristic of diseased tissue. Transcript images of tissues before and after treatment may be used for diagnostic purposes, to monitor the progression of disease, and to monitor the efficacy of drug treatments for diseases which affect cell signaling activity.
Transcript images of cell lines can be used to assess cell signaling activity and/or to identify cell lines that lack or misregulate this activity. Such cell lines may then be treated with pharmaceutical agents, and a transcript image following treatment may indicate the efficacy of these agents in restoring desired levels of this activity. A similar approach may be used to assess the toxicity of pharmaceutical agents as reflected by undesirable changes in. cell signaling activity. Candidate pharmaceutical agents may be evaluated by comparing their associated transcript iiriages with those of pharmaceutical agents of known effectiveness.
Antisense Molecules 2 o The polynucleotides of the present invention are useful in antisense technology. Antisense technology or therapy relies on the modulation of expression of a target protein through the specific binding of an antisense sequence to a target sequence encoding the target protein or directing its expression. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ; Alama, A. et al. (1997) Pharmacol. Res. 36(3):171-178; Crooke, S.T. (1997) Adv. Pharmacol.
40:1-49; Sharma, H.W. and R. Narayanan (1995) Bioessays 17(12):1055-1063; and Lavrosky, Y. et al. (1997) Biochem. Mol. Med. 62(1):11-22.) An antisense sequence is a polynucleotide sequence capable of specifically hybridizing to at least a portion of the target sequence. Antisense sequences bind to cellular mRNA and/or genomic DNA, affecting translation and/or transcription. Antisense sequences can be DNA, RNA, or nucleic acid mimics and analogs. (See, e.g., Rossi, J.J. et al. (1991) 3o Antisense Res. Dev. 1(3):285-288; Lee, R. et al. (1998) Biochemistry 37(3):900-1010; Pardridge, W.M. et al. (1995) Proc. Natl. Acad. Sci. USA 92(12):5592-5596; and Nielsen, P. E. and Haaima, G.
(1997) Chem. Soc. Rev. 96:73-78.) Typically, the binding which results in modulation of expression occurs through hybridization or binding of complementary base pairs. Antisense sequences can also bind to DNA duplexes through specific interactions in the major groove of the double helix.
The polynucleotides of the present invention and fragments thereof canbe used as antisense sequences to modify the expression of the polypeptide encoded by sptm. The antisense sequences can be produced ex vivo, such as by using any of the ABI nucleic acid synthesizer series (Applied Biosystems) or other automated systems known in the art. Antisense sequences can also be produced biologically, such as by transforming an appropriate host cell with an expression vector containing the sequence of interest. (See, e.g., Agrawal, su ra.) In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of au expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., to Slater, J.E., et al. (1998) J. Allergy Clin. Tmmunol. 102(3):469-475; and Scanlon, K.J., et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) Blood 76:271; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biolo~y, John Whey & Sons, New York NY; Uckert, W. and W. Walther (1994) Pharmacol. Ther. 63(3):323-347.) Other gene delivery s 5 mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) Br. Med. Bull. .51(1):217-225; Boado, R.J. et al. (1998) J. Pharm..
Sci. 87(11):1308-1315; and Morris, M.C. et al. (1997) Nucleic Acids Res.
25(14):2730-2736.) Expression z o In order to express a biologically active SPTM, the nucleotide sequences encoding SPTM or fragments thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding SPTM and appropriate transcriptional and z 5 translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, supra, Chapters 4, 8, 16, and 17;
and Ausubel, supra, Chapters 9, 10, 13, and 16.) A variety of expression vector/host systems may be utilized to contain and express sequences encoding SPTM. These include, but are not limited to, microorganisms such as bacteria transformed 3 o with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors;
yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus);
plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal (mammalian) cell systems. (See, e.g., Sambrook, sera; Ausubel, 1995, supra, Van Heeke, G.
3s and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Bitter, G.A. et al.
(1987) Methods Enzymol.

153:516-544; Scorer, C.A. et al. (1994) Bio/Technology 12:181-184; Engelhard, E.I~. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945;
Takamatsu, N. (1987) EMBO J. 6:307-311; Coruzzi, G. et al. (1984) EMBO J.
3:1671-1680; Brogue, R. et al. (1984) Science 224:838-843; Winter, J. et al. (1991) Results Probl.
Cell Differ. 17:85-105;
s The McGraw Hill Yearbook of Science and Technolo~y (1992) McGraw Hill, New York NY, pp.
191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; and Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, to M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al., (1993) Proc. Natl. Acad. Sci. USA
90{13):6340-6344; Buller, R.M. et al. (1985) Nature 317(6040):813-815;
McGregor, D.P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, T.M. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.
For long term production of recombinant proteins in mammalian systems, stable expression of is SPTM in cell lines is preferred. For example, sequences encoding SPTM can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Any number of selection systems may be used to recover transformed cell lines. (See, e.g., Wigler, M. et al.
(1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.; Wigler, M. et al. (1980) Proc. Natl.
2o Acad. Sci. USA 77:3567-3570; CoTbere=Garapin, F, et al. (1981) J. Mol.
Biol. 150:1-14; Hartman, S.C.
and R.C.Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051; Rhodes, C.A.
(1995) Methods Mol. Biol. 55:121-131.) Therapeutic Uses of sptm 2 s The polynucleotides encoding SPTM of the invention may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCll~)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al.
30 (1995) Science 270:475-480; Bordignon, C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Call 75:207-216; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:643-666; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:667-703), thalassemias, familialhypercholesterolemia, and hemophilia resulting from Factor VllI or Factor IX deficiencies (Crystal, R.G.
(1995) Science 270:404-410; Verma, LM. and Somia, N. (1997) Nature 389:239-242)), (ii) express a conditionally 3 5 lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (H1V) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci. USA. 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in sptm expression or regulation causes disease, the expression of sptm from an.
appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.
In a further embodiment of the invention, diseases or disorders caused by deficiencies in sptm to are treated by constructing mammalian expression vectors comprising sptm and introducing these vectors by mechanical mesas into sptm-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, -R.A. and Anderson, W.F. (1993) Anuu. Rev.
Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J-L. and Recipon, H. (1998) Curr. Opin. Biotechnol.
9:445-450).
Expression vectors that may be effective for the expression of sptm include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, 2o PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). The sptm of the invention may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or (3-actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and Bujard, H. (1992) Proc. Natl. Acad. Sci.
U.S.A. 89:5547-5551; Gossen, M. et al., (1995) Science 268:1766-1769; Rossi, F.M.V. and Blau, as H.M. (1998) C~rr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX plasmid (Invitrogen); the ecdysone-inducible promoter (available in the plasmids PVGRXR and P1ND;
Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and Blau, H.M. supra), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding SPTM from a normal individual.
3 o Commercially available liposome transformation kits (e.g., the PERFECT
LIPID
1'RANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and Eb, A.J. (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al.
35 (1982) EMBO J. 1:841-845). The introduction of DNA to primary cells involves modification of these standardized mammalian transfection protocols.
In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to sptm expression are treated by constructing a retrovirus vector consisting of (i) sptm undex the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) s appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus cis-acting RNA sequences and coding sequences required for efficient vector propagation.
Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. U.S.A.
92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) 1 o that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-1646; Adam, M.A. and Miller, A.D. (1988) J.
Virol. 62:3802-3806; Dull, T.
et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol.
72:9873-9880). U.5. Patent Number 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high s5 transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4+ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267;
Bonyhadi, M.L. (1997) ao J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci.
U.S.A. 95:1201-1206; Su, L.
(1997) Blood 89:2283-2290).
In the alternative, an adenovirus-based gene therapy delivery system is used to deliver sptm to cells which have one or more genetic abnormalities with respect to the expression of sptm. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in 25 the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) Annu. Rev. Nutr. 19:511-544 3 o and Verma, LM. and Somia, N. (1997) Nature 18:389:239-242, both incorporated by reference herein.
In another alternative, a herpes-based, gene therapy delivery system is used to deliver sptm to target cells which have one or more genetic abnormalities with respect to the expression of sptm. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing sptm to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of 3 s herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1 based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res.169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent Number 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference.
U.5. Patent Number s 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.
F. et al. 1999 J. Virol. 73:519-532 and Xu, H. et al., (1994) Dev. Biol.
163:152-161, hereby to incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the trausfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.
In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to 15 deliver sptm to target cells. The biology of the prototypic alphavirus, Semlik_i Foxest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV
genome (Garoff, H.
and Li, K-J. (1998) Curr. Opin. Biotech. 9:464-469). During alphavirus RNA
replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins.
This subgenomic RNA
replicates to higher levels than the full-length genomic RNA, resulting in the overproduction of capsid 2o proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase).
Similarly, inserting sptm into the alphavirus genome in place of the capsid-coding region results in the production of a large number of sptm RNAs and the synthesis of high levels of SPTM in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of a 5 Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) Virology 228:74-83).
The wide host range of alphaviruses will allow the introduction of sptm into a variety of cell types.
The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA
s o transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.
Antibodies Anti-SPTM autibodies may be used to analyze protein expression levels. Such antibodies 3 5 include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, and Fab fragments. For descriptions of and protocols of antibody technologies, see, e.g., Pound J.D.
(1998) Tmm__unochemical Protocols, Humane Press, Totowa, NJ.
The amino acid sequence encoded by the sptm of the Sequence Listing may be analyzed by appropriate software (e.g., LASERGENE NAVIGATOR software, DNASTAR) to determine s regions of high imrnunogenicity. The optimal sequences for immunization are selected from the C-terminus, the N-terminus, and those intervening, hydrophilic regions of the polypeptide which are likely to be exposed to the external environment when the polypeptide is in its natural conformation.
Analysis used to select appropriate epitopes is also described by Ausubel (1997, su ra, Chapter 11.7).
Peptides used for antibody induction do not need to have biological activity;
however, they should be so antigenic. Peptides used to induce specific antibodies may have an amino acid sequence consisting of at least five amino acids, preferably at least 10 amino acids, and most preferably at least 15 amino acids. A peptide which mimics an antigenic fragment of the natural polypeptide may be fused with another protein such as keyhole limpet hemocyanin (KLH; Sigma, St. Louis MO) for antibody production. A peptide encompassing ati antigenic region may be expressed from an sptm, synthesized 15 as described above, or purified from human cells.
Procedures well known in the art may be used for the production of antibodies.
Various hosts including mice, goats, and rabbits, may be immunized by injection with a peptide. Depending on the host species, various adjuvants may be used to increase immunological response.
In one procedure, peptides about 15 residues in length may be synthesized using an ABI 431A
20 ' peptide synthesizer (Applied Biosystems) using fmoc-chemistry and coupled to KLH (Sigma) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester (Ausubel, 1995, su ra). Rabbits are immunized with the peptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity by binding the peptide to plastic, blocking with 1 % bovine serum albumin (BSA), reacting with rabbit antisera, washing, and reacting with radioiodinated goat anti-rabbit IgG.
2 s Antisera with antipeptide activity are tested for anti-SPTM activity using protocols well known in the art, including ELISA, radioimmunoassay (RIA), and immunoblotting.
In another procedure, isolated and purified peptide may be used to immunize mice (about 100 ~.g of peptide) or rabbits (about 1 mg of peptide). Subsequently, the peptide is radioiodinated and used to screen the immunized animals' B-lymphocytes for production of antipeptide antibodies. Positive s o cells are then used to produce hybridomas using standard techniques. About 20 mg of peptide is sufficient for labeling and screening several thousand clones. Hybridomas of interest are detected by screening with radioiodinated peptide to identify those fusions producing peptide-specific monoclonal antibody. In a typical protocol, wells of a multi-well plate (FAST, Becton-Dickinson, Palo Alto, CA) are coated with affinity-purified, specific rabbit-anti-mouse (or suitable anti-species IgG) antibodies at 35 10 mg/ml. The coated wells are blocked with 1% BSA and washed and exposed to supernatants from hybridomas. After incubation, the wells are exposed to radiolabeled peptide at 1 mg/ml.
Clones producing antibodies bind a quantity of labeled peptide that is detectable above background. Such clones are expanded and subjected to 2 cycles of cloning.
Cloned hybridomas are injected into pristane-treated mice to produce ascites, and monoclonal antibody is purified from the ascitic fluid by affinity chromatography on protein A (Amersham Pharmacia Biotech). Several procedures for the production of monoclonal antibodies, including in vitro production, are described in Pound su ra). Monoclonal antibodies with antipeptide activity are tested for anti-SPTM activity using protocols well known in the art, including ELISA, RIA, and immunoblotting.
Antibody fragments containing specific binding sites for an epitope may also.
be generated.
s o For example, such fragments include, but are not limited to, the F(ab~2 fragments produced by pepsin digestion of the antibody molecule, and the Fab fragments generated by reducing the disulfide bridges of the F(ab~2 fragments. Alternatively, construction of Fab expression libraries in hlamentous bacteriophage allows rapid and easy identification of monoclonal fragments with desired specificity (Pound, su ra, Chaps. 45-47). Antibodies generated against polypeptide encoded by sptm can be used to purify and characterize full-length SPTM protein and its activity, binding partners, etc.
Assays Using Antibodies Anti-SPTM antibodies may be used in assays to quantify the amount of SPTM
found in a particular human cell. Such assays include methods utilizing the antibody and a label to detect ~ o expression level under normal or disease conditions. The peptides and antibodies of the invention may be used with or without modification or labeled by joining them, either covalently or noncovalently, with a reporter molecule.
Protocols for detecting and measuring protein expression using either polyclonal or monoclonal antibodies are well known in the art. Examples include ELISA, RIA, and fluorescent activated cell sorting (FAGS). Such immunoassays typically involve the formation of complexes between the SPTM
and its specific antibody and the measurement of such complexes. These and other assays are described in Pound su ra).
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, 3 o to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way 3 5 whatsoever.

The disclosures'of all patents, applications, and publications mentioned above and below, .
including U.S. Application Ser. No. 60/280,067, U.S. Application Ser. No.
60/280,068, U.S.
Application Ser. No.60/291,280, U.S. Application Ser. No. 60/291,849, U.S.
Application Ser. No.
60/291,829, U.S. Application Ser. No. 601299,428, U.S. Application Ser. No.
60/300,001, and U.S.
s Application Ser. No. 60/299,776, are hereby expressly incorporated by reference herein.
EXAMPLES
I. Construction of cDNA Libraries RNA was purchased from CLONTECH Laboratories, Inc. (Palo Alto CA) or isolated from 1 o various tissues. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TR1ZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate.
The resulting lysates were centrifuged over CsCI cushions or extracted with chloroform. RNA was precipitated with either isopropanol or sodium acetate and ethanol, or by other routine methods.
15 ~ Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA
purity. In most cases, RNA was treated with DNase. For most libraries, poly(A+) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega Corporation (Promega), Madison WI), OLIGOTEX latex particles (QIAGEN, Inc. (QIAGEN), Valencia CA), or an OLIGOTEX
mRNA
purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other 2 o RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Inc., Austin TX).
In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA
libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNI2AP vector system (Stratagene Cloning Systems, Inc. (Stratagene), La Jolla CA) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar 2s methods known in the art. (See, e.g., Ausubel, 1997, su ra, Chapters 5.1 through 6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S 1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography 3 0 (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis.
cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT
plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), PCR2-TOPOTA plasmid (Invitrogen), PCMV-ICIS
plasmid (Stratagene), pIGEN (Incyte Genomics, Palo Alto CA), pRARE (Incyte Genomics), or 3 5 pINCY (Incyte Genomics), or derivatives thereof. Recombinant plasmids were transformed into competent E. coli cells including XL,1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DHSa, DH10B, or ElectroMAX DH10B from Life Technologies.
II. Isolation of cDNA Clones Plasmids were recovered from host cells by iri viyo excision using the UNIZAP
vector system (Stratagene) or by cell lysis. Plasmids wexe purified using at least one of the following: the Magic or WIZARD Minipreps DNA purification system (Promega); the AGTC Miniprep purification kit (Edge BioSystems, Gaithersburg MD); and the QIAWELL 8, QIAWELL 8 Plus, and QIAWELL 8 Ultra plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit (QIAGEN). Following so precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.
Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format. (Rao, V.B. (1994) Anal. Biochem. 216:1-14.) Host cell lysis and thermal cycling steps were carned out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Inc. (Molecular Probes), Eugene OR) and a FLUOROSKAN
II fluorescence scanner (Labsystems Oy, Helsinki, Finland).
III. Sequencing and Analysis 2 o cDNA sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 thermal cycler (Applied Biosystems) or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific Corp., Sunnyvale CA) or the MICROLAB 2200 liquid transfer system (Hamilton). cDNA
sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA
sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE

sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence 3 o analysis systems known in the art. Reading frames within the cDNA
sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, Chapter 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example V1H.
IV. Assembly and Analysis of Sequences Component sequences from chromatograms were subject to PHRED analysis and assigned a quality score. The sequences having at least a required quality score were subject to various pre-processing editing pathways to eliminate, e.g., low quality 3' ends, vector and linker sequences, polyA
tails, Alu repeats, mitochondrial and ribosomal sequences, bacterial contamination sequences, and sequences smaller than 50 base pairs. In particular, low-information sequences and repetitive s elements (e.g., dinucleotide repeats, Alu repeats, etc.) were replaced by "rl's", or masked, to prevent spurious matches. ' Processed sequences were then subject to assembly procedures in which the sequences were assigned to gene bins (bins). Each sequence could only belong to one bin.
Sequences in each gene bin were assembled to produce consensus sequences (templates). Subsequent new sequences were so added to existing bins using BLASTN (v.1.4 Washes and CROSSMATCH. Candidate pairs were identified as all BLAST hits having a quality score greater than or equal to 150. Alignments of at least 82% local identity were accepted into the bin. The component sequences from each bin were assembled using a version of PIiRAP. Bins with several overlapping component sequences were assembled using DEEP PHR_AP. The orientation (sense or antisense) of each assembled template 15 was determined based on the number and orientation of its component sequences. Template sequences as disclosed in the sequence listing correspond to sense strand sequences (the "forward"
reading frames), to the best determination. The complementary (autisense) strands are inherently disclosed herein. The component sequences which were used to assemble each template consensus sequence are listed in Table 3 by their positions along the template nucleotide sequences.
2 o Bins were compared against each other and those having local similarity of at least 82% were combined and reassembled. Reassembled bins having templates of insufficient overlap (less than 95%
local identity) were re-split. Assembled templates were also subject to analysis by ST1TCHERIEXON MAPPER algorithms which analyze the probabilities of the presence of splice variants, alternatively spliced axons, splice junctions, differential expression of alternative spliced 2 s genes across tissue types or disease states, etc. These resulting bins were subject to several rounds of the above assembly procedures.
Once gene bins were generated based upon sequence alignments, bins were clone joined based upon clone information. If the 5' sequence of one clone was present in one bin and the 3' sequence from the same clone was present in a different bin, it was likely that the two bins actually 3 o belonged together in a single bin. The resulting combined bins underwent assembly procedures to regenerate the consensus sequences.
The final assembled templates were subsequently annotated using the following procedure.
Template sequences were analyzed using BLASTN (v2.0, NCBI) versus gbpri (GenBank version 128). "Hits" were defined as an exact match having from 95% local identity over 200 base pairs 3 5 through 100% local identity over 100 base pairs, or a homolog match having an E-value, i.e. a probability score, of <_ 1 x 10-8. The hits were subject to frameshift FASTx versus GENPEPT
(GenBank version 128). (See Table 6). In this analysis, a homolog match was defined as having an E-value of <_ 1 x 10-g. The assembly method used above was described in "System and Methods for Analyzing Biomolecular Sequences," U.S.S.N. 09/276,534, filed March 25, 1999, and the L1FESEQ
s Gold user manual (Incyte) both incorporated by reference herein.
Following assembly, template sequences were subjected to motif, BLAST, and functional analyses, and categorized in protein hierarchies using methods described in, e.g., "Database System Employing Protein Function Hierarchies for Viewing Biomolecular Sequence Data," U.S. Patent Number 6,023,659; "Relational Database for Storing Biomolecule Information,"
U.S.S.N. 08/947,845, so filed October 9, 1997; "Project-Based Full-Length Biomolecular Sequence Database," U.S. Patent Number 5,953,727; and "Relational Database and System for Storing Information Relating to Biomolecular Sequences," U.S.S.N. 09/034,807, filed March 4, 1998, all of which are incorporated by reference herein.
The template sequences were further analyzed by translating each template in all three 15 forward reading frames and searching each translation against the Pfam database of hidden Markov model-based protein families and domains using the I~VIER software package (available to the public from Washington University School of Medicine, St. Louis MO). (See also World Wide Web site http://pfam.wustl.edu/ for detailed descriptions of Pfam protein domains and families.) Additionally, the template sequences were translated in all three forward reading frames, and 2o each translation was searched against hidden Markov models for signal peptides using the I~VIMER
software package. Construction of hidden Markov models and their usage in sequence analysis has been described. (See, for example, Eddy, S.R. (1996) Curr. Opin. Str. Biol.
6:361-365.) Only those signal peptide hits with a cutoff score of 11 bits or greater are reported. A
cutoff score of 11 bits or greater corresponds to at least about 91-94% true-positives in signal peptide prediction. Template 2s sequences were also translated in all three forward reading frames, and each translation was searched against TMHIV>MER, a program that uses a hidden Markov model (F)IVIM) to delineate transmembrane segments on protein sequences and determine orientation (Sonnhammer, E.L. et al.
(1998) Proc. Sixth liitl. Con~ On Intelligent Systems for Mol. Biol., Glasgow et al., eds., The Am.
Assoc. for Artificial Iutelligence (AAAI) Press, Memo Park, CA, and MIT Press, Cambridge, MA, 3 o pp. 175-182.) Regions of templates which, when translated, contain similarity to signal peptide or transmembrane consensus sequences are reported in Table 2.
Template sequences are further analyzed using the bioinformatics tools listed in Table 6, or using sequence analysis software known in the art such as MACDNASIS PRO
software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR).
3 5 Template sequences may be further queried against public databases such as the GenBank rodent, mammalian, vertebrate, prokaryote, and eukaryote databases.
The template sequences were trauslated to derive the corresponding longest open reading frame as presented by the polypeptide sequences as reported in Table 5.
Alternatively, a polypeptide of the invention may begin at any of the methionine residues within the full length translated s polypeptide. Polypeptide sequences were subsequently analyzed by querying against the GenBank protein database (GENPEPT, (GenBank version 128)). Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLITSTAL algorithm as incorporated into the so MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.
Table 5 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (GENPEPT) database. Column 1 shows the polypeptide sequence identification number (SEQ )D NO:) for the polypeptide segments of the 15 invention. Column. 2 shows the reading frame used in the trauslation of the polynucleotide sequences encoding the polypeptide segments. Column 3 shows the length of the trauslated polypeptide segments. Columns 4 and 5 show the start and stop nucleotide positions of the polynucleotide sequences encoding the polypeptide segments. Column 6 shows the GenBank identification number (GI Number) of the nearest GenBankhomolog. Column 7 shows the probability score for the match 2 o between each polypeptide and its GenBank homolog. Column 8 shows the annotation of the GenBank homolog.
V. Analysis of Polynucleotide Expression Northern analysis is a laboratory technique used to detect the presence of a trauscript of a z s gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, su ra, ch. 7; Ausubel, 1995, su ra, ch. 4 and 16.) Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Iucyte Genomics). This analysis is 3 o much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar.
The basis of the search is the product scoxe, which is defined as:

BLAST Score x Percent Identity x minimum {length(Seq. 1), length(Seq. 2)}
The product score takes into account both the degree of similarity between two sequences and the 5 length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP
(separated by to gaps). If there is more than one HSP, then the pair with the highest BLAST
score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100%
identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50%
overlap at one end, or 79%
identity and 100% overlap.
Alternatively, polynucleotide sequences encoding SPTM are analyzed with respect to the tissue sources from which they were derived. Polynucleotide sequences encoding SPTM were assembled, at least in part, with overlapping Incyte cDNA sequences. Each cDNA
sequence is 2 o derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system;
connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male;
germ cells; heroic and immune system; liver; musculoskeletal system; nervous system; pancreas;
respiratory system; sense organs; skin; stomatognathic system;
unclassified/mixed; or urinary tract.
The number of libraries in each category for each polynucleotide sequence encoding SPTM is counted and divided by the total number of libraries across all categories for each polynucleotide sequence encoding SPTM. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category for each polynucleotide sequence encoding 3 o SPTM is counted and divided by the total number of libraries across all categories for each polynucleotide sequence encoding SPTM. The resulting percentages reflect the tissue-specific and disease-specific expression of cDNA encoding SPTM. Percentage values of tissue-specific expression are reported in . cDNA sequences and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Gehomics, Palo Alto CA).

VI. Tissue Distribution Profiling A tissue distribution profile is determined for each template by compiling the cDNA library tissue classifications of its component cDNA sequences. Each component sequence, is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; heroic and immune system; liver; musculoskeletal system; nervous system; pancreas;
respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract.
Template sequences, component sequences, and cDNA library/tissue information are found in the LIFESE(~ GOLD
to database (Incyte Genomics, Palo Alto CA).
shows the tissue distribution profile for the templates of the invention. For each template, the three most frequently observed tissue categories are shown in column 2, along with the percentage of component sequences belonging to each category. Only tissue categories with percentage values of z 20% are shown. A tissue distribution of "widely distributed" in column 2 indicates percentage values Of <10% in all tissue categories.
VII. Transcript Image Analysis Transcript images are generated as described in Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number 5,840,484, incorporated herein by reference.
VIII. Extension of Polynucleotide Sequences and Isolation of a F~11-length cDNA
Oligonucleotide primers designed using an sptm of the Sequence Listing are used to extend the wucleic acid sequence. One primer is synthesized to initiate 5' extension of the template, and the other primer, to initiate 3' extension of the template. The initial primers may be designed using OLIGO
2s 4.06 software (National Biosciences, Inc. (National Biosciences), Plymouth MN), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC
content of about 50% or more, and to anneal to the target sequence at temperatures of about 68 °C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations are avoided. Selected human cDNA libraries are used to extend the sequence. If more than one 3 o extension is necessary or desired, additional or nested sets of primers are designed.
High fidelity amplification is obtained by PCR using methods well known in the art. PCR is performed in 96-well plates using the PTC-200 thermal cycler (MJ Research).
The reaction mix contains DNA template, 200 nmol of each primer, reaction buffer containing Mg2*, (NH~)ZS04, and 13-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE
enzyme (Life s 5 Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C,1 min; Step 4: 68 °C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68 °C, 5 min;
Step 7: storage at 4 °C. In the alternative, the parameters for primer pair T7 and SK+ are as follows: Step 1:
94 °C, 3 min; Step 2:
94 °C, 15 sec; Step 3: 57 °C, 1 min; Step 4: 68 °C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times;
Step 6: 68°C, 5 min; Step 7: storage at 4°C.
The concentration of DNA in each well is determined by dispensing 100 ~.1 PICOGREEN
quantitation reagent (0.25% (v/v); Molecular Probes) dissolved in 1X Tris-EDTA
(TE) and 0.5 ,u1 of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Incorporated (Corning), Corning NY), allowing the DNA to bind to the reagent. The plate is scanned in a FLUOROSKAN lI
to (Labsystems Oy) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 ~.1 to 10 ~,1 aliquot of the reaction mixture is analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions are successful in extending the sequence.
The extended nucleotides are desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI], and s5 sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides are separated on low concentration (0.6 to 0.8%) agarose gels, fragments are excised, and agar digested with AGAR ACE
(Promega). Extended clones are religated using T4 ligase (New England Biolabs, Inc., Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerise (Stratagene) to fill-in restriction 2 o site overhangs, and transfected into competent E. coli cells. Transformed cells are selected on antibiotic-containing media, individual colonies are picked and cultured overnight at 37 °C in 384-well plates in LB/2x carbenicillin liquid media.
The cells are lysed, and DNA is amplified by PCR using Taq DNA polymerise (Amersham Phaxmacia Biotech) and Pfu DNA polymerise (Stratagene) with the following parameters: Step 1:
25 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C.
DNA is quantified by PICOGREEN
reagent (Molecular Probes) as described above. Samples with low DNA recoveries are reamplified using the same conditions as described above. Samples are diluted with 20%
dimethysulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC
3 o DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).
In like manner, the sptm is used to obtain regulatory sequences (promoters, introns, and enhancers) using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.

IX. Labeling of Probes and Southern Hybridization Analyses Hybridization probes derived from the sptm of the Sequence Listing are employed fox screening cDNAs, mRNAs, or genomic DNA. The labeling of probe nucleotides between 100 and 1000 nucleotides in length is specifically described, but essentially the same procedure may be used with larger cDNA fragments. Probe sequences are labeled at room temperature for 30 minutes using a T4 polynucleotide kinase, y3aP-ATP, and O.SX One-Phor-All Plus (Amersham Pharmacia Biotech) buffer and purified using a ProbeQuant G-50 Microcolumn (Amersham Pharmacia Biotech). The probe mixture is diluted to 10' dpm/p.g/mI hybridization buffer and used in a typical membrane-based hybridization analysis.
to The DNA is digested with a restriction endonuclease such as Eco RV and is electrophoresed through a 0.7% agarose gel. The DNA fragments are transferred from the agarose to nylon membrane (NYTRAN Plus, Schleicher & Schuell, Inc., Keene NH) using procedures specified by the manufacturer of the membrane. Prehybridization is carried out for three or more hours at 68 °C, and hybridization is carried out overnight at 68 °C. To remove non-specific signals, blots are sequentially washed at room temperature under increasingly stringent conditions, up to 0.1x saline sodium citrate (SSC) and 0.5% sodium dodecyl sulfate. After the blots are placed in a PHOSPHORIMAGER
cassette (Molecular Dynamics) or are exposed to autoradiography film, hybridization patterns of standard and experimental lanes are compared. Essentially the same procedure is employed when screening RNA.
X. Chromosome Mapping of sptm The cDNA sequences which were used to assemble SEQ ID NO:1-567 are compared with sequences from the Tncyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that match SEQ
ID NO:1-567 are assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as PHRAP (Table 6). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Genethon are used to determine if any of the clustered sequences have been previously mapped. Inclusion of a mapped sequence in a cluster will result in the 3 o assignment of all sequences of that cluster, including its particular SEQ
ID NO:, to that map location.
The genetic map locations of SEQ ID N0:1-567 are described as ranges, or intervals, of human chromosomes, The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 3 5 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Genethon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters.
XI. Microarray Analysis s Probe Preparation from Tissue or Cell Samples Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and polyA+ RNA is purified using the oligo (dT) cellulose method. Each polyA+ RNA
sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/~,l oligo-dT primer (2lmer), 1X first strand buffer, 0.03 units/pl RNase inhibitor, 500 p.M dATP, 500 ~.M dGTP, 500 p.M
dTTP, 40 ~.M dCTP, 40 so ~,M dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng polyA+ RNA with GEMBRIGHT kits (Incyte). Specific control polyA+ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA (W. Lei, unpublished). As quantitative controls, the control mRNAs at 0.002 ng, 0.02 ng, 0.2 ng, and 2 ng are diluted into reverse transcription reaction at ratios of 1:100,000, 1:10,000, 15 1:1000, 1:100 (w/w) to sample mRNA respectively. The control mRNAs are diluted into reverse transcription reaction at ratios of 1:3, 3:1, 1:10, 10:1, 1:25, 25:1 (w/w) to sample mRNA differential expression patterns. After incubation at 37° C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85° C to the stop the reaction and degrade the RNA. Probes are purified using two 2o successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH
Laboratories, Inc.
(CLONfiECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/mI), 60 mI sodium acetate, and 300 ml of 100%
ethanol. The probe is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 p1 5X SSC/0.2% SDS.
Microarray Preparation Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts.
PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are s o amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 ~,g.
Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).
Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1 % SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4%
hydrofluoric acid (VWR
s 5 Scientific Products Corporation (VWR), West Chester, PA), washed extensively in distilled water, and coated with 0.05% axninopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C
oven.
Array elements are applied to the coated glass substrate using a procedure described in US
Patent No. 5,807,522, incorporated herein by reference. 1 ~.1 of the array element DNA, at an average s concentration of 100 ng/~1, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 n1 of array element sample per slide.
Microarrays are UV-crosslinked using a STRATALINKER W-crosslinker (Stratagene).
Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water.
Non-specific binding sites are blocked by incubation of microarrays in 0.2%
casein in phosphate so buffered saline (PBS) (Tropix, Inc., Bedford, MA) for 30 minutes at 60° C followed by washes in 0.2% SDS and distilled water as before.
Hybridization Hybridization reactions contain 9 ~.1 of probe mixture consisting of 0.2 ~.g each of Cy3 and Cy5 15 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer.
The probe mixture is heated to 65° C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cma coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 ~.l of 5x SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 2o hours at 60°C. The arrays are washed for 10 min at 45°C in a first wash buffer (1X SSC, 0.1%
SDS), three times for 10 minutes each at 45° C in a second wash buffer (0.1X SSC), and dried.
Detection Reporter-labeled hybridization complexes are detected with a microscope equipped with an 2s Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 ntn for excitation of CyS. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a 3 o resolution of 20 micrometers.
In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially.
Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT 81477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The 3 s emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for CyS. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.
The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the probe mix at a known concentration. A
specific location on the s array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two probes from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding 1 o identical amounts of each to the hybridization mixture.
The output of the photomultiplier tube is digitized using a 12-bit RTI-835H
analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood, MA) installed in an IBM-compatible PC
computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high 15 Signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.
A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. 'The fluorescence signal within each element is then 2 o integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).
XII. Complementary Nucleic Acids Sequences complementary to the sptm are used to detect, decrease, or inhibit expression of 2 s the naturally occurring nucleotide. The use of oligonucleotides comprising from about 15 to 30 base pairs is typical in the art. However, smaller or larger sequence fragments can also be used.
Appropriate oligonucleotides are designed from the sptm using OLIGO 4.06 software (National Biosciences) or other appropriate programs and are synthesized using methods standard in the art or ordered from a commercial supplier. To inhibit transcription, a complementary oIigonucleotide is s o designed from the most unique 5' sequence and used to prevent transcription factor binding to the promoter sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding and processing of the transcript.
XIII. Expression of SPTM
3 5 Expression and purification of SPTM is accomplished using bacterial or virus-based expression systems. For expression of SPTM in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the trp-lac (tac) hybrid promoter and the TS or T7 bacteriophage promoter in conjunction with the lac operator s regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express SPTM upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of SPTM in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Auto~raphica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is to replaced with cDNA encoding SPTM by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases.
Infection of the latter requires additional genetic modifications to baculovirus. (See e.g., Engelhard, 15 su ra; and S andig, su ra. ) In most expression systems, SPTM is synthesized as a fusion protein with, e.g., glutathiane S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma i_aponicum, enables the purification of fusion proteins on immobilized 2 o glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from SPTM at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak Company, Rochester NY). 6-His, a stretch of six consecutive histidine residues, enables purification 25 on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, Chapters 10 and 16). Purified SPTM obtained by these methods can be used directly in the following activity assay.
XIV. Demonstration of SPTM Activity 3 o An assay for SPTM activity measures the expression of SPTM on the cell surface. cDNA
encoding SPTM is subcloned into an appropriate mammalian expression vector suitable for high levels of cDNA expression. The resulting construct is transfected into a nonhuman cell line such as NTH3T3. Cell surface proteins are labeled with biotin using methods known in the art.
T_m_m_unoprecipitations are performed using SPTM-specific antibodies, and immunoprecipitated samples 35 are analyzed using SDS-PAGE and immunoblotting techniques. The ratio of labeled immunoprecipitant to unlabeled immunoprecipitant is proportional to the amount of SPTM expressed on the cell surface.
Alternatively, an assay for SPTM activity measures the amount of SPTM in secretory, membrane bound organelles. Transfected cells as described above are harvested and lysed. The s lysate is fractionated using methods known to those of skill in the art, for example, sucrose gradient ultracentrifugation. Such methods allow the isolation of subcellular components such as the Golgi apparatus, ER, small membrane bound vesicles, and other secretory organelles.
Itnrnunoprecipitations from fractionated and total cell lysates are performed using SPTM-specific antibodies, and immunoprecipitated samples are analyzed using SDS-PAGE and immunoblotting techniques. The 1o concentration of SPTM in secretory organelles relative to SPTM in total cell lysate is proportional to the amount of SPTM in transit through the secretory pathway.
XV. Functional Assays SPTM function is assessed by expressing sptm at physiologically elevated levels in 15 mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV
SPORT (Life Technologies) and pCR3.1 (Invitrogen Corporation, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 p.g of recombinant vector are transiently transfected into a human cell line, preferably of endothelial or hematopoietic origin, using either liposome formulations 2 0 or electroporation. 1-2 ~,g of an additional plasmid containing sequences encoding a marker protein are co-transfected.
Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector.
Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP;
CLONTECITj, CD64, or a 2 s CD64-GFP fusion protein. Flow cytometxy (FCM), an automated laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties.
FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as 3 o measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the 35 cell surface. Methods in flow cytometry are discussed in Ormerod, M. G.
(1994) Flow Cytometry, Oxford, New York NY.
The influence of SPTM on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding SPTM and either CD64 or CD64-GFP.
CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human s itnmunoglobulin G (IgG). Transfected cells are efficiently separated from nontaransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Inc., Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding SPTM and other genes of interest can be analyzed by northern analysis or microarray techniques.
XVI. Production of Antibodies SPTM substantially purified using polyacrylanude gel electrophoresis (PAGE;
see, e.g., Harrington, M.G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, can be used to immunize rabbits and to produce antibodies using standard protocols.
Alternatively, the SPTM amino acid sequence is analyzed using LASERGENE
software (DNASTAR) to determine regions of high immunogenicity, and a corresponding peptide is synthesized and used to raise antibodies by means known to those of skill in the art.
Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, sours, Chapter 11.) 2o Typically, peptides 15 residues in length are synthesized using an ABI 431A
peptide synthesizer (Applied Biosystems) using finoc-chemistry and coupled to IKT .H
(Sigma) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, su ra.) Rabbits are immunized with the peptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide activity by, for example, binding the peptide to as plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG. Antisera with antipeptide activity are tested for anti-SPTM activity using protocols well known in the art, including ELISA, RIA, and ?mmunoblotting.
XVII. Purification of Naturally Occurring SPTM Using Specific Antibodies 3 o Naturally occurring or recombinant SPTM is substantially purified by irnmunoafhnity chromatography using antibodies specific for SPTM. An immunoaffinity column is constructed by covalently coupling anti-SPTM antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked~and washed according to the manufacturer's instructions.
35 Media containing SPTM are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of SPTM (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/SPTM binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and SPTM is collected.
XVIII. Identification of Molecules Which Interact with SPTM
SPTM, or biologically active fragments thereof, are labeled with 1~I Bolton-Hunter reagent.
(See, e.g., Bolton, A.E. and W.M. Hunter (1973) Biochem. J. 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled SPTM, washed, so and any wells with labeled SPTM complex are assayed. Data obtained using different concentrations of SPTM are used to calculate values for the number, affinity, and association of SPTM with the candidate molecules.
Alternatively, molecules interacting with SPTM are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) Nature 340:245-246, or using commercially is available kits based on the two hybrid system, such as the MATCHMAKER
system (CLONTECI~.
SPTM may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K.
et al. (2000) LT.S.
Patent No. 6,057,101).
All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention.
Although the invention has been described in connection with specific embodiments, it should be 2 s understood that the invention as claimed should not be unduly limited to such specific embodiments.
Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

SEQ Template ID SEQ ID ORF ID
ID NO:
NO:

1 LG:1041015.22:2001MAR30568 LG:1041015.22.orf1:2001MAR30 2 LG:106877.10:2001MAR30569 LG:106877.10.orf3:2001MAR30 3 LG:1138554.16:2001MAR30570 LG:1138554.16.orf2:2001MAR30 4 LG:1383277.7:2001MAR30571 LG:1383277.7.orf3:2001MAR30 LG:1397614.15:2001MAR30572 LG:1397614.15.orf1:2001MAR30 6 LG:1399315.8:2001MAR30573 LG:1399315.8.orf1:2001MAR30 7 LG:198782.1:2001MAR30574 LG:198782.1.orf2a:2001MAR30 7 LG:198782.1:2001MAR30575 LG:198782.1.orf2b:2001MAR30 7 LG:198782.1:2001MAR30576 LG:198782.1.orf3:2001MAR30 8 LG:236046.1:2001MAR30577 LG:236046.1.orf2:2001MAR30 9 LG:332122.6:2001MAR30578 LG:332122.6.orf3:2001MAR30 LG:345320.16:2001MAR30579 LG:345320.16.orf1:2001MAR30 11 LG:350827.10:2001MAR30580 LG:350827.10.orf3:2001MAR30 12 LG:399901.5:2001MAR30581 LG:399901.5.orf3:2001MAR30 13 LG:404563.1:2001MAR30582 LG:404563.I.orf2:2001MAR30 14 LG:977812.15:2001MAR30583 LG:977812.15.orf2:2001MAR30 LG:983810.1:2001MAR30584 LG:983810.1.orf1:2001MAR30 16 LG:984488.1:2001MAR30585 LG:984488.1.orf1:2001MAR30 17 LG:011606.1:2001MAR30586 LG:011606.1.orf1:2001MAR30 18 LG:025465.5:2001MAR30587 LG:025465.5.orf1:2001MAR30 19 LG:025724.10:2001MAR30588 LG:025724.10.orf3:2001MAR30 LG:1095426.1:2001MAR30589 LG:1095426.1.orf3:2001MAR30 21 LG:1132418.1:2001MAR30590 LG:1132418.1.orf2:2001MAR30 22 LG:1377900.14:2001MAR30591 LG:1377900.14.orf3:2001MAR30 23 LG:1383812.1:2001MAR30592 LG:1383812.1.orf2:2001MAR30 24 LG:1468687.1:2001MAR30593 LG:1468687.1.orf3:2001MAR30 LG:1505513.1:2001MAR30594 LG:1505513.1.orf1:2001MAR30 26 LG:178823.9:2001MAR30595 LG:178823.9.orf2:2001MAR30 27 LG:198342.3:2001MAR30596 LG:198342.3.orf3:2001MAR30 28 LG:210672.1:2001MAR30597 LG:210672.I.orf1:2001MAR30 29 LG:212823.8:2001MAR30598 LG:212823.8.orf1:2001MAR30 LG:220495.9:2001MAR30599 LG:220495.9.orf2:2001MAR30 31 LG:238262.1:2001MAR30600 LG:238262.1.orf3:2001MAR30 32 LG:239410.21:2001MAR30601 LG:239410.21.orf2:2001MAR30 33 LG:245854.7:2001MAR30602 LG:245854.7.orf3:2001MAR30 34 LG:294697.1:2001MAR30603 LG:294697.I.orf3:2001MAR30 LG:345884.1:2001MAR30604 LG:345884.1.orf1:2001MAR30 36 LG:400095.15:2001MAR30605 LG:400095.15.orf1:2001MAR30 37 LG:402180.1:2001MAR30606 LG:402180.1.orf3:2001MAR30 38 LG:403401.1:2001MAR30607 LG:403401.1.orf3:2001MAR30 39 LG:411327.29:2001MAR30608 LG:411327.29.orf1:2001MAR30 LG:417464.10:2001MAR30609 LG:417464.IO.orf2:2001MAR30 41 LG:481997.1:2001MAR30610 LG:481997.1.orf1:2001MAR30 42 LG:979304.7:2001MAR30611 LG:979304.7.orf3:2001MAR30 43 LG:997964.1:2001MAR30612 LG:997964.1.orf3:2001MAR30 44 LG:998845.1:2001MAR30613 LG:998845.1.orf2:2001MAR30 LG:000014.1:2001MAR30614 LG:000014.1.orf1:2001MAR30 46 LG:000290.9:2001MAR30615 LG:000290.9.orf1:2001MAR30 47 LG:001923.1:2001MAR30616 LG:001923.1.orf3a:2001MAR30 47 LG:001923.1:2001MAR30617 LG:001923.1.orf3b:2001MAR30 48 LG:008606.21:2001MAR30618 LG:008606.21.orf3:2001MAR30 49 LG:009699.32:2001MAR30619 LG:009699.32.orf3:2001MAR30 LG:016723.6:2001MAR30620 LG:016723.6.orf1:2001MAR30 51 LG:017126.S:ZOO1MAR30621 LG:017I26.5.orf2:200IMAR30, SEQ ID Template ID SEQ ID ORF ID
NO: NO:

52 LG:019362.10:2001MAR30622 LG:019362.10.orf1:2001MAR30 53 LG:022183.1:2001MAR30623 LG:022183.1.orfz:2001MAR30 54 LG:028493.1:2001MAR30624 LG:028493.I.orf3:2001MAR30 55 LG:034197.1:2001MAR30625 LG:034197.1.orf2:2001MAR30 56 LG:054096.31:2001MAR30626 LG:054096.31.orf1:2001MAR30 57 LG:054807.3:2001MAR30627 LG:054807.3.orf2:2001MAR30 58 LG:065873.12:2001MAR30628 LG:065873.12.orf2:2001MAR30 59 LG:083814.6:2001MAR30629 LG:083814.6.orf1:2001MAR30 59 LG:083814.6:2001MAR30630 LG:083814.6.orf2:2001MAR30 60 LG:093477.1:2001MAR30631 LG:093477.1.orf3:2001MAR30 61 LG:099572.12:2001MAR30632 LG:099572.12.orf1:2001MAR30 62 LG:100396.31:2001MAR30633 LG:100396.31.orf3:2001MAR30 63 LG:1026903.5:2001MAR30634 LG:1026903.5.orf2:2001MAR30 63 LG:1026903.5:2001MAR30635 LG:1026903.5.orf3:2001MAR30 64 LG:1060168.6:2001MAR30636 LG:1060168.6.orf1:2001MAR30 65 LG:1086906.41:2001MAR30637 LG:1086906.41.orf1:2001MAR30 66 LG:1089326.18:2001MAR30638 LG:1089326.18.orf2:2001MAR30 67 LG:1090862.32:2001MAR30639 LG:1090862.32.orf3:2001MAR30 68 LG:1091941.41:2001MAR30640 LG:1091941.41.orf3:2001MAR30 69 LG:1093386.8:2001MAR30641 LG:1093386.8.orf2:2001MAR30 70 LG:1094187.33:2001MAR30642 LG:1094187.33.orf3:2001MAR30 71 LG:1098692.18:2001MAR30643 LG:1098692.18.orf2:2001MAR30 72 LG:1173104.22:2001MAR30644 LG:1173104.22.orf3:2001MAR30 73 LG:1215335.7:2001MAR30645 LG:1215335.7.orf1:2001MAR30 74 LG:1256753.1:2001MAR30646 LG:1256753.1.orf2:2001MAR30 75 LG:1326702.10:2001MAR30647 LG:1326702.10.orf2:2001MAR30 76 LG:1327239.15:2001MAR30648 LG:1327239.15.orf2:2001MAR30 77 LG:1327867.15:2001MAR30649 LG:1327867.15.orf2:2001MAR30 78 LG:1383232.1:2001MAR30650 LG:1383232.1.orf1:2001MAR30 79 LG:1383368.40:2001MAR30651 LG:1383368.40.orf2:2001MAR30 80 LG:1384477.1:2001MAR30652 LG:1384477.1.orf2:2001MAR30 81 LG:1390822.1:2001MAR30653 LG:1390822.1.orf1:2001MAR30 82 LG:1398274.13:2001MAR30654 LG:1398274.13.orf3:2001MAR30 83 LG:1398646.1:2001MAR30655 LG:1398646.1.orf2:2001MAR30 84 LG:1398905.1:2001MAR30656 LG:1398905.1.orf1:2001MAR30 84 LG:1398905.1:2001MAR30657 LG:1398905.1.orf2:2001MAR30 85 LG:1399785.1:2001MAR30658 LG:1399785.1.orf1:2001MAR30 86 LG:1446193.10:2001MAR30659 LG:1446193.10.orf1:2001MAR30 87 LG:1446210.8:2001MAR30660 LG:1446210.8.orf1:2001MAR30 88 LG:1450054.6:2001MAR30661 LG:1450054.6.orf2:2001MAR30 89 LG:1452516.4:2001MAR30662 LG:1452516.4.orf3:2001MAR30 90 LG:1455293.7:2001MAR30663 LG:1455293.7.orf2:2001MAR30 91 LG:1498113.1:2001MAR30664 LG:1498113.1.orf1:2001MAR30 92 LG:1500042.1:2001MAR30665 LG:1500042.1.orf1:2001MAR30 93 LG:1500434.4:2001MAR30666 LG:1500434.4.orf3:2001MAR30 94 LG:1501102.4:2001MAR30667 LG:1501102.4.orf3:2001MAR30 95 LG:1501768.2:2001MAR30668 LG:1501768.2.orf1:2001MAR30 96 LG:1502155.6:2001MAR30669 LG:1502155.6.orf1:2001MAR30 97 LG:1512304.2:2001MAR30670 LG:1512304.2.orf3:2001MAR30 98 LG:1512931.11:2001MAR30671 LG:1512931.II.orf3:2001MAR30 99 LG:155076.18:2001MAR30672 LG:155076.18.orf3:2001MAR30 100 LG:159111.41:2001MAR30673 LG:159111.41.orf3:2001MAR30 101 LG:170604.1:2001MAR30674 LG:170604.I.orf3:2001MAR30 102 LG:190477.4:2001MAR30675 LG:190477.4.orf3:2001MAR30 SEQ ID Template ID SEQ ID ORF ID
NO: NO:

103 LG:198087.8:2001MAR30676 LG:198087.8.orf2:2001MAR30 104 LG:198743.2:2001MAR30677 LG:198743.2.orf3:2001MAR30 105 LG:199194.1:2001MAR30678 LG:199194.1.orf2:2001MAR30 106 LG:200727.6:2001MAR30679 LG:200727.6.orf2:2001MAR30 107 LG:201572.20:2001MAR30680 LG:201572.20.orf1:2001MAR30 108 LG:201669.25:2001MAR30681 LG:201669.25.orf3:2001MAR30 109 LG:208588.4:2001MAR30682 LG:208588.4.orf1:2001MAR30 110 LG:210412.29:2001MAR30683 LG:210412.29.orf1:2001MAR30 111 LG:215051.15:2001MAR30~684 LG:215051.15.orf1:2001MAR30 112 LG:215475.21:2001MAR30685 LG:215475.21.orf1:2001MAR30 113 LG:224523.1:2001MAR30686 LG:224523.1.orf1:2001MAR30 114 LG:228186.1:2001MAR30687 LG:228186.I.orfZ:2001MAR30 115 LG:233138.2:2001MAR30688 LG:233138.2.orf2:2001MAR30 116 LG:234811.10:2001MAR30689 LG:234811.10.orf2:2001MAR30 117 LG:236092.1:2001MAR30690 LG:236092.I.orf2:2001MAR30 118 LG:236098.12:2001MAR3069I LG:236098.12.orf1:2002MAR30 119 LG:236697.15:2001MAR30692 LG:236697.15.orf1:2001MAR30 120 LG:237503.21:2001MAR30693 LG:237503.21.orf3:2001MAR30 121 LG:238023.7:2001MAR30694 LG:238023.7.orf2:2001MAR30 122 LG:238209.1:2001MAR30695 LG:238209.1.orf2:2001MAR30 123 LG:238456.10:2001MAR30696 LG:238456.10.orf3:2001MAR30 124 LG:239245.1:2001MAR30697 LG:239245.1.orf3:2001MAR30 125 LG:239579.8:2001MAR30698 LG:239579.8.orf3:2001MAR30 126 LG:239601.22:2001MAR30699 LG:239601.22.orf1:2001MAR30 126 LG:239601.22:2001MAR30700 LG:239601.22.orf3:2001MAR30 127 LG:240121.1:2001MAR30701 LG:240121.1.orf3:2001MAR30 128 LG:241110.2:2001MAR30702 LG:241110.2.orf3:2001MAR30 129 LG:244948.4:2001MAR30' 703 LG:244948.4.orf3:2001MAR30 130 LG:245378.6:2001MAR30704 LG:245378.6.orf3:2001MAR30 131 LG:248203.9:2001MAR30705 LG:248203.9.orf1:2001MAR30 132 LG:249247.1:2001MAR30706 LG:249247.1.orf3:2001MAR30 133 LG:267153.16:2001MAR30707 LG:267153.16.orf2:2001MAR30 134 LG:291759.5:2001MAR30708 LG:291759.5.orf2:2001MAR30 135 LG:298102.1:2001MAR30709 LG:298102.I.orf1:200IMAR30 136 LG:308891.1:2001MAR30710 LG:308891.1.orf2:2001MAR30 137 LG:312668.4:2001MAR30711 LG:312668.4.orf1:2001MAR30 138 LG:331642.6:2001MAR30712 LG:331642.6.orf2:200IMAR30 139 LG:331851.12:2001MAR30713 LG:331851.12.orf3:2001MAR30 140 LG:332414.5:2001MAR30714 LG:332414.5.orf2:2001MAR30 141 LG:332730.12:2001MAR30715 LG:332730.12.orf2:2001MAR30 142 LG:333062.22:2001MAR30716 LG:333062.22,orf2:2001MAR30 143 LG:335705.2:2001MAR30717 LG:335705.2.orf2:2001MAR30 144 LG:337930.16:2001MAR30718 LG:337930.16.orf2:2001MAR30 145 LG:346481.15:2001MAR30719 LG:346481.15.orf1:2001MAR30 146 LG:349164.1:2001MAR30720 LG:349164.1.orf3:2001MAR30 147 LG:350957.5:2001MAR30721 LG:350957.5.orf1:2001MAR30 148 LG:383512.8:2001MAR30722 LG:383512.8.orf1:2001MAR30 149 LG:401163.10:2001MAR30723 LG:401163.IO.orf1:2001MAR30 150 LG:402133.1:2001MAR30724 LG:402133.I.orf1:2001MAR30 151 LG:405820.1:2001MAR30725 LG:405820.1.orf2:2001MAR30 152 LG:405846.1:2001MAR30726 LG:405846.I.orf3:2001MAR30 153 LG:407401.2:2001MAR30727 LG:407401.2.orf2:2001MAR30 154 LG:408448.10:2001MAR30728 LG:408448.IO.orf3:2001MAR30 155 LG:408854.13:2001MAR30729 LG:408854.13.orf2:2001MAR30 SEQ ID Template ID SEQ ID ORF ID
NO: N0:

156 LG:411150.14:2001MAR30730 LG:411150.14.orf2:2001MAR30 157 LG:411466.1:2001MAR30731 LG:411466.1.orf2:2001MAR30 158 LG:413969.68:2001MAR30732 LG:413969.68.orf1:2001MAR30 159 LG:419641.35:2001MAR30733 LG:419641.35.orf1:2001MAR30 160 LG:428206.7:2001MAR30734 LG:428206.7.orf2:200IMAR30 161 LG:430059.1:2001MAR30735 LG:430059.1.orf3:2001MAR30 162 LG:448040.3:2001MAR30736 LG:448040.3.orf2:2001MAR30 163 LG:451274.1:2001MAR30737 LG:451274.1.orf3:2001MAR30 164 LG:456110.1:2001MAR30738 LG:456110.1.orf1:2001MAR30 165 LG:456954.1:2001MAR30739 LG:456954.1.orf3:2001MAR30 166 LG:474942.12:200IMAR30740 LG:474942.12.orf3:200IMAR30 167 LG:475119.14:2001MAR30741 LG:475119.14.orf1:2001MAR30 168 LG:479908.77:2001MAR30742 LG:479908.77.orf3:2001MAR30 169 LG:480127.47:2001MAR30743 LG:480127.47.orf3:2001MAR30 170 LG:481154.12:2001MAR30744 LG:481154.12.orf1:2001MAR30 171 LG:481414.6:2001MAR30745 LG:481414.6.orf2:2001MAR30 172 LG:481941.1:2001MAR30746 LG:481941.1.orf3:2001MAR30 173 LG:887216.4:2001MAR30747 LG:887216.4.orf3:2001MAR30 174 LG:899402.3:2001MAR30748 LG:899402.3.orf1:2001MAR30 175 LG:899894.2:2001MAR30749 LG:899894.2.orf3:2001MAR30 176 LG:977908.1:2001MAR30750 LG:977908.1.orf3:2001MAR30 177 LG:977929.1:2001MAR30751 LG:977929.1.orf1:2001MAR30 178 LG:978008.14:2001MAR30752 LG:978008.14.orf3:2001MAR30 179 LG:979054.18:2001MAR30.~ 753 LG:979054.18.orf1:2001MAR30 180 LG:979185.10:2001MAR30.754 LG:979185.10.orf1:2001MAR30 181 LG:983654.1:2001MAR30755 LG:983654.1.orf2:2001MAR30 182 LG:985092.12:2001MAR30756 LG:985092.12.orf3:2001MAR30 183 LG:987396.8:2001MAR30757 LG:987396.8.orf2:2001MAR30 184 LG:987418.10:2001MAR30758 LG:987418.10.orf2:2001MAR30 184 LG:987418.10:2001MAR30759 LG:987418.10.orf3:2001MAR30 185 LG:997203.25:2001MAR30760 LG:997203.25.orf3:2001MAR30 186 LG:997477.8:2001MAR30761 LG:997477.8.orf3:2001MAR30 187 LG:998855.4:2001MAR30762 LG:998855.4.orf1:2001MAR30 188 LG:999093.1:2001MAR30763 LG:999093.1.orf2:2001MAR30 189 LG:999183.I:2001MAR30764 LG:999183.I.orf3:2001MAR30 190 LI:1032972.1:2001MAY17765 LI:1032972.1.orf1:2001MAY17 191 LI:170666.6:2001MAY17766 LI:170666.6.orf2:2001MAY17 192 LI:197048.10:2001MAY17767 LI:197048.10.orf3:2001MAY17 193 LI:228655.5:2001MAY17768 LI:228655.5.orf3:2001MAY17 194 LI:229789.6:2001MAY17769 LI:229789.6.orf3:2001MAY17 195 LI:231500.8:2001MAY770 LI:231500.8.orf 1:2001 196 LI:253851.26:2001MAY1777I LI:253851.26.orf3:2001MAY17 197 LI:373302.1:2001MAY17772 LI:373302.1.orf1:2001MAY17 198 LI:405707.12:2001MAY17773 LI:405707.12.orf2:2001MAY17 199 LI:411441.8:2001MAY17774 LI:411441.8.orf3:2001MAY17 200 LI:758193.3:2001MAY17775 LI:758193.3.orf2:2001MAY17 201 LI:1028562.3:2001MAY17776 LI:1028562.3.orf2:2001MAY17 202 LI:104650.7:2001MAY17777 LI:104650.7.orf3:2001MAY17 203 LI:1094557.4:2001MAY17778 LI:1094557.4.orf3:2001MAY17 204 LI:1143528.4:2001MAY17779 LI:I143528.4.orf2:2001MAYI7 205 LI:1172210.7:2001MAY17780 LI:1172210.7.orf2:2001MAY17 206 LI:1178659.14:2001MAY17781 LI:1178659.14.orf1:2001MAY17 207 LI:1983726.3:2001MAY17782 LI:1983726.3.orf3:2001MAY17 208 LI:2051495.3:2001MAY17783 LI:2051495.3.orf2:2001MAY17 SEQ ID Template ID SEQ ID ORF ID
NO: NO:

209 LI:2117629.1:2001MAY17784 LI:2117629.1.orf3:2001MAY17 210 LI:2118007.3:2001 785 LI:2118007.3.orf3:2001 211 LI:2118292.9:2001MAY17786 LI:2118292.9.orf1:2001MAY17 212 LI:2118733.7:2001MAY17787 LI:2118733.7.orf1:2001MAY17 213 LI:212702.3:2001MAY17788 LI:212702.3.orf1:2001MAY17 214 LI:2207871.10:2001MAY17789 LI:2207871.10.orf2:2001MAY17 215 LI:2207876.5:2001MAY17790 LI:2207876.S.orf1:2001MAY17 215 LI:2207876.5:2001MAY17791 LI:2207876.5.orf2:2001MAY17 216 LI:2208743.1:2001MAY17792 LI:2208743.1.orf3:2001MAY17 217 LI:2208744.1:2001MAY17793 LI:2208744.1.orf2:2001MAY17 218 LI:230905.3:2001MAY17794 LI:230905.3.orf2:2001MAY17 219 LI:235233.95:2001MAY17795 LI:235233.95.orf3:2001MAY17 220 ' LI:235359.24:2001MAY17796 LI:235359.24.orf3:2001MAY17 221 LI:238365.6:2001MAY17797 LI:238365.6.orf2:2001MAY17 222 LI:260259.23:200IMAY17798 LI:260259.23.orfZ:2001MAYI7 223 LI:321069.2:2001MAY17799 LI:321069.2.orf1:2001MAY17 224 LI:331499.8:2001MAY17800 LI:331499.8.orf1:2001MAY17 225 LI:332176.8:2001MAY17801 LI:332176.8.orfZ:2001MAY17 226 LI:333952.7:2001MAY17802 LI:333952.7.orf1:2001MAY17 227 LI:338428.2:2001MAY17803 LI:338428.2.orf3:2001MAY17 228 LI:343869.2:2001MAY17804 LI:343869.2.orf3:2001MAY17 229 LI:363532.1:2001MAY17805 LI:363532.1.orf1:2001MAY17 230 LI:398153.37:2001MAY17806 LI:398153.37.orf3:2001MAY17 231 LI:416650.1:2001MAY17807 LI:416650.1.orf3:2001MAY17 232 LI:444767.32:2001MAY17:. 808 LI:444767.32.orf2:2001MAY17 233 LI:759073.1:2001MAY17.809 ~ LI:759073.1.orf1:2001MAY17 .

234 LI:759902.4:2001MAY17810 LI:759902.4.orf3:2001MAY17 , 235 LI:762268.1:2001MAY17' 811 LI:762268.1.orf1:200IMAY17 ~

236 LI:813699.1:2001MAY17- 812 ~ LI:813699.1.orf3:2001MAY17 237 LI:024142.16:2001MAY17813 LI:024142.16.orf2:2001MAY17 238 LI:1018424.4:2001MAY17814 LI:1018424.4.orfZ:2001MAY17 239 LI:1085250.6:2001MAY17815 LI:1085250.6.orf1:2001MAY17 240 LI:179233.63:2001MAY17816 LI:I79233.63.orf2:2001MAY17 241 LI:2207125.3:2001MAY17817 LI:2207125.3.orf3:2001MAY17 242 LI:235153.44:2001MAY17818 LI:235153.44.orf1:2001MAY17 243 LI:007101.10:2001MAY17' 819 LI:007101.10.orf1:2001MAY17 244 LI:008541.2:2001MAY17820 LI:008541.2.orf3:2001MAY17 245 LI:009658.13:2001MAY17821 LI:009658.13.orf1:2001MAY17 246 LI:020012.14:2001MAY822 LI:020012. l4.orf3:2001 247 LI:020691.1:2001MAY17823 LI:020691.I.orf1:2001MAY17 248 LI:021188.12:200IMAY17824 LI:021188.12.orf2:2001MAY17 249 LI:021324.4:2001MAY17825 LI:021324.4.orf3:2001MAY17 250 LI:021834.15:2001MAY17826 LI:021834.15.orf1:2001MAY17 251 LI:024841.1:2001MAY17827 LI:024841.I.orf1:2001MAY17 252 LI:025724.12:2001MAY17828 LI:025724.12.orf2:2001MAY17 253 LI:029328.2:2001MAY17829 LI:029328.2.orf2:2001MAY17 254 LI:032171.5:2001MAY17830 LI:032171.5.orf2:2001MAY17 255 LI:035055.1:2001MAY17831 LI:035055.1.orf2a:2001MAY17 255 LI:035055.1:2001MAY17832 LI:035055.1.orf2b:2001MAY17 256 LI:036747.17:200IMAY17833 LI:036747.I7.orf2:2001MAYI7 257 LI:044301.2:2001MAY17834 LI:044301.2.orf3:2001 258 LI:061585.10:2001MAY17835 LI:061585.10.orf3:2001MAY17 259 LI:066742.21:2001MAY17836 LI:066742.21.orf2:2001MAY17 260 LI:075492.206:2001MAY17837 LI:075492.206.orf2:2001MAY17 SEQ ID Template ID SEQ ID ORF ID
NO: NO:

261 LI:090782.3:2001MAY17838 LI:090782.3.orf1:2001MAY17 262 LI:1031308.1:2001MAY17839 LI:1031308.1.orf2:2001MAY17 263 LI:lOS4377.1:2001MAY17840 LI:1054377.I.orf2:2001MAY17 264 LI:1072074.10:2001MAY17841 LI:1072074.10.orf2:2001MAY17 265 LI:1072889.15:2001MAY17842 LI:1072889.15.orf3:2001MAY17 266 LI:1077480.1:2001MAY17843 LI:1077480.1.orf3:2001MAY17 267 LI:1079555.1:2001MAY17844 LI:1079555.1.orf2:2001MAY17 268 LI:1084992.28:2001MAY17845 LI:1084992.28.orf2:2001MAY17 269 LI:108S472.5:2001MAY17846 LI:1085472.S.orf1:2001MAY17 270 LI:1086800.7:2001MAY17847 LI:1086800.7.orf2:2001MAY17 271 LI:1089871.9:2001MAY17848 LI:1089871.9.orf2:2001MAY17 272 LI:110297.6:2001MAY17849 LI:110297.6.orf2:2001MAY17 273 LI:1143463.8:2001MAY17850 LI:1143463.8.orf1:2001MAY17 274 LI:1144466.1:2001MAY17851 LI:1144466.1.orf2:2001MAY17 275 LI:1170624.2:2001MAY17852 LI:1170624.2.orf2:2001MAY17 276 LI:1171602.39:2001MAY17853 LI:1171602.39.orf2:2001MAY17 277 LI:1182361.3:2001MAY178S4 LI:1182361.3.orf1:2001MAY17 278 LI:1188194.15:2001MAY17855 LI:1188194.15.orf1:2001MAY17 279 LI:1189195.7:2001MAY17856 LI:1189195.7.orf3:2001MAY17 280 LI:1190092.13:2001MAY17857 LI:1190092.13.orf3:2001MAY17 281 LI:1190318.4:2001MAY178S8 LI:1190318.4.orf2:2001MAY17 282 LI:144233.1:2001MAY17859 LI:144233.1.orf3:2001MAY17 283 LI:154608.1:2001MAY17860 LI:154608.1.orf2:2001MAY17 284 LI:170101.1:2001MAY17861. LI:170101.1.orf2:2001MAY17 285 LI:180043.1:2001MAY17862 LI:180043.1.orfI:2001MAY17 286 LI:193050.1:2001MAY17- 863 LI:193050.1.orf2:2001MAY17 287 LI:197477.31:2001MAY17.864 ~ LI:197477.31.orf1:2001MAY17 288 LI:199639.12:2001MAY17865 LI:199639.I2.orfI:2001MAYI7 289 LI:200058.6:2001MAY17866 ~' LI:200058.6.orf3:2001MAY17 290 LI:201374.23:2001MAY17867 LI:201374.23.orf2:2001MAY17 291 LI:201824.1:2001MAY17868 LI:201824.1.orf2:2001MAY17 292 LI:201989.11:2001MAY17869 LI:201989.11.orf2:2001MAY17 293 LI:2035159.1:2001MAY17870 LI:2035159.1.orf3:2001MAY17 294 LI:204818.10:2001MAY17871 LI:204818.10.orf1:2001MAY17 295 LI:2048337.1:2001MAY17872 LI:2048337.1.orf3:2001MAY17 296 LI:2049697.4:2001MAY17873 LI:2049697.4.orf3:2001MAY17 297 LI:2050808.19:2001MAY17874 LI:2050808.19.orf2:2001MAY17 298 LI:209773.25:2001MAY17875 LI:209773.25.orf3:2001MAY17 299 LI:2117881.32:2001MAY17876 LI:2117881.32.orf2:2001MAY17 300 LI:2118140.9:2001MAY17877 LI:2118140.9.orf1:2001MAY17 301 LI:2118151.15:2001MAY17878 LI:2118151.15.orf2:2001MAY17 302 LI:2118324.9:2001MAY17879 LI:2118324.9.orf2:2001MAY17 303 LI:2118368.12:2001MAY17880 LI:2118368.12.orf2:2001MAY17 304 LI:2119448.5:2001MAY17881 LI:2119448.5.orf3:2001MAY17 305 LI:212023.7:2001MAY17882 LI:212023.7.orf2:2001MAY17 306 LI:2120556.1:2001MAY17883 LI:2120556.I.orf2:2001MAY17 307 LI:2121577.3:2001MAY17884 LI:2121577.3.orf3:2001MAY17 308 LI:2123395.11:2001MAY17885 LI:2123395.11.orf3:2001MAY17 309 LI:2123452.9:2001MAY17886 LI:2123452.9.orf2:2001MAY17 3I0 LI:2164109.1:2001MAY17887 LI:2164I09.1.orf3:2001MAY17 311 LI:2168320.1:2001MAY17888 LI:2168320.1.orf1:2001MAY17 312 LI:2173577.1:2001MAY17889 LI:2173577.1.orf1:2001MAY17 313 LI:2179256.1:2001MAY17890 LI:2179256.1.orf1:2001MAY17 314 LI:2180388.1:2001MAY17891 LI:2180388.1.orf1:2001MAY17 SEQ ID Template ID SEQ ID ORF ID
NO: NO:

315 LI:2199713.8:2001MAY17892 LI:2199713.8.orf1:2001MAY17 316 LI:2200587.2:2001MAY17893 LI:2200587.2.orf1:2001MAY17 317 LI:2200761.12:2001MAY17894 LI:2200761.12.orf2:2001MAY17 318 LI:2203624.1:2001MAY17895 LI:2203624.1.orf2:2001MAY17 319 LI:220495.9:2001MAY17896 LI:220495.9.orf2:2001MAY17 320 LI:2205532.1:2001MAY17897 LI:2205532.1.orf3:2001MAY17 321 LI:2206277.1:2001MAY17898 LI:2206277.1.orf3:2001MAY17 322 LI:2207765.8:2001MAY17899 LI:2207765.8.orf3:2001MAY17 323 LI:2208404.4:2001MAY17900 LI:2208404.4.orf2:2001MAY17 324 LI:2208715.3:2001MAY17901 LI:2208715.3.orf1:2001MAY17 325 LI:2208766.2:2001MAY17902 LI:2208766.2.orf3:2001MAY17 326 LI:2209636.3:2001MAY17903 LI:2209636.3.orf1:2001MAY17 327 LI:221864.68:2001MAY17904 LI:221864.68.orf1:2001MAY17 328 LI:229267.1:2001MAY17905 LI:229267.1.orf3:2001MAY17 329 LI:229648.2:2001MAY17906 LI:229648.2.orf1:2001MAY17 330 LI:231016.1:2001MAY17907 LI:231016.1.orf3:2001MAY17 331 LI:231140.5:2001MAY17~ 908 LI:231140.5.orf1:2001MAY17 332 LI:231695.14:2001MAY17909 LI:231695.14.orf3:2001MAY17 333 LI:232846.24:2001MAY17910 LI:232846.24.orf3:2001MAY17 334 LI:233411.11:2001MAY17911 LI:233411.11.orf3:2001MAY17 335 LI:233545.13:2001MAY17912 LI:233545.13.orf3:2001MAY17 336 LI:234671.101:2001MAY17913 LI:234671.1O1.orf3:2001MAY17 337 LI:236098.14:2001MAY17914 LI:236098.14.orf3:2001MAY17 338 LI:236196.15:2001MAY17915 , LI:236196.15.orf1:2001MAY17 339 LI:237086.1:2001MAY17916 LI:237086.1.orf2:2001MAY17 340 LI:238585.30:2001MAY17917 ' LI:238585.30.orf2:2001MAY17 341 LI:238672.6:2001MAY17918 LI:238672.6.orf2:2001MAY17 342 LI:239579.9:2001MAY17919 LI:239579.9.orf2:2001MAY17 343 LI:239720.1:2001MAY17920 ~ LI:239720,1.orf3:2001MAY17 .

344 . LI:240037.6:2001MAY17921 LI:240037.6.orf2:2001MAY17 345 LI:243900.7:2001MAY17922 LI:243900.7.orf3:2001MAY17 346 LI:244378.1:2001MAY17923 LI:244378.1.orf2:2001MAY17 347 LI:245500.3:2001MAY17924 LI:245500.3.orf1:2001MAY17 348 LI:245982.24:2001MAY17925 LI:245982.24.orf2:2001MAY17 349 LI:246054.1:2001MAY17926 LI:246054.1.orf3:2001MAY17 350 LI:256051.229:2001MAY17927 LI:256051.229.orf3:2001MAY17 351 LI:260629.7:2001MAY17928 LI:260629.7.orf1:2001MAY17 352 LI:272723.1:2001MAY17929 LI:272723.1.orf3a:2001MAY17 352 LI:272723.1:2001MAY17930 LI:272723.1.orf3b:2001MAY17 353 LI:272766.1:2001MAY17931 LI:272766.1.orf2:2001MAY17 354 LI:275726.1:2001MAY17932 LI:275726.1.orf2:2001MAY17 355 LI:276815.1:2001MAY17933 LI:276815.1.orf2:2001MAY17 356 LI:283562.5:2001MAY17934 LI:283562.5.orf3:2001MAY17 357 LI:289066.15:2001MAY17935 LI:289066.15.orf3:2001MAY17 358 LI:331040.17:2001MAY17936 LI:331040.17.orf1:2001MAY17 359 LI:332414.5:2001MAY17937 LI:332414.5.orf1:2001MAY17 360 LI:332730.16:2001MAY17938 LI:332730.16.orf2:2001MAY17 361 LI:333849.21:2001MAY17939 LI:333849.21.orf3:2001MAY17 362 LI:337038.15:2001MAY17940 LI:337038.15.orf1:2001MAY17 363 LI:337606.6:2001MAY17941 LI:337606.6.orf2:2001MAY17 364 LI:338032.10:2001MAY17942 LI:338032.10.orf2:2001MAY17 365 LI:339265.16:2001MAY17943 LI:339265.16.orf3:2001MAY17 366 LI:344646.4:2001MAY17944 LI:344646.4.orf3:2001MAY17 367 LI:347393.7:2001MAY17945 LI:347393.7.orf2:2001MAY17 , SEQ ID Template ID SEQ ID ORF ID
NO: NO:

368 LI:348107.36:2001MAY17946 LI:348107.36.orf3:2001MAY17 369 LI:351120.6:2001MAY17947 LI:351120.6.orf3:2001MAY17 370 LI:358762.41:2001MAY17948 LI:358762.41.orf3:2001MAY17 371 LI:363003.48:2001MAY17949 LI:363003.48.orf2:2001MAY17 372 LI:370899.6:2001MAY17950 LI:370899.6.orf1:2001MAY17 373 LI:376470.1:2001MAY17951 LI:376470.1.orf2:2001MAY17 374 LI:400961.18:2001MAY17952 LI:400961.18.orf1:2001MAY17 375 LI:404482.20:2001MAY17953 LI:404482.20.orf3:2001MAY17 376 LI:405985.1:2001MAY17954 LI:405985.1.orf2:2001MAY17 377 LI:406389.1:2001MAY17955 LI:406389.1.orf2:2001MAY17 378 LI:406833.1:2001MAY17956 LI:406833.1.orf2:2001MAY17 379 LI:407921.3:2001MAY17957 LI:407921.3.orf1:2001MAY17 380 LI:409078.54:2001MAY17958 LI:409078.54.orf3:2001MAY17 381 LI:423601.6:2001MAY17959 LI:423601.6.orf3:2001MAY17 382 LI:425024.5:2001MAY17960 LI:425024.S.orf1:2001MAY17 383 LI:427909.29:2001MAY17961 LI:427909.29.orf1:2001MAY17 384 LI:428198.20:2001MAY17962 LI:428198.20.orf3:2001MAY17 385 LI:429738.6:2001MAY17963 ~ LI:429738.6.orf3:2001MAY17 386 LI:449437.1:2001MAY17964 LI:449437.1.orf1:2001MAY17 387 LI:459269.25:2001MAY17965 LI:459269.25.orf1:2001MAY17 388 LI:464206.1:2001MAY17966 LI:464206.1.orf3:2001MAY17 389 LI:465821.2:2001MAY17967 LI:465821.2.orf1:2001MAY17 390 LI:474414.28:2001MAY17968 LI:474414.28.orf1:2001MAY17 391 LI:474435.14:2001MAY17969 LI:474435:14.orf2:2001MAY17 392 LI:474458.11:2001MAY17970 LI:474458.11.orf3:2001MAY17 393' LI:477127.18:2001MAY17971 L:I:477127.18.orf3:2001MAY17 394 LI:480375.55:2001MAY17972 LI:480375:SS.orf3:2001MAY17 395 LI:480467.24:2001MAY17973 LI:480467:24.orf2,:2001MAY17 396 LI:480587.1:2001MAY17974 LI:480587.1.orf3:2001MAY17 397 LI:480798.13:2001MAY17975 LI:480798.13.orf2:2001MAY17 398 LI:481203.14:2001MAY17976 LI:481203.14.orf1:2001MAY17 399 LI:481237.11:2001MAY17977 LI:481237.11.orf1:2001MAY17 400 LI:481368.12:2001MAY17978 LI:481368.12.orf3:2001MAY17 401 LI:482301.8:2001MAY17979 LI:482301.8.orf3:2001MAY17 402 LI:482482.29:2001MAY17980 LI:482482.29.orf1:2001MAY17 403 LI:758877.26:2001MAY17981 LI:758877.26.orf3:2001MAY17 404 LI:791042.1:2001MAY17982 LI:791042.1.orf3:2001MAY17 405 LI:808999.26:2001MAY17983 LI:808999.26.orf3:2001MAY17 406 LI:815715.10:2001MAY17984 LI:815715.10.orf1:2001MAY17 407 LI:902980.16:2001MAY17985 LI:902980.16.orf3:2001MAY17 408 LI:903196.25:2001MAY17986 LI:903196.25.orf2:2001MAY17 409 LI:903914.10:2001MAY17987 LI:903914.10.orf2:2001MAY17 410 LG:006764.2:2001JUN22~ 988 LG:006764.2.orf2:2001JUN22 411 LG:014704.8:2001JUN22989 LG:014704.8.orf3:2001JUN22 412 LG:1447607.7:2001JUN22990 LG:1447607.7.orf1:2001JUN22 413 LG:1455032.3:2001JUN22991 LG:1455032.3.orf2:2001JUN22 414 LG:1501898.18:2001JUN22992 LG:1501898.18.orf1:2001JUN22 415 LG:1502692.5:2001JUN22993 LG:1502692.S.orf2:2001JUN22 416 LG:208949.8:2001JUN22994 LG:208949.8.orf2:2001JUN22 417 LG:240501.10:2001JUN22995 LG:240501.10.orf3:2001JUN22 418 LG:329228.27:2001JLTN22996 LG:329228.27.orf2:2001JUN22 419 LG:337056.11:2001JUN22997 LG:337056.11.orf2:2001JUN22 420 LG:346663.9:2001JUN22998 LG:346663.9.orf3:2001JUN22 421 LG:7685586.2:2001JUN22999 LG:7685586.2.orf3:2001JUN22 SEQ ID Template ID SEQ ID ORF ID
NO: NO:

422 LG:407730.13:2001JUN221000 LG:407730.13.orf1:2001JUN22 423 LG:025465.5:2001JUN221001 LG:025465.5.orf3:2001JUN22 424 LG:054509.14:2001JUN221002 LG:054509.14.orf3:2001JUN22 425 LG:1067876.1:2001JUN221003 LG:1067876.1.orf1:2001JUN22 426 LG:1327699.55:2001JUN221004 LG:1327699.55.orf3:2001JUN22 427 LG:1482904.10:2001JUN221005 LG:1482904.10.orf3:2001JUN22 428 LG:222317.4:2001JUN221006 LG:222317.4.orf2:2001JUN22 429 LG:332701.3:2001JUN221007 LG:332701.3.orf1:2001JUN22 430 LG:369881.5:2001JUN221008 LG:369881.5.orf1:2001JUN22 431 LG:404381.2:2001JUN221009 LG:404381.2.orfZ:2001JUN22 432 LG:405709.2:2001JUN221010 LG:405709.2.orf2:2001JUN22 433 LG:406664.17:2001JUN221011 LG:406664.17.orf3:2001JUN22 434 LG:7670681.1:2001JUN221012 LG:7670681.1.orf1:2001JUN22 435 LG:7687404.1:2001JUN221013 LG:7687404.1.orfZ:2001JUN22 436 LG:7690030.24:2001JUN221014 LG:7690030.24.orf3:2001JUN22 437 LG:7690229.3:2001JUN221015 LG:7690229.3.orf1:2001JUN22 438 LG:7690533.16:2001JUN221016 LG:7690533.16.orf3:2001JUN22 439 LG:7691131.2:2001JUN221017 LG:7691131.2.orf3:2001JUN22 440 LG:7692559.6:2001JUN221018 LG:7692559.6.orf3:2001JUN22 441 LG:7684866.10:2001JLTN221019 LG:7684866.10.orf2:2001JUN22 442 LG:002106.5:2001JUN221020 LG:002106.S.orf1:2001JUN22 443 LG:004064.1:2001JUN221021 LG:004064.1.orf2:2001JUN22 444 LG:007916.8:2001JUN221022 LG:007916.8.orf2:2001JUN22 445 LG:014719.14:2001JUN221023 LG:014719.14.orf3:2001JUN22 446 LG:021763.31:2001JLTN221024 LG:OZI763.31.orf3:2001JUN22 447 LG:025397.1:2001JUN221025 LG:025397.1.orf3:2001JUN22 448 LG:029880.20:2001JUN221026 LG:029880.20.orf2:2001JUN22 449 LG:040422.37:2001JUN221027 LG:040422.37.orf1:2001JUN22 450 LG:065935.11:2001JUN221028 LG:065935.11.orf2:2001JUN22 451 LG:074381.1:2001JUN221029 LG:074381.1.orf2:2001JUN22 452 LG:083814.6:2001JUN221030 LG:083814.6.orf3:2001JUN22 453 LG:090985.1:2001JUN221031 LG:090985.1.orf2:2001JUN22 454 LG:093750.2:2001JUN221032 LG:093750.2.orf3:2001JUN22 455 LG:1013708.26:2001JUN221033 LG:1013708.26.orf1:2001JUN22 456 LG:1022283.8:2001JUN221034 LG:1022283.8.orf1:2001JUN22 457 LG:1034386.1:2001JUN221035 LG:1034386.1.orf3:2001JUN22 458 LG:1045617.36:2001JUN221036 LG:1045617.36.orf1:2001JUN22 459 LG:1063303.1:200IJUN221037 LG:1063303.1.orf1:2001JUN22 460 LG:1094200.1:2001JUN221038 LG:1094200.1.orf1:2001JUN22 461 LG:1099249.19:2001JUN221039 LG:1099249.19.orf3:2001JUN22 462 LG:110667.1:2001JUN221040 LG:110667.1.orf1:2001JUN22 463 LG:1132386.20:2001JUN221041 LG:1132386.20.orf2:2001JUN22 464 LG:116015.2:2001JUN221042 LG:116015.2.orf1:2001JUN22 465 LG:1173104.15:2001JUN221043 LG:1173104.15.orf3:2001JUN22 466 LG:1285109.14:2001JUN221044 LG:1285109.14.orf3:2001JUN22 467 LG:131477.11:2001JUN221045 LG:131477.11.orf3:2001JUN22 468 LG:1333618.1:2001JUN221046 LG:1333618.1.orf2:2001JUN22 469 LG:1347760.16:2001JUN221047 LG:1347760.16.orf1:2001JUN22 470 LG:1383039.369:2001JUN221048 LG:1383039.369.orf3:2001JUN22 471 LG:1383313.3:2001JUN221049 LG:1383313.3.orf3:2001JUN22 472 LG:1384075.8:2001JUN221050 LG:1384075.8.orf2:2001JUN22 473 LG:1384155.1:2001JUN221051 LG:1384155.1.orf1:2001JUN22 474 LG:1385280.12:2001JUN221052 , LG:1385280.12.orf3:2001JUN22 475 LG:1390535.25:2001JUN221053 LG:1390535.25.orf3:2001JUN22 SEQ ID Template ID SEQ ID ORF ID
NO: NO:

476 LG:1397047.1:2001JUN221054 LG:1397047.1.orf3:2001JUN22 477 LG:1398646.15:2001JUN221055 LG:1398646.15.orf2:2001JUN22 478 LG:1446193.10:2001JUN221056 LG:1446193.10.orf1:2001JUN22 479 LG:1446405.14:2001JUN221057 LG:1446405.14.orf2:2001JUN22 480 LG:1448148.1:2001JUN221058 LG:1448148.1.orf1:2001JUN22 481 LG:1452619.13:2001JUN221059 LG:1452619.13.orf1:2001JUN22 482 LG:1452783.22:2001JUN221060 LG:1452783.22.orf3:2001JUN22 483 LG:I453417.5:2001JUN221061 LG:I453417.S.orf3:2001JUN22 484 LG:1455222.23:2001JUN221062 LG:1455222.23.orf1:2001JUN22 485 LG:149121.8:2001JUN221063 LG:I49121.8.orfI:2001JUN22 486 LG:1500175.18:2001JUN221064 LG:1500175.18.orf3:2001JUN22 487 LG:1500434.6:2001JUN221065 LG:1500434.6.orf2:200IJUN22 488 LG:1501550.19:2001JUN221066 LG:1501550.19.orf1:2001JUN22 489 LG:1501923.26:2002JUN221067 LG:1501923.26.orf2:2001JUN22 490 LG:150960.9:2001JUN221068 LG:150960.9.orf2:2001JUN22 491 LG:182744.29:2001JUN221069 LG:182744.29.orf1;2001JUN22 492 LG:197166.1:200IJUN221070 LG:197I66.1.orfI:2001JUN22 493 LG:197455.5:2001JUN221071 LG:197455.S.orf2:2001JUN22 494 LG:198251.8:200IJUN221072 LG:198251.8.orfZ:2001JUN22 495 LG:200149.3:2001JUN221073 LG:200149.3.orf1:2001JUN22 496 LG:203483.3:2001JUN221074 LG:203483.3.orf2:2001JUN22 497 LG:209701.7:2001JUN221075 LG:209701.7.orfI:2001JUN22 498 LG:210614.1:2001JUN221076 LG:210614.1.orf1:2001JUN22 499 ~ LG:210672.I:2001JUN221077 LG:210672.1.orf1:2001JUN22 .

500 LG:215051.10:2001JUN221078 LG:215051.10.orf3:2001JUN22 501 LG:218989.3:2001JUN221079 LG:218989.3.orf2:2001JUN22 502 LG:228107.11:2001JUN221080 LG:228107.I1.orf3:2001JUN22 503 LG:231016.1:2001JUN221081 LG:231016.1.orf2;2001JUN22 504 LG:235943.60:2001JUN221082 LG:235943.60.orf1:200IJUN22 505 LG:235970.14:2001JUN221083 LG:235970.14.orf2:2001JUN22 506 LG:236697.15:2001JUN221084 LG:236697.15.orf1:2001JUN22 507 LG:238576.3:2001JUN221085 LG:238576.3.orf2:2001JUN22 508 LG:238602.2:2001JUN221086 LG:238602.2.orf1:2001JUN22 509 LG:241291.46:2001JUN221087 LG:241291.46.orf1:2001JUN22 510 LG:241742.1:2001JUN221088 LG:241742.1.orf3:2001JUN22 511 LG:244520.33:2001JUN221089 LG:244520.33.orf2:200IJUN22 512 LG:247556.1:2001JUN221090 LG:247556.1.orf1:2001JUN22 513 LG:247792.5:2001JUN221091 LG:247792.S.orf3:200IJUN22 514 LG:253580.6:2001JUN221092 LG:253580.6.orf3:2001JUN22 515 LG:291759.5:2001JUN221093 LG:291759.S.orf3:2001JUN22 SI6 LG:298226.1:2001JUN221094 LG:298226.I.orf1:2001JUN22 517 LG:306342.1:2001JUN221095 LG:306342.1.orf2:2001JUN22 518 LG:327144.5:2001JUN221096 LG:327144.S.orf2:200IJUN22 519 LG:331499.8:2001JUN221097 LG:331499.8.orf3:2001JUN22 520 LG:331582.I2:200IJUN221098 LG:331582.12.orf2:2001JUN22 521 LG:333017.12:2001JUN221099 LG:333017.12.orf2:2001JUN22 522 LG:334438.8:2001JUN221100 LG:334438.8.orf2:2001JUN22 523 LG:337835.7:2001JUN221101 LG:337835.7.orf3:2001JUN22 524 LG:346536.12:2001JUN221102 LG:346536.12.orf2:2001JUN22 525 LG:348117.5:2001JUN221103 LG:348117.S.orf1:2001JUN22 526 LG:350407.22:2001JUN221104 LG:350407.22.orf3:2001JUN22 527 LG:373219.13:2001JUN221105 LG:373219.I3.orf2:2001JUN22 528 LG:375048.15:2001JUN221106 LG:375048.15.orf3:2001JUN22 529 LG:400114.3:2001 1107 LG:400114.3.orf3:2001 SEQ ID Template ID SEQ ID ORF ID
NO; NO:

530 LG:400652.1:2001JUN221108 LG:400652.1.orf1:2001JUN22 531 LG:401313.10:2001JUN221109 LG:401313.10.orf1:2001JUN22 532 LG:406389.1:2001JUN221110 LG:406389.1.orf2:2001JUN22 533 LG:406595.2:2001JUN221111 LG:406595.2.orf1:2001JUN22 534 LG:410628.21:2001JUN221112 LG:410628.21.orf2:2001JUN22 535 LG:413583.15:2001JUN221113 LG:413583.15.orf3:2001JUN22 536 LG:419641.35:2001JUN221114 LG:419641.35.orf3:2001JUN22 537 LG:420759.4:2001JUN221115 LG:420759.4.orf1:2001JUN22 538 LG:425448.18:2001JUN221116 LG:425448.18.orf1:2001JUN22 539 LG:435717.5:2001JUN221117 LG:435717.5.orf1:2001JUN22 540 LG:441159.31:2001JUN221118 LG:441159.31.orf1:2001JUN22 541 LG:461375.2:2001JUN221119 LG:461375.2.orf1:2001JUN22 542 LG:474674.34:2001JUN221120 LG:474674.34.orf3:2001JUN22 543 LG:481414.8:2001JUN221121 LG:481414.8.orf1:2001JUN22 544 LG:7669276.1:2001JUN221122 LG:7669276.1.orf2:2001JUN22 545 LG:7677848.1:2001JUN22_ LG:7677848.1.orf3:2001JUN22 546 LG:7684981.3:2001JUN221124 LG:7684981.3.orf3:2001JUN22 547 LG:7685048.6:2001JUN221125 LG:7685048.6.orf2:2001JUN22 548 LG:7688302.1:2001JUN221126 LG:7688302.1.orf3:2001JUN22 549 LG:7690463.3:2001JUN221127 LG:7690463.3.orf1:2001JUN22 550 LG:7691479.5:2001JUN221128 LG:7691479.S.orf1:2001JUN22 551 LG:7691527.4:2001JUN221129 LG:7691527.4.orf1:2001JUN22 552 LG:7691663.1:2001JUN221130 LG:7691663.1.orf2:2001JUN22 553 LG:7691854.1:2001JUN221131 LG:7691854.1.orf2:2001JUN22 554 LG:7692235.2:2001JUN221132 LG:7692235.2.orf2:2001JUN22 555. LG:7692239.1:2001JUN221133 LG:7692239.1.orf1:2001JUN22 556 LG:7692575.1:2001JUN221134 LG:7692575.1.orf1:2001JUN22 557 LG:7692742.1:2001JUN221135 LG:7692742.1.orf1:2001JUN22 S58 LG:7693942.1.:2001JUN221136 LG:7693942.1.orf3;2001JUN22 559 LG:899248.22:2001JUN221137 LG:899248.22.orf1:2001JUN22 S60 LG:979051.25:2001JUN221138 LG:979051.25.orf2:2001JUN22 S61 LG:979054.18:2001JUN221139 LG:979054.18.orf2:2001JUN22 562 LG:979415.1:2001JUN221140 LG:979415.1.orf1:2001JUN22 562 LG:979415.1:2001JUN221141 LG:979415.1.orf3:2001JUN22 563 LG:980685.1:2001JUN221142 LG:980685.1.orf3:2001JUN22 564 LG:981272.6:2001JUN221143 LG:981272.6.orf1:2001JUN22 565 LG:982723.4:2001JUN221144 LG:982723.4.orf3:2001JUN22 566 LG:982915.8:2001JUN221145 LG:982915.8.orf2:2001JUN22 567 LG:987785.10:2001JUN221146 LG:987785.10.orf2:2001JUN22 SEQ Template ID StartStopFrame Domain Topology D Type NO:

1 LG:1041015.22:2001MAR301 19 forwardTM Non-Cytosolic 1 LG:1041015.22:2001MAR3020 42 forwardTM Transmembrane 1 LG:1041015.22:2001MAR3043 54 forwardTM Cytosolic 1 LG:1041015.22:2001MAR3055 77 forwardTM Transmembrane 1 LG:1041015.22:2001MAR3078 290 forwardTM Non-Cytosolic 1 LG:1041015.22:2001MAR31 60 0 TM Cytosolic forward 1 LG:1041015.22:2001MAR3061 83 forwardTM Transmembrane 1 LG:1041015.22:2001MAR3084 290 forwardTM Non-Cytosolic 2 LG:106877.10:2001MAR301 78 forwardTM Non-Cytosolic 2 LG:106877.10:2001MAR3079 101 forwardTM Transmembrane 2 LG:106877.10:2001MAR30102 127 forwardTM Cytosolic 2 LG:106877.10:2001MAR30128 150 forwardTM Transmembrane 2 LG:106877.10:2001MAR30151 952 forwardTM Non-Cytosolic I

2 LG:106877.10:2001MAR301 71 forwardTM Non-Cytosolic 2 LG:106877.10:2001MAR3072 94 forwardTM Transmembrane 2 LG:106877.10:2001MAR3095 177 forwardTM Cytosolic 2 LG:106877.10:200IMAR30178 200 forwardTM Transmembrane 2 LG:106877.10:2001MAR30201 742 forwardTM Non-Cytosolic 2 LG:106877.10:2001MAR30743 765 forwardTM Transmembrane 2 LG:106877.10:2001MAR30766 952 forwardTM Cytosolic 3 LG:1138554.16:2001MAR301 227 forwardTM Non-Cytosolic 3 LG:1138554.16:2001MAR30228 250 forwardTM Transmembrane 3 LG:1138554.16:2001MAR30251 256 forwardTM Cytosolic 3 LG:1138554.16:2001MAR30257 279 forwardTM Transmembrane 3 LG:1138554.16:2001MAR30280 293 forwardTM Non-Cytosolic 3 LG:1138554.16:2001MAR30294 316 forwardTM Transmembrane 3 LG:1138554.16:2001MAR30317 332 forwardTM Cytosolic 4 LG:1383277.7:2001MAR301 44 forwardTM Cytosolic 4 LG:1383277.7:2001MAR3045 67 forwardTM Transmembrane 4 LG:1383277.7:2001MAR3068 155 forwardTM Non-Cytosolic 4 LG:1383277.7:2001MAR30156 I78 forward~ TM Transmembrane 4 LG:1383277.7:2001MAR30179 198 forwardTM Cytosolic 4 LG:1383277.7:2001MAR30I99 218 forwardTM Transmembrane 4 LG:1383277.7:2001MAR30219 221 forwardTM Non-Cytosolic 4 LG:1383277.7:2001MAR301 52 forwardTM Non-Cytosolic 4 LG:1383277.7:2001MAR3053 75 forwardTM Transmembrane 4 LG:1383277.7:2001MAR3076 221 forwardTM Cytosolic 4 LG:1383277.7:ZOO1MAR301 67 forwardT'M CytosoIic 4 LG:1383277.7:2001MAR3068 90 forwardTM Transmembrane 4 LG:1383277.7:2001MAR3091 93 forwardTM Non-Cytosolic 4 LG:1383277.7:2001MAR3094 113 forwardTM Transmembrane 4 LG:1383277.7:2001MAR30114 153 forwardTM Cytosolic 4 LG:1383277.7:2001MAR30154 176 forwardTM Transmembrane 4 LG:1383277.7:2001MAR30177 I98 forwardTM Non-Cytosolic 4 LG:1383277.7:2001MAR30199 218 forwardTM Transmembrane 4 LG:1383277.7:2001MAR30219 220 forwardTM Cytosolic LG:I397614.15:2001MAR301 I forwardTM Cytosolic 5 LG:1397614.15:2001MAR302 21 forwardTM Transmembrane 5 LG:13976I4.15:2001MAR3022 35 forwardTM Non-Cytosolic 5 LG:1397614.15:2001MAR3036 58 forwardTM Transmembrane 5 LG:1397614.15:2001MAR3059 193 forwardTM Cytosolic 5 LG:1397614.15:2001MAR30194 216 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30217 225 forwardTM Non-Cytosolic 5 LG:1397614.I5:ZOOIMAR30226 243 forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D NO: Type LG:1397614.I5:200IMAR30244 259 forwardTM Cytosolic 5 LG:1397614.15:2001MAR30260 282 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30283 458 forwardTM Non-Cytosolic 5 LG:13976I4.15:2001MAR30459 481 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30482 534 forwardTM Cytosolic 5 LG:1397614.15:2001MAR30535 557 forwardTM Transmemb;"ane I

5 LG:1397614.15:2001MAR30558 566 forwardTM Non-Cytosolic 5 LG:1397614.15:2001MAR30567 589 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30590 644 forwardTM Cytosolic 5 ~ LG:1397614.15:2001MAR301 43 forwardTM Non-Cytosolic 5 LG:1397614.15:2001MAR3044 66 forwardTM Transmembrane 5 LG:1397614.15:2001MAR3067 97 forwardTM Cytosolic 5 LG:1397614.15:2001MAR3098 120 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30121 195 forwardTM Non-Cytosolic 5 LG:1397614.15:2001MAR30196 218 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30219 260 forwardTM Cytosolic 5 LG;1397614.15:2001MAR30261 283 forwardTM Transmembrane 5 LG;1397614.15:2001MAR30284 342 forwardTM Non-Cytosolic 5 LG;1397614.15:2001MAR30343 365 forwardTM Transmembrane 5 LG:I397614.15:2001MAR30366 457 forwardTM CytosoIic 5 LG:1397614.15:200IMAR30458 480 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30481 499 forwardTM Non-Cytosolic 5 LG:1397614.I5:2001MAR30500 522 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30523 644 forwardTM Cytosolic 5 LG:1397614.15:2001MAR301 1 forwardTM Cytosolic 5 LG:1397614.15:2001MAR30'2 19 forwardTM Transmembrane 5 LG:1397614.15:2001MAR3020 33 forwardTM Non-Cytosolic 5 LG:1397614.15:2001MAR3034 56 forwardTM Transmembrane 5 LG:1397614.15:2001MAR3057 195 forwardTM Cytosolic 5 LG:1397614.15:2001MAR30196 218 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30219 263 forwardTM - Non-Cytosolic 5 LG:1397614.15:2001MAR30264 286 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30287 292 forwardTM Cytosolic 5 LG:1397614.15:2001MAR30293 315 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30316 324 forwardTM Non-Cytosolic 5 LG:1397614.15:2001MAR30325 347 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30348 396 forwardTM Cytosolic 5 LG:1397614.15:2001MAR30397 4I6 forwardTM Transmembrane 5 LG:2397614.15:2001MAR30417 457 forwardTM ' Non-Cytosolic 5 LG:1397614.15:200IMAR30458 480 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30481 533 forwardTM Cytosolic 5 LG:1397614.15:2001MAR30534 556 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30557 565 forwardTM Non-Cytosolic 5 LG:1397614.15:2001MAR30566 588 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30589 644 forwardTM Cytosolic 6~ LG:1399315.8:2001MAR30I 612 forwardTM Non-Cytosolic 6 LG:1399315.8:2001MAR30613 635 forwardTM Transmembrane 6 LG:1399315.8:2001MAR30636 742 forwardTM Cytosolic 6 LG:1399315.8:2001MAR30743 760 forwardTM Transmembrane 6 LG:1399315.8:2001MAR30761 987 forwardTM Non-Cytosolic 6 LG:1399315.8:2001MAR301 243 forwardTM Non-Cytosolic 6 LG:1399315.8:2001MAR30244 261 forwardTM Transmembrane 6 LG:1399315.8:2001MAR30262 292 forwardTM Cytosolic 6 LG:1399315.8:2001MAR30293 315 forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D Type NO:

6 LG:1399315.8:2001MAR30316 986 forwardTM Non-Cytosolic 7 LG:198782.1:2001MAR301 735 forwardTM Non-Cytosolic 7 LG:198782.1:2001MAR30736 758 forwardTM Transmembrane 7 LG:198782.1:2001MAR30759 770 forwardTM Cytosolic 7 LG:198782.1:2001MAR30771 793 forwardTM Transmembrane 7 LG:198782.1:2001MAR30794 851 forwardTM Non-Cytosolic 7 LG:I98782.I:2001MAR30I 27 forwardTM Non-Cytosolic 7 LG:198782.1:2001MAR3028 50 forwardTM Transmembrane 7 LG:198782.1:2001MAR3051 377 forwardTM Cytosolic 7 LG:198782.1:2001MAR30378 400 forwardTM Transmembrane 7 LG:198782.1:2001MAR30401 404 forwardTM Non-Cytosolic 7 LG:198782.1:2001MAR30405 424 forwardTM Transmembrane 7 LG:198782.1:2001MAR30425 769 forwardTM Cytosolic 7 LG:198782.1:2001MAR30770 792 forwardTM Transmembrane 7 LG:198782.1:2001MAR30793 80I forwardTM Non-CytosoIic 7 LG:198782.1:2001MAR30802 819 forwardTM Transmembrane 7 LG:198782.1:2001MAR30820 850 forwardTM Cytosolic 7 LG:198782.I:2001MAR301 33 forwardTM Non-Cytosolic 7 LG:198782.1:2001MAR3034 51 forwardTM Transmembrane 7 LG:198782.1:2001MAR3052 380 forwardTM Cytosolic 7 LG:198782.1:2001MAR3038I 403 forwardTM Transmembrane 7 LG:198782.1:2001MAR30404 406 forwardTM Non-Cytosolic 7 LG:198782.1:2001MAR30407 424 forwardTM Transmembrane 7 LG:198782.1:2001MAR30425 436 forwardTM Cytosolic 7 LG:198782.1:2001MAR30437 459 forwardTM Transmembrane 7 LG:198782.1:2001MAR30460 541 forwardTM Non-Cytosolic 7 LG:198782.1:2001MAR30542 564 forwardTM Transmembrane 7 LG:198782.1:2001MAR30~ - forwardTM Cytosolic ~ 565 770 3 7 LG:I98782.1 ' 793 forwardTM Transmembrane :2001MAR30 771 3 .

7 LG:198782.1:2001MAR30794 802 forwardTM Non-Cytosolic 7 LG:198782.1:2001MAR30803 822 forwardTM Transmembrane 7 LG:198782.1:2001MAR30823 850 forwardTM Cytosolic 8 LG:236046.1:2001MAR30r 160 forwardTM Non-Cytosolic 8 LG:236046.1:2001MAR30161 183 forwardTM Transmembrane 8 LG:236046.1:2001MAR30184 203 forwardTM Cytosolic 8 LG:236046.1:2001MAR30204 226 forwardTM Transmembrane 8 LG:236046.1:2001MAR30227 235 forwardTM Non-Cytosolic 8 LG:236046.1:2001MAR30236 253 forwardTM Transmembrane 8 LG:236046.1;2001MAR30254 273 forwardTM Cytosolic 8 LG:236046.1:2001MAR30274 296 forwardTM Transmembrane 8 LG:236046.1:2001MAR30297 367 forwardTM Non-Cytosolic 8 LG:236046.1:2001MAR30368 390 forwardTM Transmembrane 8 LG:236046.1:2001MAR30391 396 forwardTM Cytosolic 8 LG:236046.1:2001MAR30397 416 forwardTM Transmembrane 8 LG:236046.1:2001MAR30417 848 forwardTM Non-Cytosolic 9 LG:332122.6:2001MAR301 389 forwardTM Non-Cytosolic 9 LG:332122.6:2001MAR30390 412 forwardTM Transmembrane 9 LG:332122.6:2001MAR30413 447 forwardTM Cytosolic ~ 1 9 LG;332122.6:2001MAR30448 470 forwardTM Transmembrane 9 LG:332122.6:2001MAR30471 557 forwardTM Non-Cytosolic 9 LG:332122.6:2001MAR30558 575 forwardTM Transmembrane 9 LG:332122.6:2001MAR30576 655 forwardTM Cytosolic 9 LG:332122.6:2001MAR30656 678 forwardTM Transmembrane 9 LG:332122.6:2001MAR30679 681 forwardTM Non-Cytosolic SEQ Template ID Start StopFrame Domain Topology D NO: Type 9 LG:332122.6:2001MAR30682 701forwardTM Transmembrane 9 LG:332122.6:2001MAR30702 758forwardTM Cytosolic 9 LG:332122.6:2001MAR30759 778forwardTM Transmembrane 9 LG:332122.6:2001MAR30779 797forwardTM Non-Cytosolic 9 LG:332122.6:2001MAR30798 817forwardTM Transmembrane 9 LG:332122.6:2001MAR30818 837forwardTM Cytosolic 9 LG:332122.6:2001MAR301 66 forwardTM Cytosolic 9 LG:332122.6:2001MAR3067 84 forwardTM Transmembrane 9 LG:332122.6:2001MAR3085 120forwardTM Non-Cytosolic 9 LG:332122.6:2001MAR30121 140forwardTM Transmembrane 9 LG:332122.6:2001MAR30141 235forwardTM Cytosolic 9 LG:332122.6:2001MAR30236 255forwardTM Transmembrane 9 LG:332122.6:2001MAR30256 269forwardTM Non-Cytosolic 9 LG:332122.6:2001MAR30270 289forwardTM Transmembrane 9 LG:332122.6:2001MAR30290 347forwardTM Cytosolic 9 LG:332122.6:2001MAR30348 370forwardTM Transmembrane 9 LG:332122.6:2001MAR30371' 396forwardTM Non-Cytosolic 9 LG:332122.6:2001MAR30397 419forwardTM Transmembrane 9 LG:332122.6:2001MAR30420 431forwardTM Cytosolic 9 LG:332122.6:2001MAR30432 451forwardTM Transmembrane 9 LG:332122.6:2001MAR30452 465forwardTM Non-Cytosolic 9 LG:332122.6:2001MAR30466 488forwardTM Transmembrane 9 LG:332122.6:2001MAR30489 554forwardTM Cytosolic 9 LG:332122.6:2001MAR30555 574forwardTM Transmembrane 9 LG:332122.6:2001MAR30575 837forwardTM Non-Cytosolic ~ 2 9 LG:332122.6:2001MAR301 231forwardTM Cytosolic 9 LG:332122.6:2001MAR30232 254forwardTM _ Transmembrane 9 LG:332122.6:2001MAR30255 X68''forwardTM Non-Cytosolic 9 LG:332122.6:2001MAR30269 286forwardTM Transmembrane ' 3 9 LG:332122.6:2001MAR30287 328forwardTM Cytosolic 9 LG:332122.6:2001MAR30329 351forwardTM Transmembrane 9 LG:332122.6:2001MAR30352 393forwardTM Non-Cytosolic 9 LG:332122.6:2001MAR30394 416forwardTM Transmembrane 9 LG:332122.6:2001MAR30417 428forwardTM Cytosolic 9 LG:332122.6:2001MAR30429 451forwardTM Transinembrane 9 LG:332122.6:2001MAR30452 836forwardTM Non-Cytosolic LG:345320.16:2001MAR301 82 ForwardTM Cytosolic 10 LG:345320.16:2001MAR3083 105forwardTM Transmembrane 10 LG:345320.16:2001MAR30106 114forwardTM Non-Cytosolic 1 ~

10 LG:345320.16:2001MAR30115 137forwardTM Transmembrane 10 LG:345320.16:2001MAR30138 290forwardTM Cytosolic 10 LG:345320.16:2001MAR30291 313forwardTM Transmembrane 10 LG:345320.16:2001MAR30314 327forwardTM Non-Cytosolic 10 LG:345320.16:2001MAR30328 350forwardTM Transmembrane 10 LG:345320.16:2001MAR30351 424forwardTM Cytosolic 10 LG:345320.16:2001MAR30425 417forwardTM Transmembrane 10 LG:345320.16:2001MAR30448 764forwardTM Non-Cytosolic 10 LG:345320.16:2001MAR301 98 forwardTM Cytosolic 10 LG:345320.16:2001MAR3099 121forwardTM Transmembrane 10 LG:345320.16:2001MAR30122 159forwardTM Non-Cytosolic 10 LG:345320.16:2001MAR30160 182forwardTM Transmembrane 10 LG:345320.16:2001MAR30183 188forwardTM Cytosolic 10 LG:345320.16:2001MAR30189 211forwardTM Transmembrane 10 LG:345320.16:2001MAR30212 331forwardTM Non-Cytosolic SEQ Template ID StartStopFrame Domain Topology D Type NO:

LG:13976I4.15:2001MAR30244 259 forwardTM Cytosolic 5 LG:1397614.15:2001MAR30260 282 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30283 458 forwardTM Non-Cytosolic 5 LG:1397614.15:2001MAR30459 481 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30482 534 forwardTM Cytosolic 5 LG:1397614.15:2001MAR30535 557 forwardTM Transmembfane 5 LG:1397614.15:2001MAR30558 566 forwardTM Non-Cytosolic 5 LG:1397614.15:2001MAR30567 589 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30590 644 forwardTM Cytosolic 5 LG:1397614.15:2001MAR301 43 forwardTM Non-Cytosolic 5 LG:1397614.15:2001MAR3044 66 forwardTM Transmembrane 5 LG:1397614.15:2001MAR3067 97 forwardTM Cytosolic 5 LG:1397614.15:2001MAR3098 120 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30121 195 forwardTM Non-Cytosolic 5 LG:1397614.15:2001MAR30196 218 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30219 260 forwardTM Cytosolic 5 LG:1397614.15:2001MAR30261 283 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30284 342 forwardTM Non-Cytosolic 5 LG:1397614.15:2001MAR30343 365 foxwardTM Transmembrane 5 LG:1397614.15:2001MAR30366 457 forwardTM Cytosolic 5 LG:1397614.15:2001MAR30458 480 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30481 499 forwardTM Non-Cytosolic 5 LG:1397614.15:200IMAR30500 522 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30523 644 forwardTM Cytosolic 5 LG:1397614.15:2001MAR301 1 forwardTM Cytosolic 5 LG:1397614.15:2001MAR302 19 forward, TM Transmembrane 5 LG:1397614.15:2001MAR3020 33 forwardTM Non-Cytosolic 5 LG:1397614.I5:2001MAR3034 56 forwardTM Transmembrane 5 LG:1397614.15:2001MAR3057 195 forwardTM Cytosolic 5 LG:1397614.15:2001MAR30196 218 forwardTM Transmembrane 3 ~

5 LG:1397614.15:2001MAR30219 263 forwardTM Non-Cytosolic 5 LG:1397614.15:2001MAR30264 286 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30287 292 forwardTM Cytosolic 5 LG:1397614.15:2001MAR30293 315 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30316 324 forwardTM Non-Cytosolic 5 LG:1397614.15:2001MAR30325 347 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30348 396 forwardTM Cytosolic 5 LG:1397614.15:2001MAR30397 416 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30417 457 forwardTM Non-Cytosolic 5 LG:1397614.15:2001MAR30458 480 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30481 533 forwardTM Cytosolic 5 LG:1397614.15:2001MAR30534 556 forwardTM Transmembrane 5 LG:1397614.15:2001MAR30557 565 forwardTM Non-Cytosolic 5 LG:1397614.15:2001MAR30566 S88 forwardTM Transmembrane 5 LG:1397614.15:200IMAR30589 644 forwardTM Cytosolic 6 LG:1399315.8:2001MAR301 612 forwardTM Non-Cytosolic 6 LG:1399315.8:2001MAR30613 635 forwardTM Transmembrane 6 LG:1399315.8:2001MAR30636 742 forwardTM Cytosolic 6 LG:1399315.8:2001MAR30743 760 forwardTM Transmembrane 6 LG:1399315.8:ZOO1MAR30761 987 forwardTM Non-Cytosolic 6 LG:1399315.8:2001MAR301 243 forwardTM Non-Cytosolic 6 LG:1399315.8:2001MAR30244 261 forwardTM Transmembrane 6 LG:1399315.8:2001MAR30262 292 forwardTM Cytosolic 6 LG:1399315.8:2001MAR30293 315 forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D Type NO:

6 LG:1399315.8:2001MAR30316 986 forwardTM Non-Cytosolic 7 LG:198782.1:2001MAR301 735 forwardTM Non-Cytosolic 7 LG:198782.1:2001MAR30736 758 forwardTM Transmembrane 7 LG:198782.1:2001MAR30759 770 forwardTM Cytosolic 7 LG:198782.1:2001MAR30771 793 forwardTM Transmembrane 7 LG:198782.1:2001MAR30794 851 forwardTM Non-Cytosolic 7 LG:198782.1:2001MAR301 27 forwardTM Non-Cytosolic 7 LG:198782.1:2001MAR3028 50 forwardTM Transmembrane 7 LG:I98782.1:2001MAR305I 377 forwardTM Cytosolic 7 LG:198782.1:2001MAR30378 400 forwardTM Transmembrane 7 LG:198782.1:2001MAR30401 404 forwardTM Non-Cytosolic 7 LG:198782.1:2001MAR30405 424 forwardTM Transmembrane 7 LG:198782.1:2001MAR30425 769 forwardTM Cytosolic 7 LG:198782.1:2001MAR30770 792 forwardTM Transmembrane 7 LG:198782.1:2001MAR30793 801 forwardTM Non-Cytosolic 7 LG:198782.1:2001MAR30802 819 forwardTM Transmembrane 7 LG:198782.1:2001MAR30820 850 forwardTM Cytosolic 7 LG:198782.1:2001MAR301 33 forwardTM Non-Cytosolic 7 LG:198782.1:2001MAR3034 51 forwardTM Transmembrane 7 LG:198782.1:2001MAR3052 380 forwardTM Cytosolic 7 LG:198782.1:2001MAR30381 403 forwardTM Transmembrane 7 LG:198782.1:2001MAR30404 406 forwardTM Non-Cytosolic 7 LG:198782.1:2001MAR30407 " forwardTM Transmembrane 7 LG:198782.1:2001MAR30425 436 forwardTM Cytosolic 7 LG:198782.1:2001MAR30437 459 forwardTM Transmembrane 7 LG:198782.1:2001MAR30460 541 forwardTM Non-Cytosolic 7 LG:198782.1:2001MAR30542 564 forwardTM Transmembrane 7 LG:198782.1:2001MAR30565 770 forward~ TM Cytosolic 7 LG:198782.1:2001MAR30771 793 forwardTM Transmembrane 7 LG:198782.1:2001MAR30794 802 forwardTM Non-Cytosolic 7 LG:198782.1:2001MAR30803 822 forwardTM Transmembrane 7 LG:198782.1:2001MAR30823 850 forwardTM Cytosolic 8 LG:236046.1:2001MAR301 160 forwardTM Non-Cytosolic 8 LG:236046.1:2001MAR30161 183 forwardTM Transmembrane 8 LG:236046.1:2001MAR30184 203 forwardTM Cytosolic 8 LG:236046.1:2001MAR30204 226 forwardTM Transmembrane 8 LG:236046.1:2001MAR30227 235 forwardTM Non-Cytosolic 8 LG:236046.1:2001MAR30236 253 forwardTM Transmembrane 8 LG:236046.1:2001MAR30254 273 forwardTM Cytosolic 8 LG:236046.1:2001MAR30274 296 forwardTM Transmembrane 8 LG:236046.1:2001MAR30297 367 forwardTM Non-Cytosolic 8 LG:236046.1:2001MAR30368 390 forwardTM Transmembrane 8 LG:236046.1:2001MAR30391 396 forwardTM Cytosolic 8 LG:236046.1:2001MAR30397 416 forwardTM Transmembrane 8 LG:236046.I:200IMAR30417 848 forwardTM Non-Cytosolic 9 LG:332122.6:2001MAR301 389 forwardTM Non-Cytosolic 9 LG:332122.6:2001MAR30390 412 forwardTM Transmembrane 9 LG:332122.6:2001MAR30413 447 forwardTM Cytosolic 9 LG:332122.6:2001MAR30448 470 forwardTM Transmembrane 9 LG:332122.6:2001MAR30471 557 forwardTM Non-Cytosolic 9 LG:332122.6:2001MAR30558 575 forwardTM Transmembrane 9 LG:332122.6:2001MAR30576 655 forwardTM Cytosolic 9 LG:332122.6:2001MAR30656 678 forwardTM Transmembrane 9 LG:332122.6:2001MAR30679 681 forwardTM Non-Cytosolic SEQ Template ID StartStopFrame Domain Topology D NO: Type 9 LG:332122.6:ZOOlMAR30682 701 forwardTM Transmembrane 9 LG:332122.6:2001MAR30702 7S8 forwardTM Cytosolic 9 LG:332122.6:2001MAR30759 778 forwardTM Transmembrane 9 LG:332122.6:2001MAR30779 797 forwardTM Non-Cytosolic 9 LG:332122.6:2001MAR30798 817 forwardTM Transmembrane 9 LG:332122.6:2001MAR30818 837 forwardTM Cytosolic 9 LG:332122.6:2001MAR301 66 forwardTM Cytosolic 9 LG:332122.6:2001MAR3067 84 forwardTM Transmembrane 9 LG:332122.6:2001MAR3085 120 forwardTM Non-Cytosolic 9 LG:332122.6:2001MAR30121 140 forwardTM Transmembrane 9 LG:332122.6:2001MAR30141 235 forwardTM Cytosolic 9 LG:332122.6:2001MAR30236 2S5 forwardTM Transmembrane 9 LG:332122.6:2001MAR30256 269 forwardTM Non-Cytosolic 9 LG:332122.6:2001MAR30270 289 forwardTM Transmembrane 9 LG:332122.6:2001MAR30290 347 forwardTM Cytosolic 9 LG:332122.6:2001MAR30348 370 forwardTM Transmembrane 9 LG:332122.6:2001MAR30371 396 forwardTM Non-Cytosolic 9 LG:332122.6:2001MAR30397 419 forwardTM Transmembrane 9 LG:332122.6:2001MAR30420 431 forwardTM Cytosolic 9 LG:332122.6:2001MAR30432 451 forwardTM Transmembrane 9 LG:332122.6:2001MAR30452 46S forwardTM Non-Cytosolic 9 LG:332122.6:2001MAR30466 488 forwardTM Transmembrane 9 LG:332I22.6:200IMAR30489 554 forwardTM Cytosolic 9 LG:332122.6:2001MAR30S55 574 forwardTM Transmembrane 9 LG:332122.6:2001MAR30575 837 forwardTM Non-Cytosolic 9 LG:332122.6:2001MAR301 231 forwardTM Cytosolic 9 LG:332122.6:2001MAR30232 254 forwardTM Transmembrane 9 LG:332122.6:2001MAR30255 268 forwardTM Non-Cytosolic 9 LG:332122.6:2001MAR30269 286 forwardTM Transmembrane 9 LG:332122.6:2001MAR30287 328 forwardTM Cytosolic 9 LG:332122.6:2001MAR30329 351 forwardTM Transmembrane 9 LG:332122.6:2001MAR30352 393 forwardTM Non-Cytosolic 9 LG:332122.6:2001MAR30394 416 forwardTM Transmembrane 9 LG:332122.6:2001MAR30417 428 forwardTM Cytosolic 9 LG:332122.6:2001MAR30429 451 forwardTM Transmembrane 9 LG:332122.6:2001MAR30452 836 forwardTM Non-Cytosolic LG:345320.16:2001MAR301 82 forwardTM Cytosolic 10 LG:345320.16:2001MAR3083 105 forwardTM Transmembrane 10 LG:345320.16:2001MAR30106 114 forwardTM Non-Cytosolic 10 LG:34S320.16:2001MAR30115 137 forwardTM Transmembrane 10 LG:345320.16:2001MAR30138 290 forwardTM Cytosolic 10 LG:345320.16:2001MAR3029I 313 forwardTM Transmembrane 10 LG:345320.16:2001MAR30314 327 forwardTM Non-Cytosolic 10 LG:345320.16:2001MAR30328 350 forwardTM Transmembrane 10 LG:345320.16:2001MAR30351 424 forwardTM Cytosolic 10 LG:345320.16:2001MAR30425 447 forwardTM Transmembrane 10 LG:345320.16:2001MAR30448 764 forwardTM Non-Cytosolic 10 LG:345320.16:2001MAR301 98 forwardTM Cytosolic 10 LG:345320.16:2001MAR3099 121 forwardTM Transmembrane 10 LG:345320.16:2001MAR30122 159 forwardTM Non-Cytosolic 10 LG:345320.16:2001MAR30160 182 forwardTM Transmembrane 10 LG:345320.16:2001MAR30183 188 forwardTM Cytosolic 10 LG:34S320.16:2001MAR30189 211 forwardTM Transmembrane 10 LG:345320.16:2001MAR30212 331 forwardTM Non-Cytosolic SEQ Template ID Start StopFrame Domain Topology D Type NO:

LG:345320.16:2001MAR30332 354forwardTM Transmembrane 10 LG:345320.16:2001MAR30355 447forwardTM Cytosolic 10 LG:345320.16:2001MAR30448 470forwardTM Transmembrane 10 LG:345320.16:2001MAR30471 764forwardTM Non-Cytosolic 10 LG:345320.16:2001MAR301 $8 forwardTM Cytosolic 10 LG:345320.16:2001MAR3089 111forwardTM Transmembrane 10 LG:345320.16:2001MAR30112 114forwardTM Non-Cytosolic IO LG:345320.16:2001MAR30115 137forwardTM Transmembrane 10 LG:345320.16:2001MAR30138 172forwardTM Cytosolic 10 LG:345320.16:2001MAR30173 195forwardTM Transmembrane 10 LG:345320.16:2001MAR30196 330forwardTM Non-Cytosolic 10 LG:345320.16:2001MAR30331 353forwardTM Transmembrane 10 LG:345320.16:2001MAR30354 438forwardTM Cytosolic 10 LG:345320.16:2001MAR30439 461forwardTM Transmembrane 10 LG:345320.16:2001MAR30462 764forwardTM Non-Cytosolic 11 LG:350827.10:2001MAR301 9 forwardTM Non-Cytosolic 11 LG:350827.10:2001MAR3010 32 forwardTM Transmembrane 11 LG:350827.10:2001MAR3033 82 forwardTM Cytosolic 11 LG:350827.10:2001MAR3083 105forwardTM Transmembrane I 1 LG:350827.10:2001MAR30106 109forwardTM Non-Cytosolic 11 LG:350827.10:2001MAR30110 129forwardTM Transmembrane 11 LG:350827.10:2001MAR30130 149forwardTM Cytosolic 11 LG:350827.10:2001MAR30150 172forwardTM Transmembrane 11 LG:350827.10:2001MAR30173 181forwardTM Non-Cytosolic 11 LG:350827.10:2001MAR30182 204forwardTM Transmembrane 11 LG:350827.10:2001MAR30205 273forwardTM Cytosolic 11 LG:350827.10:2001MAR30274 296forwardTM Transmembrane 11 LG:350827.10:2001MAR30297 352forwardTM Non-Cytosolic 11 LG:350827.10:2001MAR30I 9 forwardTM Non-Cytosolic 11 LG:350827.10:2001MAR3010 32 forwardTM Transmembrane 11 LG:350827.10:2001MAR3033 140forwardTM Cytosolic 11 LG:350827.10:2001MAR30141 163forwardTM Transmembrane 11 LG:350827.10:2001MAR30164 177forwardTM Non-Cytosolic 11 LG:350827.10:2001MAR30178 197forwardTM Transmembrane 11 LG:350827.10:2001MAR30198 351forwardTM Cytosolic 12 LG:399901.5:2001MAR30I 308forwardTM Non-Cytosolic 12 LG:399901.5:200IMAR30309 331forwardTM Transmembrane I

12 LG:399901.5:2001MAR30332 343forwardTM Cytosolic 12 LG:399901.5:2001MAR30344 366forwardTM Transmembrane 12 LG:399901.5:2001MAR30367 376forwardTM Non-Cytosolic I3 LG:404563.1:2001MAR30l 351forwardTM Non-Cytosolic 13 LG:404563.1:2001MAR30352 374forwardTM Transmembrane 13 LG:404563.1:2001MAR30375 662forwardTM Cytosolic 13 LG:404563.1:2001MAR30663 685forwardTM Transmembrane 13 LG:404563.1:2001MAR30686 1103forwardTM Non-Cytosolic I3 LG:404563.1:ZOO1MAR301 33 forwardTM Cytosolic 13 LG:404563.1:2001MAR3034 51 forwardTM Transmembrane 13 LG:404563.1:2001MAR3052 894forwardTM Non-Cytosolic 13 LG:404563.1:2001MAR30895 917forwardTM Transmembrane 13 LG:404563.1:2001MAR30918 999forwardTM Cytosolic 13 LG:404563.1:2001MAR301000 1022forwardTM Transmembrane 13 LG:404563.1:2001MAR301023 I forwardTM Non-Cytosolic 13 LG:404563.1:2001MAR30I 896forwardTM Non-Cytosolic 13 LG:404563.1:2001MAR30897 919forwardTM Transmembrane SEQ Template ID Start StopFrame Domain Topology D NO: Type 13 LG:404563.1:2001MAR30920 996forwardTM Cytosolic 13 LG:404563.1:2001MAR30997 1014forwardTM Transmembrane 13 LG:404563.1:2001MAR301015 1102forwardTM Non-Cytosolic 14 LG:977812.15:2001MAR301 23 forwardTM Cytosolic 14 LG:977812.15:2001MAR3024 43 forwardTM Transmembrane 14 LG:977812.15:2001MAR3044 52 forwardTM Non-Cytosolic 14 LG:977812.15:2001MAR3053 75 forwardTM Transmembrane 14 LG:977812.15:2001MAR3076 94 forwardTM Cytosolic 14 LG:977812.15:2001MAR3095 112forwardTM Transmembrane 14 LG:977812.15:2001MAR30113 115forwardTM Non-Cytosolic 14 LG:977812.15:2001MAR30116 138forward~ TM Transmembrane 14 LG:977812.15:2001MAR30139 158forwardTM Cytosolic 14 LG:977812.15:2001MAR30159 177forwardTM Transmembrane 14 LG:977812.15:2001MAR30178 210forwardTM Non-Cytosolic 14 LG:977812.15:2001MAR30211 228forwardTM Transmembrane 14 LG:977812.I5:200IMAR30229 247forwardTM Cytosolic 14 LG:977812.15:2001MAR30248 270forwardTM Transmembrane 14 LG:977812.15:2001MAR30271 284forwardTM Non-Cytosolic 14 LG:977812.15:2001MAR30285 307forwardTM Transmembrane I

14 LG:977812.15:2001MAR30308 339forwardTM Cytosolic 14 LG:977812.15:2001MAR30340 357forwardTM Transmembrane 14 LG:977812.15:2001MAR30358 446forwardTM Non-Cytosolic 14 LG:977812.15:2001MAR30447 466forwardTM Transmembrane 14 LG:977812.15:2001MAR30467 482forwardTM Cytosolic 14 LG:977812.15:2001MAR301 89 forwardTM Non-Cytosolic 14 LG:977812.15:2001MAR3090 107forwardTM Transmembrane 14 LG:977812.15:2001MAR30108 113forwardTM Cytosolic 14 LG:977812.15:2001MAR30114 136forwardTM Transmembrane 14 ~ LG:977812.15:2001MAR30137 150forwardTM Non-Cytosolic 14 LG:977812.15:2001MAR30151 173forwardTM Transmembrane 14 LG:977812.15:2001MAR30174 259forwardTM Cytosolic 14 LG:977812.15:2001MAR30260 282forwardTM Transmembrane 14 LG:977812.15:2001MAR30283 333forwardTM Non-Cytosolic 14 LG:977812.15:2001MAR30334 356forwardTM Transmembrane 14 LG:977812.15:2001MAR30357 417forwardTM Cytosolic 14 LG:977812.15:2001MAR30418 440forwardTM Transmembrane 14 LG:977812.15:2001MAR30441 449forwardTM Non-Cytosolic 14 LG:977812.15:2001MAR30450 467forwardTM Transmembrane 14 LG:977812.15:2001MAR30468 481forwardTM Cytosolic 14 LG:977812.15:2001MAR301 93 forwardTM Cytosolic 14 LG:977812.15:2001MAR3094 116forwardTM Transmembrane 14 LG:977812.15:2001MAR30117 125forwardTM Non-Cytosolic 14 LG:977812.15:2001MAR30126 148forwardTM Transmembrane 14 LG:977812.15:2001MAR30149 154forwardTM Cytosolic 14 LG:977812.15:2001MAR30155 174forwardTM Transmembrane 14 LG:977812.15;2001MAR30175 209forwardTM Non-Cytosolic 14 LG:977812.15:2001MAR30210 227forwardTM Transmembrane 14 LG:977812.15:2001MAR30228 246forwardTM Cytosolic 14 LG:977812.15:200IMAR30247 269forwardTM Transmembrane 14 LG:977812.15:2001MAR30270 283forwardTM Non-Cytosolic 14 LG:977812.15:200IMAR30284 306forwardTM Transmembrane 14 LG:977812.15:2001MAR30307 337forwardTM Cytosolic 14 LG:977812.15:2001MAR30338 355forwardTM Transmembrane 14 LG:977812.15:2001MAR30356 381forward'TM Non-Cytosolic SEQ Template ID Start StopFrame Domain Topology D N~: Type 14 LG:977812.15:2001MAR30382 404forwardTM Transmembrane 14 LG:977812.15:2001MAR30405 446forwardTM Cytosolic 14 LG:977812.15:2001MAR30447 469forwardTM Transmembrane 14 LG:977812.15;2001MAR30470 481forwardTM Non-Cytosolic 15 LG:983810.1:2001MAR301 86 forwardW'M Non-Cytosolic 15 LG:983810.1:2001MAR3087 109forwardTM Transmembrane 15 LG:983810.1:2001MAR30110 115forwardTM Cytosolic 15 LG:983810.1:2001MAR30116 138forwardTM Transmembrane 15 LG:983810.1:2001MAR30139 380forwardTM Non-Cytosolic I5 LG:983810.1:2001MAR30381 403forwardTM Transmembrane 15 LG:983810.1:2001MAR30404 451forwardTM Cytosolic 15 LG:983810.1:2001MAR30452 474forwardTM Transmembrane I

15 LG:983810.1:2001MAR30475 493forwardTM Non-Cytosolic 15 LG:983810.1:2001MAR30494 516forwardTM Transmembrane l 15 LG:983810.1:2001MAR30517 528forwardTM Cytosolic 15 LG:983810.1:2001MAR30529 551forwardTM Transmembrane 15 LG:983810.1:2001MAR30552 615forwardTM Non-Cytosolic 15 LG:983810.1:2001MAR30616 638forwardTM Transmembrane 15 LG:983810.1:2001MAR30639 650forwardTM Cytosolic 15 LG:983810.1:2001MAR30651 673forwardTM Transmemtirane 15 LG:983810.1:2001MAR30674 773forwardTM Non-Cytosolic 15 LG:983810.1:2001MAR301 93 forwardTM Cytosolic 15 LG:983810.1:2001MAR3094 116forwardTM Transmembrane 15 LG:983810.1:2001MAR30117 331forwardTM Non-Cytosolic 15 LG:983810.1:2001MAR30332 351forwardTM Transmembrane 15 LG:983810.1:2001MAR30' 352 455forwardTM Cytosolic 15 LG:983810.1:2001MAR30456 478forwardTM Transmembrane 15 LG:983810:1:2001MAR30479 521forwardTM Non-Cytosolic 15 LG:9'83810.1:2001MAR30522 541forwardTM Transmembrane 15 LG:983810.1:2001MAR30542 553forwardTM Cytosolic 15 LG:983810.1;2001MAR30554 571forwardTM Transmembrane 15 LG:983810.1:2001MAR30572 613forwardTM Non-Cytosolic 15 LG:983810.1:2001MAR30614 636forwardTM Transmembrane 15 LG:983810.1:2001MAR30637 642forwardTM Cytosolic 15 LG:983810.1:2001MAR30643 665forwardTM Transmembrane 15 LG:983810.1:2001MAR30666 684forwardTM Non-Cytosolic 15 LG:983810.1:2001MAR30685 707forwardTM Transmembrane 15 LG:983810.1:2001MAR30708 772forwardTM Cytosolic 15 LG:983810.1:2001MAR301 94 forwardTM Non-Cytosolic 15 LG:983810.1:2001MAR3095 117forwardTM Transmembrane 15 LG:983810.1:2001MAR30118 123forwardTM Cytosolic 15 LG:983810.1:2001MAR30124 146forwardTM Transmembrane 15 LG:983810.1:2001MAR30147 772forwardTM Non-Cytosolic 16 LG:984488.1:2001MAR301 12 forwardTM Cytosolic 16 LG:984488.1:2001MAR3013 35 forwardTM Transmembrane 16 LG:984488.1:2001MAR3036 54 forwardTM Non-Cytosolic I6 LG:984488.1:2001MAR3055 77 forwardTM Transmembrane 16 LG:984488.1:2001MAR3078 218forwardTM Cytosolic 16 LG:984488.1:2001MAR301 14 forward, TM Non-Cytosolic 16 LG:984488.1:2001MAR3015 37 forwardTM Transmembrane 16. LG:984488.1:2001MAR3038 218forwardTM Cytosolic 17 LG:011606.1:2001MAR301 92 forwardTM Cytosolic 17 LG:011606.1:2001MAR3093 115forwardTM Transmembrane 17 LG:011606.1:2001MAR30116 129forwardTM Non-Cytosolic SEQ Template ID StartStopFrame Domain Topolojy D Type NO;

17 LG:011606.1:2001MAR30130 152 forwardTM Transmembrane 17 LG:011606.1:2001MAR30153 400 forwardTM Cytosolic 18 LG:025465.5:2001MAR301 374 forwardTM Non-Cytosolic 18 LG:025465.5:2001MAR30375 397 forwardTM Transmembrane 18 LG:025465.5:2001MAR30398 453 forward.2TM Cytosolic 18 LG:025465.5:2001MAR30454 476 forwardTM Transmembrane 18 LG:025465.5:2001MAR30477 661 forwardTM Non-Cytosolic 19 LG:025724.10:2001MAR301 92 forwardTM Non-Cytosolic 19 LG:025724.10:2001MAR3093 115 forwardTM Transmembrane 19 LG:025724.10:2001MAR30116 403 forwardTM Cytosolic 19 LG:025724.10:2001MAR30404 426 forwardTM Transmembrane 19 LG:025724.10:2001MAR30427 638 forwardTM Non-Cytosolic 19 LG:025724.10:2001MAR30639 656 forwardTM Transmembrane . 1 19 LG:025724.10:2001MAR30657 662 forwardTM Cytosolic 19 LG:025724.10:2001MAR30663 685 forwardT'M Transmembrane 19 LG:025724.10:2001MAR30686 694 forwardTM Non-Cytosolic 19 LG:025724.10:2001MAR30695 717 forwardTM Transmembrane 19 LG:025724.10:2001MAR30718 728 forwardTM Cytosolic 19 LG:025724.10:2001MAR30729 748 forwardTM Transmembrane 19 LG:025724.10:2001MAR30749 762 forwardTM Non-Cytosolic 19 LG:025724.10:2001MAR30763 785 forwardTM Transmembrane 19 LG:025724.10:2001MAR30786 805 forwardTM Cytosolic 19 LG:025724.10:2001MAR30806 828 forwardTM Transmembrane 19 LG:025724.10:2002MAR30829 831 .forwardTM Non-Cytosolic 19 LG:025724.10:2001MAR30832 854 forwardTM Transmembrane 19 LG:025724.10:2001MAR30855 860 : forwardTM Cytosolic 19 LG:025724.10:2001MAR30861 883 ; forwardTM Transmembrane . 1 19 LG:025724.10:2001MAR30' 929 forwardTM Non-Cytosolic 19 LG:025724.10:2001MAR30930 952 forwardTM Transmembrane 19 LG:025724.10;2001MAR30953 993 forwardTM Cytosolic 19 LG:025724.10:2001MAR30994 1016forwardTM Transmembrane 19 LG:025724.10:2001MAR301017 1'151forwardTM Non-Cytosolic 19 LG:025724.10:2001MAR301 683 forwardTM Non-Cytosolic 19 LG:025724.10:2001MAR30684 703 forwardTM Transmembrane 19 LG:025724.10:2001MAR30704 714 forwardT'M Cytosolic 19 LG:025724.10:200IMAR30715 732 forwardTM Transmembrane 19 LG:025724.10:2001MAR30733 746 forwardTM Non-Cytosolic 19 LG:025724.10:2001MAR30747 769 forwardTM Transmembrane 19 LG:025724.10:2001MAR30770 845 forwardTM Cytosolic I9 LG:025724.10:2001MAR30846 868 forwardTM Transmembrane 19 LG:025724.10:2001MAR30869 934 forwardTM Non-Cytosolic 19 LG:025724.10:2001MAR30935 9S7 forwardTM Transmembrane 19 LG:025724.10:2001MAR30958 968 forwardTM Cytosolic 19 LG:025724.10:2001MAR30969 991 forwardTM Transmembrane 19 LG:025724.10:2001MAR30992 1024forwardTM Non-Cytosolic 19 LG:025724.10:2001MAR301025 1047forwardTM Transmembrane 19 LG:025724.10:2001MAR301048 1151forwardTM Cytosolic I9 LG:025724.10:2001MAR301 9 forwardTM Non-Cytosolic 19 LG:025724.10:2001MAR3010 28 forwardTM Transmembrane 19 LG:025724.10:2001MAR3029 74 forwardTM Cytosolic 19 LG:025724.10:2001MAR3075 97 forwardTM Transmembrane 19 LG:025724.10:2001MAR3098 396 forwardTM Non-Cytosolic 19 LG:025724.10:2001MAR30397 419 forwardTM Transmembrane ,19 LG:025724.10:2001MAR30420 635 forwardTM Cytosolic SEQ Template ID StartStopFrame Domain Topology D NO: Type 19 LG:025724.10:2001MAR30636 653forwardTM Transmembrane 19 LG:025724.10:2001MAR30654 680forwardTM Non-Cytosolic 19 LG:025724.10:2001MAR30681 703forwardTM Transmembrane 19 LG:025724.10:2001MAR30704 871forwardTM Cytosolic 19 LG:025724.10:2001MAR30872 889forwardTM Transmembrane 19 LG:025724.10:2001MAR30890 968forwardTM Non-Cytosolic 19 LG:025724.10:2001MAR30969 991forwardTM Transmembrane 19 LG:025724.10:2001MAR30992 1083forwardTM Cytosolic 19 LG:025724.10:2001MAR301084 1106forwardTM Transmembrane 19 LG:025724.10:2001MAR301107 1115forwardTM Non-Cytosolic 19 LG:025724.10:2001MAR301116 1135forwardTM Transmembrane 19 LG:025724.10:2001MAR301136 1151forwardTM Cytosolic 20 LG:1095426.1:2001MAR30I 168forwardTM Non-Cytosolic 20 LG:1095426.1:2001MAR30169 19IforwardTM Transmembrane 20 LG:1095426.1:2001MAR30192 202forwardTM Cytosolic 20 LG:1095426.1:2001MAR30203 225forwardTM Transmembrane 20 LG:1095426.1:2001MAR30226 883forwardTM Non-Cytosolic 20 LG:1095426.1:2001MAR301 119forwardTM Cytosolic 20 LG:1095426.1:2001MAR30120 142forwardTM Transmembrane 20 LG:1095426.1:2001MAR30143 882forwardTM Non-Cytosolic 2I LG:I I324I8.I:ZOOIMAR30I 141forwardTM Cytosolic 21 LG:1132418.1:2001MAR30142 164forwardTM Transmembrane 21 LG:1132418.1:2001MAR30165 260forwardTM Non-Cytosolic 22 LG:1377900.14:2001MAR301 157forwardTM Cytosolic , 1 22 LG:1377900.14:2001MAR30158 180forwardTM Transmembrane 22 LG:1377900.14:2001MAR30181 M99forwardTM Non-Cytosolic 22 LG:1377900.14:2001MAR30200 222forwardTM Transmembrane 22 LG:1377900.14:2001MAR30223 230forwardTM Cytosolic 23 LG:1383812.1:2001MAR301 83 forward, TM Non-Cytosolic 23 LG:1383812.1:2001MAR3084 106forwardTM Transmembrane 23 LG:I383812.1:2001MAR30107 125forwardTM Cytosolic 23 LG:1383812.1:2001MAR30126 143forwardTM Transmembrane 23 LG:1383812.1:2001MAR30144 152forwardTM Non-Cytosolic 23 LG:1383812.1:2001MAR30153 170forwardTM Transmembrane 23 LG:1383812.1:2001MAR30171 176forwardTM Cytosolic 23 LG:1383812.1:2001MAR30177 196forwardTM Transmembrane 23 LG:I383812.I:ZOO1MAR30197 Z00forwardTM Non-Cytosolic 23 LG:1383812.1:2001MAR30201 218forwardTM Transmembrane 23 LG:1383812.1:2001MAR30219 224forwardTM Cytosolic 23 LG:1383812.1:2001MAR30225 247forwardTM Transmembrane 23 LG:1383812.1:2001MAR30248 732forwardTM Non-Cytosolic 24 LG:1468687.1:2001MAR301 48 forwardTM Non-Cytosolic 24 LG:1468687.1:2001MAR3049 71 forwardTM Transmembrane 24 LG:1468687.1:2001MAR3072 152forwardTM Cytosolic 25 LG:1505513.1:2001MAR301 14 forwardTM Non-Cytosolic 25 LG:1505513.1:2001MAR3015 37 forwardTM Transmembrane 25 LG:1505513.1:2001MAR3038 I10forwardTM Cytosolic 25 LG:1505513.1:2001MAR30111 133forwardTM Transmembrane 25 LG:1505513.1:2001MAR30134 152forwardTM Non-Cytosolic I

25 LG:1505513.1:2001MAR30153 172forwardTM Transmembrane 25 LG:1505513.1:2001MAR30173 344forwardTM Cytosolic 25 LG:1505513.1:2001MAR301 12 forwardTM Cytosolic 25 LG:1505513.1:2001MAR3013 35 forwardTM Transmembrane 25 LG:1505513.1:2001MAR3036 49 forwardTM Non-Cytosolic SEQ Template ID Start StopFrame Domain Topolojy D NO: Type 25 LG:1505513.1:2001MAR3050 72 forwardTM Transmembrane 25 LG:1505513.1:2001MAR3073 I10forwardTM Cytosolic 25 LG:1505513.1:2001MAR30111 133forwardTM Transmembrane 25 LG:I505513.I:2001MAR30134 343forwardTM Non-Cytosolic 25 LG:1505513.1:2001MAR301 14 forwardTM Non-Cytosolic 25 LG:1505513.1:2001MAR3015 37 forwardTM Transmembrane 25 LG:1505513.1:2001MAR3038 108forwardTM Cytosolic 25 LG:1505513.1:2001MAR30109 126forwardTM Transmembrane 25 LG:1505513.1:2001MAR30127 343forwardTM Non-Cytosolic 26 ~ LG:178823.9:2001MAR301 262forwardTM Non-Cytosolic 26 LG:178823.9:2001MAR30263 281forwardTM Transmembrane 26 LG:178823.9:2001MAR30282 292forwardTM Cytosolic 26 LG:178823.9:2001MAR30293 312forwardTM Transmembrane 26 LG:178823.9:2001MAR30313 316forwardTM Non-Cytosolic 26 LG:178823.9:2001MAR30317 334forwardTM Transmembrane 26 LG:178823.9:2001MAR30335 346forwardTM Cytosolic 26 LG:178823.9:2001MAR30347 369forwardTM Transmembrane 26 LG:178823.9:2001MAR30370 398forwardTM Non-Cytosolic 26 LG:178823.9:2001MAR301 90 forwardTM Cytosolic 26 LG:178823.9:2001MAR3091 113forwardTM Transmembrane 26 LG:178823.9:2001MAR30114 127forwardTM Non-Cytosolic 26 LG:178823.9:2001MAR30128 150forwardTM Transmembrane 26 LG:178823.9:2001MAR30I51 296forwardTM Cytosolic 26 LG:178823.9:2001MAR30297 319forwardTM Transmembrane 26 LG:178823.9:2001MAR30320 333forwardTM Non-Cytosolic 26 LG:178823.9:2001MAR30334 351. forwardTM Transmembrane ' 2 26 LG:178823.9:2001MAR30352 398forwardTM Cytosolic 27 LG:198342.3:2001MAR301 1418forwardTM Non-Cytosolic 27 LG:198342.3:2001MAR301419 1441forwardTM Transmembrane 27 LG:198342.3:2001MAR301442 1545forwardTM Cytosolic 27 LG:198342.3:2001MAR301546 1568forwardTM Transmembrane 27 LG:198342.3:2001MAR301569 1597forwardTM Non-Cytosolic 28 LG:210672.1:ZOO1MAR301 397forwardTM Cytosolic 28 LG:210672.1:2001MAR30398 420forwardTM Transmembrane 28 LG:210672.1:2001MAR30421 468forwardTM Non-Cytosolic 28 LG:210672.1:2001MAR30469 491forwardTM Transmembrane 28 LG:2I0672.1:2001MAR30492 585forwardTM Cytosolic 28 LG:210672.1:2001MAR301 76 forwardTM Cytosolic 28 LG:2I0672.1:2001MAR3077 99 forwardTM Transmembrane 28 LG:210672.1:2001MAR30100 102forwardTM Non-Cytosolic 28 LG:210672.1:2001MAR30103 125forwardTM Transmembrane 28 LG:210672.1:2001MAR30126 402forwardTM Cytosolic 28 LG:210672.1:2001MAR30403 425forwardTM Transmembrane 28 LG:210672.1:2001MAR30426 585forwardTM Non-Cytosolic 29 LG:212823.8:2001MAR301 58 forwardTM Non-Cytosolic 29 LG:212823.8:2001MAR3059 81 forwardTM Transmembrane 29 LG:212823.8:2001MAR3082 100forwardTM Cytosolic 29 LG:212823.8:2001MAR30101 123forwardTM Transmembrane 29 LG:212823.8:2001MAR30124 569forwardTM Non-Cytosolic 29 LG:212823.8:2001MAR30570 588forwardTM Transmembrane 29 LG:212823.8:2001MAR30589 594forwardTM Cytosolic 29 LG:212823.8:2001MAR30595 617forwardTM Transmembrane 29 LG:212823.8:2001MAR30618 835forwardTM Non-Cytosolic 29 LG:212823.8:2001MAR301 37 forwardTM Cytosolic SEQ Template ID Start StopFrame Domain Topology D Type NO:

29 LG;212823.8:2001MAR3038 60 forwardTM Transmembrane 29 LG:212823.8:2001MAR3061 64 forwardTM Non-Cytosolic 29 LG:212823.8:2001MAR3065 82 forwardTM Transmembrane 29 LG:212823.8:2001MAR3083 88 forwardTM Cytosolic 29 LG:212823.8:2001MAR3089 111forwardTM Transmembrane 29 LG:212823.8:2001MAR30112 835forwardTM Non-Cytosolic 29 LG:212823.8:2001MAR301 9 forwardTM Non-Cytosolic 29 LG:212823.8:2001MAR3010 32 forwardTM Transmembrane 29 LG:212823.8:2001MAR3033 51 forwardTM Cytosolic 29 LG:212823.8:2001MAR3052 74 forwardTM Transmembrane 29 LG:212823.8:2001MAR3075 587forwardTM Non-Cytosolic 29 LG:212823.8:2001MAR30588 610forwardTM Transmembrane 29 LG:212823.8:2001MAR30611 834forwardTM Cytosolic 30 LG:220495.9:2001MAR301 14 forwardTM Non-Cytosolic 30 LG:220495.9:2001MAR3015 37 forwardTM Transmembrane 30 LG:220495.9:2001MAR3038 446forwardTM Cytosolic 30 LG:220495.9:2001MAR30447 465forwardTM Transmembrane 30 LG:220495.9:2001MAR30466 484forwardTM Non-Cytosolic 30 LG:220495.9:2001MAR30485 507forwardTM Transmembrane 30 LG:220495.9:2001MAR30508 567forwardTM Cytosolic 30 LG:220495.9:2001MAR30568 590forwardTM Transmembrane 30 LG:220495.9:2001MAR30591 599forwardTM Non-Cytosolic 30 LG:220495.9:2001MAR30600 622forwardTM Transmembrane 30 LG:220495.9:2001MAR30623 737forwardTM Cytosolic 30 LG:220495.9:2001MAR301 40 forwardTM Non-Cytosolie 30 LG:220495.9:2001MAR3041 63 forwardTM Transmembrane ' 2 30 LG:220495.9:2001MAR3064 163forwardTM Cytosolic 30 LG:220495.9:2001MAR30164 183forwardTM Transmembrane 30 LG:220495.9:2001MAR30184 192forwardTM Non-Cytosolic 30 LG:220495.9:2001MAR30193 210forwardTM Transmembrane 30 LG:220495.9:2001MAR30211 247forwardTM Cytosolic 30 LG:220495.9:2001MAR30248 270forwardTM Transmembrane 30 LG:220495.9:2001MAR30271 284forwardTM Non-Cytosolic 30 LG:220495.9:2001MAR30285 307forwardTM Transmembrane 30 LG:220495.9:2001MAR30308 486forwardTM Cytosolic 30 LG:220495.9:2001MAR30487 509forwardTM Transmembrane 30 LG:220495.9:2001MAR30510 737forwardTM Non-Cytosolic 31 LG:238262.1:2001MAR301 327forwardTM Cytosolic 31 LG:238262.1:2001MAR30328 350forwardTM Transmembrane 31 LG:238262.1:2001MAR30351 369forwardTM Non-Cytosolic 31 LG:238262.1:2001MAR30370 392forwardTM Transmembrane 31 LG:238262.1:2001MAR30393 405forwardTM Cytosolic 31 LG:238262.1:2001MAR301 334forwardTM Non-Cytosolic 31 LG:238262.1:2001MAR30335 357forwardTM Transmembrane 31 LG:238262.1:2001MAR30358 404forwardTM Cytosolic 32 LG:239410.21:2001MAR301 816forwardTM Non-Cytosolic 32 LG:239410.21:2001MAR30817 834forwardTM Transmembrane 32 LG:239410.21:2001MAR30835 963forwardTM Cytosolic 32 LG:239410.21:2001MAR301 139forwardTM Non-Cytosolic 32 LG:239410.21:2001MAR30140 162forwardTM Transmembrane ~ 2 32 LG:239410.21:ZOOlMAR30163 163forwardTM Cytosolic 32 LG:239410.21:2001MAR30164 186forwardTM Transmembrane 32 LG:239410.21:2001MAR30187 219forwardTM Non-Cytosolic 32 LG:239410.21:2001MAR30220 242forwardTM Transmembrane _ SEQ Template ID StartStopFrame Domain Topology D NO: Type 32 LG:239410.21:2001MAR30243 267 forwardTM Cytosolic 32 LG:239410.21:2001MAR30268 290 forwardTM Transmembrane 32 LG:239410.21:2001MAR30291 365 forwardTM Non-Cytosolic 32 LG:2394I0.21:2001MAR30366 388 forwardTM Transmembrane 32 LG:239410.2I:2001MAR30389 408 forwardTM Cytosolic 32 LG:239410.21:2001MAR30409 431 forwardTM Transmembrane 32 LG:239410.2I:2001MAR30432 470 forwardTM Non-Cytosolic 32 LG:239410.21:2001MAR30471 493 forwardTM Transmembrane 32 LG:239410.21:2001MAR30494 508 forwardTM Cytosolic 32 LG:239410.21:2001MAR30509 531 forwardTM Transmembrane 32 LG:239410.21:2001MAR30532 550 forwardTM Non-Cytosolic 32 LG:239410.21:2001MAR30551 573 forwardTM Transmembrane 32 LG:239410.21:2001MAR30574 963 forwardTM Cytosolic 33 LG:245854.7:2001MAR301 68 forwardTM Cytosolic 33 LG:245854.7:2001MAR3069 88 forwardTM Transmembrane 33 LG:245854.7:200IMAR3089 1346forwardTM Non-Cytosolic 34 LG:294697.1:2001MAR301 61 forwardTM Cytosolic ' 1 34 LG:294697.1:2001MAR3062 84 forwardTM Transmembrane 34 LG:294697.1:2001MAR3085 225 forwardTM Non-Cytosolic 34 LG:294697.1:2001MAR301 85 forwardTM Cytosolic 34 LG:294697.1:2001MAR3086 105 forwardTM Transmembrane 34 LG:294697.1:2001MAR30106 178 forwardTM Non-Cytosolic 34 LG:294697.1:2001MAR30179 201 forwardTM Transmembrane 34 LG:294697.1:2001MAR30202 224 forwardTM Cytosolic 35 LG:345884.1:2001MAR301 28 forwardTM Cytosolic 35 LG:345884.1:2001MAR3029 51 forwardTM Transmembrane 35 LG:345884.1:2001MAR3052 192 forwardTM Non-Cytosolic 36 LG:400095.15:2001MAR301 970 forwardTM Non-Cytosolic 36 LG:400095.15:2001MAR30971 993 forwardTM Transmembrane 36 LG:400095.15:2001MAR30994 997 forwardTM Cytosolic 36 LG:400095.I5:2001MAR30998 1015forwardTM Transmembrane 36 LG:400095.15:2001MAR301016 1018forwardTM Non-Cytosolic 36 LG:400095.15:2001MAR301019 1036forwardTM Transmembrane 36 LG:400095.15:2001MAR301037 1062forwardTM Cytosolic 37 LG:402180.1:2001MAR301 162 forwardTM Cytosolic 37 LG:402180.1:2001MAR30163 185 forwardTM Transmembrane 37 LG:402180.1:2001MAR30186 204 forwardTM Non-Cytosolic 37 LG:402180.1:2001MAR30205 227 forwardTM Transmembrane 37 LG:402180.1:2001MAR30228 283 forwardTM Cytosolic 37 LG:402180.1:2001MAR30284 306 forwardTM Transmembrane 37 LG:402I80.I:200IMAR30307 325 forwardTM Non-Cytosolic I

37 LG:402180.1:2001MAR30326 348 forwardTM Transmembrane I

37 LG:402180.1:2001MAR30349 560 forwardTM Cytosolic I

37 LG:402180.1:2001MAR30561 583 forwardTM Transmembrane . 1 37 LG:402180.1:2001MAR30584 614 forwardTM Non-Cytosolic 37 LG:402180.1:2001MAR306I5 637 forwardTM Transmembrane 37 LG:402180.1:2001MAR30638 658 forwardTM Cytosolic 37 LG:402180.1:2001MAR301 318 forwardTM Non-Cytosolic 37 LG:402180.1:2001MAR30319 341 forwardTM Transmembrane 37 LG:402180.1:2001MAR30342 562 forwardTM Cytosolic 37 LG:402180.I:200IMAR30563 585 forwardTM Transmembrane 37 LG:402180.1:2001MAR30586 658 forwardTM Non-Cytosolic 38 LG:403401.1:2001MAR301 176 forwardTM Cytosolic I

38 LG:403401.I:2001MAR30177 199 forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D NO: Type 38 LG:403401.1:2001MAR30200 218 forwardTM Non-Cytosolic 38 LG:403401.1:2001MAR30219 238 forwardTM Transmembrane 38 LG:403401.1:200.1MAR30239 250 forwardTM Cytosolic 38 LG:403401.1:2001MAR30251 273 forwardTM Transmembrane 38 LG:403401.1:2001MAR30274 350 forward~ TM Non-Cytosolic 38 LG:403401.1:2001MAR301 14 forwardTM Non-Cytosolic 38 LG:403401.1:2001MAR3015 37 forwardTM Transmembrane 38 LG:403401.1:2001MAR3038 176 forwardTM Cytosolic 38 LG:403401.1:2001MAR30177 199 forwardTM Transmembrane 38 LG:403401.1:2001MAR30200 213 forwardTM Non-Cytosolic 38 LG:403401.1:2001MAR30214 236 forwardTM Transmembrane 38 LG:403401.1:2001MAR30237 350 forwardTM Cytosolic 38 LG:403401.I:2001MAR30I 138 forwardTM Cytosolic 38 LG:403401.1:2001MAR30139 161 forwardTM Transmembrane 38 LG:403401.1:2001MAR30I62 192 forwardTM Non-CytosoIic 38 LG:403401.1:2001MAR30193 215 forwardTM Transmembrane 38 LG:403401.1:2001MAR30216 226 forwardTM ~ Cytosolic 38 LG:403401.1:200IMAR30227 249 forwardTM Transmembrane 38 LG:403401.1:2001MAR30250 350 forwardTM Non-Cytosolic 39 LG:411327.29:2001MAR301 97 forwardTM Cytosolic 39 LG:411327.29:2001MAR3098 120 forwardTM Transmembrane 39 LG:411327.29:2001MAR30121 371 forwardTM Non-Cytosolic 40 LG:417464.10:2001MAR301 19 forwardTM Non-Cytosolic 40 LG:417464.10:2001MAR3020 42 forwardTM Transmembrane 40 LG:417464.10:2001MAR3043 298 forwardTM Cytosolic 40 LG:417464.10:2001MAR30299 321 forwardTM Transmembrane 40 LG:417464.10:2001MAR30322 340 forwardTM Non-Cytosolic 40 LG:417464.10:2001MAR30341 363 forwardTM Transmembrane 40 LG:417464.10:2001MAR30364 418 forwardTM Cytosolic 40 LG:417464.10:2001MAR301 287 forwardTM Non-Cytosolic 40 LG:417464.10:2001MAR30288 310 forwardTM Transmembrane 40 LG:417464.10:2001MAR30311 330 forwardTM Cytosolic 40 LG:417464.10:2001MAR30331 353 forwardTM Transmembrane 40 LG:4I7464.10:200IMAR30354 367 forwardTM Non-Cytosolic 40 LG:4I7464.10:2001MAR30368 390 forwardTM Transmembrane 40 LG:417464.10:2001MAR30391 418 forwardTM Cytosolic 40 LG:417464.10:2001MAR301 1 forwardTM Cytosolic 40 LG:417464.10:2001MAR302 24 forwardTM Transmembrane 40 LG:417464.10:2001MAR3025 95 forwardTM Non-Cytosolic 40 LG:417464.10:2001MAR3096 118 forwardTM Transmembrane 40 LG:417464.10:2001MAR30119 328 forwardTM Cytosolic 40 LG:417464.10:2001MAR30329 351 forwardTM Transmembrane 40 LG:417464.10:2001MAR30352 417 forwardTM Non-Cytosolic 41 LG:481997.1:2001MAR301 82 forwardTM Cytosolic 41 LG:481997.1:2001MAR3083 105 forwardTM Transmembrane 41 LG:481997.1:2001MAR30106 152 forwardTM Non-Cytosolic 41 LG:481997.1:2001MAR30153 175 forwardTM Transmembrane 41 LG:481997.1:2001MAR30176 253 forwardTM Cytosolic 41 LG:481997.1:2001MAR30254 276 forwardTM Transmembrane 41 LG:481997.1:2001MAR30277 279 forwardTM Non-Cytosolic 4I LG:481997.I:ZOO1MAR30280 302 forwardTM Transmembrane 41 LG:481997.1:2001MAR30303 383 forwardTM Cytosolic 41 LG:481997.1:2001MAR301 81 forwardTM Cytosolic 41 LG:481997.1:ZOO1MAR3082 104 forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D Type NO:

41 LG:481997.1:2001MAR30105 382 forwardTM Non-Cytosolic 42 LG:979304.7:2001MAR301 319 forwardTM Non-Cytosolic 42 LG:979304,7:2001MAR30320 342 forwardTM Transmembrane 42 LG:979304.7:ZOOIMAR30343 354 forwardTM Cytosolic 42 LG:979304.7:2001MAR30355 377 forwardTM Transmembrane 42 LG:979304.7:2001MAR30378 391 forwardTM Non-Cytosolic 42 LG:979304.7:ZOO1MAR30392 414 forwardTM Transmembrane 42 LG:979304.7:2001MAR30415 426 forwardTM Cytosolic 43 LG:997964.1:2001MAR3021 110 forwardSP

43 LG:997964.1:2001MAR301 356 forwardTM Cytosolic 43 LG:997964.1:2001MAR30357 379 forwardTM Transmembrane 43 LG:997964.1:2001MAR30380 1082forwardTM Non-Cytosolic 44 LG:998845.1:2001MAR301 66 forwardTM Non-Cytosolic 44 LG:998845.1:2001MAR3067 89 forwardTM Transmembrane 44 LG:998845.1:2001MAR3090 281 forwardTM Cytosolic 44 LG:998845.1:2001MAR301 67 forwardTM Non-Cytosolic 44 LG:998845.1:2001MAR3068 90 forwardTM Transmembrane 44 LG:998845.1:2001MAR3091 102 forwardTM Cytosolic 44 LG:998845.1:2001MAR30103 125 forwardTM Transmembrane 44 LG:998845.1:2001MAR30126 185 forwardTM Non-Cytosolic 44 LG:998845.1:2001MAR30186 208 forwardTM Transmembrane 44 LG:998845.1:2001MAR30209 281 forwardTM Cytosolic 45 LG:000014.1:2001MAR301 92 forwardTM Cytosolic 45 LG:000014.1:2001MAR3093 115 forwardTM Transmembrane 45 LG:000014.1:2001MAR30116 156 forwardTM Non-Cytosolic 45 LG:000014.1:2001MAR30157 179 forwardTM Transmembrane 45 LG:000014.1:2001MAR30180 198 forwardTM Cytosolic 45 LG:000014.1:2001MAR30199 221 forwardTM Transmembrane 45 LG:000014.1:2001MAR30222 300 forwardTM Non-Cytosolic 45 LG:000014.1:2001MAR3030I 323 forwardTM Transmembrane 45 LG:000014.1:2001MAR30324 327 forwardTM Cytosolic 45 LG:000014.1:2001MAR30328 347 forwardTM Transmembrane 45 LG:000014.1:2001MAR30348 363 forwardTM Non-Cytosolic 45 LG:000014.1:2001MAR30I 183 forwardTM Non-Cytosolic 45 LG:000014.1:2001MAR30184 206 forwardTM Transmembrane 45 LG:000014.1:2001MAR30207 276 forwardTM Cytosolic 45 LG:000014.1:2001MAR30277 296 forwardTM Transmembrane 45 LG:000014.1:2001MAR30297 363 forwardTM Non-Cytosolic 45 LG:000014.1:2001MAR301 94 forwardTM Cytosolic 45 LG:000014.1:2001MAR3095 117 forwardTM Transmembrane 45 LG:000014.1:2001MAR30118 120 forwardTM Non-Cytosolic 45 LG:000014.1:2001MAR30121 140 forwardTM Transmembrane 45 LG:000014.1:2001MAR30141 160 forwardTM Cytosolic 45 LG:000014.1:2001MAR30161 183 forwardTM Transmembrane 45 LG:000014.1:2001MAR30184 363 forwardTM Non-Cytosolic 46 LG:000290.9:2001MAR301 559 forwardTM Non-Cytosolic 46 LG:000290.9:2001MAR30560 582 forwardTM Transmembrane 46 LG:000290.9:2001MAR30583 617 forwardTM Cytosolic 47 LG:001923.1:2001MAR301 109 forwardTM Cytosolic 47 LG:001923.1:2001MAR30110 132 forwardTM Transmembrane 47 LG:001923.1:2001MAR30133 141 forwardTM Non-Cytosolic 47 LG:001923.1:2001MAR30142 164 forwardTM Transmembrane 47 LG:001923.1:2001MAR30165 176 forwardTM Cytosolic 47 LG:001923.1:2001MAR30177 199 forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D NO: Type 47 LG:001923.1:2001MAR30200 265forwardTM Non-Cytosolic 47 LG:001923.1:2001MAR30266 288forwardTM Transmembrane 47 LG:001923.1:2001MAR30289 461forwardTM Cytosolic 47 LG:001923.I:2001MAR30462 484forwardTM Transmembrane 47 LG:001923.1:2001MAR30485 503forwardTM Non-Cytosolic 47 LG:001923.1:2001MAR30504 526forwardTM Transmembrane 47 LG:001923.1:2001MAR30527 532forwardTM Cytosolic 47 LG:001923.1:2001MAR30533 555forwardTM Transmembrane 47 LG:001923.1:2001MAR30556 590forwardTM Non-Cytosolic 47 LG:001923.1:2001MAR301 135forwardTM Non-Cytosolic 47 LG:001923.1:2001MAR30136 158forwardTM Transmernbrane 47 LG:001923.1:2001MAR30159 164forwardTM Cytosolic 47 LG:001923.1:2001MAR30I65 I87forwardTM Transmembrane 47 LG:001923.1:2001MAR30188 201forwardTM Non-Cytosolic 47 LG:00I923.1:200IMAR30202 221forwardTM Transmembrane 47 LG:001923.1:2001MAR30222 241forwardTM Cytosolic 47 LG:001923.1:2001MAR30242 264forwardTM Transmembrane 47 LG:001923.1:2001MAR30265 589forwardTM Non-Cytosolic 48 LG:008606.21:2001MAR301 160forwardTM Cytosolic 48 LG:008606.21:2001MAR30161 183forwardTM Transmembrane 48 LG:008606.21:2001MAR30184 202forwardTM Non-Cytosolic 48 LG:008606.2I:2001MAR30203 225forwardTM Transmembrane I

48 LG:008606.21:2001MAR30226 401forwardTM Cytosolic 48 LG:008606.21:2001MAR30402 424forwardTM Transmembrane 48 LG:008606.21:2001MAR30425 443forwardTM Non-Cytosolic 48 LG:008606.21:2001MAR30444 466forwardTM Transmembrane 48 LG:008606.21:2001MAR30467 668forwardTM Cytosolic 48 LG:008606.21:2001MAR301 404forwardTM Non-Cytosolic' 48 LG:008606.21:2001MAR30405 427forwardTM Transmeinbrane 48 LG:008606.21:2001MAR30428 439forwardTM Cytosolic 48 LG:008606.2I:2001MAR30440 462forwardTM Transmembrane 48 LG:008606.21:2001MAR30463 667forwardTM Non-Cytosolic 48 LG:008606.21:2001MAR301 169forwardTM Cytosolic 48 LG:008606.21:2001MAR30170 192forwardTM Transmembrane 48 LG:008606.2I:2001MAR30193 201forwardTM Non-Cytosolic 48 LG:008606.21:2001MAR30202 224forwardTM Transmembrane 48 LG:008606.21:2001MAR30225 230forwardTM Cytosolic 48 LG:008606.21:2001MAR30231 253forwardTM Transmembrane 48 LG:008606.21:2001MAR30254 410forwardTM Non-Cytosolic 48 LG:008606.21:2001MAR30411 433forwardTM Transmembrane 48 LG:008606.21:2001MAR30434 439forwardTM Cytosolic 48 LG:008606.21:2001MAR30440 462forwardTM Transmembrane 48 LG:008606.21:2001MAR30463 667forwardTM Non-Cytosolic 49 LG:009699.32:2001MAR30I 6 forwardTM Cytosolic 49 LG:009699.32:2001MAR307 25 forwardTM Transmembrane 49 LG:009699.32:2001MAR3026 127forwardTM Non-Cytosolic 49 LG:009699.32:2001MAR30128 150forwardTM Transmembrane 49 LG:009699.32:2001MAR30151 180forwardTM Cytosolic 49 LG:009699.32:200IMAR301 128forwardTM Non-Cytosolic 49 LG:009699.32:2001MAR30129 151forwardTM Transmembrane 49 LG:009699.32:2001MAR30152 180forwardTM Cytosolic 50 LG:016723.6:2001MAR301 187forwardTM Cytosolic I

50 LG:016723.6:2001MAR30188 205forwardTM Transmembrane 50 LG:016723.6:2001MAR30206 276forwardTM Non-Cytosolic SEQ Template ID StartStopFrame Domain Topology D Type NO:

S1 LG:017126.5:2001MAR301 310 forwardTM Cytosolic S1 LG:017126.5:2001MAR30311 333 forwardTM Transmembrane S1 LG:017126.5:2001MAR30334 360 forwardTM Non-Cytosolic SI LG:017I26.S:2001MAR30361 383 forward' TM Transmembrane S1 LG:017126.5:2001MAR30384 413 forwardTM Cytosolic S1 LG:017126.5:2001MAR30414 433 forwardTM Transmembrane 51 LG:017126.5:2001MAR30434 9S2 forwardTM Non-Cytosolic 52 LG:019362.10:2001MAR301 20 forwardTM Cytosolic S2 LG:019362.10:2001MAR3021 40 forwardTM Transmembrane S2 LG:019362.10:2001MAR3041 49 forwardTM Non-Cytosolic ~ 1 S2 LG:019362.I0:2001MAR30SO 72 forwardTM Transmembrane S2 LG:019362.20:2001MAR3073 304 forwardTM Cytosolic S2 LG:019362.10:2001MAR3030S 323 forwardTM Transmembrane S2 LG:019362.10:2001MAR30324 337 forward~ TM Non-Cytosolic S2 LG:019362.10:2001MAR30338 3S7 forwardTM Transmembrane S2 LG:019362.10:2001MAR30358 377 forwardTM Cytosolic 52 LG:019362.10:2001MAR30378 400 forwardTM Transmembrane S2 LG:019362.10:2001MAR30401 494 forwardTM Non-Cytosolic S2 LG:OI9362.10:2001MAR3049S S14 forwardTM Transmembrane I

S2 LG:019362.10:2001MAR30S1S S34 forwardTM Cytosolic S2 LG:019362.10:2001MAR30S3S SS7 forwardTM Transmembrane 52 LG:019362.10:2001MAR30SS8 572 forwardTM Non-Cytosolic 52 LG:019362.10:2001MAR301 47 forwardTM Non-Cytosolic S2 LG:019362:10:2001MAR3048 70 forwardTM Transmembrane S2 LG:OI9362.10:2001MAR3071 377 forwardTM Cytosolic S2 LG:019362.10:2001MAR30378 397 forwardTM Transmembrane S2 LG:019362.10:2001MAR30398 463 forwardTM Non-Cytosolic 52 LG:019362.10:2001MAR30464 483 forwardTM Transmembrane 52 LG:019362.10:2001MAR30484 49S forwardTM Cytosolic S2 LG:019362.10:2001MAR30496 S18 forwardTM Transmembrane S2 LG:019362.10:2001MAR30S19 S46 forwardTM Non-Cytosolic S2 LG:019362.10:2001MAR30S47 S69 forwardTM Transmembrane 52 LG:019362.10:2001MAR30S70 S71 forwardTM Cytosolic S3 LG:022183.1:2001MAR301 19 forwardTM Cytosolic S3 LG:022183.1:2001MAR3020 42 forwardTM Transmembrane S3 LG:022183.1:2001MAR3043 272 forwardTM Non-Cytosolic 54 LG:028493.1:2001MAR301 S21 forwardTM Non-Cytosolic S4 LG:028493.1:2001MAR30522 S44 forwardTM Transmembrane S4 LG:028493.I:ZOO1MAR30S4S 689 forwardTM Cytosolic SS LG:034I97.1:2001MAR301 12 forwardTM Cytosolic SS LG:034197.1:200IMAR3013 35 forwardTM Transmembrane SS LG:034197.1:200IMAR3036 139 forwardTM Non-Cytosolic 3 .

SS LG:034197.1:2001MAR30140 162 forwardTM Transmembrane 55 LG:034197.1:2001MAR30163 192 forwardTM Cytosolic 56 LG:054096.31:2001MAR301 723 forwardTM Non-Cytosolic S6 LG:OS4096.31:2001MAR30724 746 forward1'IvI Transmembrane S6 LG:OS4096.31:2001MAR30747 7S2 forwardTM Cytosolic S6 LG:OS4096.31:2001MAR30753 77S forwardTM Transmembrane 56 LG:OS4096.31:2001MAR30776 789 forwardTM Non-Cytosolic S6 LG:OS4096.31:2001MAR30790 812 forwardTM Transmembrane S6 LG:OS4096.31:2001MAR30813 844 forwardTM Cytosolic 57 LG:054807.3:2001MAR301 2S3 forwardTM Non-Cytosolic S7 LG:054807.3:2001MAR30254 276 forwardTM Transmembrane 57 LG:OS4807.3:2001MAR30277 330 forwardTM Cytosolic SEQ Template ID Start StopFrame bomain Topology D Type NO:

57 LG:054807.3:2001MAR30331 350forwardTM Transmembrane 57 LG:054807.3:ZOOlMAR30351 353forwardTM Non-CytosoIic 57 LG:054807.3:2001MAR30354 373forwardTM Transmembrane 57 LG:054807.3:2001MAR30374 385forwardTM Cytosolic 57 LG:054807.3:2001MAR30386 408forwardTM Transmembrane 57 LG:054807.3:2001MAR30409 458forwardTM Non-Cytosolic 57 LG:054807.3:2001MAR30459 481forwardTM Transmembrane 57 LG:054807.3:2001MAR30482 551forwardTM Cytosolic 57 LG:054807.3:2001MAR30552 574forwardTM Transmembrane 57 LG:054807.3:2001MAR30575 577forwardTM Non-Cytosolic 57 LG:054807.3:2001MAR30578 600forwardTM Transmembrane 57 LG:054807.3:2001MAR30601 694forwardTM Cytosolic 57 LG:054807.3:2001MAR30695 717forwardTM Transmembrane 57 LG:054807.3:2001MAR30718 815forwardTM Non-Cytosolic 57 LG:054807.3:2001MAR301 426forwardTM Non-Cytosolic 57 LG:054807.3:2001MAR30427 449forwardTM Transmembrane 57 LG:054807.3:2001MAR30450 461forwardTM Cytosolic 57 LG:054807.3:200IMAR30462 484forwardTM Transmembrane 57 LG:054807.3:2001MAR30485 692forwardTM Non-Cytosolic 57 LG:054807.3:2001MAR30693 7I0forwardTM Transmembrane 57 LG:054807.3:2001MAR30711 751forwardTM Cytosolic 57 LG:054807.3:2001MAR30752 774forwardTM Transmembrane 57 LG:054807.3:2001MAR30775 788forwardTM Non-Cytosolic 57 LG:054807.3:2001MAR30789 808forwardTM Transmembrane ~ , 2 57 LG:054807.3:2001MAR30809 814forwardTM Cytosolic 57 LG:054807.3:2001MAR301 I77forwardTM Cytosolic 57 LG:054807.3:2001MAR30178 197forwardTM Transmembrane 57 LG:054807.3:2001MAR30198 247forwardTM Non-Cytosolic 57 LG:054807.3:2001MAR30248 270forwardTM Transmembrane 57 LG:054807.3:2001MAR30271 327forwardTM Cytosolic 57 LG:054807.3:2001MAR30328 350forwardTM Transmembrane 57 LG:054807.3:2001MAR30351 433forwardTM Non-Cytosolic 57 LG:054807.3:2001MAR30434 456forwardTM Transmembrane 57 LG:054807.3:2001MAR30457 462forwardTM Cytosolic 57 LG:054807.3:2001MAR30463 485forwardTM Transmembrane 57 LG:054807.3:2001MAR30486 489forwardTM Non-Cytosolic 57 LG:054807.3:2001MAR30490 512forwardTM Transmembrane 57 LG:054807.3:2001MAR30513 550forwardTM Cytosolic 57 LG:054807.3:2001MAR3055I 573forwardTM Transmembrane 57 LG:054807.3:2001MAR30574 576forwardTM Non-Cytosolic 57 LG:054807.3:2001MAR30577 596forwardTM Transmembrane 57 LG:054807.3:2001MAR30597 692forwardTM Cytosolic 57 LG:054807.3:2001MAR30693 712forwardTM Transmembrane 57 LG:054807.3:2001MAR30713 814forwardTM Non-Cytosolic 58 LG:065873.12:2001MAR301 38 forwardTM Cytosolic 58 LG:065873.12:2001MAR3039 58 forwardTM Transmembrane 58 LG:065873.12:2001MAR3059 925forwardTM Non-Cytosolic 58 LG:065873.12:2001MAR301 19 forwardTM Cytosolic 58 LG:065873.12:2001MAR3020 42 forwardTM Transmembrane 58 LG:065873.12:2001MAR3043 867forwardTM Non-Cytosolic 58 LG:065873.12:ZOO1MAR30868 890forwardTM Transmembrane 58 LG:065873.12:2001MAR30891 924forwardTM Cytosolic 59 LG:083814.6:2,OO1MAR301 660forwardTM Non-Cytosolic 59 LG:083814.6:2001MAR30661 680forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D NO; Type S9 LG:083814.6:2001MAR30681 714 forwardTM Cytosolic S9 LG:083814.6:2001MAR3071S 733 forwardTM Transmembrane S9 LG:083814.6:2001MAR30734 741 forwardTM Non-Cytosolic S9 LG:083814.6:2001MAR301 68I forwardTM Non-Cytosolic S9 LG:083814.6:2001MAR30682 701 forwardTM Transmembrane S9 LG:083814.6:2001MAR30702 712 forwardTM Cytosolic S9 LG:083814.6:2001MAR30713 730 forwardTM Transmembrane S9 LG:083814.6:2001MAR30731 740 forwardTM Non-Cytosolic 60 LG:093477.1:2001MAR301 12 forwardTM Cytosolic 60 LG:093477.1:2001MAR3013 3S forwardTM Transmembrane 60 LG:093477.1:200IMAR3036 291 forwardTM Non-Cytosolic 60 LG:093477.1:2001MAR301 6 forwardTM Cytosolic 60 LG:093477.1:2001MAR307 29 forwardTM Transmembrane 60 LG:093477.1:2001MAR3030 291 forwardTM Non-Cytosolic 61 LG:099S72.12:2001MAR301 803 forwardTM Non-Cytosolic 61 LG:099S72.12:2001MAR30804 826 forwardTM Transmembrane 61 LG:099S72.12:2001MAR30827 960 forwardTM Cytosolic 61 LG:099S72.12:2001MAR30961 97S forwardTM Transmembrane 61 LG:099S72.12:2001MAR30976 984 forwardTM Non-Cytosolic 61 LG:099S72.12:2001MAR3098S 1007forwardTM Transmembrane 61 LG:099S72.12:2001MAR3010081043forwardTM Cytosolic 61 LG:099S72.12:2001MAR3010441066forwardTM Transmembrane 61 LG:099S72.12:200IMAR3010671510forwardTM Non-Cytosolic 61 LG:099572.12:2001MAR3015111533forwardTM Transmembrane 61 LG:099S72.12:2001MAR3015341$46forwardTM Cytosolic 61 LG:099572.12:2001MAR301 1008forwardTM Non-Cytosolic 61 LG:099S72.12:2001MAR30.10091031forwardTM Transmembrane 61 LG:099S72.12:2001MAR3010321089' forwardTM Cytosolic 61 LG:099S72.12:2001MAR3010901112' forwardTM Transmembrane 61 LG:099S72.12:2001MAR3011131546forwardTM Non-Cytosolic 62 LG:100396.31:2001MAR301 247 forwardTM Non-Cytosolic 62 LG:100396.31:2001MAR30248 26S forwardTM Transmembrane 62 LG:100396.31:2001MAR30266 318 forwardTM Cytosolic I

62 LG:100396.31:2001MAR30319 338 forwardTM Transmembrane 62 LG:100396.31:2001MAR30339 373 forwardTM Non-Cytosolic I

62 LG:100396.31:2001MAR30374 393 forwardTM Transmembrane 62 LG:100396.31:2001MAR30394 394 forwardTM Cytosolic 62 LG:100396.31:2001MAR301 361 forwardTM Non-Cytosolic 62 LG:100396.31:2001MAR30362 393 forwardTM Transmembrane 62 LG:100396.31:2001MAR30394 394 forwardTM Cytosolic 63 LG:1026903.5:2001MAR301 84 forwardTM Cytosolic 63 LG:1026903.5:2001MAR308S 107 forwardTM Transmembrane 63 LG:1026903.5:2001MAR30108 4S2 forwardTM Non-Cytosolic 64 LG:1060168.6:2001MAR301 147 forward' TM Cytosolic 6S LG:1086906.41:2001MAR301 417 forwardTM Non-Cytosolic 6S LG:1086906.41:2001MAR30418 435 forwardTM Transmembrane 6S LG:1086906.41:2001MAR30436 SS1 forwardTM Cytosolic 6S LG:1086906.41:2001MAR301 412 forwardTM Non-Cytosolic 6S LG:1086906.41:2001MAR30413 43S forwardTM Transmembrane 6S LG:1086906.41:2001MAR30436 SS1 forwardTM Cytosolic 66 LG:1089326.18:2001MAR301 73 forwardTM Cytosolic 66 LG:1089326.18:2001MAR3074 96 forwardTM Transmembrane 66 LG:1089326.18:2001MAR3097 807 forwardTM Non-Cytosolic 67 LG:1090862.32:2001MAR301 47 forwardTM Cytosolic SEQ Template ID StartStopFrame Domain Topology D NO: Type 67 LG:1090862.32:2001MAR3048 70 forwardTM Transmembrane 67 LG:1090862.32:200IMAR307I 568forwardTM Non-Cytosolic 68 LG:1091941.41:2001MAR301 6 forwardTM Cytosolic 68 LG:1091941.41:2001MAR307 29 forwardTM Transmembrane 68 LG:1091941.41:2001MAR3030 260forward~ TM Non-Cytosolic 69 LG:1093386.8:2001MAR301 22 forwardTM Non-Cytosolic 69 LG:1093386.8:2001MAR3023 42 forwardTM Transmembrane 69 LG:1093386.8:2001MAR3043 254forwardTM Cytosolic 69 LG:1093386.8:2001MAR30255 274forwardTM Transmembrane 69 LG:1093386.8:2001MAR30275 612forwardTM Non-Cytosolic 69 LG:I093386.8:2001MAR30613 635forwardTM Transmembrane 69 LG:1093386.8:2001MAR30636 647forwardTM Cytosolic 69 LG:1093386.8:2001MAR30648 670forwardTM Transmembrane 69 LG:1093386.8:2001MAR30671 680forwardTM Non-Cytosolic 69 LG:1093386.8:2001MAR301 123forwardTM Non-Cytosolic 69 LG:1093386.8:2001MAR30124 146forwardTM Transmembrane 69 LG:1093386.8:2001MAR30147 597forwardTM Cytosolic 69 LG:1093386.8:2001MAR30598 620forwardTM Transmembrane 69 LG:1093386.8:2001MAR30621 642forwardTM Non-Cytosolic 69 LG:I093386.8:2001MAR30643 665forwardTM Transmembrane 69 LG:1093386.8:2001MAR30666 679forwardTM Cytosolic 69 LG:1093386.8:2001MAR301 252forwardTM Non-Cytosolic 69 LG:1093386.8:2001MAR30253 275forwardTM Transmembrane 69 LG:1093386.8:2001MAR30276 294forwardTM Cytosolic 69 LG:1093386.8:2001MAR30295 317forwardTM Transmembrane 69 LG:1093386.8:2001MAR30318 596forwardTM Non-Cytosolic 69 LG:1093386.8:2001MAR30597 619forward.3TM Transmembrane 69 LG:1093386.8:2001MAR30620 639forwardTM Cytosolic 69 LG:1093386.8:2001MAR30640 662forwardTM Transmembrane 69 LG:1093386.8:2001MAR30663 679forwardTM Non-Cytosolic 70 LG:1094187.33:2001MAR301 128forwardTM Cytosolic 70 LG:1094187.33:2001MAR30129 151forwardTM Transmembrane 70 LG:1094187.33:2001MAR30152 154forwardTM Non-Cytosolic 70 LG:1094187.33:2001MAR30155 177forwardTM Transmembrane 70 LG:1094187.33:2001MAR30178 373forwardTM Cytosolic 70 LG:1094187.33:2001MAR30374 396forwardTM Transmembrane 70 LG:1094187.33:2001MAR30397 415forwardTM Non-Cytosolic 70 LG:1094187.33:2001MAR30416 438forwardTM - Transmembrane 70 LG:1094187.33:2001MAR30439 472forwardTM Cytosolic 70 LG:1094187.33:2001MAR301 126forwardTM Cytosolic 70 LG:1094187.33:2001MAR30127 149forwardTM Transmembrane 70 LG:1094187.33:2001MAR30150 181forwardTM Non-Cytosolic 70 LG:1094187.33:2001MAR30182 199forwardTM Transmembrane 70 LG:1094187.33:2001MAR30200 372forwardTM Cytosolic 70 LG:1094187.33:2001MAR30373 395forwardTM Transmembrane 70 LG:1094187.33:2001MAR30396 421forwardTM Non-Cytosolic 70 LG:1094187.33:2001MAR30422 444forwardTM Transmembrane 70 LG:1094187.33:2001MAR30445 47IforwardTM Cytosolic 70 LG:1094187.33:2001MAR301 129forwardTM Non-Cytosolic 70 LG:1094187.33:2001MAR30130 149forwardTM Transmembrane 70 LG:1094187.33:2001MAR30150 150forwardTM Cytosolic 70 LG:1094187.33:2001MAR30151 170forwardTM Transmembrane 70 LG:1094187.33:2001MAR30171 179forwardTM Non-Cytosolic 70 LG:1094187.33:2001MAR30180 197forwardTM Transmembrane SEQ D NO: Template ID - StartStopFrame Domain Topology Type 70 LG:1094187.33:2001MAR30198 355 forwardTM Cytosolic 70 LG:1094187.33:2001MAR30356 375 forwardTM Transmembrane 70 LG:1094187.33:2001MAR30376 404 forwardTM Non-Cytosolic 70 LG:1094187.33:200IMAR30405 427 forwardTM Transmembrane 70 LG:1094187.33:2001MAR30428 439 forward,3TM Cytosolic 70 LG:1094187.33:2001MAR30440 462 forwardTM Transmembrane 70 LG:1094187.33:2001MAR30463 471 forwardTM Non-Cytosolic 71 LG:1098692.18:2001MAR301 37 forwardTM Non-Cytosolic 71 LG:1098692.28:2001MAR3038 57 forwardTM Transmembrane 71 LG:1098692.18:2001MAR3058 124 forwardTM Cytosolic 71 LG:1098692.18:2001MAR30125 147 forwardTM Transmembrane 71 LG:1098692.18:2001MAR30148 176 forwardTM Non-Cytosolic 71 LG:1098692.18:ZOO1MAR30177 199 forwardTM Transmembrane 71 LG:1098692.18:2001MAR30200 211 forwardTM Cytosolic 71 LG:1098692.18:2001MAR30212 231 forwardTM Transmembrane 71 LG:1098692.18:2001MAR30232 250 forwardTM Non-Cytosolic 71 LG:1098692.18:2001MAR30251 273 forwardTM Transmembrane 71 LG:1098692.18:2001MAR30274 588 forwardTM Cytosolic 72 LG:1173104.22:2001MAR301 180 forwardTM Non-Cytosolic 72 LG:1173104.22:2001MAR30181 203 forwardTM Transmembrane 72 LG:1173104.22:2001MAR30204 265 forwardTM Cytosolic 72 LG:1173104.22:200IMAR30266 288 forwardTM Transmembrane I

72 LG:1173104.22:2001MAR30289 297 forwardTM Non-Cytosolic 72 LG:1173104.22:2001MAR30298 320 forwardTM Transmembrane 72 LG:1173104.22:2001MAR30321 389 forwardTM Cytosolic 72 LG:1173104.22:2001MAR30:1 265 forwardT'M Cytosolic 2' 72 LG:1173104.22:2001MAR30266 285 forwardT'M Transmembrane 72 LG:1173104.22:2001MAR30286 .'299forwardTM Non-Cytosolic 2' 72 LG:1173104.22:2001MAR30300 322 .forwardT'M Transmembrane 72 LG:1173104.22:2001MAR30323 389 forwardTM Cytosolic 72 LG:1I73I04.22:2001MAR301 267 forwardT'M Non-Cytosolic 72 LG:1173104.22:2001MAR30268 290 forwardT'M Transmembrane 72 LG:1173104.22:2001MAR30291 296 forwardTM Cytosolic 72 LG:1173104.22:2001MAR30297 319 forwardT'M Transmembrane 72 LG:1173104.22:2001MAR30320 388 forwardTM Non-Cytosolic 73 LG:1215335.7:2001MAR301 971 forwardT'M Non-Cytosolic 73 LG:1215335.7:2001MAR30972 994 forwardTM Transmembrane 73 LG:1215335.7:2001MAR30995 1050forwardTM Cytosolic 73 LG:1215335.7:2001MAR301 160 forwardTM Non-Cytosolic 73 LG:1215335.7:2001MAR30161 183 forwardT'M Transmembrane 73 LG:1215335.7:2001MAR30184 467 forwardT'M Cytosolic 73 LG:1215335.7:2001MAR30468 490 forwardTM Transmembrane 73 LG:1215335.7:2001MAR30491 1050forwardTM Non-Cytosolic 74 LG:1256753.1:2001MAR301 10 forwardTM Cytosolic 74 LG:1256753.I:2001MAR3011 33 forwardT'M Transmembrane 74 LG:1256753.1:2001MAR3034 614 forwardTM Non-Cytosolic 74 LG:1256753.1:2001MAR30615 637 forwardTM Transmembrane 74 LG:1256753.1:2001MAR30638 669 forwardT'M Cytosolic 74 LG:1256753.1:2001MAR301 573 forwardT'M Cytosolic 74 LG:1256753.1:2001MAR30574 596 forwardTM Transmembrane 74 LG:1256753.1:2001MAR30597 615 forwardTM Non-Cytosolic 74 LG:1256753.1:2001MAR30616 638 forwardTM Transmembrane 74 LG:1256753.1:2001MAR30639 669 forwardTM Cytosolic . 2 74 LG:1256753.1:2001MAR301 45 forwardTM Non-Cytosolic SEQ Template ID StartStopFrame Domain Topology D NO: Type 74 LG:1256753.1:2001MAR3046 68 forwardTM Transmembrane 74 LG:1256753.1:2001MAR3069 74 forwardTM Cytosolic 74 LG:1256753.1:2001MAR3075 97 forwardTM Transmembrane 74 LG:1256753.1:2001MAR3098 503forwardTM Non-Cytosolic 74 LG:1256753.1:2001MAR30504 523forwardTM Transmembrane 74 LG:1256753.1:2001MAR30524 669forwardTM Cytosolic 75 LG:I326702.10:2001MAR30I 2173forwardTM Non-Cytosolic 75 LG:1326702.10:2001MAR302174 2196forwardTM Transmembrane 75 LG:1326702.10:2001MAR302197 2202forwardTM Cytosolic 75 LG:1326702.10:2001MAR302203 2225forwardTM Transmembrane 75 LG:1326702.10:2001MAR302226 2234forwardTM Non-Cytosolic 75 LG:1326702.10:2001MAR302235 2257forwardTM Transmembrane 75 LG:1326702.10:2001MAR302258 2258forwardTM Cytosolic 75 LG:1326702.10:2001MAR301 2174forwardTM Non-Cytosolic 75 LG:1326702.I0:200IMAR302175 2197forwardTM Transmembrane 75 LG:1326702.10:2001MAR302198 2209forwardTM Cytosolic 75 LG:1326702.10:2001MAR302210 2232forwardTM Transmembrane 75 LG:1326702.10:2001MAR302233 2257forwardTM Non-Cytosolic 75 LG:1326702.10:2001MAR301 1425forwardTM Non-Cytosolic ~ 3 75 LG:1326702.10:2001MAR301426 1448forwardTM Transmembrane 75 LG:1326702.10:2001MAR301449 1521forwardTM Cytosolic 75 LG:1326702.10:2001MAR301522 1541forwardTM Transmembrane 75 LG:1326702.10:2001MAR301542 1608forwardTM Non-Cytosolic 75 LG:1326702.10:2001MAR301609 1631forwardTM Transmembrane 75 LG:1326702.10:2001MAR301632 2174forwardTM Cytosolic 75 LG:1326702.10:2001MAR302175 2197forwardTM Transmembrane 75 LG:1326702.10:2001MAR302198 2211forwardTM Non-Cytosolic 75 L,G:1326702.10:2001MAR302212 2234''forwardTM Transmembrane 75 LG:1326702.10:2001MAR302235 2257forwardTM Cytosolic 76 LG:1327239.15:2001MAR301 59 forwardTM Cytosolic 76 LG:1327239.15:2001MAR3060 82 forwardTM Transmembrane 76 LG:1327239.15:2001MAR3083 253forwardTM Non-Cytosolic 76 LG:1327239.15:2001MAR30254 276forwardTM Transmembrane 76 LG:1327239.15:2001MAR30277 287forwardTM Cytosolic 76 LG:1327239.15:2001MAR30288 310forwardTM Transmembrane 76 LG:1327239.15:2001MAR30311 499forwardTM Non-Cytosolic 76 LG:1327239.15:2001MAR301 60 forwardTM Cytosolic 76 LG:1327239.15:2001MAR3061 83 forwardTM Transmembrane 76 LG:1327239.15:2001MAR3084 120forwardTM Non-Cytosolic 76 LG:1327239.15:2001MAR30121 143forwardTM Transmembrane 76 LG:1327239.15:2001MAR30144 155forwardTM Cytosolic 76 LG:1327239.15:200IMAR30I56 178forwardTM Transmembrane 76 LG:1327239.15:2001MAR30179 499forwardTM Non-Cytosolic 76 LG:1327239.15:2001MAR301 33 forwardTM Cytosolic 76 LG:1327239.15:2001MAR3034 56 forwardTM Transmembrane 76 LG:1327239.15:2001MAR3057 60 forwardTM Non-Cytosolic 76 LG:1327239.15:2001MAR3061 83 forwardTM Transmembrane 76 LG:1327239.15:2001MAR3084 190forwardTM Cytosolic 76 LG:1327239.15:2001MAR30191 213forwardTM Transmembrane 76 LG:1327239.15:2001MAR30214 254forwardTM Non-Cytosolic 76 LG:1327239.I5:2001MAR30255 277forwardTM Transmembrane 76 LG:I327239.15:2001MAR30278 468forwardTM Cytosolic 76 LG:1327239.15:2001MAR30469 491forwardTM Transmembrane 76 LG:1327239.15:2001MAR30492 499forwardTM Non-Cytosolic 5EQ Template ID StartStopFrame Domain Topolojy D NO: Type 77 LG:1327867.I5:2001MAR301 508 forwardTM Non-Cytosolic 77 LG:1327867.15:2001MAR30509 528 forwardTM Transmembrane 77 LG:1327867.15:2001MAR30529 548 forwardTM Cytosolic 77 LG:1327867.15:2001MAR30549 571 forwardTM Transmembrane 77 LG:1327867.15:2001MAR30572 575 forwardTM Non-Cytosolic 77 LG:I327867.15:2001MAR30576 593 forwardTM Transmembrane 77 LG:1327867.15:2001MAR30594 706 forwardTM Cytosolic 77 LG:1327867.15:2001MAR30707 729 forwardTM Transmembrane 77 LG:1327867.15:2001MAR30730 774 forwardTM Non-Cytosolic 77 ' LG:1327867.15:2001MAR30775 797 forwardTM Transmembrane 77 LG:1327867.15:2001MAR30798 803 forwardTM Cytosolic 77 LG:1327867.15:2001MAR30804 826 forwardTM Transmembrane 77 LG:1327867.15:2001MAR30827 851 forwardTM Non-Cytosolic 77 LG:1327867.15:2001MAR30852 874 forwardTM Transmembrane 77 LG:1327867.15:2001MAR30875 893 forwardTM Cytosolic 77 LG:1327867.15:2001MAR30894 916 forwardTM Transmembrane 77 LG:I327867.I5:2001MAR30917 930 forwardTM Non-Cytosolic _ 1 77 LG:1327867.15:2001MAR30931 953 forwardTM Transmembrane 77 LG:1327867.15:2001MAR30954 1158forwardTM Cytosolic 77 LG:1327867.15:2001MAR3011591181forward'TM Transmembrane 77 LG:1327867.15:2001MAR3011821212forwardTM Non-Cytosolic 77 LG:1327867.15:2001MAR301 450 forwardTM Non-Cytosolic 77 LG:1327867.15:2001MAR30451 473 forwardTM Transmembrane 77 LG:1327867.15:2001MAR30474 477 forwardTM Cytosolic 77 LG:1327867.15:2001MAR30478 496 forwardTM Transmembrane 77 LG:1327867.15:2001MAR30497 505 forwardTM Non-Cytosolic . 2 .

77 LG:1327867.15:2001MAR30506 528 forwardTM Transmembrane 77 LG:I327867.15:2001MAR30529 548 forwardTM ' Cytosolic 77 LG:I327867.15:2001MAR30549 571 forwardTM Transmembrane 77 LG:1327867.15:2001MAR30572 574 forwardTM Non-Cytosolic, 77 LG:I327867.15:2001MAR30575 593 forwardTM Transmembrane 77 LG:1327867.15:2001MAR30594 718 forwardTM Cytosolic 77 LG:1327867.I5:2001MAR30719 741 forwardTM Transmembrane 77 LG:1327867.15:2001MAR30742 760 forwardTM Non-Cytosolic 77 LG:1327867.15:2001MAR30761 783 forwardTM Transmembrane 77 LG:1327867.15:2001MAR30784 789 forwardTM Cytosolic 77 LG:1327867.15:2001MAR30790 812 forwardTM Transmembrane 77 LG:1327867.15:2001MAR30813 854 forwardTM Non-Cytosolic 77 LG:1327867.15:2001MAR30855 877 forwardTM Transmembrane 77 LG:1327867.15:2001MAR30878 897 forwardTM Cytosolic 77 LG:1327867.15:2001MAR30898 920 forwardTM Transmembrane 77 LG:1327867.15:2001MAR30921 934 forwardTM Non-Cytosolic 77 LG:1327867.15:2001MAR30935 952 forwardTM Transmembrane 77 LG:1327867.15:2001MAR30953 1211forwardTM Cytosolic 77 LG:1327867.15:2001MAR301 447 forwardTM Non-Cytosolic 77 LG:1327867.15:2001MAR30448 470 forwardTM Transmembrane 77 LG:1327867.15:2001MAR30471 548 forwardTM Cytosolic 77 LG:1327867.15:2001MAR30549 571 forwardTM Transmembrane 77 LG:1327867.15:2001MAR30572 574 forwardTM Non-Cytosolic 77 LG:1327867.15:2001MAR30575 592 forwardTM Transmembrane 77 LG:1327867.15:2001MAR30S93 771 forwardTM Cytosolic 77 LG:1327867.15:2001MAR30772 794 forwardTM Transmembrane 77 LG:1327867.15:2001MAR30795 798 forwardTM Non-Cytosolic 77 LG:1327867.15:2001MAR30799 821 forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D Type NO:

77 LG:1327867.15:2001MAR30822 833 forwardTM Cytosolic 77 LG:1327867.15:2001MAR30834 856 forwardTM Transmembrane 77 LG:1327867.15:2001MAR30857 1174forwardTM Non-Cytosolic 77 LG:1327867.15:2001MAR3011751197forwardTM Transmembrane 77 LG:1327867.15:2001MAR3011981211forwardTM Cytosolic 78 LG:1383232.1:2001MAR301 20 forwardTM Cytosolic 78 LG:1383232.1:2001MAR3021 43 forwardTM Transmembrane 78 LG:1383232.1:2001MAR3044 754 forwardTM Non-Cytosolic I

78 LG:1383232.1:2001MAR30755 777 forwardTM Transmembrane 78 LG:1383232.1:2001MAR30778 788 forwardTM Cytosolic 78 LG:1383232.1:2001MAR301 14 forwardTM Non-Cytosolic 78 LG:1383232.1:2001MAR3015 34 forwardTM Transmembrane 78 LG:1383232.1:2001MAR3035 71 forwardTM Cytosolic 78 LG:1383232.1:2001MAR3072 94 forwardTM Transmembrane 78 LG:I383232.I:200IMAR3095 I forwardTM Non-Cytosolic 78 LG:1383232.1:2001MAR30114 136 forwardTM Transmembrane 78 LG:1383232.1:2001MAR30137 190 forwardTM Cytosolic 78 LG:1383232.1:2001MAR30191 213 forwardTM Transmembrane 78 LG:1383232.1:2001MAR30214 401 forwardTM Non-Cytosolic 78 LG:1383232.1:2001MAR30402 424 forwardTM Transmembrane 78 LG:1383232.1:2001MAR30425 604 forwardTM Cytosolic 78 LG:I383232.1:2001MAR30605 627 forwardTM Transmembrane 78 LG:1383232.1:2001MAR30628 720 forwardTM Non-Cytosolic 78 LG:1383232.1:200IMAR30721 743 forwardTM Transmembrane 78 LG:1383232.1:2001MAR30744 749 forwardTM Cytosolic 78 LG:1383232.1:2001MAR30750 769 forwardTM Transmembrane , 2 78 LG:1383232.1:2001MAR30770 787 forwardTM Non-Cytosolic 78 LG:1383232.1:2001MAR301 405 forwardTM Non-Cytosolic 3.

78 LG:1383232.1:2001MAR30406 428 forwardTM Transmembrane 78 LG:1383232.1:2001MAR30429 480 forwardTM Cytosolic 78 LG:1383232.1:2001MAR30481 503 forwardTM Transmembrane 78 LG:1383232.1:2001MAR30504 699 forwardTM Non-Cytosolic 78 LG:1383232.1:2001MAR30700 722 forwardTM Transmembrane 78 LG:1383232.1:2001MAR30723 728 forwardTM Cytosolic 78 LG:1383232.1:2001MAR30729 747 forwardTM Transmembrane 78 LG:I383232.I:2001MAR30748 756 forwardTM Non-Cytosolic 78 LG:1383232.1:2001MAR30757 776 forwardTM Transmembrane 78 LG:1383232.1:2001MAR30777 787 forwardTM Cytosolic 79 LG:1383368.40:2001MAR301 393 forwardTM Cytosolic 79 LG:1383368.40:2001MAR30394 416 forwardTM Transmembrane 79 LG:1383368.40:2001MAR30417 482 forwardTM Non-Cytosolic 79 LG:1383368.40:2001MAR30483 500 forwardTM Transmembrane 79 LG:I383368.40:2001MAR30501 574 forwardTM Cytosolic 79 LG:1383368.40:2001MAR30575 597 forwardTM Transmembrane 79 LG:1383368.40:2001MAR30598 695 forwardTM Non-Cytosolic 79 LG:1383368.40:2001MAR30696 718 forwardTM Transmembrane 79 LG:1383368.40:2001MAR30719 753 forwardTM Cytosolic 79 LG:1383368.40:2001MAR30754 776 forwardTM Transmembrane 79 LG:1383368.40:2001MAR30777 795 forwardTM Non-Cytosolic 79 LG:I383368.40:2001MAR30796 818 forwardTM Transmembrane I

79 LG:1383368.40:2001MAR30819 838 forwardTM Cytosolic 79 LG:1383368.40:2001MAR30839 861 forwardTM Transmembrane 79 LG:1383368.40:2001MAR30862 922 forwardTM Non-Cytosolic 79 LG:1383368.40:2001MAR30923 945 forwardTM Transmembrane SEQ Template ID StartStopFrame Domain TopoIoQy D NO: Type 79 LG:1383368.40:2001MAR30946 1030forwardTM Cytosolic 79 LG:1383368.40:2001MAR3010311050forwardTM Transmembrane 79 LG:1383368.40:2001MAR3010511077forwardTM Non-Cytosolic 79 LG:1383368.40:2001MAR3010781100forwardTM Transmembrane 79 LG:1383368.40:2001MAR3011011112forwardTM Cytosolic 79 LG:1383368.40:ZOOIMAR301 398 forwardTM Non-Cytosolic 79 LG:1383368.40:2001MAR30399 421 forwardTM Transmembrane 79 LG:1383368.40:2001MAR30422 578 forwardTM Cytosolic 79 LG:1383368.40:2001MAR30579 601 forwardTM Transmembrane 79 LG:1383368.40:2001MAR30602 604 forwardTM Non-Cytosolic 79 LG:1383368.40:2001MAR30605 627 forwardTM Transmembrane 79 LG:1383368.40:2001MAR30628 704 forwardTM Cytosolic 79 LG:1383368.40:2001MAR30705 724 forwardTM Transmembrane 79 LG:1383368.40:2001MAR30725 733 forwardTM Non-Cytosolic 79 LG:1383368.40:2001MAR30734 756 forwardTM Transmembrane 79 LG:1383368.40:2001MAR30757 767 forwardTM Cytosolic 79 LG:1383368.40:2001MAR30768 790 forwardTM Transmembrane 79 LG:1383368.40:2001MAR30791 804 forwardTM Non-Cytosolic 79 LG:1383368.40:2001MAR30805 823 forwardTM Transmembrane 79 LG:1383368.40:2001MAR30824 829 forwardTM Cytosolic 79 LG:1383368.40:2001MAR30830 847 forwardTM Transmembrane 79 LG:1383368.40:2001MAR30848 856 forwardTM Non-Cytosolic 79 LG:1383368.40:200IMAR30857 879 forwardTM Transmembrane 79 LG:1383368.40:200IMAR30880 1005forwardTM Cytosolic 79 LG:1383368.40:2001MAR3010061028forwardTM Transmembrane 79 LG:1383368.40:2001MAR3010291032forward. TM Non-Cytosolic 79 LG:1383368.40:2001MAR3010331052forwardTM Transmembrane 79 LG:1383368.40:2001MAR3010531077forwardTM Cytosolic 79 LG:1383368.40: 200IMAR3010781100forwardTM Transmembrane 79 LG:1383368.40:2001MAR3011011112forwardTM Non-Cytosolic 79 LG:1383368.40:2001MAR301 129 forwardTM Cytosolic 79 LG:1383368.40:2001MAR30130 152 forwardTM Transmembrane 79 LG:1383368.40:2001MAR30153 396 forwardTM Non-Cytosolic 79 LG:1383368.40:2001MAR30397 419 forwardTM Transmembrane 79 LG:1383368.40:2001MAR30420 443 forwardTM Cytosolic 79 LG:1383368:40:2001MAR30444 466 forwardTM Transmembrane 79 LG:1383368.40:2001MAR30467 485 forwardTM Non-Cytosolic 79 LG:1383368.40:2001MAR30486 508 forwardTM Transmembrane 79 LG:1383368.40:2001MAR30509 574 forwardTM Cytosolic 79 LG:1383368.40:2001MAR30575 597 forwardTM Transmembrane 79 LG:1383368.40:2001MAR30598 ~ forwardTM Non-Cytosolic I

79 LG:1383368.40:2001MAR30612 631 forwardTM Transmembrane 79 LG:1383368.40:2001MAR30632 855 forwardTM Cytosolic 79 LG:1383368.40:2001MAR30856 878 forwardTM Transmembrane 79 LG:1383368.40:2001MAR30879 913 forwardTM Non-Cytosolic 79 LG:1383368.40:2001MAR30914 936 forwardTM Transmembrane 79 LG:1383368.40:2001MAR30937 1002forwardTM Cytosolic 79 LG:1383368.40:2001MAR3010031025forwardTM Transmembrane 79 LG:1383368.40:2001MAR3010261081forwardTM Non-Cytosolic 79 LG:1383368.40:2001MAR3010821104forwardTM Transmembrane 79 LG:1383368.40:2001MAR30110511 forwardTM Cytosolic I

80 LG:1384477.1:2001MAR301 77 forwardTM Non-Cytosolic 80 LG:1384477.1:2001MAR3078 100 forwardTM Transmembrane 80 LG:1384477.1:2001MAR30101 I forwardTM Cytosolic SEQ Template ID StartStopFrame Domain Topolojy D Type NO:

80 LG:1384477.1:2001MAR30113 135 forwardTM Transmembrane I

80 LG:1384477.1:2001MAR30136 601 forwardTM Non-Cytosolic 80 LG:1384477.1:2001MAR30602 624 forwardTM Transmembrane 80 LG:1384477.1:2001MAR30625 639 forwardTM Cytosolic 80 LG:1384477.1:2001MAR301 127 forward~ TM Cytosolic 80 LG:1384477.1:2001MAR30128 150 forwardTM Transmembrane 80 LG:1384477.1:2001MAR30151 639 forwardTM Non-Cytosolic 80 LG:1384477.1:2001MAR301 62 forwardTM Cytosolic 80 LG:1384477.1:2001MAR3063 80 forwardTM Transmembrane 80 LG:I384477.1:2001MAR3081 639 forwardTM Non-Cytosolic 81 LG:1390822.1:2001MAR301 550 forwardTM Non-Cytosolic 81 LG:1390822.1:2001MAR30551 573 forwardTM Transmembrane 81 LG:1390822.1:2001MAR30574 744 forwardTM Cytosolic 81 LG:1390822.1:2001MAR30745 767 forwardTM Transmembrane 81 LG:1390822.1:2001MAR30768 776 forwardTM Non-Cytosolic 81 LG:1390822.1:2001MAR30777 799 forwardTM Transmembrane 81 LG:1390822.1:2001MAR30800 811 forwardTM Cytosolic 81 LG:1390822.1:2001MAR30812 834 forwardTM Transmembrane 81 LG:1390822.1:2001MAR30835 921 forwardTM Non-Cytosolic I

81 LG:I390822.1:2001MAR30922 944 forwardTM Transmembrane I

81 LG:I390822.1:2001MAR30945 977 forwardTM Cytosolic I

81 LG:1390822.1:2001MAR30978 1000forwardTM Transmembrane 81 LG:1390822.1:2001MAR3010011049forwardTM Non-Cytosolic 81 LG:1390822.1:2001MAR3010501067forwardTM Transmembrane 81 LG:1390822.1:2001MAR3010681102forwardTM Cytosolic 81 LG:1390822.1:2001MAR3011031125forwardTM Transmembrane 81 LG:1390822.1:2001MAR3011261134forwardTM Non-Cytosolic 8~1 LG:1390822.1:2001MAR30' 1157forwardTM Transmembrane 81 LG:1390822.1:2001MAR3011581236forwardTM Cytosolic 81 LG:1390822.1:2001MAR301 549 forwardTM Non-Cytosolic 81 LG:1390822.1:2001MAR30550 572 forwardTM Transmembrane 81 LG:1390822.1:2001MAR30573 765 forwardTM Cytosolic 81 LG:1390822.1:2001MAR30766 788 forwardTM Transmembrane 81 LG:1390822.1:2001MAR30789 816 forwardTM Non-Cytosolic 81 LG:1390822.1:2001MAR30817 839 forwardTM Transmembrane 81 LG:1390822.I:2001MAR30840 910 forwardTM Cytosolic 81 LG:I390822.1:2001MAR30911 933 forwardTM Transmembrane 8I LG:1390822.1:2001MAR30934 1049forwardTM Non-Cytosolic 81 LG:1390822.1:2001MAR3010501067forwardTM Transmembrane 81 LG:1390822.1:2001MAR3010681097forwardTM Cytosolic 81 LG:1390822.1:2001MAR3010981120forwardTM Transmembrane 81 LG:1390822.1:2001MAR3011211236forwardTM Non-Cytosolic 82 LG:1398274.13:2001MAR30I 9 forwardTM Non-Cytosolic 82 LG:1398274.13:2001MAR3010 32 forwardTM Transmembrane 82 LG:1398274.13:2001MAR3033 36 forwardTM Cytosolic 82 LG:1398274.13:2001MAR3037 54 forwardTM Transmembrane 82 LG:1398274.13:2001MAR3055 901 forwardTM Non-Cytosolic I

82 LG:1398274.13:2001MAR30902 924 forwardTM Transmembrane 82 LG:1398274.13:200IMAR30925 973 forwardTM Cytosolic I

82 LG:1398274.13:2001MAR30974 996 forwardTM Transmembrane 82 LG:1398274.13:2001MAR30997 1354forwardTM Non-Cytosolic 82 LG:1398274.13:2001MAR3013551377forwardTM Transmembrane 82 LG:1398274.13:2001MAR3013781410forwardTM Cytosolic 82 LG:1398274.13:2001MAR301 4 forwardTM Non-Cytosolic SEQ Template ID StartStopFrame Domain Topology D N~: Type 82 LG:1398274.13:2001MAR305 27 forwardTM Transmembrane 82 LG:1398274,13:2001MAR3028 33 forwardTM Cytosolic 82 LG:1398274.13:2001MAR3034 56 forwardTM Transmembrane 82 LG:1398274.13:2001MAR3057 498forwardTM Non-Cytosolic 82 LG:1398274.13:2001MAR30499 516forwardTM Transmembrane 82 LG:1398274.13:2001MAR30517 522forwardTM Cytosolic 82 LG:1398274.13:2001MAR30523 545forwardTM Transmembrane 82 LG:1398274.13:2001MAR30546 891forwardTM Non-Cytosolic 82 LG:1398274.13:2001MAR30892 914forwardTM Transmembrane 82 LG:1398274.13:2001MAR30915 934forwardTM Cytosolic 82 LG:1398274.13:2001MAR30935 952forwardTM Transmembrane 8Z LG:1398274.13:2001MAR30953 96IforwardTM Non-Cytosolic 82 LG:1398274.13:2001MAR30962 984forwardTM Transmembrane 82 LG:1398274.13;2001MAR30985 1349forwardTM Cytosolic 82 LG:1398274.13;2001MAR301350 1372forwardTM Transmembrane 82 LG:1398274.13:2001MAR301373 1410forwardTM Non-Cytosolic 82 LG:1398274.13:2001MAR301 236forwardTM Non-Cytosolic 82 LG:1398274.13:2001MAR30237 259forwardTM Transmembrane 82 LG:1398274.13:2001MAR30260 353forwardTM Cytosolic 82 LG:1398274.13:2001MAR30354 376forwardTM Transmembrane 82 LG:1398274.13:2001MAR30377 390forwardTM Non-Cytosolic 82 LG:1398274.13:2001MAR30391 413forwardTM Transmembrane 82 LG:I398274.13:2001MAR30414 448forwardTM Cytosolic 82 LG:1398274.13:2001MAR30449 471forwardTM Transmembrane 82 LG:1398274.13:2001MAR30472 485forwardTM Non-Cytosolic 82 LG:1398274.13:2001MAR30486 508forwardTM Transmembrane 82 LG:1398274.13:2001MAR30509 520forwardTM Cytosolic 82 LG:I398274.13:2001MAR3052I 538forwardTM Transmembrane 82 LG:1398274.13:2001MAR30539 754forwardTM Non-Cytosolic 82 LG;1398274.13:2001MAR30755 774forwardTM Transmembrane 82 LG;1398274.13:2001MAR30775 802forwardTM Cytosolic 82 LG:1398274.13:2001MAR30803 825forwardTM Transmembrane 82 LG:1398274.13:2001MAR30826 839forwardTM Non-Cytosolic 82 LG:1398274.13:2001MAR30840 862forwardTM Transmembrane 82 LG:1398274.13:2001MAR30863 894forwardTM Cytosolic 82 LG:1398274.13:2001MAR30895 914forwardTM Transmembrane 82 LG:1398274.13:2001MAR30915 1286forwardTM Non-Cytosolic 82 LG:1398274.13:2001MAR301287 1309forwardTM Transmembrane 82 LG:1398274.13:2001MAR301310 1320forwardTM Cytosolic 82 LG:1398274.13:2001MAR301321 1343forwardTM Transmembrane 82 LG:1398274.13:2001MAR301344 1352forwardTM Non-Cytosolic 82 LG:1398274.13:2001MAR301353 1375forwardTM Transmembrane 82 LG:1398274.13:2001MAR301376 1410forwardTM Cytosolic 83 LG:1398646.1:2001MAR301 6 forwardTM Cytosolic 83 LG:1398646.1:2001MAR307 26 forwardTM Transmembrane 83 LG:1398646.1:2001MAR3027 431forwardTM Non-Cytosolic 83 LG:1398646.1:2001MAR30432 454forwardTM Transmembrane 83 LG:1398646.1:2001MAR30455 820forwardTM Cytosolic 83 LG:1398646.1:2001MAR30821 843forwardTM Transmembrane 83 LG:1398646.1:2001MAR30844 852forwardTM Non-Cytosolic I

83 LG:1398646.1:2001MAR30853 872forwardTM Transmembrane 83 LG:1398646.1:2001MAR30873 873forwardTM Cytosolic 83 LG:1398646.1:2001MAR30874 891forwardTM Transmembrane 83 LG:1398646.1:2001MAR30892 905forwardTM Non-Cytosolic SEQ Template ID StartStopPrame Domain Topology D NO: Type 83 LG:1398646.1:2001MAR30906 928forwardTM Transmembrane 83 LG:1398646.1:2001MAR30929 1081forwardTM Cytosolic 83 LG:1398646.1:2001MAR301 867forwardTM Non-Cytosolic 83 LG:1398646.1:2001MAR30868 890forwardTM Transmembrane 83 LG:1398646.1:2001MAR30891 1033forwardTM Cytosolic 83 LG:1398646.1:2001MAR301034 1053forwardTM Transmembrane 83 LG:1398646.I:2001MAR301054 1080forwardTM Non-Cytosolic 83 LG:1398646.1:2001MAR301 12 forwardTM Cytosolic 83 LG:1398646.1:2001MAR3013 35 forwardTM Transmembrane 83 LG:1398646.1:2001MAR3036 614forwardTM Non-Cytosolic 83 LG:1398646.1:2001MAR30615 634forwardTM Transmembrane 83 LG:1398646.1:2001MAR30635 866forwardTM Cytosolic 83 LG:I398646.1:2001MAR30867 889forwardTM Transmembrane 83 LG:1398646.I:2001MAR30890 903forwardTM Non-Cytosolic 83 LG:1398646.1:2001MAR30904 926forwardTM Transmembrane 83 LG:1398646.1:2001MAR30927 1032forwardTM Cytosolic 83 LG:1398646.1:2001MAR301033 1055forwardTM Transmembrane 83 LG:1398646.1:2001MAR301056 1080forwardTM Non-Cytosolic 84 LG:1398905.1:2001MAR301 278forwardTM Non-Cytosolic 84 LG:1398905.1:200IMAR30279 296forwardTM Transmembrane 84 LG:I398905.I:2001MAR30297 308forwardTM Cytosolic 84 LG:1398905.1:2001MAR30309 331forwardTM Transmembrane 84 LG:1398905.1:2001MAR30332 488forwardTM Non-Cytosolic 84 LG:1398905.1:2001MAR301 277forwardTM Non-Cytosolic 84 LG:1398905.1:2001MAR30278 295forwardTM Transmembrane 84 LG:1398905.1:2001MAR30296 487forwardTM Cytosolic 85 LG:1399785.1:2001MAR301 104forwardTM Non-Cytosolic 85 LG:1399785.12001MAR30105 124forwardTM Transmembrane 85 LG:1399785.1:2001MAR30125 145forwardTM Cytosolic 85 LG:1399785.1:2001MAR30146 168forwardTM Transmembrane 85 LG:1399785.1:2001MAR30169 1902forwardTM Non-Cytosolic 86 LG:1446193.10:2001MAR301 941forwardTM Non-Cytosolic 86 LG:1446193.10:2001MAR30942 961forwardTM Transmembrane 86 LG:1446193.10:2001MAR30962 1020forwardTM Cytosolic 87 LG:1446210.8:2001MAR301 50 forwardTM Cytosolic 87 LG:1446210.8:2001MAR30S1 70 forwardTM Transmembrane 87 LG:1446210.8:2001MAR3071 74 forwardTM Non-Cytosolic 87 LG:1446210.8:2001MAR3075 97 forwardTM Transmembrane 87 LG:1446210.8:2001MAR3098 117forwardTM Cytosolic 87 LG:1446210.8:2001MAR30118 140forwardTM Transmembrane . 1 87 LG:1446210.8:2001MAR30141 159forwardTM Non-Cytosolic 87 LG:1446210.8:2001MAR30160 182forwardTM Transmembrane 87 LG:1446210.8:2001MAR30183 333forwardTM Cytosolic I

87 LG:1446210.8:2001MAR30334 356forwardTM Transmembrane 87 LG:14462I0.8:2001MAR30357 375forwardTM Non-Cytosolic 87 LG:14462I0.8:2001MAR30376 398forwardTM Transmembrane 87 LG:1446210.8:2001MAR30399 404forwardTM Cytosolic 87 LG:1446210.8:2001MAR30405 427forwardTM Transmembrane 87 LG:1446210.8:2001MAR30428 596forwardTM Non-Cytosolic 87 LG:1446210.8:2001MAR301 43 forwardTM Cytosolic 87 LG:1446210.8:2001MAR3044 66 forwardTM Transmembrane 87 LG:I446210.8:2001MAR3067 369forwardTM Non-Cytosolic 87 LG:1446210.8:2001MAR30370 392forwardTM Transmembrane 87 LG:1446210.8:2001MAR30393 563forwardTM Cytosolic SEQ Template ID StartStopFrame Domain Topology D Type N0:

87 LG:1446210.8:2001MAR30564 586 forwardTM Transmembrane 87 LG:1446210.8:2001MAR30587 596 forwardTM Non-Cytosolic 88 LG:1450054.6:2001MAR301 1807forwardTM Non-Cytosolic 88 LG:1450054.6:2001MAR3018081827forwardTM Transmembrane 88 LG:1450054.6:2001MAR3018281865forwardTM Cytosolic 89 LG:1452516.4:2001MAR301 567 forwardTM Non-Cytosolic 89 LG;1452516.4:2001MAR30S68 590 forwardTM Transmembrane 89 LG:1452516.4:2001MAR30S91 634 forwardTM Cytosolic 90 LG:1455293.7:2001MAR301 27 forwardTM Non-Cytosolic 90 LG:1455293.7:2001MAR3028 46 forwardTM Transmembrane 90 LG:1455293.7:2001MAR3047 202 forwardTM Cytosolic 90 LG:1455293.7:200IMAR30203 225 forwardTM Transmembrane 90 LG:I455293.7:200IMAR30226 544 forwardTM Non-CytosoIic 90 LG:1455293.7:2001MAR301 23 forwardTM Non-Cytosolic 90 LG:1455293.7:2001MAR3024 46 forwardTM Transmembrane 90 LG:1455293.7:2001MAR3047 200 forwardTM Cytosolic 90 LG:1455293.7:2001MAR30201 223 forwardTM Transmembrane 90 LG:1455293.7:2001MAR30224 242 forwardTM Non-Cytosolic 90 LG:1455293.7:2001MAR30243 260 forwardTM Transmembrane 90 LG:1455293.7:2001MAR30261 272 forwardTM Cytosolic 90 LG:1455293.7:2001MAR30273 290 forwardTM Transmembrane 90 LG:1455293.7:2001MAR30291 485 forwardTM Non-Cytosolic 90 LG:1455293.7:2001MAR30486 505 forwardTM Transmembrane 90 LG:1455293.7:2001MAR30506 511 forwardTM Cytosolic 90 LG:1455293.7:2001MAR30512 534 forwardTM Transmembrane 90 LG:1455293,7:2001MAR30535 543 forwardTM Non-Cytosolic 90 LG:1455293.7:2001MAR301 202 forwardTM Cytosolic 90 LG:1455293.7:2001MAR30203 225 forwardTM Transmembrane ~ 3 90 LG:14S5293.7:2001MAR30.226 262 forwardTM Non-Cytosolic 90 LG:1455293.7:2001MAR30263 285 forwardTM Transmembrane 90 LG:I455293.7:2001MAR30286 305 forwardTM Cytosolic 90 LG:1455293.7:2001MAR30306 328 forwardTM Transmembrane 90 LG:1455293.7:2001MAR30329 401 forwardTM Non-Cytosolic 90 LG:1455293.7:2001MAR30402 424 forwardTM Transmembrane 90 LG:1455293.7:2001MAR30425 461 forwardTM Cytosolic 90 LG:1455293.7:2001MAR30462 484 forwardTM Transmembrane 90 LG:1455293.7:2001MAR30485 489 forwardTM Non-Cytosolic 90 LG:145S293.7:2001MAR30490 512 forwardTM Transmembrane 90 LG:145S293.7:2001MAR30513 543 forwardTM Cytosolic 91 LG:1498113.1:2001MAR301 216 forwardTM Cytosolic 92 LG:1500042.1:2001MAR301 4 forwardTM Non-Cytosolic 92 LG:1500042.1:2001MAR305 27 forwardTM Transmembrane 92 LG:1500042.1:2001MAR3028 31 forwardTM Cytosolic I

92 LG:1500042.I:ZOOIMAR3032 54 forwardTM Transmembrane 92 LG:1500042.1:2001 55 68 forwardTM Non-Cytosolic 92 LG:1500042.1:2001MAR3069 91 forwardTM Transmembrane 92 LG:1500042.1:2001MAR3092 97 forwardTM Cytosolic 92 LG:1500042.1:2001MAR3098 117 forwardTM Transmembrane 92 LG:1500042.1:2001MAR301l8 122 forwardTM Non-Cytosolic I

92 LG:1500042.1:2001MAR301 6 forwardTM Cytosolic 92 LG:1500042.1:2001MAR307 29 forwardTM Transmembrane 92 LG:1500042.1:2001MAR3030 33 forwardTM Non-CytosoIic 92 LG:1500042.1:2001 34 56 forwardTM Transmembrane 92 LG:1500042.1:2001MAR3057 62 forwardTM Cytosolic SEQ Template ID StartStopFrame Domain Topology D Type NO:

92 LG:1500042.1:2001MAR3063 85 forwardTM Transmembrane 92 LG:1500042.1:2001MAR3086 122 forwardTM Non-Cytosolic 92 LG:1500042.1:2001MAR301 1 forwardTM Cytosolic 92 LG:1500042.1:2001MAR302 24 forwardTM Transmembrane 92 LG:1500042.1:2001MAR3025 38 forwardTM Non-Cytosolic 92 LG:1500042.1:2001MAR3039 61 forwardTM Transmembrane 92 LG:I500042.1:200IMAR3062 87 forwardTM Cytosolic 92 LG:1500042.1:200IMAR3088 110 forwardTM Transmembrane 92 LG:1500042.1:2001MAR3011I 122 forwardTM Non-Cytosolic 93 LG:1500434.4:2001MAR301 179 forwardTM Non-Cytosolic 93 LG:1500434.4:2001MAR30180 202 forwardTM Transmembrane 93 LG:1500434.4:2001MAR30203 405 forwardTM Cytosolic ~ 1 93 LG:1500434.4:2001MAR30406 423 forwardTM Transmembrane 93 LG:1500434.4:2001MAR30424 479 forwardTM Non-Cytosolic 93 LG:1500434.4:2001MAR30480 502 forwardTM Transmembrane 93 LG:1S00434.4:2001MAR30503 543 forwardTM Cytosolic 93 LG:IS00434.4:2001MAR30544 566 forwardTM Transmembrane 93 LG:1500434.4:2001MAR30567 593 forwardTM Non-Cytosolic 93 LG:1500434.4:200IMAR30594 616 forwardTM Transmembrane 93 LG:1500434.4:200IMAR30617 660 forwardTM Cytosolic 93 LG:1500434.4:2001MAR30661 683 forwardTM Transmembrane 93 LG:1500434.4:2001MAR30684 697 forwardTM Non-Cytosolic 93 LG:1500434.4:2001MAR30698 720 forwardTM Transmembrane 93 LG:1500434.4:2001MAR30721 726 forwardTM Cytosolic 93 LG:1500434.4:2001MAR30727 749 forwardTM Transmembrane 93 LG:1500434.4:2001MAR30-750 763 forwardTM Non-Cytosolic . 1 93 LG:1500434.4:2001MAR30764 786 forwardlTM Transmembrane 93 LG:I500434.4:2001MAR30787 951 forwardTM Cytosolic 93 LG:1500434.4:2001MAR30952 974 forwardTM Transmembrane 93 LG:1500434.4:2001MAR30975 1002forwardTM Non-Cytosolic 93 LG:1500434.4:2001MAR301003 1025forwardTM Transmembrane 93 LG:1500434.4:2001MAR301026 1098forwardTM Cytosolic 93 LG:1500434.4:2001MAR301099 1121forwardTM Transmembrane 93 LG:1500434.4:2001MAR301122 1135forwardTM Non-Cytosolic 93 LG:1500434.4:2001MAR301136 1158forwardTM Transmembrane 93 LG:1500434.4:2001MAR301159 1249forwardTM Cytosolic 93 LG:1500434.4:2001MAR301 428 forwardTM Non-Cytosolic 93 LG:1500434.4:2001MAR30429 451 forwardTM Transmembrane 93 LG:1500434.4:2001 452 551 forwardTM Cytosolic 93 LG:1500434.4:2001MAR30552 574 forwardTM Transmembrane 93 LG:1500434.4:2001MAR30575 588 forwardTM Non-Cytosolic 93 LG:1500434.4:2001MAR30589 611 forwardTM Transmembrane 93 LG:1500434.4:2001MAR30612 696 forwardTM Cytosolic 93 LG:1500434.4:2001MAR30697 719 forwardTM Transmembrane 93 LG:1500434.4:2001MAR30720 733 forwardTM Non-Cytosolic 93 LG:1500434.4:2001MAR30734 753 forwardTM Transmembrane 93 LG:1500434.4:2001MAR30754 834 forwardTM Cytosolic 93 LG:1500434.4:200IMAR30835 857 forwardTM Transmembrane 93 LG:1500434.4:2001MAR30858 871 forwardTM Non-Cytosolic 93 LG:1500434.4:ZOO1MAR30872 894 forwardTM Transmembrane 93 LG:1500434.4:2001MAR30895 984 forwardTM Cytosolic 93 LG:1500434.4:2001MAR30985 1007forwardTM Transmembrane 93 LG:I500434.4:2001MAR301008 1096forwardTM Non-Cytosolic 93 LG:1500434.4:2001MAR301097 1119forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D NO: Type 93 LG:1500434.4:2001MAR3011201145forwardTM Cytosolic 93 LG:1500434.4:2001MAR3011461168forwardTM Transmembrane 93 LG:1500434.4:2001MAR3011691172forwardTM Non-Cytosolic 93 LG:1500434.4:2001MAR301173I forwardTM Transmembrane 93 LG:1500434.4:2001MAR3011961249forwardTM Cytosolic 93 LG:1500434.4:2001MAR301 511 forwardTM Non-Cytosolic 93 LG:1500434.4:200IMAR30512 531 forwardTM Transmembrane 93 LG:1500434.4:2001MAR30532 551 forwardTM Cytosolic 93 LG:1500434.4:2001MAR30552 574 forwardTM Transmembrane 93 LG:1500434.4:2001MAR30575 610 forwardTM Non-CytosoIic 93 LG:1500434.4:2001MAR30611 633 forwardTM Transmembrane 93 LG:1500434.4:2001MAR30634 655 forwardTM Cytosolic 93 LG:1500434.4:2001MAR30656 678 forwardTM Transmembrane 93 LG:1500434.4:2001MAR30679 697 forwardTM Non-Cytosolic 93 LG:1500434.4:2001MAR30698 720 forwardTM Transmembrane 93 LG:1500434.4:2001MAR30721 732 forwardTM Cytosolic 93 LG:1500434.4:200IMAR30733 755 forwardTM Transmembrane 93 LG:1500434.4:2001MAR30756 963 forwardTM Non-Cytosolic 93 LG;1500434.4:2001MAR30964 986 forwardTM Transmembrane 93 LG:1500434.4:2001MAR30987 998 forwardTM Cytosolic 93 LG:1500434.4:2001MAR30999 1021forwardTM Transmembrane 93 LG:1500434.4:2001MAR3010221060forwardTM Non-Cytosolic 93 LG:1500434.4:2001MAR3010611078forwardTM Transmembrane 93 LG:I500434.4:2001MAR3010791145forwardTM Cytosolic 3' 93 LG:1500434.4:2001MAR3011461168forwardTM Transmembrane 93 LG:1500434.4:2001MAR3011691171forwardTM, Non-Cytosolic 93 LG:1500434.4:2001MAR3011721189forwardTM Transmembrane 93 LG:1500434.4:2001MAR3011901208forwardTM Cytosolic 93 LG:1500434.4:2001MAR3012091231forwardTM Transmembrane 93 LG:1500434.4:2001MAR3012321249forwardTM Non-Cytosolic 94 LG:1501102.4:2001MAR301 45 forwardTM Non-Cytosolic 94 LG:1501102.4:2001IvIAR3046 68 forwardTM Transmembrane 94 LG:1501102.4:2001MAR3069 98 forwardTM Cytosolic 94 LG:1501102.4:2001MAR3099 121 forwardTM Transmembrane I

94 LG:1501102.4:2001MAR30122 426 forwardTM Non-Cytosolic 94 LG:1501102.4:2001MAR301 91 forwardTM Cytosolic 94 LG:1501102.4:2001MAR3092 111 forwardTM Transmembrane 94 LG:1501102.4:2001MAR30112 114 forwardTM Non-Cytosolic 94 LG:1501102.4:2001MAR301 134 forwardTM Transmembrane 94 LG:1501102.4:2001MAR30135 170 forwardTM Cytosolic 94 LG:1501102.4:2001MAR30171 193 forwardTM Transmembrane 94 LG:1501102.4:2001MAR30194 425 forwardTM Non-Cytosolic 95 LG:1501768.2;2001MAR301 6 forwardTM Cytosolic 95 LG:1501768.2;2001MAR307 29 forwardTM Transmembrane 95 LG:1501768.2:2001MAR3030 85 forwardTM Non-Cytosolic 96 LG:1502155.6:2001MAR301 315 forwardTM Non-Cytosolic 96 LG:1502155.6:2001MAR30316 338 forwardTM Transmembrane 96 LG:1502155.6:2001MAR30339 401 forwardTM Cytosolic 97 LG:1512304.2:2001MAR301 92 forwardTM Cytosolic 97 LG:1512304.2:2001MAR3093 115 forwardTM Transmembrane 97 LG:1512304.2:2001MAR30116 180 forwardTM Non-Cytosolic 97 LG:1512304.2:2001MAR30181 203 forwardTM Transmembrane 97 LG:1512304.2:2001MAR30204 245 forwardTM Cytosolic 97 LG:1512304.2:2001MAR30246 268 forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D Type NO:

97 LG:1512304.2:2001MAR30269 278 forwardTM Non-Cytosolic 97 LG:1512304.2:2001MAR301 240 forwardTM Non-Cytosolic 97 LG:1512304.2:2001MAR30241 263 forwardTM Transmembrane 97 LG:1512304.2:2001MAR30264 278 forwardTM Cytosolic 97 LG:1512304.2:2001MAR301 89 forward~ TM Cytosolic 97 LG:1512304.2:2001MAR3090 112 forwardTM Transmembrane 97 LG:1512304.2:2001MAR30113 137 forwardTM Non-Cytosolic 97 LG:1512304.2:2001MAR30138 160 forwardTM Transmembrane 97 LG:1512304.2:2001MAR30161 176 forwardTM Cytosolic 97 LG:1512304.2:2001MAR30177 199 forwardTM Transmembrane 97 LG:1512304.2:2001MAR30200 231 forwardTM Non-Cytosolic 97 LG:1512304.2:2001MAR30232 254 forwardTM Transmembrane 97 LG:1512304.2:2001MAR30255 277 forwardTM Cytosolic 98 LG:1512931.11:2001MAR301 260 forwardTM Non-Cytosolic 98 LG:1512931.11:2001MAR30261 280 forwardTM Transmembrane 98 LG:1512931.11:2001MAR30281 296 forwardTM Cytosolic 98 LG:1512931.11:2001MAR301 260 forwardTM Cytosolic 98 LG:15I2931.I1:2001MAR30261 283 forwardTM Transmembrane 98 LG:1512931.11:2001MAR30284 296 forwardTM Non-Cytosolic 99 LG:155076.18:2001MAR301 1165forwardTM Non-Cytosolic 99 LG:155076.18:2001MAR3011661188forwardTM Transmembrane 99 LG:I55076.I8:2001MAR3011891194forwardTM Cytosolic 99 LG:155076.18:2001MAR3011951214forwardTM Transmembrane 99 LG:155076.18:2001MAR3012151590forwardTM Non-Cytosolic 100 LG:159111.41:2001MAR301 193 forwardTM Non-Cytosolic 100 LG:159111.41:2001MAR30194 216 forwardTM - Transmembrane I''' 100 LG:159111.41:2001MAR30217 351 forwardTM Cytosolic l 100 LG:159111.41:2001MAR30352 374 forward' TM ~ Transmembrane 100 LG:159111.41:2001MAR30375 383 forward' ' TM Non-Cytosolic 100 LG:159111.41:2001MAR30384 406 forwardTM Transmembrane 100 LG:159111.41:2001MAR30407 412 forwardTM Cytosolic 100 LG:159111.41:2001MAR30413 430 forwardTM Transmembrane 100 LG:159111.41:2001MAR30431 2269forwardTM Non-Cytosolic 100 LG:159111.41:200IMAR301 19I forwardTM Non-Cytosolic 100 LG:159111.41:2001MAR30192 214 forwardTM Transmembrane 100 LG:159111.41:2001MAR30215 382 forwardTM Cytosolic 100 LG:159111.41:2001MAR30383 405 forwardTM Transmembrane 100 LG:159111.41:2001MAR30406 2269forwardTM Non-Cytosolic 101 LG:170604.1:2001MAR301 240 forwardTM Cytosolic 101 LG:170604.1:2001MAR30241 260 forwardTM Transmembrane ~ 3 101 LG:I70604.I:2001MAR30261 262 forwardTM Non-Cytosolic 102 LG:I90477.4:2001MAR301 4 forwardTM Non-Cytosolic 102 LG:190477.4:2001MAR305 27 forwardTM Transmembrane 102 LG:190477.4:2001MAR3028 70 forwardTM Cytosolic 102 LG:190477.4:2001MAR3071 93 forwardTM Transmembrane 102 LG:190477.4:2001MAR3094 124 forwardTM Non-Cytosolic 102 LG:190477.4:2001MAR30125 147 forwardTM Transmembrane 102 LG:190477.4:2001MAR30148 153 forwardTM Cytosolic 102 LG:I90477.4:2001MAR30154 176 forwardTM Transmembrane 102 LG:190477.4:2001MAR30177 207 forwardTM Non-Cytosolic 102 LG:190477.4:2001MAR30208 230 forwardTM Transmembrane 102 LG:190477.4:2001MAR30231 341 forwardTM Cytosolic 102 LG:190477.4:2001MAR30342 364 forwardTM Transmembrane 102 LG:190477.4:2001MAR30365 401 forwardTM Non-Cytosolic SEQ Template ID Start StopFrame Domain Topology D Type NO:

102 LG:190477.4:2001MAR30402 421forwardTM Transmembrane 102 LG:190477.4:2001MAR30422 427forwardTM Cytosolic 102 LG:190477.4:2001MAR30428 44SforwardTM Transmembrane 102 LG:190477.4:2001MAR30446 449forwardTM Non-Cytosolic 102 LG:190477.4:2001MAR30450 472forwardTM Transmembrane ~

102 LG:190477.4:2001MAR30473 S02forwardTM Cytosolic l 102 LG:190477.4:2001MAR30S03 S2SforwardTM Transmembrane I

102 LG:190477.4:2001MAR30S26 623forwardTM Non-Cytosolic 102 LG:190477.4:2001MAR30624 646forwardTM Transmembrane 102 LG:190477.4:2001MAR30647 6S2forwardTM Cytosolic 102 LG:190477.4:2001MAR306S3 672forwardTM Transmembrane 102 LG:190477.4:2001MAR30673 691forwardTM Non-Cytosolic 102 LG:190477.4:200IMAR30692 714forwardTM Transmembrane I

102 LG:190477.4:2001MAR3071S 720forwardTM Cytosolic 102 LG:190477.4:2001MAR30721 743forwardTM Transmembrane 102 LG:I90477.4:2001MAR30744 7S7forwardTM Non-Cytosolic 102 LG:190477.4:2001MAR307S8 780forwardTM Transmembrane 102 LG:190477.4:2001MAR30781 827forwardTM Cytosolic 102 LG:190477.4:2001MAR301 S1 forwardTM Cytosolic 102 LG:190477.4:2001MAR30S2 74 forwardTM Transmembrane 102 LG:190477.4:2001MAR3075 83 forwardTM Non-Cytosolic 102 LG:190477.4:2001MAR3084 106forwardTM Transmembrane 102 LG:190477.4:2001MAR30107 126forwardTM Cytosolic 102 LG:190477.4:2001MAR30127 149forwardTM Transmembrane 102 LG:190477.4:2001MAR30150 S79forwardTM Non-Cytosolic 102 LG:190477.4:2001MAR30S80 602forwardTM Transmembrane 102 LG:190477.4:2001MAR30603 622forwardTM ' Cytosolic 102 LG:190477.4:2001MAR30623 64SforwardTM ' Tran'smembrane 102 LG:190477.4:2001MAR30646 664forwardTIvI Non-Cytosolic . 2 102 LG:190477.4:2001MAR3066S 682forwardTM Transmembrane 102 LG:190477.4:2001MAR30683 826forwardTM Cytosolic 102 LG:190477.4:2001MAR301 6S forwardTM Cytosolic 102 LG:190477.4:2001MAR3066 83 forwardTM Transmembrane 102 LG:190477.4:2001MAR30'84 97 forwardTM Non-Cytosolic 102 LG:190477.4:200IMAR3098 117forwardTM Transmembrane 102 LG:190477.4:2001MAR30118 123forwardTM Cytosolic 102. LG:190477.4:2001MAR30124 146forwardTM Transmembrane 102 LG:190477.4:2001MAR30147 206forwardTM Non-Cytosolic 102 LG:190477.4:2001MAR30207 229forwardTM Transmembrane 102 LG:190477.4:2001MAR30230 283forwardTM Cytosolic 102 LG:190477.4:2001MAR30284 306forwardTM Transmembrane 102 LG:190477.4:2001MAR30307 333forwardTM Non-Cytosolic 102 LG:190477.4:2001MAR30334 3S6forwardTM Transmembrane 102 LG:190477.4:2001MAR30357 399forwardTM Cytosolic 102 LG:190477.4:2001MAR30400 417forwardTM Transmembrane 102 LG:190477.4:2001MAR30418 436forwardTM Non-Cytosolic 102 LG:190477.4:2001MAR30437 4S6forwardTM Transmembrane 102 LG:190477.4:2001MAR30457 S84forwardTM Cytosolic 102 LG:190477.4:2001MAR30S8S 607forwardTM Transmembrane 102 LG:190477.4:2001MAR30608 626forwardTM Non-Cytosolic 102 LG:190477.4:2001MAR30627 649forwardTM Transmembrane 102 LG:190477.4:200IMAR306S0 661forwardTM Cytosolic 102 LG:190477.4:2001MAR30662 684forwardTM Transmembrane 102 LG:190477.4:2001MAR3068S 693forwardTM Non-Cytosolic SEQ Template ID Start StopFrame Domain TopoloDy D NO: Type 102 LG:190477.4:2001MAR30694 713forwardTM Transmembrane 102 LG:190477.4:2001MAR30714 719forwardTM Cytosolic 102 LG:I90477.4:2001MAR30720 742forwardTM Transmembrane 102 LG:190477.4:2001MAR30743 7S6forwardTM Non-CytosoIic 102 LG:190477.4:2001MAR30757 779forwardTM Transmembrane 102 LG:190477.4:2001MAR30780 826forwardTM Cytosolic 103 LG:198087.8:2001MAR301 312forwardTM Non-Cytosolic 103 LG:198087.8:2001MAR30313 33SforwardTM Transmembrane 103 LG:198087.8:2001MAR30336 399forwardTM Cytosolic 103 LG:198087.8:2001MAR30400 419forwardTM Transmembrane 103 LG:198087.8:2001MAR30420 433forwardTM Non-Cytosolic 103 LG:198087.8:2001MAR30434 456forwardTM Transmembrane 103 LG:I98087.8:2001MAR304S7 468forwardTM Cytosolic 103 LG:198087.8:2001MAR30469 491forwardTM Transmembrane 103 LG:198087.8:2001MAR30492 S84forwardTM Non-Cytosolic 103 LG:198087.8:2001MAR30S8S 607forwardTM Transmembrane 103 LG:198087.8:2001MAR30608 781forwardTM Cytosolic 103 LG:I98087.8:ZOO1MAR30782 804forwardTM Transmembrane 2' 103 LG:198087.8:2001MAR3080S 835forwardTM Non-Cytosolic 103 LG:198087.8:2001MAR30836 8S8forwardTM Transmembrane 103 LG:198087.8:2001MAR308S9 864forwardTM Cytosolic 103 LG:198087.8:2001MAR3086S 887forwardTM Transmembrane 103 LG:198087.8:2001MAR30888 997forwardTM Non-Cytosolic 103 LG:198087.8:2001.MAR30998 1017forwardTM Transmembrane 103 LG:198087.8:200IMAR301018 1023forwardTM Cytosolic 103 LG:198087.8:2001MAR301024 1046forwardTM Transmembrane 103 LG:198087.8:2001MAR301047 lOSSforwardTM Non-Cytosolic 103 LG:198087.8:2001MAR3010S6 1073forwardTM' Transmembrane 103 LG:198087.8:2001MAR301074 1310forwardTM Cytosolic 103 LG:I98087.8:2001MAR301 40SforwardTM Non-Cytosolic 103 LG:198087.8:2001MAR30406 428forwardTM Transmembrane 103 LG:198087.8:2001MAR30429 434forwardTM Cytosolic 103 LG:198087.8:2001MAR30435 457forwardTM Transmembrane 103 LG:198087.8:2001MAR304S8 987forwardTM Non-Cytosolic 103 LG:198087.8:2001MAR30988 1010forwardTM Transmembrane 103 LG:198087.8:2001MAR301011 1022forwardTM Cytosolic 103 LG:198087.8:2001MAR301023 1040forwardTM Transmembrane 103 LG:198087.8:2001MAR301041 IOS4forwardTM Non-Cytosolic 103 LG:198087.8:2001MAR30LOSS 1072forwardTM Transmembrane 103 LG:198087.8:2001MAR301073 1310forwardTM Cytosolic 104 LG:198743.2:2001MAR30I 1132forwardTM Non-Cytosolic 104 LG:198743.2:2001MAR301133 1152forwardTM Transmembrane 104 LG:198743.2:2001MAR301153 1164forwardTM Cytosolic I04 LG:198743.2:2001MAR301165 1187forwardTM Transmembrane 104 LG:198743.2:200IMAR301188 I21SforwardTM Non-Cytosolic 104 LG:198743.2:2001MAR301 1038forwardTM Non-Cytosolic I04 LG:198743.2:200IMAR301039 IOS8forwardTM Transmembrane 104 LG:198743.2:200IMAR301059 1105forwardTM Cytosolic 104 LG:198743.2:2001MAR301106 1128forwardTM Transmembrane 104 LG:198743.2:2001MAR301129 1215forwardTM Non-Cytosolic 104 LG:198743.2:2001MAR301 983forwardTM Non-Cytosolic 104 LG:198743.2:2001MAR30984 1006forwardTM Transmembrane 104 LG:198743.2:2001MAR301007 1012forwardTM Cytosolic 104 LG:198743.2:2001MAR301013 1035forwardTM Transmembrane SEQ D NO: Template ID StartStopFrame Domain Topolojy Type 104 LG:198743.2:2001MAR301036 1044forwardTM Non-Cytosolic 104 LG:198743.2:2001MAR301045 1067forwardTM Transmembrane 104 LG:198743.2:2001MAR301068 1214forwardTM Cytosolic 105 LG:199194.1:2001MAR301 75 forwardTM Cytosolic 105 LG:199194.1:2001MAR3076 95 forwardTM Transmembrane 105 LG:199194.1:2001MAR3096 1183forwardTM Non-Cytosolic 105 LG:199194.1:2001MAR301 479 forwardTM Non-Cytosolic 105 LG:199194.1:2001MAR30480 502 forwardTM Transmembrane 105 LG:199194.1:2001MAR30503 597 forwardTM Cytosolic 105 ' LG:199194.1:2001MAR30598 617 forwardTM Transmembrane 105 LG:199194.1:2001MAR30618 631 forwardTM Non-Cytosolic 105 ' LG:199194.1:2001MAR30632 654 forwardTM Transmembrane 105 LG:199194.1:2001MAR30655 658 forwardTM Cytosolic 105 LG:199194.1:2001MAR30659 681 forwardTM Transmembrane 105 LG:199194.1:2001MAR30682 1182forwardTM Non-Cytosolic 106 LG:200727.6:2001MAR301 351 forwardTM Non-Cytosolic 106 LG:200727.6:2001MAR3Q352 374 forwardTM Transmembrane I06 LG:200727.6:2001MAR30375 474 forwardTM Cytosolic 107 LG:201572.20:2001MAR301 12 forwardTM Non-Cytosolic 107 LG:201572.20:2001MAR3013 35 forwardTM Transmembrane 107 LG:201572.20:200IMAR3036 74 forwardTM Cytosolic 107 LG:201572.20:2001MAR3075 97 forwardTM Transmembrane 107 LG:201572.20:2001MAR3098 185 forwardTM Non-Cytosolic 107 LG:201572.20:2001MAR30186 203 forwardTM Transmembrane 107 LG:201572.20:2001MAR30204 485 forwardTM Cytosolic 107 LG:201572.20:2001MAR30486 508 forwardTM Transmembrane 107 LG:201572.20:2001MAR30509 546 forwardTM Non-Cytosolic I07 LG:201572.20:200IMAR30547 569 forwardTM Transmembrane 107 LG:201572.20:2001MAR30570 589 forwardTM Cytosolic 107 LG:201572.20:2001MAR30590 612 forwardTM Transmembrane I07 LG:201572.20:2001MAR30613 706 forwardTM Non-Cytosolic 107 LG:201572.20:2001MAR30707 729 forwardTM Transmembrane 107 LG:201572.20:2001MAR30730 861 forwardTM Cytosolic 107 LG:201572.20:2001MAR30862 884 forwardTM Transmembrane 107 LG:201572.20:2001MAR30885 898 forwardTM Non-Cytosolic 107 LG:201572.20:2001MAR30899 918 forwardTM Transmembrane 107 LG:201572.20:2001MAR30919 930 forwardTM Cytosolic 107 LG:201572.20:2001MAR30931 948 forwardTM Transmembrane 107 LG:201572.20:2001MAR30949 1215forwardTM Non-Cytosolic 107 LG:201572.20:2001MAR301 14 forwardTM Non-Cytosolie 107 LG:201572.20:2001MAR3015 37 forwardTM Transmembrane 107 LG:201572.20:2001MAR3038 234 forwardTM Cytosolic 107 LG:201572.20:2001MAR30235 257 forwardTM Transmembrane 107 LG:201572.20:2001MAR30258 486 forwardTM Non-Cytosolic 107 LG:201572.20:2001MAR30487 505 forwardTM Transmembrane 107 LG:201572.20:2001MAR30506 589 forwardTM Cytosolic 107 LG:201572.20:2001MAR30590 612 forwardTM Transmembrane 107 LG:201572.20:200IMAR30613 703 forwardTM Non-Cytosolic 107 LG:201572.20:2001MAR30704 726 forwardTM Transmembrane I07 LG:201572.ZO:ZOO1MAR30727 790 forwardTM Cytosolic 107 LG:201572.20:2001MAR30791 813 forwardTM Transmembrane 107 LG:201572.20:2001MAR30814 897 forwardTM Non-Cytosolic 107 LG:201572.20:2001MAR30898 920 forwardTM Transmembrane 107 LG:201572.20:2001MAR30921 938 forwardTM Cytosolic SEQ Template ID StartStopFrame Domain Topology D Type NO:

107 LG:201572.20:2001MAR30939 961 forwardTM Transmembrane 107 LG:201572.20:2001MAR30962 964 forwardTM Non-Cytosolic I07 LG:201572.20:2001MAR30965 982 forwardTM Transmembrane 107 LG:201572.20:2001MAR30983 1215forwardTM Cytosolic 107 LG:201572.20:2001MAR301 14 forwardTM Non-Cytosolic 107 LG:201572.20:2001MAR3015 37 forwardTM Transmembrane 107 LG:201572.20:2001MAR3038 88 forwardTM Cytosolic 107 LG:201572.20:2001MAR3089 111 forwardTM Transmembrane 107 LG:201572.20:2001MAR30112 180 forwardTM Non-Cytosolic I07 LG:20I572.20:2001MAR30I8I 203 forwardTM Transmembrane 107 LG:201572.20:2001MAR30204 348 forwardTM Cytosolic 107 LG:201572.20:ZOO1MAR30349 368 forwardTM Transmembrane 107 LG:201572.20:2001MAR30369 494 forwardTM Non-Cytosolic 107 LG:201572.20:2001MAR30495 517 forwardTM Transmembrane 107 LG:201572.20:2001MAR30518 523 forwardTM Cytosolic 107 LG:201572.20:2001MAR30524 542 forwardTM Transmembrane 107 LG:201572.20:2001MAR30543 561 forwardTM Non-Cytosolic 107 LG:201572.20:2001MAR30562 584 forwardTM Transmembrane 107 LG:201572.20:2001MAR30585 590 forwardTM Cytosolic 107 LG:201572.20:2001MAR30591 613 forwardTM Transmembrane 107 LG:201572.20:2001MAR30614 808 forwardTM Non-Cytosolic 107 LG:201572.20:2001MAR30809 826 forwardTM Transmembrane 107 LG:201572.20:2001MAR30827 900 forwardTM Cytosolic 107 LG:201572.20:2001MAR30901 918 forwardTM Transmembrane 107 LG:201572.20:2001MAR30919 937 forwardTM Non-Cytosolic 107 LG:201572.20:2001MAR30938. 960 forwardTM Transmembrane . 3 107 LG:201572.20:2001MAR30961 1118forwardTM Cytosolic 107 LG:201572.20:2001MAR301119 1141forwardTM Transmembrane . 3 107 LG:201572.20:2001MAR301142 1214forwardTM Non-Cytosolic 108 LG:201669.25:2001MAR301 20 forwardTM Cytosolic 108 LG:201669.25:2001MAR3021 43 forwardTM Transmembrane 108 LG:201669.25:2001MAR3044 1148forwardTM Non-Cytosolic' 108 LG:201669.25:2001MAR301 195 forwardTM Non-Cytosolic 108 LG:201669.25:2001MAR30196 218 forwardTM Transmembrane 108 LG:201669.25:2001MAR30219 244 forwardTM Cytosolic 108 LG:201669.25:2001MAR30245 267 forwardTM Transmembrane 108 LG:201669.25:2001MAR30268 271 forwardTM Non-Cytosolic 108 LG:201669.25:2001MAR30272 294 forwardTM Transmembrane 108 LG:201669.25:2001MAR30295 320 forwardTM Cytosolic 108 LG:201669.25:2001MAR30321 338 forwardTM Transmembrane 108 LG:201669.25:2001MAR30339 342 forwardTM Non-Cytosolic 108 LG:201669.25:2001MAR30343 360 forwardTM Transmembrane 108 LG:201669.25:2001MAR30361 372 forwardTM Cytosolic 108 LG:201669.25:2001MAR30373 392 forwardTM Transmembrane 108 LG:201669.25:2001MAR30393 436 forwardTM Non-Cytosolic 108 LG:201669.25:2001MAR30437 454 forwardTM Transmembrane 108 LG:201669.25:2001MAR30455 466 forwardTM Cytosolic 108 LG:201669.25:2001MAR30467 489 forwardTM Transmembrane 108 LG:201669.25:2001MAR30490 1147forwardTM Non-Cytosolic 109 LG:208588.4:2001MAR301 35 forwardTM Cytosolic 109 LG:208588.4:2001MAR3036 55 forwardTM Transmembrane 109 LG:208588.4:2001MAR3056 93 forwardTM Non-Cytosolic 110 LG:210412.29:2001MAR301 33 forwardTM Cytosolic 110 LG:210412.29:2001MAR3034 S6 forwardTM Transmembrane SEQ Template ID Start StopFrame Domain Topology D Type NO:

110 LG:210412.29:2001MAR3057 373forwardTM Non-Cytosolic 110 LG:210412.29:2001MAR301 31 forwardTM Non-Cytosolic 110 LG:210412.29:2001MAR3032 54 forwardTM Transmembrane 110 LG:210412.29:2001MAR3055 134forwardTM Cytosolic 110 LG:210412.29:2001MAR30135 157forwardTM Transmembrane I10 LG:210412.29:20.O1MAR30158 373forwardTM Non-Cytosolic 110 LG:210412.29:2001MAR301 31 forwardTM Cytosolic 110 LG:210412.29:2001MAR3032 S1 forwardTM Transmembrane 110 LG:210412.29:2001MAR3052 54 forwardTM Non-Cytosolic 110 LG:210412.29:2001MAR3055 77 forwardTM Transmembrane 110 LG:210412.29:2001MAR3078 372forwardTM Cytosolic 111 LG:215051.15:2001MAR301 67 forwardTM Non-Cytosolic 111 LG:215051.15:2001MAR3068 85 forwardTM Transmembrane 111 LG:215051.15:2001MAR3086 167forwardTM Cytosolic 111 LG:215051.15:2001MAR30168 190forwardTM Transmembrane 111 LG:215051.15:2001MAR30191 234forwardTM Non-Cytosolic 111 LG:2ISOSl.1S:2001MAR30235 254forwardTM Transmembrane 111 LG:215051.15:2001MAR30255 292forwardTM Cytosolic 111 LG:215051.15:2001MAR30293 315forwardTM Transmembrane 111 LG:2150S1.1S:2001MAR30316 329forwardTM Non-Cytosolic 111 LG:215051.15:2001MAR30330 352forwardTM Transmembrane 111 LG:215051.15:2001MAR30353 6S1forwardTM Cytosolic I

111 LG:215051.15:2001MAR30652 674forwardTM Transmembrane I11 LG:215051.15:2001MAR30~ 675 841forwardTM Non-Cytosolic 111 LG:215051.15:2001MAR30842 864forwardTM Transmembrane 111' LG:215051.15:2001MAR30865 931forwardTM Cytosolic 111 LG:21S051:15:2001MAR301 167forwardTM Non-Cytosolic 111 LG:215051:15:2001MAR30~ '168190forwardTM Transmembrane 11 LG:21S051.15:2001MAR30'191 201forwardTM Cytosolic I 11 LG:215051.15:2001MAR30202 224forwardTM Transmembrane 111 LG:215051.15:2001MAR30225 846forwardTM Non-Cytosolic 111 LG:215051.15:2001MAR30847 869forwardTM Transmembrane 11 LG:215051.15:2001MAR30870 930forwardTM Cytosolic 112 LG:215475.21:2001MAR301 153forwardTM Cytosolic 112 LG:215475.21:2001MAR30154 176forwardTM Transmembrane 112 LG:215475.21:2001MAR30177 185forwardTM Non-Cytosolic 112 LG:215475.21:2001MAR30186 208forwardTM Transmembrane 112 LG:215475.21:2001MAR30209 293forwardTM Cytosolic 112 LG:21S475.21:2001MAR30294 316forwardTM Transmembrane 112 LG:215475.21:2001MAR30317 445forwardTM Non-Cytosolic 112 LG:215475.21:2001MAR30446 468forwardTM Transmembrane 112 LG:215475.21:2001MAR30469 474forwardTM Cytosolic 112 LG:215475.21:2001MAR30475 497forwardTM Transmembrane 112 LG:215475.21:2001MAR30498 506forwardTM Non-Cytosolic l l2 LG:215475.21:2001MAR30507 529forwardTM Transmembrane 112 LG:21S475.21:2001MAR30530 S80forwardTM Cytosolic . 1 112 LG:215475.21:2001MAR30581 603forwardTM Transmembrane 112 LG:21S47S.21:2001MAR30604 622forwardTM Non-Cytosolic 112 LG:215475.21:2001MAR30623 641forwardTM Transmembrane 112 LG:21S475.21:2001MAR30642 647forwardTM Cytosolic 112 LG:21S47S.21:2001MAR30648 670forwardTM Transmembrane 112 LG:215475.21:2001MAR30671 684forwardTM Non-Cytosolic 112 LG:21S475.21:2001MAR30685 707forwardTM Transmembrane 112 LG:215475.21:2001MAR30708 734forwardTM Cytosolic SEQ Template ID StartStopFrame Domain Topology D Type NO:

112 LG:215475.21:2001MAR30735 757 forwardTM Transmembrane 112 LG:215475.21:2001MAR30758 795 forwardTM Non-Cytosolic 1I2 LG:2I5475.21:2001MAR30796 818 forwardTM Transmembrane 112 LG:215475.21:2001MAR30819 922 forwardTM Cytosolic 112 LG:215475.21:2001MAR30923 945 forward~ TM Transmembrane 112 LG:215475.21:2001MAR30946 976 forwardTM Non-Cytosolic 112 LG:215475.21:2001MAR30977 999 forwardTM Transmembrane 112 LG:215475.21:2001MAR301000 1128forwardTM Cytosolic 112 LG:215475.21:2001MAR301 142 forwardTM Cytosolic 112 LG:215475.21:2001MAR30143 165 forwardTM Transmembrane 112 LG:215475.21:2001MAR30166 231 forwardTM Non-Cytosolic 112 LG:215475.21:2001MAR30232 251 forwardTM Transmembrane 112 LG:215475.21:2001MAR30252 334 forwardTM Cytosolic 112 LG:215475.21:2001MAR30335 357 forwardTM Transmembrane 112 LG:215475.21:2001MAR30358 664 forwardTM Non-CytosoIic 112 LG:2I5475.21:2001MAR30665 687 forwardTM Transmembrane 112 LG:215475.21:2001MAR30688 693 forwardTM Cytosolic 112 LG:215475.21:2001MAR30694 716 forwardTM Transmembrane 112 LG:215475.21:2001MAR30717 730 forwardTM Non-Cytosolic 112 LG:215475.21:2001MAR30731 753 forwardTM Transmembrane 112 LG:215475.21:2001MAR30754 799 forwardTM Cytosolic 112 LG:215475.21:2001MAR30800 822 forwardTM Transmembrane 112 LG:215475.21:2001MAR30823 971 forwardTM Non-Cytosolic 112 LG:2I5475.21:2001MAR30972 994 forwardTM Transmembrane 112 LG:215475.21:2001MAR30995 1000forward' TM Cytosolic 112 LG:215475.21:2001MAR301001 1023forwardTM - Transmembrane 112 LG:215475.21:2001MAR301024 1128forwardT'M Non-Cytosolic 112 LG:215475.21:2001MAR301 589'forwardTM Non-Cytosolic 112 LG:215475.21:2001MAR30590 612 forwardTM Transmembrane . 3 112 LG:215475.21:2001MAR30613 793 forwardTM Cytosolic 112 LG:215475.21:2001MAR30794 816 forwardTM Transmembrane I I2 LG:215475.21:2001MAR30817 1127forwardTM Non-Cytosolic 113 LG:224523.1:2001MAR301 19 forwardTM Non-Cytosolic l l3 LG:224523.1:2001MAR3020 42 forwardTM Transmembrane 113 LG:224523.1:2001MAR3043 116 forwardTM Cytosolic 113 LG:224523.1:2001MAR30117 134 forwardTM Transmembrane I

113 LG:224523.1:2001MAR30135 148 forwardTM Non-Cytosolic I

113 LG:224523.1:2001MAR30149 171 forwardTM Transmembrane 113 LG:224523.1:2001MAR30172 213 forwardTM Cytosolic 113 LG:224523.1:200IMAR301 116 forwardTM Cytosolic 113 LG:224523.1:2001MAR30117 139 forwardTM Transmembrane 113 LG:224S23.1:2001MAR30140 148 forwardTM Non-Cytosolic 113 LG:224523.1:2001MAR30149 171 forwardTM Transmembrane I I3 LG:224523.I:2001MAR30172 212 forwardTM Cytosolic 1 13 LG:224523.1:2001MAR301 115 forwardTM Cytosolic 113 LG:224523.1:2001MAR30116 13S forwardTM Transmembrane 113 LG:224523.1:2001MAR30136 139 forwardTM Non-Cytosolic 113 LG:224523.1:2001MAR30140 162 forwardTM Transmembrane I 13 LG:224523.1:200IMAR30163 212 forwardTM Cytosolic 114 LG:228186.1:2001MAR301 32 forwardTM Non-Cytosolic 114 LG:228186.1:2001MAR3033 SS forwardTM Transmembrane 114 LG:228186.1:2001MAR3056 105 forwardTM Cytosolic 114 LG:228186.1:2001MAR30106 125 forwardTM Transmembrane 114 LG:228186.1:2001MAR30126 139 forwardTM Non-Cytosolic I

SEQ Template ID StartStopFrame Domain Topology D NO: Type 114 LG:228186.1:2001MAR30140 162 forwardTM Transmembrane 114 LG:228186.1:2001MAR30163 168 forwardTM Cytosolic I

114 LG:228186.1:2001 169 191 forwardTM Transmembrane 114 LG:228186.1:2001MAR30192 1292forwardTM Non-Cytosolic 114 LG:228186.1:2001MAR3012931315forwardTM Transmembrane 114 LG:228186.1:2001MAR3013161569forwardTM Cytosolic 114 LG:228186.1:2001 15701592forwardTM Transmembrane 114 LG:228186.1:2001MAR3015931723forwardTM Non-Cytosolic 114 LG:228186.1:2001MAR301 6 forwardTM Cytosolic 114 LG:228186.1:2001MAR307 25 forwardTM Transmembrane 114 LG:228186.1:2001MAR3026 39 forwardTM Non-Cytosolic 114 LG:228186.1:2001MAR3040 62 forwardTM Transmembrane 114 LG:228186.1:2001MAR3063 74 forwardTM Cytosolic 114 LG:228186.1:2001MAR3075 92 forwardTM Transmembrane 114 LG:228186.1:2001MAR3093 106 forwardTM Non-Cytosolic 114 LG:228186.1:2001MAR30107 126 forwardTM Transmembrane 114 LG:228186.1:2001MAR30127 167 forwardTM Cytosolic 114 LG:228186.1:2001MAR30168 190 forwardTM Transmembrane 114 LG:228186.1:2001MAR30191 1316forwardTM Non-Cytosolic 114 LG:228186.1:2001MAR3013171339forwardT'M Transmembrane 114 LG:228186.1:2001MAR3013401449forwardTM Cytosolic 114 LG:228186.1:2001MAR3014501472forwardTM Transmembrane 114 LG:228186.1:2001MAR3014731723forwardTM Non-Cytosolic 114 LG:228186.I:2001MAR30, 102 forwardTM Non-Cytosolic 114 LG:228186.1:2001MAR30I03 122 forwardTM Transmembrane 114 LG:228186.1:2001MAR30123 134 forwardTM Cytosolic 114 LG:228186.1:2001MAR30. 157 forwardTM Transmembrane .135 3 114 LG:228186.1:2001MAR30158 467.forward3TM Non-Cytosolic 114 LG:228186.1:2001MAR30468 485 forwardTM Transmembrane 114 LG:228186.1:2001MAR30486 589 forwardTM Cytosolic 114 LG:228186.1:2001MAR30590 612 forwardTM Transmembrane 114 LG:228186.1:2001MAR30613 1448forwardTM Non-Cytosolic 114 LG:228186.1:2001MAR3014491471forwardTM Transmembrane 114 LG:228186.1:2001MAR3014721594forwardTM Cytosolic 114 LG:228186.1:2001MAR3015951617forwardTM Transmembrane 114 LG:228186.1:2001MAR3016181631forwardTM Non-Cytosolic 114 LG:228186.1:2001MAR3016321651forwardTM Transmembrane 114 LG:228186.1:2001MAR3016521671forwardTM Cytosolic 114 LG:228186.1:2001MAR3016721694forwardTM Transmembrane 114 LG:228186.1:2001MAR3016951722forwardTM Non-Cytosolic 115 LG:233138.2:2001MAR301 1464forwardTM Non-Cytosolic 115 LG:233138,2:2001MAR3014651487forwardTM Transmembrane 115 LG:233138.2:2001MAR3014881554forwardTM Cytosolic 115 LG:233138.2:2001MAR301 434 forwardTM Non-Cytosolic 115 LG:233138.2:2001MAR30435 457 forwardTM Transmembrane 115 LG:233138.2:2001MAR30458 463 forwardTM Cytosolic 115 LG:233138.2:2001MAR30464 486 forwardTM Transmembrane 115 LG:233138.2:2001MAR30487 1554forwardTM Non-Cytosolic 116 LG:234811.10:2001MAR30I 312 forwardTM Non-Cytosolic 116 LG:234811.10:2001MAR30313 335 forwardTM Transmembrane 116 LG:234811.10:2001MAR30336 350 forwardTM Cytosolic 116 LG:234811.10:2001MAR301 326 forwardTM Non-Cytosolic 116 LG:234811.10:2001MAR30327 346 forwardTM Transmembrane 116 LG:234811.10:2001MAR30347 349 forwardTM Cytosolic SEQ Template ID StartStopFrame Domain Topology D NO: Type 117 LG:236092.1:2001MAR301 114forwardTM Cytosolic 1I7 LG:236092.1:2001MAR30115 137forwardTM Transmembrane 117 LG:236092.1:2001MAR30138 290forwardTM Non-Cytosolic 117 LG:236092.1:2001MAR3029I 313forwardTM Transmembrane I

117 LG:236092.1:2001MAR30314 399forwardTM Cytosolic I17 LG:236092.1:2001MAR30400 422forwardTM Transmembrane 117 LG:236092.1:2001MAR30423 441forwardTM Non-Cytosolic 117 LG:236092.1:200IMAR30442 464forwardTM Transmembrane I

117 LG:236092.1:2001MAR30465 534forwardTM Cytosolic 117 LG:236092.1:2001MAR30535 557forwardTM Transmembrane 117 LG:236092.1:2001MAR30558 728forwardTM Non-Cytosolic 117 LG:236092.1:2001MAR301 54 forwardTM Non-Cytosolic 117 LG:236092.1:2001MAR3055 74 forwardTM Transmembrane 117 LG:236092.1:2001MAR3075 111forwardTM Cytosolic 117 LG:236092.1:2001MAR30112 134forwardTM Transmembrane 117 LG:236092.1:2001MAR30135 155forwardTM Non-Cytosolic 117 LG:236092.1:2001MAR30156 178forwardTM Transmembrane 117 LG:236092.1:2001MAR30179 416forwardTM Cytosolic 117 LG:236092.1:2001MAR30417 439forwardTM Transmembrane 117 LG:236092.1:2001MAR30440 448forwardTM Non-Cytosolic 117 LG:236092.1:2001MAR30449 471forwardTM Transmembrane 117 LG:236092.1:2001MAR30472 526forwardTM Cytosolic 117 LG:236092.1:2001MAR30527 549forwardTM Transmembrane 117 LG:236092.1:2001MAR30550 591forwardTM Non-Cytosolic 117 LG:236092.1:2001MAR30592 609forwardTM Transmembrane 117 LG:236092.1:2001MAR30610 728forward. .TM Cytosolic 117 LG:236092.1:2001MAR301 14 forwardTM Non-Cytosolic 117 LG:236092.1:2001MAR3015 37 forward~TM Transmembrane 117 LG:236092.1:2001MAR3038 57 forwardTM Cytosolic 117 LG:236092.1:2001MAR3058 80 forwardTM Transmembrane 117 LG:236092.1:2001MAR3081 111forwardTM Non-Cytosolic 117 LG:236092.1:2001MAR30112 131forwardTM Transmembrane 117 LG:236092.1:2001MAR30132 143forwardTM Cytosolic 117 LG:236092.1:2001MAR30144 166forwardTM Transmembrane 117 LG:236092.2:2001MAR30167 453forwardTM Non-Cytosolic 117 LG:236092.1:2001MAR30454 476forwardTM Transmembrane I I7 LG:236092.1:2001MAR30477 551forwardTM Cytosolic 117 LG:236092.1:2001MAR30552 574forwardTM Transmembrane 117 LG:236092.1:2001MAR30575 593forwardTM Non-Cytosolic 117 LG:236092.1:2001MAR30594 616forwardTM Transmembrane 117 LG:236092.I:ZOO1MAR30617 622forwardTM Cytosolic 117 LG:236092.1:2001MAR30623 642forwardTM Transmembrane 117 LG:236092.1:2001MAR30643 673forwardTM Non-Cytosolic 117 LG:236092.1:2001MAR30674 696forwardTM Transmembrane 11Z LG:236092.1:2001MAR30697 727forwardTM Cytosolic 118 LG:236098.12:2001MAR301 437forwardTM Non-Cytosolic 118 LG:236098.12:2001MAR30438 460forwardTM Transmembrane 118 LG:236098.12:2001MAR30461 504forwardTM Cytosolic 118 LG:236098.12:2001MAR30505 526forwardTM Transmembrane 118 LG:236098.12:2001MAR30527 1270forwardTM Non-Cytosolic 118 LG:236098.12:2001MAR301271 1293forwardTM Transmembrane 118 LG:236098.12:2001MAR301294 1346forwardTM Cytosolic 118 LG:236098.12:2001MAR301347 1369forwardTM Transmembrane 118 LG:236098.12:2001MAR301370 1378forwardTM Non-Cytosolic SEQ Template ID StartStopFrame Domain Topology D NO: Type 118 LG:236098.12:2001MAR301379 1401forwardTM Transmembrane 118 LG:236098.12:2001MAR301402 1421forwardTM Cytosolic 118 LG:236098.12:2001MAR301422 1444forwardTM Transmembrane 118 LG:236098.12:2001MAR301445 1458forwardTM Non-Cytosolic 118 LG:236098.12:2001MAR301459 1481forwardTM Transmembrane 118 LG:236098.12:2001MAR301482 1494forwardTM Cytosolic 118 LG:236098.12:2001MAR301 400forwardTM Non-Cytosolic 118 LG:236098.12:2001MAR30401 423forwardTM Transmembrane 118 LG:236098.12:2001MAR30424 442forwardTM Cytosolic 118 LG:236098.12:2001MAR30443 460forwardTM Transmembrane ~ 2 118 LG:236098.12:2001MAR30461 469forwardTM Non-Cytosolic 118 LG:236098.12:2001MAR30470 487forwardTM Transmembrane 118 LG:236098.12:2001MAR30488 499forwardTM Cytosolic 118 LG:236098.12:2001MAR30500 522forwardTM Transmembrane 118 LG:236098.12:2001MAR30523 541forwardTM Non-Cytosolic 118 LG:236098.12:2001MAR30542 564forwardTM Transmembrane 118 LG:236098.12:2001MAR30565 584forwardTM Cytosolic 118 LG:236098.12:2001MAR30585 602forwardTM Transmembrane 118 LG:236098.12:2001MAR30603 616forwardTM Non-Cytosolic 118 LG:236098.12:2001MAR30617 639forwardTM Transmembrane 118 LG:236098.12:2001MAR30640 888forwardTM Cytosolic 118 LG:236098.12:2001MAR30889 911forwardTM Transmembrane 118 LG:236098.12:2001MAR30912 920forwardTM Non-Cytosolic 118 LG:236098.12:2001MAR30921 943forwardTM Transmembrane 118 LG:236098.12:2001MAR30944 963forwardTM Cytosolic 118 LG:236098.12:2001MAR30964 9$6forwardTM Transmembrane 118 LG:236098.12:2001MAR30987 1005'forwardTM Non-Cytosolic 2' 118 LG:236098.12:2001MAR301006 1028forwardTM Transmembrane 118 LG:236098.12:2001MAR301029 1169forwardTM Cytosolic 118 LG:236098.12:2001MAR301170 1192forwardTM Transmembrane 118 LG:236098.12:2001MAR301193 1494forwardTM Non-Cytosolic 118 LG:236098.12:2001MAR301 433forwardTM Non-Cytosolic 118 LG:236098.12:2001MAR30434 456forwardTM Transmembrane 118 LG:236098.12:2001MAR30457 492forwardTM Cytosolic 118 LG:236098.12:2001MAR30493 515forwardTM Transmembrane 118 LG:236098.12:2001MAR30516 529forwardTM Non-Cytosolic 118 LG:236098.12:2001MAR30530 552forwardTM Transmembrane 118 LG:236098.12:2001MAR30553 615forwardTM Cytosolic 118 LG:236098.12:2001MAR30616 638forwardTM Transmembrane 118 LG:236098.12:2001MAR30639 759forwardTM Non-Cytosolic 118 LG:236098.12:2001MAR30760 782forwardTM Transmembrane 118 LG:236098.12:2001MAR30783 898forwardTM Cytosolic 118 LG:236098.12:2001MAR30899 921forwardTM Transmembrane 118 LG:236098.12:2001MAR30922 935forwardTM Non-Cytosolic 118 LG:236098.12:2001MAR30936 953forwardTM Transmembrane 118 LG:236098.12:2001MAR30954 957forwardTM Cytosolic 118 LG:236098.12:2001MAR30958 980forwardTM Transmembrane 118 LG:236098.12:2001MAR30981 1494forwardTM Non-Cytosolic 119 LG:236697.15:2001MAR301 90 forwardTM Cytosolic 119 LG:236697.15:2001MAR3091 113forwardTM Transmembrane 119 LG:236697.15:2001MAR30114 127forwardTM Non-Cytosolic 119 LG:236697.15:2001MAR30128 150forwardTM Transmembrane 119 LG:236697.15:2001MAR30151 219forwardTM Cytosolic 119 LG:236697.15:2001MAR30220 239forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D Type NO:

119 LG:236697.15:2001MAR30240 258forwardTM Non-Cytosolic 119 LG:236697.15:2001MAR30259 281forwardTM Transmembrane 119 LG:236697.15:2001MAR30282 287forwardTM Cytosolic 119 LG:236697.15:2001MAR30288 307forwardTM Transmembrane 119 LG:236697.I5:2001MAR30308 316forwardTM Non-Cytosolic 119 LG:236697.15:2001MAR30317 336forwardTM Transmembrane I

119 LG:236697.15:2001MAR30337 524forwardTM Cytosolic I

119 LG:236697.15:2001MAR30525 547forwardTM Transmembrane I

119 LG:236697.15:2001MAR30548 566forwardTM Non-Cytosolic 119 LG:236697.15:2001MAR30567 589forwardTM Transmembrane 119 LG:236697.15:2001MAR30590 608forwardTM Cytosolic 119 LG:236697.15:2001MAR30609 631forwardTM Transmembrane 119 LG:236697.15:2001MAR30632 673forwardTM Non-Cytosolic 119 LG:236697.15:2001MAR301 80 forwardTM Non-Cytosolic 119 LG:236697.15:2001MAR3081 100forwardTM Transmembrane 119 LG:236697.15:2001MAR30101 251forwardTM Cytosolic 119 LG:236697.15:2001MAR30252 271forwardTM Transmembrane 119 LG:236697.15:2001MAR30272 533forwardTM Non-Cytosolic 119 LG:236697.15:2001MAR30534 556forwardTM Transmembrane 119 LG:236697.I5:2001MAR30557 568forwardTM Cytosolic 119 LG:236697.15:2001MAR30569 586forwardTM Transmembrane 119 LG:236697.15:2001MAR30587 600forwardTM Non-Cytosolic 119 LG:236697.15:2001MAR30601 620forwardTM Transmembrane 119 LG:236697.15:2001MAR30621 640forwardTM Cytosolic 119 LG:236697.15:200IMAR30641 663forwardTM Transmembrane 119 LG:236697.15:2001MAR30664 673forwardTM Non-Cytosolic 119 LG:236697.15:2001MAR301 454forwardTM Non-Cytosolic 1'19 LG:236697.15:2001MAR30455 477forwardTM Transmembrane 119 LG:236697.15:2001MAR30478 526forwardTM Cytosolic 119 LG:236697.15:2001MAR30527 549forwardTM Transmembrane 119 LG:236697.15:2001MAR30550 563forwardTM Non-Cytosolic 119 LG:236697.15:2001MAR30564 583forwardTM Transmembrane 119 LG:236697.15:2001MAR30584 605forwardTM Cytosolic 119 LG:236697.15:2001MAR30606 628forwardTM Transmembrane 119 LG:236697.15:2001MAR30629 672forwardTM Non-Cytosolic 120 LG:237503.21:2001MAR301 960forwardTM Non-Cytosolic 120 LG:237503.21:2001MAR30961 983forwardTM Transmembrane 120 LG:237503.21:2001MAR30984 989forwardTM Cytosolic 120 LG:237503.21:2001MAR30990 1007forwardTM Transmembrane . 1 120 LG:237503.21:2001MAR301008 1072forwardTM Non-Cytosolic 120 LG:237503.21:2001MAR301073 1095forwardTM Transmembrane 120 LG:237503.21:ZOOIMAR301096 12,18forwardTM Cytosolic I

120 LG:237503.21:2001MAR301 9 forwardTM Non-Cytosolic 120 LG:237503.21:2001MAR3010 32 forwardTM Transmembrane 120 LG:237503.21:2001MAR3033 44 forwardTM Cytosolic 120 LG:237503.21:2001MAR3045 64 forwardTM Transmembrane 120 LG:237503.21:2001MAR3065 926forwardTM Non-Cytosolic 120 LG:237503.21:2001MAR30927 949forwardTM Transmembrane 120 LG:237503.21:2001MAR30950 961forwardTM Cytosolic 120 LG:237503.21:2001MAR30962 984forwardTM Transmembrane 120 LG:237503.21:2001MAR30985 1218forwardTM Non-Cytosolic 120 LG:237503.21:2001MAR301 115forwardTM Non-Cytosolic 120 LG:237503.21:2001MAR30116 138forwardTM Transmembrane 120 LG:237503.21:2001MAR30139 144forwardTM Cytosolic SEQ D NO: Template ID StartStopFrame Domain Topology Type 120 LG:237503.21:2001MAR30145 167 forwardTM Transmembrane 120 LG:237503.21:2001MAR30168 232 forwardTM Non-Cytosolic 120 LG:237503.21:2001MAR30233 255 forwardTNI Transmembrane 120 LG:237503.21:2001MAR30256 465 forwardTM Cytosolic 120 LG:237503.21:2001MAR30466 488 forwardTM Transmembrane 120 LG:237503.21:2001MAR30489 960 forwardTM Non-Cytosolic 120 LG:237503.21:2001MAR30961 983 forwardTM Transmembrane 120 LG:237503.21:2001MAR30984 989 forwardTM Cytosolic 120 LG:237503.21:2001MAR30990 1009forwardTM Transmembrane 120 LG:237503.21:2001MAR301010 1217forwardTM Non-Cytosolic 121 LG:238023.7:2001MAR301 753 forwardTM Non-Cytosolic 121 LG:238023.7:2001MAR30754 776 forwardTM Transmembrane I21 LG:238023.7:200IMAR30777 843 forwardTM Cytosolic 121 LG:238023.7:2001MAR30844 866 forwardTM Transmembrane 121 LG:238023.7:2001MAR30867 893 forwardTM Non-Cytosolic 121 LG:238023.7:2001MAR301 19 forwardTM Non-Cytosolic 121 LG:238023.7:2001MAR3020 42 forwardTM Transmembrane 121 LG:238023.7:2001MAR3043 53 forwardTM Cytosolic 121 LG:238023.7:2001MAR3054 76 forwardTM Transmembrane 121 LG:238023.7:2001MAR3077 85 forwardTM Non-Cytosolic 121 LG:238023.7:2001MAR3086 108 forwardTM Transmembrane 121 LG:238023.7:200IMAR30109 I28 forwardTM Cytosolic 121 LG:238023.7:2001MAR30129 151 forwardTM Transmembrane 121 LG:238023.7:2001MAR30152 597 forwardTM Non-Cytosolic 121 LG:238023.7:2001MAR30598 620 forwardTM Transmembrane 121 LG:238023.7:2001MAR30621 639 forwardTM Cytosolic 12.1 . LG:238023.7:200LMAR30640 659 forwardTM Transmembrane 121 LG:238023.7:2001MAR30660 859 forwardTM Non-Cytosolic 121 LG:238023.7:2001MAR30860 882 forwardTM Transmembrane 121 LG:238023.7:2001MAR30883 893 forwardTM Cytosolic 122 LG:238209.1:2001MAR301 1179forwardTM Non-Cytosolic 122 LG:238209.1:2001MAR301180 1202forwardTM Transmembrane 122 LG:238209.1:2001MAR301203 1302forwardTM Cytosolic 122 LG:238209.1:2001MAR301 1111forwardTM Non-Cytosolic 122 LG:238209.1:2001MAR301112 1134forwardTM Transmembrane 122 LG:238209.1:2001MAR301135 1154forwardTM Cytosolic 122 LG:238209.1:2001MAR301155 1172forward' TM Transmembrane 122 LG:238209.1:2001MAR301173 1186forwardTM Non-Cytosolic 122 LG:238209.1:2001MAR301187 1209forwardTM Transmembrane 122 LG:238209.1:2001MAR301210 1215forwardTM Cytosolic 122 LG:238209.1:2001MAR301216 1235forwardTM Transmembrane 122 LG:238209.1:2001MAR301236 1268forwardTM Non-Cytosolic 122 LG:238209.1:2001MAR301269 1291forwardTM Transmembrane 122 LG:238209.1:2001MAR301292 1302forwardTM Cytosolic 123 LG:238456.10:2001MAR301 6 forwardTM Cytosolic 123 LG:238456.10:2001MAR307 29 forwardTM Transmembrane 123 LG:238456.10:2001MAR3030 431 forwardTM Non-Cytosolic 124 LG:239245.1:2001MAR301 158 forwardTM Cytosolic 124 LG:239245.1:2001MAR30159 181 forwardTM Transmembrane 124 LG:239245.1:2001MAR30182 782 forwardTM Non-Cytosolic 124 LG:239245.1:2001MAR30783 805 forwardTM Transmembrane 124 LG:239245.1:200IMAR30806 842 forwardTM Cytosolic 124 LG:239245.1:2001MAR301 162 forwardTM Non-Cytosolic 124 LG:239245.1:2001MAR30163 185 forward' TM Transmembrane SEQ Template ID StartStopFrame Domain Topology D NO: Type 124 LG:239245.1:2001MAR30186 479forwardTM Cytosolic 124 LG:239245.1:2001MAR30480 499forwardTM Transmembrane 124 LG:239245.1:2001MAR30500 777forwardTM Non-Cytosolic 124 LG:239245.1:2001MAR30778 800forwardTM Transmembrane 124 LG:239245.1:2001MAR30801 842forward. TM Cytosolic 124 LG:239245.1:2001MAR301 159forwardTM Cytosolic 124 LG:239245.1:2001 160 182forwardTM Transmembrane 124 LG:239245.1:2001MAR30183 475forwardTM Non-Cytosolic 124 LG:239245.1:2001MAR30476 498forwardTM Transmembrane 124 LG:239245.1:2001MAR30499 732forwardTM Cytosolic 124 LG:239245.1:2001MAR30733 752forwardTM Transmembrane 124 LG:239245.1:2001MAR30753 773forwardTM Non-Cytosolic 124 LG:239245.1:2001MAR30774 796forwardTM Transmembrane 124 LG:239245.1:2001MAR30797 842forwardTM Cytosolic 125 LG:239579.8:2001MAR301 45 forwardTM Non-Cytosolic 125 LG:239579.8:2001MAR3046 63 forwardTM Transmembrane 125 LG:239579.8:2001MAR3064 210forwardTM Cytosolic 125 LG:239579.8:2001MAR30211 233forwardTM Transmembrane 125 LG:239579.8:2001MAR30234 418forwardTM Non-Cytosolic 125 LG:239579.8:2001MAR30419 441forwardTM Transmembrane 125 LG:239579.8:2001MAR30442 469forwardTM Cytosolic 125 LG:239579.8:2001MAR301 224forwardTM Non-Cytosolic 125 LG:239579.8:2001MAR30225 247forwardTM Transmembrane 125 LG:239579.8:2001MAR30248 420forwardTM Cytosolic 125 LG:239579.8:2001MAR30421 443forwardTM ~ Transmembrane 125 LG:239579.8:2001MAR30444 469forwardTM Non-Cytosolic .125 LG:239579.8:2001MAR301 222forwardTM Non-Cytosolic ~ 3 125 LG:239579.8:2001MAR30223 245forwardTM Transmembrane 125 LG:239579.8:2001MAR30246 264forwardTM Cytosolic 125 LG:239579.8:2001MAR30265 287forwardTM Transmembrane 125 LG:239579.8:2001MAR30288 301forwardTM Non-Cytosolic 125 LG:239579.8:2001MAR30302 324forwardTM Transmembrane 125 LG:239579.8:2001MAR30325 418forwardTM Cytosolic 125 LG:239579.8:2001MAR30419 441forwardTM Transmembrane 125 LG:239579.8:2001MAR30442 468forwardTM Non-Cytosolic 126 LG:239601.22:2001MAR301 105forwardTM Cytosolic 126 LG:239601.22:2001MAR30106 128forwardTM Transmembrane 126 LG:239601.22:2001MAR30129 243forwardTM Non-Cytosolic 126 LG:239601.22:2001MAR30244 266forwardTM Transmembrane 126 LG:239601.22:2001MAR30267 314forwardTM Cytosolic 126 LG:239601.22:2001MAR30315 337forwardTM Transmembrane 126 LG:239601.22:2001MAR30338 346forwardTM Non-Cytosolic 126 LG:239601.22:2001MAR30347 369forwardTM Transmembrane 126 LG:239601.22:2001MAR30370 518forwardTM Cytosolic 126 LG:239601.22:2001MAR30519 541forwardTM Transmembrane 126 LG:239601.22:2001MAR30542 934forwardTM Non-Cytosolic 126 LG:239601.22:2001MAR301 114forwardTM Non-Cytosolic 126 LG:239601.22:2001MAR30115 137forwardTM Transmembrane 126 LG:239601.22:2001MAR30138 175forwardTM Cytosolic 126 LG:239601.22:2001MAR30176 198forwardTM Transmembrane 126 LG:239601.22:2001MAR30199 248forwardTM Non-Cytosolic 126 LG:239601.22:2001MAR30249 271forwardTM Transmembrane 126 LG:239601.22:2001MAR30272 291forwardTM Cytosolic 126 LG:239601.22:2001MAR30292 314forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D Type NO:

126 LG:239601.22:2001MAR30315 318 forwardTM Non-Cytosolic 126 LG:239601.22:2001MAR30319 341 forwardTM Transmembrane 126 LG:239601.22:2001MAR30342 352 forwardTM Cytosolic 126 LG:239601.22:2001MAR30353 375 forwardTM Transmembrane 126 LG:239601.22:2001MAR30376 933 forwardTM Non-Cytosolic 126 LG:239601.22:2001MAR301 25 forwardTM Non-Cytosolic 126 LG:239601.22:2001MAR3026 45 forwardTM Transmembrane 126 LG:239601.22:2001MAR3046 109 forwardTM Cytosolic 126 LG:239601.22:2001MAR30110 129 forwardTM Transmembrane 126 LG:239601.22:2001MAR30130 182 forwardTM Non-Cytosolic 126 LG:239601.22:2001MAR30183 205 forwardTM Transmembrane 126 LG:239601.22:2001MAR30206 231 forwardTM Cytosolic 126 LG:239601.22:2001MAR30232 254 forwardTM Transmembrane 126 LG:239601.22:200IMAR30255 268 forwardTM Non-Cytosolic 126 LG:239601.22:2001MAR30269 291 forwardTM Transmembrane 126 LG:239601.22:2001MAR30292 303 forwardTM Cytosolic 126 LG:239601.22:2001MAR30304 326 forwardTM Transmembrane 126 LG:239601.22:2001MAR30327 933 forwardTM Non-Cytosolic 127 LG:240121.1:2001MAR301 409 forwardTM Non-Cytosolic 127 LG:240121.1:2001MAR30410 432 forwardTM Transmembrane 127 LG:240121.1:2001MAR30433 723 forwardTM Cytosolic 127 LG:240121.1:2001MAR30724 742 forwardTM Transmembrane 127 LG:240121.1:2001MAR30743 756 forwardTM Non-Cytosolic 127 LG:240121.1:2001MAR30757 774 forwardTM Transmembrane 127 LG:240121.1:2001MAR30775 793 forwardTM Cytosolic 127 LG:240121.1:2001MAR30794 816 forwardTM Transmembrane ' 1 127 LG:240121.1:2001MAR30817 820 forwardTM Non-Cytosolic 127 LG:240121.1:2001MAR30821 843 forwardTM Transmembrane 127 LG:240121.1:2001MAR30844 898 forwardTM Cytosolic 127 LG:240121.1:2001MAR30I 409 forwardTM Non-Cytosolic 127 LG:240121.1:2001MAR30410 432 forwardTM Transmembrane 127 LG:240121.1:2001MAR30433 729 forwardTM Cytosolic 127 LG:240121.1:2001MAR30730 747 forwardTM Transmembrane 127 LG:240121.1:2001MAR30748 756 forwardTM Non-Cytosolic 127 LG:240121.1:2001MAR30757 774 forwardTM Transmembrane 127 LG:240121.1:2001MAR30775 785 forwardTM Cytosolic 127 LG:240121.1:2001MAR30786 808 forwardTM Transmembrane 127 LG:240121.1:2001MAR30809 827 forwardTM Non-Cytosolic . 2 127 LG:240121.1:2001MAR30828 850 forwardTM Transmembrane 127 LG:240121.1:2001MAR30851 898 forwardTM Cytosolic 127 LG:240121.1:2001MAR301 405 forwardTM Non-Cytosolic 127 LG:240121.1:2001MAR30406 428 forwardTM Transmembrane 127 LG:240121.1:2001MAR30429 785 forwardTM Cytosolic 127 LG:240121.1:2001MAR30786 808 forwardTM Transmembrane 127 LG:240121.1:2001MAR30809 827 forwardTM Non-Cytosolic 127 LG:240121.1:2001MAR30828 850 forwardTM Transmembrane 127 LG:240121.1:2001MAR30851 897 forwardTM Cytosolic 128 LG:241110.2:2001MAR301 1348forwardTM Non-Cytosolic 128 LG:241110.2:2001MAR301349 1371forwardTM Transmembrane 128 LG:241110.2:2001MAR301372 1377forwardTM Cytosolic 128 LG:241110.2:2001MAR301378 1400forwardTM Transmembrane 128 LG:241110.2:2001MAR301401 2121forwardTM Non-Cytosolic 129 LG:244948.4:2001MAR301 309 forwardTM Cytosolic 129 LG:244948.4:2001MAR30310 332 forwardTM Transmembrane SEQ Template ID Start StopFrame Domain Topology D NO: Type 129 LG:244948.4:2001MAR30333 336forwardTM Non-Cytosolic 130 LG:245378.6:2001MAR301 294forwardTM Cytosolic 130 LG:245378.6:2001MAR30295 312forwardTM Transmembrane 130 LG:245378.6:2001MAR30313 321forwardTM Non-Cytosolic 130 LG:245378.6:2001MAR30322 344forwardTM Transmembrane 130 LG:245378.6:2001MAR30345 390forwardTM Cytosolic 130 LG:245378.6:2001MAR30391 413forwardTM Transmembrane 130 LG:245378.6:2001MAR30414 464forwardTM Non-Cytosolic 130 LG:245378.6:2001MAR30465 487forwardTM Transmembrane 130 LG:245378.6:2001MAR30488 574forwardTM Cytosolic 130 LG:245378.6:2001MAR30575 597forwardTM Transmembrane 130 LG:245378.6:2001MAR30598 606forwardTM Non-Cytosolic 130 LG:245378.6:2001MAR30607 629forwardTM Transmembrane 130 LG:245378.6:2001MAR30630 805forwardTM Cytosolic 130 LG:245378.6:2001MAR30806 828forwardTM Transmembrane 130 LG:245378.6:2001MAR30829 842forwardTM Non-Cytosolic 130 LG:245378.6:2001MAR30843 862forwardTM Transmembrane 130 LG:245378.6:2001MAR30863 886forwardTM Cytosolic 130 LG:245378.6:2001MAR30887 909forwardTM Transmembrane 130 LG:245378.6:2001MAR30910 955forwardTM Non-Cytosolic 130 LG:245378.6:2001MAR30956 978forwardTM Transmembrane 130 LG:245378.6:2001MAR30979 989forwardTM Cytosolic 130 LG:245378.6:2001MAR30990 1009forwardTM Transmembrane 130 LG:245378.6:2001MAR301010 1013forwardTM Non-Cytosolic 130 LG:245378.6:2001MAR301014 1036forwardTM Transmembrane 130 LG:245378.6:2001MAR301037 1070forwardTM Cytosolic 130 LG:245378.6:2001MAR301071 1090forwardTM Transmembrane 130 LG:245378.6:2001MAR301091 1179forwardTM Non-Cytosolic 130 LG:245378.6:2001MAR301180 1202forwardTM Transmembrane 130 LG:245378.6:2001MAR301203 1347forwardTM Cytosolic 130 LG:245378.6:2001MAR301348 1370forwardTM Transmembrane 130 LG:245378.6:2001MAR301371 1412forwardTM Non-Cytosolic 130 LG:245378.6:2001MAR301413 1430forwardTM Transmembrane 130 LG:245378.6:2001MAR301431 1509forwardTM Cytosolic 130 LG:245378.6:2001MAR301510 1532forwardTM Transmembrane 130 LG:245378.6:2001MAR301533 1583forwardTM Non-Cytosolic 130 LG:245378.6:2001MAR301584 1606forwardTM Transmembrane 130 LG:245378.6:2001MAR301607 1683forwardTM Cytosolic 130 LG:245378.6:2001MAR301684 1706forwardTM Transmembrane 130 LG:245378.6:2001MAR301707 1725forwardTM Non-Cytosolic 130 LG:245378.6:2001MAR301726 1748forwardTM Transmembrane 130 LG:245378.6:2001MAR301749 1760forwardTM Cytosolic 130 LG:245378.6:2001MAR301761 1783forwardTM Transmembrane 130 LG:245378.6:2001MAR301784 1796forwardTM Non-Cytosolic 130 LG:245378.6:2001MAR30l 389forwardTM Non-Cytosolic 130 LG:245378.6:2001MAR30390 412forwardTM Transmembrane 130 LG:245378.6:2001MAR30413 473forwardTM Cytosolic 130 LG:245378.6:2001MAR30474 493forwardTM Transmembrane 130 LG:245378.6:2001MAR30494 597forwardTM Non-Cytosolic 130 LG:245378.6:2001MAR30598 620forwardTM Transmembrane 130 LG:245378.6:2001MAR30621 690forwardTM Cytosolic 130 LG:245378.6:2001MAR30691 713forwardTM Transmembrane 130 LG:245378.6:2001MAR30714 839forwardTM Non-Cytosolic 130 LG:245378.6:2001MAR30840 862forwardTM Transmembrane SEQ Template ID StartStopFrame bomain Topology D NO: Type 130 LG:24S378.6:2001MAR30863 874 forwardTM Cytosolic 130 LG:24S378.6:2001MAR30875 897 forwardTM Transmembrane 130 LG:24S378.6:200IMAR30898 916 forwardTM Non-Cytosolic 130 LG:24S378.6:2001MAR30917 939 forwardTM Transmembrane 130 LG:24S378.6:2001MAR30940 958 forwardTM Cytosolic 130 LG:24S378.6:2001MAR30959 981 forwardTM Transmembrane 130 LG:24S378.6:2001MAR30982 1086forwardTM Non-Cytosolic 130 LG:24S378.6:2001MAR301087 1109forwardTM Transmembrane 130 LG:24S378.6:2001MAR301110 1257forwardTM Cytosolic 130 LG:24S378.6:2001MAR301258 1280forwardTM Transmembrane 130 LG:24S378.6:2001MAR301281 1440forwardTM Non-Cytosolic 130 LG:24S378.6:2001MAR301441 1463forwardTM Transmembrane 130 LG:245378.6:2001MAR301464 1483forwardTM Cytosolic 130 LG:24S378.6:2001MAR301484 1506forwardTM Transmembrane 130 LG:245378.6:2001MAR301507 1580forwardTM Non-Cytosolic 130 LG:24S378.6:2001MAR301581 1598forwardTM Transmembrane 130 LG:245378.6:200IMAR301599 1641forwardTM Cytosolic 130 LG:24S378.6:2001MAR301642 1664forwardTM Transmembrane 130 LG:24S378.6:2001MAR301665 1683forwardTM Non-Cytosolic 130 LG:24S378.6:2001MAR301684 1706forwardTM Transmembrane 130 LG:245378.6:2001MAR301707 1722forwardTM Cytosolic 130 LG:24S378.6:2001MAR301723 1745forwardTM Transmembrane 130 LG:24S378.6:2001MAR301746 1754forwardTM Non-Cytosolic 130 LG:24S378.6:2001MAR301755 1777forwardTM Transmembrane . 2 130 LG:24S378.6:2001MAR301778 1796forwardTM Cytosolic 130 LG:24S378.6:2001MAR301 78 forwardTM Non-Cytosolic ' 3 130 LG:24S378.6:2001~MAR3079 101 forwardT1VI Transmembrane 130 LG:245378.6:200fMAR30102 392 forwardTM Cytosolic ' 3 130 LG:24S378.6:2001MAR30393 415 forwardTM Transmembrane 130 LG:24S378.6:2001MAR30416 468 forwardTM Non-Cytosolic 130 LG:24S378.6:2001MAR30469 486 forwardTM Transmembrane 130 LG:24S378.6:2001MAR30487 569 forwardTM Cytosolic 130 LG:24S378.6:2001MAR30570 592 forwardTM Transmembrane 130 LG:24S378.6:2001MAR30593 615 forwardTM Non-Cytosolic 130 LG:24S378.6:2001MAR30616 638 forwardTM Transmembrane 130 LG:24S378.6:2001MAR30639 691 forwardTM Cytosolic 130 LG:24S378.6:2001MAR30692 714 forwardTM Transmembrane 130 LG:24S378.6:2001MAR30715 728 forwardTM Non-Cytosolic 130 LG:24S378.6:2001MAR30729 748 forwardTM Transmembrane 130 LG:245378.6:2001MAR30749 772 forwardTM Cytosolic 130 LG:24S378.6:2001MAR30.773 795 forwardTM Transmembrane 130 LG:24S378.6:2001MAR30796 914 forwardTM Non-Cytosolic 130 LG:24S378.6:2001MAR30915 937 forwardTM Transmembrane 130 LG:24S378.6:2001MAR30938 957 forwardTM Cytosolic 130 LG:24S378.6:2001MAR30958 980 forwardTM Transmembrane 130 LG:24S378.6:2001MAR30981 1021forwardTM Non-Cytosolic 130 LG:24S378.6:2001MAR301022 1044forwardTM Transmembrane 130 LG:24S378.6:2001MAR301045 1064forwardTM Cytosolic 130 LG:24S378.6:2001MAR301065 1087forwardTM Transmembrane 130 LG:24S378.6:2001MAR301088 1096forwardTM Non-Cytosolic 130 LG:24S378.6:2001MAR301097 1114forwardTM Transmembrane 130 LG:24S378.6:2001MAR301115 1143forwardTM Cytosolic 130 LG:24S378.6:2001MAR301144 1166forwardTM Transmembrane 130 LG:24S378.6:2001MAR301167 1185forwardTM Non-Cytosolic SEQ Template ID StartStopFrame Domain Topology D NO: Type 130 LG:245378.6:2001MAR301186 1208forwardTM Transmembrane 130 LG:245378.6:2001MAR301209 1368forwardTM Cytosolic 130 LG:245378.6:2001MAR301369 1391forwardTM Transmembrane 130 LG:245378.6:2001MAR301392 1405forwardTM Non-Cytosolic 130 LG:245378.6:2001MAR301406 1428forwardTM Transmembrane 130 LG:245378.6:2001MAR301429 1440forwardTM Cytosolic 130 LG:245378.6:2001MAR301441 1463forwardTM Transmembrane 130 LG:245378.6:2001MAR301464 1477forwardTM Non-Cytosolic 130 LG:245378.6:2001MAR301478 1500forwardTM Transmembrane 130 LG:245378.6:2001IvIAR301501 1512forwardTM Cytosolic 130 LG:245378.6:2001MAR301513 1532forwardTM Transmembrane 130 LG:245378.6:2001MAR301533 1572forwardTM Non-Cytosolic 130 LG:245378.6:2001MAR301573 1590forwardTM Transmembrane 130 LG:245378.6:2001MAR301591 1752forwardTM Cytosolic 130 LG:245378.6:2001MAR301753 1775forwardTM Transmembrane 130 LG:245378.6:2001MAR301776 1795forwardTM Non-Cytosolic 131 LG:248203.9:2001MAR301 197forwardTM Non-Cytosolic 131 LG:248203.9:2001MAR30198 220forwardTM Transmembrane 131 LG:248203.9:2001MAR30221 240forwardTM Cytosolic 131 LG:248203.9:2001MAR30241 263forwardTM Transmembrane 131 LG:248203'.9:2001MAR30264 656forwardTM Non-Cytosolic 131 LG:248203.9:2001MAR301 242forwardTM Non-Cytosolic 131 LG:248203.9:2001MAR30243 265forwardTM Transmembrane 131 LG:248203.9:2001MAR30.266 280forwardTM Cytosolic , 3 131 LG:248203.9:2001MAR30281 303forwardTM Transmembrane 131 LG:248203.9:2001MAR30304 '656forwardTM Non-Cytosolic 132 LG:249247.1:2001MAR301 489forwardTM Non-Cytosolic ~ 1 132 LG:249247.1:2001MAR30490 512forwardTM Transmembrane ' 1 132 LG:249247.1:2001MAR30~513 579forwardTM Cytosolic.
. 1 132 LG:249247.1:2001MAR30580 602forwardTM Transmembrane 132 LG:249247.1:2001MAR30603 769forwardTM Non-Cytosolic 132 LG:249247.1:2001MAR301 480forwardTM Non-Cytosolic 132 LG:249247.1:2001MAR30481 503forwardTM Transmembrane 132 LG:249247.1:2001MAR30504 532forwardTM Cytosolic 132 LG:249247.1:2001MAR30533 555forwardTM Transmembrane 132 LG:249247.1:2001MAR30556 768forwardTM Non-Cytosolic 133 LG:267153.16:2001MAR301 1106forwardTM Non-Cytosolic 133 LG:267153.16:2001MAR301107 1129forwardTM Transmembrane 133 LG:267153.16:2001MAR301130 1135forwardTM Cytosolic 133 LG:267153.16:2001MAR301136 1158forwardTM Transmembrane 133 LG:267153.16:2001MAR301159 1190forwardTM Non-Cytosolic 134 LG:291759.5:2001MAR301 16 forwardTM Cytosolic 134 LG:291759.5:2001MAR3017 39 forwardTM Transmembrane 134 LG:291759.5:2001MAR3040 406forwardTM Non-Cytosolic 134 LG:291759.5:2001MAR301 4 forwardTM Cytosolic 134 LG:291759.5:2001MAR305 34 forwardTM Transmembrane 134 LG:291759.5:2001MAR3035 405forwardTM Non-Cytosolic 135 LG:298102.1:2001MAR301 52 forwardTM Cytosolic 135 LG:298102.1:2001MAR3053 70 forwardTM Transmembrane 135 LG:298102.1:2001MAR3071 276forwardTM Non-Cytosolic 135 LG:298102.1:2001MAR301 9 forwardTM Non-Cytosolic 135 LG:298102.1:2001MAR3010 28 forwardTM Transmembrane 135 LG:298102.1:2001MAR3029 40 forwardTM Cytosolic 135 LG:298102.1:2001MAR3041 63 forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D Type NO:

135 LG:298102.1:2001MAR3064 276forwardTM Non-Cytosolic 136 LG:308891.1:2001MAR301 14 forwardTM Non-Cytosolic 136 LG:308891.1:2001MAR3015 37 forwardTM Transmembrane 136 LG:308891.1:2001MAR3038 191forwardTM Cytosolic 136 LG:308891.1:2001MAR30192 214forwardTM Transmembrane 136 LG:308891.1:2001MAR30215 219forwardTM Non-Cytosolic 137 LG:312668.4:2001MAR301 270forwardTM Non-Cytosolic 137 LG:312668.4:2001MAR30271 293forwardTM Transmembrane 137 LG:312668.4:2001MAR30294 408forwardTM Cytosolic 137 LG:312668.4:2001MAR30409 431forwardTM Transmembrane 137 LG:312668.4:2001MAR30432 625forwardTM Non-Cytosolic ~ 3 138 LG:331642.6:2001MAR301 19 forwardTM Cytosolic 138 LG:331642.6:2001MAR3020 42 forwardTM Transmembrane 138 LG:331642.6:2001MAR3043 630forwardTM Non-Cytosolic 138 LG:331642.6:2001MAR301 12 forwardTM Cytosolic 138 LG:331642.6:2001MAR3013 35 forwardTM Transmembrane 138 LG:331642.6:2001MAR3036~ 65 forwardTM Non-Cytosolic 138 LG:331642.6:2001MAR3066 85 forwardTM Transmembrane 138 LG:331642.6:2001MAR3086 266forwardTM Cytosolic 138 LG:331642.6:2001MAR30267 289forwardTM Transmembrane 138 LG:331642.6:2001MAR30290 629forwardTM Non-Cytosolic 139 LG:331851.12:2001MAR301 904forwardTM Non-Cytosolic 139 LG:331851.12:2001MAR30905 927forwardTM Transmembrane 139 LG:331851.12:2001MAR30928 946forwardTM Cytosolic . 2 139 LG:331851.12:2001MAR30947 969forwardTM Transmembrane 139 LG:331851.12:2001MAR30970 2183forwardTM Non-Cytosolic 139 LG:331851.12:2001MAR302184 2206forwardTM Transmembrane 139 LG:331851.12:2001MAR302207 2218forwardTM Cytosolic 2' 139 LG:331851.12:2001MAR30l 833forward.3TM Non-Cytosolic , 139 LG:331851.12:2001MAR30834 856forwardTM Transmembrane 139 LG:331851.12:2001MAR30857 875forwardTM Cytosolic 139 LG:331851.12:2001MAR30876 898forwardTM Transmembrane 139 LG:331851.12:2001MAR30899 902forwardTM Non-Cytosolic 139 LG:331851.12:2001MAR30903 925forwardTM Transmembrane 139 LG:331851.12:2001MAR30926 992forwardTM Cytosolic 139 LG:331851.12:2001MAR30993 1015forwardTM Transmembrane 139 LG:331851.12:2001MAR301016 2217forwardTM Non-Cytosolic 140 LG:332414.5:2001MAR30I 482forwardTM Non-Cytosolic 140 LG:332414.5:2001MAR30483 505forwardTM Transmembrane 140 LG:332414.5:2001MAR30506 521forwardTM Cytosolic 140 LG:332414.5:2001MAR301 111forwardTM Non-Cytosolic 140 LG:332414.5:2001MAR30112 134forwardTM Transmembrane 140 LG:332414.5:2001MAR3013S 218forwardTM Cytosolic 140 LG:332414.5:2001MAR30219 236forwardTM Transmembrane 140 LG:332414.5:2001MAR30237 250forwardTM Non-Cytosolic 140 LG:332414.5:2001MAR30251 273forwardTM Transmembrane 140 LG:332414.5:2001MAR30274 480forwardTM Cytosolic 140 LG:332414.5:2001MAR30481 503forwardTM Transmembrane 140 LG:332414.5:2001MAR30504 521forwardTM Non-Cytosolic 141 LG:332730.12:2001MAR301 516forwardTM Non-Cytosolic 141 LG:332730.12:2001MAR30517 539forwardTM Transmembrane 141 LG:332730.12:2001MAR30540 684forwardTM Cytosolic 141 LG:332730.12:2001MAR30685 707forwardTM Transmembrane 141 LG:332730.12:2001MAR30708 710forward~TM Non-Cytosolic SEQ Template ID StartStopFrame Domain Topology D Type NO:

141 LG:332730.12:2001MAR30711 733forwardTM Transmembrane 141 LG:332730.12:2001MAR30734 739forwardTM Cytosolic 141 LG:332730.12:2001MAR30740 762forwardTM Transmembrane 141 LG:332730.12:2001MAR30763 781forwardTM Non-Cytosolic 141 LG:332730.12:2001MAR30782 804forward~ TM Transmembrane 141 LG:332730.12:2001MAR30805 1011forwardTM Cytosolic 141 LG:332730.12:2001MAR301012 1034forwardTM Transmembrane 141 LG:332730.12:2001MAR301035 1043forwardTM Non-Cytosolic 141 LG:332730.12:2001MAR301044 1063forwardTM Transmembrane 141 LG:332730.12:2001MAR301064 1083forwardTM Cytosolic 141 LG:332730.12:2001MAR301084 1106forwardTM Transmembrane 141 LG:332730.12:2001MAR301107 1302forwardTM Non-Cytosolic 141 LG:332730.12:2001MAR301 526forwardTM Non-Cytosolic 141 LG:332730.12:2001MAR30527 549forwardTM Transmembrane 141 LG:332730.12:2001MAR30550 739forwardTM Cytosolic 141 LG:332730.12:2001MAR30740 762forwardTM Transmembrane 141 LG:332730.12:2001MAR30763 781forwardTM Non-Cytosolic 141 LG:332730.12:2001MAR30782 804forwardTM Transmembrane 141 LG:332730.12:2001MAR30805 891forwardTM Cytosolic 141 LG:332730.12:2001MAR30892 914forwardTM Transmembrane 141 LG:332730.12:2001MAR30915 946forwardTM Non-Cytosolic 141 LG:332730.12:2001MAR30947 969forwardTM Transmembrane 141 LG:332730.12:2001MAR30970 1001forwardTM Cytosolic 141 LG:332730.12:2001MAR301002 1024.forwardTM Transmembrane 2, 141 LG:332730.12:2001MAR301025 1028forwardTM Non-Cytosolic 141 LG:332730.12:2001MAR301029 1048forwardTM . Transmembrane 141 LG:332730.12:2001MAR301049 1079forwardTM Cytosolic 2 .

141 LG:332730.12:2001MAR301080 1102forwardTM Transmembrane 141 LG:332730.12:2001MAR301103 1302forwardTM Non-Cytosolic .2 141 LG:332730.12:2001MAR301 514forwardTM Non-Cytosolic 141 LG:332730.12:2001MAR30515 537forwardTM Transmembrane 141 LG:332730.12:2001MAR30538 738forwardTM Cytosolic 141 LG:332730.12:2001MAR30739 761forwardTM Transmembrane 141 LG:332730.12:2001MAR30762 780forwardTM Non-Cytosolic 141 LG:332730.12:2001MAR30781 803forwardTM Transmembrane 141 LG:332730.12:2001MAR30804 1094forwardTM Cytosolic 141 LG:332730.12:2001MAR301095 1117forwardT'M Transmembrane 141 LG:332730.12:2001MAR301 1181forwardTM Non-Cytosolic 141 LG:332730.12:2001MAR30I 1201forwardTM Transmembrane 141 LG:332730.12:2001MAR301202 1212forwardTM Cytosolic 141 LG:332730.12:ZOO1MAR301213 1235forwardT'M Transmembrane 141 LG:332730.12:2001MAR301236 1269forwardTM Non-Cytosolic 141 LG:332730.12:2001MAR301270 1287forwardTM Transmembrane 141 LG:332730.12:2001MAR301288 1301forwardTM Cytosolic 142 LG:333062.22:2001MAR301 14 forwardTM Non-Cytosolic 142 LG:333062.22:2001MAR3015 37 forwardTM Transmembrane 142 LG:333062.22:2001MAR3038 133forwardTM Cytosolic 142 LG:333062.22:2001MAR30134 151forwardTM Transmembrane 142 LG:333062.22:2001MAR30152 160forwardTM Non-Cytosolic 142 LG:333062.22:2001MAR30161 180forwardTM Transmembrane 142 LG:333062.22:2001MAR30181 229forwardTM Cytosolic 142 LG:333062.22:2001MAR301 100forwardTM Non-Cytosolic 142 LG:333062.22:2001MAR30101 120forwardTM Transmembrane 142 LG:333062.22:2001MAR30121 204forwardTM Cytosolic SEQ Template ID StartStopFrame Domain Topology D Type NO:

142 LG:333062.22:2001MAR30205 227forwardTM Transmembrane 142 LG:333062.22:2001MAR30228 229forwardTM Non-Cytosolic 143 LG:335705.2:2001MAR301 1114forwardTM Non-Cytosolic 143 LG:335705.2:2001MAR301115 1137forwardTM Transmembrane 143 LG:335705.2:2001MAR301138 1233forwardTM Cytosolic 143 LG:335705.2:2001MAR301234 1256forwardTM Transmembrane 143 LG:335705.2:2001MAR301257 1747forwardTM Non-Cytosolic 143 LG:335705.2:2001MAR301748 1770forwardTM Transmembrane 143 LG:335705.2:2001MAR301771 1790forwardTM Cytosolic 143 LG:335705.2:2001MAR301 1249forwardTM Non-Cytosolic 143 LG:335705.2:2001MAR301250 1272forwardTM Transmembrane 143 LG:335705.2:2001MAR301273 1283forwardTM Cytosolic 143 LG:335705.2:2001MAR301284 1306forwardTM Transmembrane 143 LG:335705.2:2001MAR301307 1315forwardTM Non-Cytosolic 143 LG:335705.2:2001MAR301316 1338forwardTM Transmembrane 143 LG:335705.2:2001MAR301339 1496forwardTM Cytosolic 143 LG:335705.2:2001MAR301497 1514forwardTM Transmembrane 143 LG:335705.2:2001MAR301515 1730forwardTM Non-Cytosolic 143 LG:335705.2:2001MAR301731 1753forwardTM Transmembrane 143 LG:335705.2:2001MAR301754 1790forwardTM Cytosolic 143 LG:335705.2:2001MAR301 1248forwardTM Non-Cytosolic 143 LG:335705.2:2001MAR301249 1271forward~ TM Transmembrane 143 LG:335705.2:2001MAR301272 1283forwardTM Cytosolic 143 LG:335705.2:2001MAR301284 1306forwardTM Transmembrane 143 LG:335705.2:2001MAR301307 1315forwardTM Non-Cytosolic 143 LG:335705.2:2001MAR301316 1335forwardTM Transmembrane 143 LG:335705.2:2001MAR301336 1346forwardTM Cytosolic 143 LG:335705.2:2001MAR301347 1366forward' TM Transmembrane 143 LG:335705.2:2001MAR301367 1789forwardTM Non-Cytosolic 144 LG:337930.16:2001MAR301 12 forwardTM Cytosolic 144 LG:337930.16:2001MAR3013 35 forwardTM Transmembrane 144 LG:337930.16:2001MAR3036 645forwardTM Non-Cytosolic 145 LG:346481.15:2001MAR301 106forwardTM Non-Cytosolic 145 LG:346481.15:2001MAR30107 129forwardTM Transmembrane 145 LG:346481.15:2001MAR30130 161forwardTM Cytosolic 146 LG:349164.1:2001MAR301 48 forwardTM Cytosolic 146 LG:349164.1:2001MAR3049 67 forwardTM Transmembrane 146 LG:349164.1:2001MAR3068 76 forwardTM Non-Cytosolic 146 LG:349164.1:2001MAR3077 99 forwardTM Transmembrane 146 LG:349164.1:2001MAR30100 123forwardTM Cytosolic 146 LG:349164.1:2001MAR30124 146forwardTM Transmembrane 146 LG:349164.1:2001MAR30147 738forwardTM Non-Cytosolic 146 LG:349164.1:2001MAR30739 761forwardTM Transmembrane 146 LG:349164.1:2001MAR30762 807forwardTM Cytosolic 146 LG:349164.1:2001MAR30808 830forwardTM Transmembrane 146 LG:349164.1:2001MAR30~ 844forwardTM Non-Cytosolic 146 LG:349164.1:2001MAR30845 867forwardTM Transmembrane 146 LG:349164.1:2001MAR30868 943forwardTM Cytosolic 146 LG:349164.1:2001MAR30944 966forwardTM Transmembrane 146 LG:349164.1:2001MAR30967 973forwardTM Non-Cytosolic 146 LG:349164.1:2001MAR301 45 forwardTM Cytosolic 146 LG:349164.1:2001MAR3046 68 forwardTM Transmembrane 146 LG:349164.1:2001MAR3069 124forwardTM Non-Cytosolic 146 LG:349164.1:2001MAR30125 144forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D Type NO:

146 LG:349164.1:2001MAR30145 150 forwardTM Cytosolic 146 LG:349164.1:2001MAR30151 173 forwardTM Transmembrane 146 LG:349164.1:2001MAR30174 187 forwardTM Non-Cytosolic 146 LG:349164.1:2001MAR30188 210 forwardTM Transmembrane 146 LG:349164.1:2001MAR30211 389 forwardTM Cytosolic 146 LG:349164.1:2001MAR30390 408 forwardTM Transmembrane 146 LG:349164.1:2001MAR30409 422 forwardTM Non-Cytosolic 146 LG:349164.1:2001MAR30423 442 forwardTM Transmembrane 146 LG:349164.1:2001MAR30443 478 forwardTM Cytosolic 146 LG:349164.1:2001MAR30479 496 forwardTM Transmembrane 146 LG:349164.1:2001MAR30497 660 forwardTM Non-Cytosolic 146 LG:349164.1:2001MAR30661 683 forwardTM Transmembrane 146 LG:349164.1:2001MAR30684 695 forwardTM Cytosolic 146 LG:349164.1:2001MAR30696 715 forwardTM Transmembrane 146 LG:349164.1:2001MAR30716 734 forwardTM Non-Cytosolic 146 LG:349164.1:2001MAR30735 757 forwardTM Transmembrane 146 LG:349164.1:2001MAR30758 776 forwardTM Cytosolic 146 LG:349164.1:2001MAR30777 799 forwardTM Transmembrane 146 LG:349164.1:2001MAR30800 824 forwardTM Non-Cytosolic 146 LG:349164.1:2001MAR30825 847 forwardTM Transmembrane 146 LG:349164.1:2001MAR30848 853 forwardTM Cytosolic 146 LG:349164.1:2001MAR30854 873 forwardTM Transmembrane 146 LG:349164.1:2001MAR30874 876 forwardTM Non-Cytosolic 146 LG:349164.1:2001MAR30877 899 forwardTM Transmembrane 146 LG:349164.1:2001MAR30900 932 forwardTM Cytosolic 146 LG:349164.1:2001MAR30933 955 forward. TM Transmembrane . 2 146 LG:349164.1:2001MAR30956 973 forwardTM Non-Cytosolic 146 LG:349164:1:2001MAR30~ 663 forwardTM Non-Cytosolic 146 LG:349164.1:2001MAR30664 681 forwardTM Transmembrane 146 LG:349164.1:2001MAR30682 692 forwardTM Cytosolic 146 LG:349164.1:2001MAR30693 715 forwardTM Transmembrane 146 LG:349164.1:2001MAR30716 741 forwardTM Non-Cytosolic 146 LG:349164.1:2001MAR30742 764 forwardTM Transmembrane 146 LG:349164.1:2001MAR30765 776 forwardTM Cytosolic f 3 146 LG:349164.1:2001MAR30777 799 forwardTM Transmembrane 146 LG:349164.1:2001MAR30800 818 forwardTM Non-Cytosolic 146 LG:349164.1:2001MAR30819 841 forwardTM Transmembrane 146 LG:349164.1:2001MAR30842 852 forwardTM Cytosolic 146 LG:349164.1:2001MAR30853 875 forwardTM Transmembrane 146 LG:349164.1:2001MAR30876 878 forwardTM Non-Cytosolic 146 LG:349164.1:2001MAR30879 898 forwardTM Transmembrane 146 LG:349164.1:2001MAR30899 909 forwardTM Cytosolic 146 LG:349164.1:2001MAR30910 932 forwardTM Transmembrane 146 LG:349164.1:2001MAR30933 941 forwardTM Non-Cytosolic 146 LG:349164.1:2001MAR30942 964 forwardTM Transmembrane 146 LG:349164.1:2001MAR30965 973 forwardTM Cytosolic 147 LG:350957.5:2001MAR301 71 forwardTM Non-Cytosolic 147 LG:350957.5:2001MAR3072 94 forwardTM Transmembrane 147 LG:350957.5:2001MAR3095 106 forwardTM Cytosolic 147 LG:350957.5:2001MAR30107 129 forwardTM Transmembrane 147 LG:350957.5:2001MAR30130 151 forwardTM Non-Cytosolic 147 LG:350957.5:2001MAR30152 174 forwardTM Transmembrane 147 LG:350957.5:2001MAR30175 238 forwardTM Cytosolic 147 LG:350957.5:2001MAR30239 261 forwardTM Transmembrane SEQ D NO: Template ID StartStopFrame Domain Topology Type 147 LG:350957.5:2001MAR30262 286forwardTM Non-Cytosolic 147 LG:350957.5:2001MAR30287 309forwardTM Transmembrane 147 LG:350957.5:2001MAR30310 379forwardTM Cytosolic 147 LG:350957.5:2001MAR301 18 forwardTM Cytosolic 147 LG:350957.5:2001MAR3019 41 forwardTM Transmembrane 147 LG:350957.5:2001MAR3042 71 forwardTM Non-Cytosolic 147 LG:350957.5:2001MAR3072 94 forwardTM Transmembrane 147 LG:350957.5:2001MAR3095 151forwardTM Cytosolic 147 LG:350957.5:2001MAR30152 174forwardTM Transmembrane 147 ~ LG:350957.5:2001MAR30175 212forwardTM Non-Cytosolic 147 LG:350957.5:2001MAR30213 232forwardTM Transmembrane 147 LG:350957.5:2001MAR30233 244forwardTM Cytosolic 147 LG:350957.5:2001MAR30245 262forwardTM Transmembrane 147 LG:350957.5:2001MAR30263 271forwardTM Non-Cytosolic 147 LG:350957.5:2001MAR30272 294forwardTM Transmembrane 147 LG:350957.5:2001MAR30295 298forwardTM Cytosolic 147 LG:350957.5:2001MAR30299 321forwardTM Transmembrane 147 LG:350957.5:2001MAR30322 379forwardTM Non-Cytosolic 148 LG:383512.8:2001MAR301 833forwardTM Non-Cytosolic 148 LG:383512.8:2001MAR30834 856forwardTM Transmembrane 148 LG:383512.8:2001MAR30857 876forwardTM Cytosolic 148 LG:383512.8:2001MAR30877 899forwardTM Transmembrane 148 LG:383512.8:2001MAR30900 1052forwardTM Non-Cytosolic 149 LG:401163.10:2001MAR301 1167forwardTM Non-Cytosolic 149 LG:401163.10:2001MAR301168 1190forwardTM Transmembrane 149 LG:401163.10:2001MAR301191 1270forwardTM Cytosolic ~ 1 149 ' ' LG:401163.10:2001MAR301271 1290forwardTM Transmembrane 149 ' ' LG:401163.10:2001MAR301291 1492forwardTM Non-Cytosolic 150' ~ LG:402133.1:2001MAR301 6 forwardTM Cytosolic 150 LG:402133.1:2001MAR307 26 forwardTM Transmembrane 150 LG:402I33.1:2001MAR3027 68 forwardTM Non-Cytosolic 150 LG:402133.1:2001MAR3069 91 forwardTM Transmembrane 150 LG:402133.1:2001MAR3092 476forwardTM Cytosolic 150 LG:402133.1:2001MAR30477 499forwardTM Transmembrane 3' 150 LG:402133.1:2001MAR30500 543forwardTM Non-Cytosolic 151 LG:405820.1:2001MAR301 242forwardTM Non-Cytosolic 151 LG:405820.1:2001MAR30243 262forwardTM Transmembrane 151 LG:405820.1:2001MAR30263 303forwardTM Cytosolic 152 LG:405846.1:2001MAR301 297forwardTM Non-Cytosolic 152 LG:405846.1:2001MAR30298 320forwardTM Transmembrane 152 LG:405846.1:2001MAR30321 356forwardTM Cytosolic 153 LG:407401.2:2001MAR30I 542forwardTM Non-Cytosolic 153 LG:407401.2:2001MAR30543 565forwardTM Transmembrane 153 LG:407401.2:2001MAR30566 573forwardTM Cytosolic 153 LG:407401.2:2001MAR30574 591forwardTM Transmembrane 153 LG:407401.2:2001MAR30592 888forwardTM Non-Cytosolic 154 LG:408448.10:2001MAR301 636forwardTM Non-Cytosolic 154 LG:408448.10:2001MAR30637 659forwardTM Transmembrane 154 LG:408448.10:2001MAR30660 716forwardTM Cytosolic 154 LG:408448.10:2001MAR30I 281forwardTM Non-Cytosolic 154 LG:408448.10:2001MAR30282 304forwardTM Transmembrane 154 LG:408448.10:2001MAR30305 324forwardTM Cytosolic 154 LG:408448.10:2001MAR30325 347forwardTM Transmembrane 154 LG:408448.10:2001MAR30348 715forwardTM Non-Cytosolic SE(~ Template ID StartStopFrame Domain Topology D Type NO:

154 LG:408448.10:2001MAR301 281 forwardTM Non-Cytosolic 154 LG:408448.10:2001MAR30282 304 forwardTM Transmembrane 154 LG:408448.I0:2001MAR30305 324 forwardTM Cytosolic 154 LG:408448.10:2001MAR30325 347 forwardTM Transmembrane 154 LG:408448.10:2001MAR30348 715 forwardTM Non-Cytosolic 155 LG:408854.13:2001MAR301 128 forwardTM Non-Cytosolic 155 LG:408854.13:2001MAR30129 148 forwardTM Transmembrane 155 LG:408854.13:2001MAR30149 191 forwardTM Cytosolic 155 LG:408854.13:2001MAR30192 214 forwardTM Transmembrane 155 LG:408854.13:2001MAR30215 218 forwardTM Non-Cytosolic 155 LG:408854.13:2001MAR30219 238 forwardTM Transmembrane 155 LG:408854.13:2001MAR30239 242 forwardTM Cytosolic 155 LG:408854.13:2001MAR30243 265 forwardTM Transmembrane 155 LG:408854.13:2001MAR30266 305 forwardTM Non-Cytosolic 155 LG:408854.13:2001MAR30306 328 forwardTM Transmembrane 155 LG:408854.13:2001MAR30329 544 forwardTM Cytosolic 156 LG:411150.14:2001MAR301 676 forwardTM Non-Cytosolic 156 LG:411150.14:2001MAR30677 699 forwardTM Transmembrane 156 LG:411150.14:2001MAR30700 822 forwardTM Cytosolic 156 LG:411150.14:2001MAR301 676 forwardTM Non-Cytosolic 156 LG:411150.14:2001MAR30677 699 forwardTM Transmembrane 156 LG:411150.14:2001MAR30700 822 forwardTM Cytosolic 156 LG:411150.14:2001MAR301 99 forwardTM Cytosolic 156 LG:411150.14:2001MAR30100 117 forwardTM Transmembrane , 3 .

156 LG:411150.14:2001MAR30118 699 forwardTM Non-Cytosolic 156 LG:411150.14:2001MAR30700 722 forwardTM Transmembrane 156 LG:411150.14:2001MAR30723 733 forwardTM Cytosolic 156 LG:411150:14:2001MAR30. 751 forwardTM Transmembrane 156 LG:411150.14:2001MAR30752 754 forwardTM Non-Cytosolic 156 LG:411150.14:2001MAR30755 777 forwardTM Transmembrane 156 LG:411150.14:2001MAR30778 821 forwardTM Cytosolic 157 LG:411466.1:2001MAR301 111 forwardTM Non-Cytosolic 157 LG:411466.1:2001MAR30112 134 forwardTM Transmembrane 157 LG:411466.1:2001MAR30135 146 forwardTM Cytosolic 157 LG:411466.1:2001MAR30147 169 forwardTM Transmembrane 157 LG:411466.1:2001MAR30170 188 forwardTM Non-Cytosolic 157 LG:411466.1:2001MAR30189 211 forwardTM Transmembrane 157 LG:411466.1:2001MAR30212 217 forwardTM Cytosolic 157 LG:411466.1:2001MAR30218 240 forwardTM Transmembrane 157 LG:411466.1:2001MAR30241 254 forwardTM Non-Cytosolic 157 LG:411466.1:2001MAR3025S 274 forwardTM Transmembrane 157 LG:411466.1:2001MAR30275 333 forwardTM Cytosolic 157 LG:411466.1:2001MAR30334 351 forwardTM Transmembrane 157 LG:411466.1:2001MAR30352 404 forwardTM Non-Cytosolic 157 LG:411466.1:2001MAR30405 427 forwardTM Transmembrane 157 LG:411466.1:2001MAR30428 525 forwardTM Cytosolic 157 LG:411466.1:2001MAR30526 548 forwardTM Transmembrane 157 LG:411466.1:2001MAR30549 918 forwardTM Non-Cytosolic 157 LG:411466.1:2001MAR301 70 forwardTM Cytosolic 157 LG:411466.1:2001MAR3071 93 forwardTM Transmembrane 157 LG:411466.1:2001MAR3094 110 forwardTM Non-Cytosolic 157 LG:411466.1:2001MAR30I1 133 forwardTM Transmembrane 157 LG:411466.1:2001MAR30134 145 forwardTM Cytosolic 157 LG:411466.1:2001MAR30146 168 forwardTM Transmembrane TABLE

SEQ Template ID StartStopFrame Domain Topology D Type NO:

157 LG:411466.1:2001MAR30169 202forwardTM Non-Cytosolic 157 LG:411466.1:2001MAR30203 225forwardTM Transmembrane 157 LG:411466.1:2001MAR30226 231forwardTM Cytosolic 157 LG:411466.1:200IMAR30232 254forwardTM Transmembrane 157 LG:411466.1:2001MAR30255 918forwardTM Non-Cytosolic 158 LG:413969.68:2001MAR301 741forwardTM Non-Cytosolic 158 LG:413969.68:2001MAR30742 764forwardTM Transmembrane 158 LG:413969.68:2001MAR30765 770forwardTM Cytosolic 158 LG:413969.68:2001MAR30771 793forwardTM Transmembrane 158 LG:413969.68:2001MAR30794 807forwardTM Non-Cytosolic 158 LG:413969.68:2001MAR30808 830forwardTM Transmembrane , 2 158 LG:413969.68:2001MAR30831 842forwardTM Cytosolic 158 LG:413969.68:2001MAR30843 865forwardTM Transmembrane 158 LG:413969.68:2001MAR30866 911forwardTM Non-Cytosolic 159 LG:419641.35:2001MAR301 347forwardTM Non-Cytosolic 159 LG:419641.35:2001MAR30348 370forwardTM Transmembrane 159 LG:419641.35:2001MAR30371 450forwardTM Cytosolic 159 LG:419641.35:2001MAR301 20 forwardTM Cytosolic 159 LG:419641,35:2001MAR3021 40 forwardTM Transmembrane 159 LG:419641.35:200IMAR3041 450forwardTM Non-Cytosolic 159 LG:419641.35:2001MAR301 352forwardTM Non-Cytosolic 159 LG:419641.35:2001MAR30353 370forwardTM Transmembrane 159 LG:419641.35:2001MAR30371 382forwardTM Cytosolic 159 LG:419641.35:2001MAR30383 405forwardTM Transmembrane 159 LG:419641.35:2001MAR30406 424forwardTM Non-Cytosolic 159 ~LG:419641.35:2001MAR30425 447forwardTM Transmembrane 159 LG:419641.35:2001MAR30448 450forwardTM Cytosolic 160 LG:428206.7:2001MAR301 367forwardTM Non-Cytosolic 160 LG:428206.7:2001MAR30368 385forwardTM Transmembrane 160 LG:428206.7:2001MAR30386 512forwardTM Cytosolic 161 LG:430059.1:2001MAR301 72 forwardTM Non-Cytosolic 161 LG:430059.1:2001MAR3073 95 forwardTM Transmembrane 161 LG:430059.1:2001MAR3096 106forwardTM Cytosolic 161 LG:430059.1:2001MAR30107 129forwardTM Transmembrane 161 LG:430059.1:2001MAR30130 143forwardTM Non-Cytosolic 161 LG:430059.1:2001MAR30144 163forwardTM Transmembrane 161 LG:430059.1:2001MAR30164 583forwardTM Cytosolic 161 LG:430059.1:2001MAR30584 606forwardTM Transmembrane 161 LG:430059.1:2001MAR30607 653forwardTM Non-Cytosolic 161 LG:430059.I:2001MAR30654 676forwardTM Transmembrane 161 LG:430059.1:2001MAR30677 783forwardTM Cytosolic 161 LG:430059.1:2001MAR30784 806forwardTM Transmembrane 161 LG:430059.1:2001MAR30807 869forwardTM Non-Cytosolic 161 LG:430059.1:2001MAR30870 889forwardTM Transmembrane 161 LG:430059.1:2001MAR30890 1017forwardTM Cytosolic 161 LG:430059.1:2001MAR301 20 forwardTM Cytosolic 161 LG:430059.1:2001MAR3021 43 forwardTM Transmembrane 161 LG:430059.1:2001MAR3044 76 forwardTM Non-Cytosolic 161 LG:430059.1:2001MAR3077 96 forwardTM Transmembrane 161 LG:430059.1:2001MAR3097 102forwardTM Cytosolic 161 LG:430059.1:2001MAR30103 122forwardTM Transmembrane 161 LG:430059.1:2001MAR30123 595forwardTM Non-Cytosolic 161 LG:430059.1:2001MAR30596 618forwardTM Transmembrane 161 LG:430059.1:2001MAR30619 645forward'TM Cytosolic SEQ Template ID StartStopFrame Domain Topology D NO: Type 161 LG:430059.1:2001MAR30646 668 forwardTM Transmembrane 161 LG:430059.1:2001MAR30669 671 forwardTM Non-Cytosolic 161 LG:430059.1:2001MAR30672 694 forwardTM Transmembrane 161 LG:430059.1:2001MAR30695 787 forwardTM Cytosolic 161 LG:430059.1:2001MAR30788 810 forward~ TM Transmembrane 161 LG:430059.1:2001MAR30811 835 forwardTM Non-Cytosolic 161 LG:430059.1:2001MAR30836 858 forwardTM Transmembrane 161 LG:430059.1:2001MAR30859 1017forwardTM Cytosolic 161 LG:430059.1:2001MAR301 75 forwardTM Cytosolic 161 LG:430059.1:2001MAR3076 95 forwardTM Transmembrane 161 LG:430059.1:2001MAR3096 104 forwardTM Non-Cytosolic 161 LG:430059.1:2001MAR30105 122 forwardTM Transmembrane 161 LG:430059.1:2001MAR30123 128 forwardTM Cytosolic 161 LG:430059.1:2001MAR30129 151 forwardTM Transmembrane 161 LG:430059.1:2001MAR30152 190 forwardTM Non-Cytosolic 161 LG:430059.1:2001MAR30191 213 forwardTM Transmembrane 161 LG:430059.1:2001MAR30214 456 forwardTM Cytosolic 161 LG:430059.1:2001MAR30457 479 forwardTM Transmembrane 161 LG:430059.1:2001MAR30480 513 forwardTM Non-Cytosolic 161 LG:430059.1:2001MAR30514 536 forwardTM Transmembrane 161 LG:430059.1:2001MAR30537 582 forwardTM Cytosolic 161 LG:430059.1:2001MAR30583 605 forwardTM Transmembrane 161 LG:430059.1:2001MAR30606 609 forwardTM Non-Cytosolic 161 LG:430059.1:2001MAR30610 632 forwardTM Transmembrane 161 LG:430059.1:2001MAR30633 651 forwardTM Cytosolic 1.61 LG:430059.1:2001MAR30652 674 forwardTM Transmembrane 161 LG:430059.1:2001MAR30675 710 forwardTM Non-Cytosolic . 3 161 LG:430059.1:2001MAR30711 733 forwardTM Transmembrane 161 LG:430059.1:2001MAR30734 737 forwardTM Cytosolic 161 LG:430059.1:2001MAR30738 757 forwardTM Transmembrane 161 LG:430059.1:2001MAR30758 1017forwardTM Non-Cytosolic 162 LG:448040.3:2001MAR301 37 forwardTM Cytosolic 162 LG:448040.3:2001MAR3038 57 forward. TM Transmembrane 162 LG:448040.3:2001MAR3058 169 forwardTM Non-Cytosolic 162 LG:448040.3:2001MAR301 39 forwardTM Cytosolic 162 LG:448040.3:2001MAR3040 62 forwardTM Transmembrane 162 LG:448040.3:2001MAR3063 66 forwardTM Non-Cytosolic 162 LG:448040.3:2001MAR3067 86 forwardTM Transmembrane 162 LG:448040.3:2001MAR3087 168 forwardTM Cytosolic 162 LG:448040.3:2001MAR301 39 forwardTM Cytosolic 162 LG:448040.3:2001MAR3040 62 forwardTM Transmembrane 162 LG:448040.3:2001MAR3063 168 forwardTM Non-Cytosolic 163 LG:451274.1:2001MAR301 25 forwardTM Non-Cytosolic 163 LG:451274.1:2001MAR3026 48 forwardTM Transmembrane 163 LG:451274.1:2001MAR3049 54 forwardTM Cytosolic 163 LG:451274.1:2001MAR3055 77 forwardTM Transmembrane 163 LG:451274.1:2001MAR3078 467 forwardTM Non-Cytosolic 164 LG:456110.1:2001MAR301 103 forwardTM Cytosolic 164 LG:456110.1:2001MAR30104 126 forwardTM Transmembrane 164 LG:456110.1:2001MAR30127 140 forwardTM Non-Cytosolic 164 LG:456110.1:2001MAR30141 160 forwardTM Transmembrane 164 LG:456110.1:2001MAR30161 199 forwardTM Cytosolic 165 LG:456954.1:2001MAR301 35 forwardTM Cytosolic 165 LG:456954.1:2001MAR3036 58 forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D NO: Type 16S LG:4S69S4.1:200IMAR30S9 I02forwardTM Non-Cytosolic 16S LG:4S69S4.1:2001MAR30103 12SforwardTM Transmembrane 16S LG:4S69S4.1:2001MAR30126 242forwardTM Cytosolic 16S LG:4S69S4.1:2001MAR301 38 forwardTM Cytosolic 165 LG:456954.1:2001MAR3039 58 forwardTM Transmembrane 16S LG:4S69S4.1:2001MAR30S9 117forwardTM Non-Cytosolic 16S LG:4S69S4.1:2001MAR30118 140forwardTM Transmembrane 16S LG:4S69S4.1:2001MAR30141 242forwardTM Cytosolic 166 LG:474942.12:2001MAR301 6 forwardTM Cytosolic 166 LG:474942.12:2001MAR307 29 forwardTM Transmembrane 166 LG:474942.12:2001MAR3030 872forwardTM Non-Cytosolic 166 LG:474942.12:2001MAR301 16SforwardTM Cytosolic 166 LG:474942.12:2001MAR30166 188forwardTM Transmembrane 166 LG:474942.12:2001MAR30189 872forwardTM Non-Cytosolic 167 LG:4751I9.14:2001MAR301 122forwardTM CytosoIic 167 LG:47S 119.14:2001MAR30123 14SforwardTM Transmembrane 167 LG:475119.14:2001MAR30146 149forwardTM Non-Cytosolic 167 LG:47S 119.14:2001MAR301S0 169forwardTM Transmembrane 167 LG:47S 119.14:2001MAR30170 181forwardTM Cytosolic 167 LG:475119.14:2001MAR30182 201forwardTM Transmembrane 167 LG:47S 119.14:2001MAR30202 242forwardTM Non-Cytosolic 167 LG:47S119.14:2001MAR30243 265forwardTM Transmembrane 167 LG:47S 119.14:2001MAR30266 4S9forwardTM Cytosolic 168 LG:479908.77:2001MAR30. 41 forwardTM Cytosolic 1. 3 168 LG:479908.77:2001MAR3042 64 forwardTM Transmembrane 168 LG:479908.77:2001MAR306S 1S0forwardTM Non-Cytosolic ~ 3 169 LG:480127.47:2001MAR301 78 forwardTM Non-Cytosolic 169 LG:480127.47:2001MAR30~ 101'forwardTM Transmembrane 79' 3 169 LG:480127.47:2001MAR30102 190forwardTM Cytosolic 170 LG:481154.12:2001MAR301 91 forwardTM Cytosolic 170 LG:481154.12:2001MAR3092 111forwardTM Transmembrane 170 LG:481154.12:2001MAR30112 1082forwardTM Non-Cytosolic 170 LG:481154.12:2001MAR301083 1105forwardTM Transmembrane 170 LG:481154.12:2001MAR301106 1152forwardTM Cytosolic 171 LG:481414.6:2001MAR301 376forwardTM Non-Cytosolic 171 LG:481414.6:2001MAR30377 399forwardTM Transmembrane 171 LG:481414.6:2001MAR30400 S31forwardTM Cytosolic 171 LG:481414.6:2001MAR30S32 SS4forwardTM Transmembrane 171 LG:481414.6:2001MAR30SSS 877forwardTM Non-Cytosolic 171 LG:481414.6:2001MAR301 7S2forwardTM Non-Cytosolic 171 LG:481414.6:2001MAR307S3 77SforwardTM Transmembrane 171 LG:481414.6:2001MAR30776 781forwardTM Cytosolic 171 LG:481414.6:2001MAR30782 801forwardTM Transmembrane 171 LG:481414,6:2001MAR30802 877forwardTM Non-Cytosolic 172 LG:481941.1:2001MAR301 19 forwardTM Non-Cytosolic 172 LG:481941,1:2001MAR3020 41 forwardTM Transmembrane 172 LG:481941,1:2001MAR3042 491forwardTM Cytosolic 172 LG:481941,1:2001MAR30492 S14forwardTM Transmembrane 172 LG:481941.1:2001MAR30S1S S23forwardTM Non-Cytosolic 172 LG:481941.1:2001M'AR30S24 546forwardTM Transmembrane 172 LG:481941.1:2001MAR30S47 7S9forwardTM Cytosolic 172 LG:481941.1:2001MAR30760 782forwardTM Transmembrane 172 LG:481941.1:2001MAR30783 801forwardTM Non-Cytosolic 172 LG:481941.1:2001MAR30802 824forwardTM Transmembrane SEQ Template ID Start StopFrame Domain Topology D NO: Type 172 LG:481941.1:2001MAR30825 836forwardTM Cytosolic 172 LG:481941.1:2001MAR30837 8S9forwardTM Transmembrane 172 LG:481941.1:2001MAR30860 1184forwardTM Non-Cytosolic 172 LG:48194I.1:2001MAR301185 1204forwardTM Transmembrane 172 LG:48194I.1:2001MAR301205 1263forwardTM Cytosolic 172 LG:481941.1:2001MAR301 11 forwardTM Cytosotic 172 LG:481941.1:2001MAR3012 34 forwardTM Transmembrane 272 LG:48194I.1:2002MAR3035 1263forwardTM Non-Cytosolic 273 LG:887216.4:2001MAR30I 248forwardTM Cytosolic 173 LG:887216.4:2001MAR30249 266forwardTM Transmembrane 173 LG:887226.4:2001MAR30267 283forwardTM Non-Cytosolic 174 LG:899402.3:2001MAR30I 754forwardTM Non-Cytosolic 174 LG:899402.3:2001MAR30755 774forwardTM Transmembrane 174 LG:899402.3:2001MAR30775 914forwardTM Cytosolic 174 LG:899402.3:2001MAR30915 937forwardTM Transmembrane 174 LG:899402.3:2002MAR30938 1020forwardTM Non-Cytosolic 174 LG:899402.3:200IMAR301021 1043ForwardTM Transmembrane 174 LG:899402.3:2001MAR301044 1098forwardTM Cytosolic 174 LG:899402.3:2001MAR301099 1121forwardTM Transmembrane 174 LG:899402.3:2001MAR301122 1784forwardTM Non-Cytosolic 174 LG:899402.3:2002MAR301 840forwardTM Non-Cytosolic 174 LG:899402.3:2001MAR30841 863forwardTM Transmembrane 174 LG:899402.3:2002MAR30864 875forwardTM Cytosolic 174 LG:899402.3:2001MAR30876 898forward. TM Transmembrane 174 LG:899402.3:2001MAR30899 926forwardTM Non-Cytosolic 174 LG:899402.3:2001MAR30927 949forward, TM Transmembrane 174 LG:899402.3:2001MAR30950 1136forwardTM Cytosolic 174 LG:899402.3:2001MAR301137 1159forwardTM Transmembrane ' 3 174 LG:899402.3:2001MAR301160 1649' forwardTM Non-Cytosolic 174 LG:899402.3:2002MAR301650 1672forwardTM Transmembrane 174 LG:899402.3:2001MAR301673 1711forwardTM Cytosolic 174 LG:899402.3:2001MAR302712 1731forwardTM Transmembrane 274 LG:899402.3:2002MAR301732 1761forwardTM Non-Cytosolic . 3 174 LG:899402.3:2001MAR301762 1779forwardTM Transmembrane 174 LG:899402.3:2002MAR301780 1783forwardTM Cytosolic 3 .

175 LG:899894.2:2001MAR302 8 forwardTM Cytosolic 175 LG:899894.2:2001MAR309 26 forwardTM Transmembrane 275 LG:899894.2;2001MAR3027 35 forwardTM Non-Cytosolic 17S LG:899894.2;2001MAR3036 53 forwardTM Transmembrane 27S LG:899894.2:2002MAR3054 72 forwardTM Cytosolic 175 LG:899894.2:2001MAR3073 95 forwardTM Transmembrane 175 LG:899894.2:2001MAR3096 563forwardTM Non-Cytosolic 175 LG:899894.2:2001MAR301 495forwardTM Non-Cytosolic 175 LG:899894.2:2001MAR30496 S18forwardTM Transmembrane 175 LG:899894.2:2001MAR30519 563forwardTM Cytosolic 176 LG:977908.1:2001MAR301 200forwardTM Cytosolic 176 LG:977908.1:2001MAR30201 223forwardTM Transmembrane 176 LG:977908.1:2001MAR30224 242forwardTM Non-Cytosolic 176 LG:977908.1:2001MAR30243 262forwardTM Transmembrane 176 LG:977908.1:2001MAR30263 563forwardTM Cytosolic 176 LG:977908.1:2001MAR30564 586forwardTM Transmembrane 176 LG:977908.1:2002MAR30587 595forwardTM Non-Cytosolic 176 LG:977908.I:2001MAR30596 618forwardTM Transmembrane 176 LG:977908.1:2001MAR30619 710forwardTM Cytosolic SEQ Template ID StartStopFrame Domain Topology D Type NO:

176 LG:977908.1:2001MAR30711 733 forwardTM Transmembrane 176 LG:977908.1:2001MAR30734 1236forwardTM Non-Cytosolic 176 LG:977908.1:2001MAR301 561 forwardTM Non-Cytosolic 176 LG:977908.1:2001MAR30562 584 forwardTM Transmembrane 176 LG:977908.1:2001MAR30585 596 forwardTM Cytosolic 176 LG:977908.1:2001MAR30597 619 forward' TM Transmembrane 176 LG:977908.1:2001MAR30620 1236forwardTM Non-Cytosolic 177 LG:977929.1:2001MAR301 688 _ TM Non-Cytosolic forward 177 LG:977929.1:2001MAR30689 708 forwardTM Transmembrane 177 LG:977929.1:2001MAR30709 810 forwardTM Cytosolic 177 LG:977929.1:2001MAR30811 828 forwardTM Transmembrane 177 LG:977929.1:2001MAR30829 837 forwardTM Non-Cytosolic 177 LG:977929.1:2001MAR30838 860 forwardTM Transmembrane 177 LG:977929.1:2001MAR30861 890 forwardTM Cytosolic 177 LG:977929.1:2001MAR30891 913 forwardTM Transmembrane 177 LG:977929.1:2001MAR30914 1006forwardTM Non-Cytosolic 177 LG:977929.1:2001MAR301 837 forwardTM Non-Cytosolic 177 LG:977929.1:2001MAR30838 860 forwardTM Transmembrane 177 LG:977929.1:2001MAR30861 1005forwardTM Cytosolic 177 LG:977929.1:2001MAR301 776 forwardTM Non-Cytosolic 177 LG:977929.1:2001MAR30777 799 forwardTM Transmembrane 177 LG:977929.1:2001MAR30800 834 forwardTM Cytosolic 177 LG:977929.1:2001MAR30835 857 forwardTM Transmembrane 177 LG:977929.1:2001MAR30858 889 forwardTM Non-Cytosolic . 3 177 LG:977929.1:2001MAR30890 912 forwardTM Transmembrane 277 LG:977929.1:2001MAR30913 924 'forward~ ,TM Cytosolic . 3 -177 LG:977929.1:2001MAR30925 947:forwardTM Transmembrane 177 LG:977929.1:2001MAR30948 974 forwardTM Non-Cytosolic 177 LG:977929.1:2001MAR30975 997 forwardTM Transmembrane 177 LG:977929.1;2001MAR30998 1005forwardTM Cytosolic 178 LG:978008.14:2001MAR301 991 forwardTM Non-Cytosolic 178 LG:978008.14:2001MAR30992 1014forwardTM Transmembrane 178 LG:978008.14:2001MAR3010151118forwardTM Cytosolic 178 LG:978008.14:2001MAR3011191136forwardTM Transmembrane 178 LG:978008.14:2001MAR3011371202forwardTM Non-Cytosolic 178 LG:978008.14:2001MAR3012031222forwardTM Transmembrane 178 LG:978008.14:2001MAR3012231431forwardTM Cytosolic 178 LG:978008.14:2001MAR3014321449forwardTM Transmembrane 178 LG:978008.14:2001MAR3014501463forwardTM Non-Cytosolic 178 LG:978008.14:2001MAR3014641486forwardTM Transmembrane 178 LG:978008.14:2001MAR3014871499forwardTM Cytosolic 179 LG:979054.18:2001MAR301 491 forwardTM Non-Cytosolic 179 LG:979054.18:2001MAR30492 514 forwardTM Transmembrane 179 LG:979054.18:2001MAR30515 520 forwardTM Cytosolic 179 LG:979054.18:2001MAR30521 543 forwardTM Transmembrane 179 LG:979054.18:2001MAR30544 1150forwardTM Non-Cytosolic 179 LG:979054.18:2001MAR301 490 forwardTM Non-Cytosolic 179 LG:979054.18:2001MAR30491 513 forwardTM Transmembrane 179 LG:979054.18:2001MAR30514 514 forwardTM Cytosolic 179 LG:979054.18:2001MAR30515 537 forwardTM Transmembrane 179 LG:979054.I8:2001MAR30538 1149forwardTM Non-Cytosolic 180 LG:979185.10:2001MAR30I 3 forwardTM Non-Cytosolic 180 LG:979185.10:2001MAR304 26 forwardTM Transmembrane 180 LG:979185.10:2001MAR3027 277 forwardTM Cytosolic SEQ Template ID StartStopFrame Domain Topology D Type NO:

180 LG:979I85.I0:2001MAR30278 300forwardTM Transmembrane 180 LG:979185.10:2001MAR30301 319forwardTM Non-Cytosolic 180 LG:979185.10:2001MAR30320 339forwardTM Transmembrane 180 LG:979185.10:2001MAR30340 533forwardTM Cytosolic 180 LG:979185.10:2001MAR301 241forwardTM Non-Cytosolic 180 LG:979185.10:2001MAR30242 264forwardTM Transmembrane 180 LG:979185.10:2001MAR30265 276forwardTM Cytosolic 180 LG:979185.10:2001MAR30277 296forwardTM Transmembrane 180 LG:979185.10:2001MAR30297 501forwardTM Non-Cytosolic 180 LG:979185.10:2001MAR30502 524forwardTM Transmembrane I80 LG:979185.10:2001MAR30525 533forwardTM Cytosolic 180 LG:979185.10:2001MAR301 6 forwardTM Cytosolic 180 LG:979185.10:2001MAR307 24 forwardTM ~ Transmembrane 180 LG:979185.10:2001MAR3025 38 forwardTM Non-Cytosolic 180 LG:979185.10:2001MAR3039 61 forwardTM Transmembrane 180 LG:979185.10:2001MAR3062 241forwardTM Cytosolic 180 LG:979185.10:2001MAR30242 264forwardTM Transmembrane 180 LG:979185.10:2001MAR30265 273forwardTM Non-Cytosolic 180 LG:979185.10:2001MAR30274 296forwardTM Transmembrane 180 LG:979185.10:2001MAR30297 315forwardTM Cytosolic 180 LG:979185.10:2001MAR30316 338forwardTM Transmembrane 180 LG:979185.10:2001MAR30339 362forwardTM Non-Cytosolic 180 LG:979185.10:2001MAR30363 385forwardTM Transmembrane 180 LG:979185.10:2001MAR30386 404forwardTM Cytosolic 180 LG:979185.10:2001MAR30405 427forwardTM Transmembrane 180 LG:979185.10:2001MAR30428 532forwardTM Non-Cytosolic 181 LG:983654.1:2001MAR301 319forwardTM Non-Cytosolic 18I LG:983654.I:2001MAR30320 342. forwardTM Transmembrane 181 LG:983654.1:2001MAR30343 348forward,TM . . Cytosolic 181 LG:983654.1:2001MAR30349 368forwardTM Transmembrane 181 LG:983654.1:2001MAR30369 369forwardTM Non-Cytosolic 181 LG:983654.1:2001MAR301 237forwardTM Cytosolic 181 LG:983654.1:2001MAR30238 255forwardTM Transmembrane 181 LG:983654.1:2001MAR30256 319forwardTM Non-Cytosolic 181 LG:983654.1:2001MAR30320 342forwardTM Transmembrane 181 LG:983654.1:2001MAR30343 368forwardTM CytosoIic 182 LG:985092.12:2001MAR301 118forwardTM Cytosolic 182 LG:985092.12:2001MAR30l 141forwardTM Transmembrane l9 3 182 LG:985092.12:2001MAR30142 369forwardTM Non-Cytosolic 183 LG:987396.8:2001MAR301 132forwardTM Non-Cytosolic 183 LG:987396.8:200IMAR30133 152forwardTM Transmembrane 183 LG:987396.8:2001MAR30153 273forwardTM Cytosolic 183 LG:987396.8:2001MAR30274 296forwardTM Transmembrane 183 LG:987396.8:2001MAR30297 924forwardTM Non-Cytosolic 183 LG:987396.8:2001MAR301 270forwardTM Non-Cytosolic 183 LG:987396.8:2001MAR30271 293forwardTM Transmembrane 183 LG:987396.8:2001MAR30294 358forwardTM Cytosolic 183 LG:987396.8:2001MAR30359 381forwardTM Transmembrane 183 LG:987396.8:2001MAR30382 924forwardTM Non-Cytosolic 184 LG:987418.10:2001MAR301 454forwardTM Non-Cytosolic 184 LG:987418.10:2001MAR30455 474forwardTM Transmembrane 184 LG:987418.10:2001MAR30475 479forwardTM Cytosolic 185 LG:997203.25:2001MAR301 801forwardTM Non-Cytosolic 185 LG:997203.25:2001MAR30802 824forwardTM Transmembrane SEQ D NO: Template ID StartStopFrame Domain Topology Type 18S LG:997203.25:2001MAR3082S 830 forwardTM Cytosolic 185 LG:997203.25:2001MAR3083I 846 forwardTM Transmembrane 18S LG:997203.25:2001MAR30847 855 forwardTM Non-Cytosolic 18S LG:997203.25:2001MAR30856 875 forwardTM Transmembrane I

185 LG:997203.25:2001MAR30876 924 forwardTM Cytosolic 18S LG:997203.25:2001MAR30925 947 forwardT'M Transmembrane 18S LG:997203.25:2001MAR30948 980 forwardTM Non-Cytosolic 18S LG:997203.25:2001MAR30981 1003forwardTM Transmembrane I

185 LG:997203.25:2001MAR301004 1292forwardTM Cytosolic I

185 LG:997203.25:2001MAR301 974 forwardTM Non-Cytosolic 185 LG:997203.25:2001MAR30975 992 forwardTM Transmembrane 185 LG:997203.25:2001MAR30993 1048forwardTM Cytosolic 185 LG:997203.25:2001MAR301049 1071forwardTM Transmembrane 185 LG:997203.25:2001MAR301072 1291forwardTM Non-Cytosolic 186 LG:997477.8:2001MAR301 59 forwardTM Non-Cytosolic 186 LG:997477.8:2001MAR3060 82 forwardTM Transmembrane 186 LG:997477.8:2001MAR3083 275 forwardTM Cytosolic 186 LG:997477.8:2001MAR30276 298 forwardTM Transmembrane 186 LG:997477.8:2001MAR30299 301 forwardTM Non-Cytosolic 186 LG:997477.8:2001MAR30302 324 forwardTM Transmembrane 186 LG:997477.8:2001MAR30325 401 forwardTM Cytosolic 187 LG:998855.4:2001MAR301 50 forwardTM Cytosolic 187 LG:998855.4:2001MAR3051 73 forwardTM Transmembrane 187 LG:998855.4:2001MAR3074 333 forwardTM Non-Cytosolic 188 LG:999093.1:2001MAR301 1115forwardTM Non-Cytosolic 188 LG:999093.1:2001MAR301116 1138forwardTM Transmembrane 188 LG:999093.1:2001MAR301139 1316forwardTM Cytosolic 188 LG:999093.1:2001MAR301317 1339forwardTM Transmembrane 188 LG:999093.1:2001MAR301340 1554forwardTM Non-Cytosolic 188 LG:999093.1:2001MAR301 1073forwardTM Non-Cytosolic 188 LG:999093.1:2001MAR301074 1093forwardTM Transmembrane 1$8 LG:999093.1:2001MAR301094 1099forwardTM Cytosolic 188. LG:999093.1:2001MAR301100 1119forwardTM Transmembrane 188 LG:999093.1:2001MAR301120 1123forwardTM Non-Cytosolic 188 LG:999093.1:2001MAR301124 1143forwardTM Transmembrane 188 LG:999093.1:2001MAR301144 1163forwardTM Cytosolic 188 LG:999093.1:2001MAR301164 1186forwardTM Transmembrane 188 LG:999093.1:2001MAR301187 1261forwardTM Non-Cytosolic 188 LG:999093.1:2001MAR301262 1284forwardTM Transmembrane 188 LG:999093.1:2001MAR301285 1296forwardTM Cytosolic 188 LG:999093.1:2001MAR301297 1314forwardTM Transmembrane 188 LG:999093.1:2001MAR301315 1318forwardTM Non-Cytosolic 188 LG:999093.1:2001MAR301319 1341forwardTM Transmembrane 188 LG:999093.1:2001MAR301342 1394forwardTM Cytosolic 188 LG:999093.1:2001MAR301395 1417forwardTM Transmembrane 188 LG:999093.1:2001MAR301418 1554forwardTM Non-Cytosolic 188 LG:999093.1:2001MAR301 422 forwardTM Non-Cytosolic 188 LG:999093.1:2001MAR30423 445 forwardTM Transmembrane 188 LG:999093.1:2001MAR30446 536 forwardTM Cytosolic 188 LG:999093.1:2001MAR30537 559 forwardTM Transmembrane 188 LG:999093.1:2001MAR30560 760 forwardTM Non-Cytosolic 188 LG:999093.1:2001MAR30761 783 forwardTM Transmembrane 188 LG:999093.1:2001MAR30784 1077forwardTM Cytosolic 188 LG:999093.1:2001MAR301078 1100forward'TM Transmembrane SEQ D NO: Template ID StartStopFrame Domain Topology Type 188 LG:999093.1:2001MAR301101 1109forwardTM Non-Cytosolic 188 LG:999093.1:2001MAR301110 1132forwardTM Transmembrane 188 LG:999093.1:2001MAR301133 1317forwardTM Cytosolic 188 LG:999093.1:2001MAR301318 1340forwardTM Transmembrane 188 LG:999093.1:2001MAR301341 1343forward~ TM Non-Cytosolic 188 LG:999093.1:2001MAR301344 1363forwardTM Transmembrane 188 LG:999093.1:2001MAR301364 1375forwardTM Cytosolic 188 LG:999093.1:2001MAR301376 1395forwardTM Transmembrane 188 LG:999093.1:2001MAR301396 1468forwardTM Non-Cytosolic 188 LG:999093.1:2001MAR301469 1488forwardTM Transmembrane 188 LG:999093.1:2001MAR301489 1499forwardTM Cytosolic 188 LG:999093.1:2001MAR301500 1522forwardTM Transmembrane 188 LG:999093.1:2001MAR301523 1553forwardTM Non-Cytosolic 189 LG:999183.1:2001MAR301 1406forwardTM Non-Cytosolic 189 LG:999183.1:2001MAR301407 1424forwardTM Transmembrane 189 LG:999183.1:2001MAR301425 1443forwardTM Cytosolic 189 LG:999183.I:2001MAR301444 1463forwardTM Transmembrane 189 LG:999183.1:2001MAR301464 1477forwardTM Non-Cytosolic 189 LG:999183.1:2001MAR301478 1500forwardTM Transmembrane 189 LG:999183.1:2001MAR301501 1615forwardTM Cytosolic 189 LG:999183.1:2001MAR301616 1638forwardTM Transmembrane 189 LG:999183.1:2001MAR301639 1642forwardTM Non-Cytosolic I90 LI:1032972.I:2001MAY171 55 forwardTM Cytosolic 190 LI:1032972.1:2001MAY1756 78 forwardTM Transmembrane 190 LI:1032972.1:2001MAY1779 336 forwardTM Non-Cytosolic 190 LI:1032972.1:2001MAY171 58 forwardTM Cytosolic 190 LI:1032972.1:2001MAY1759 81 forwardTM Transmembrane 190 LI:1032972:I:ZOO1MAY1782 295 forwardTM Non-Cytosolic 190 LI:1032972.1:2001MAY17296 318 forwardTM Transmembrane 190 LI:1032972.1:2001MAY17319 335 forwardTM Cytosolic 190 LI:1032972.1:2001MAY171 12 forwardTM Non-Cytosolic 190 LI:1032972.1:2001MAY1713 35 forwardTM Transmembrane 190 LI:1032972.1:2001MAY1736 55 forwardTM Cytosolic 190 LI:1032972.1:200IMAYI756 78 forwardTM Transmembrane 190 LI:1032972.1:2001MAY1779 335 forwardTM Non-Cytosolic 191 LI:170666.6:2001MAY171 155 forwardTM Non-Cytosolic 191 LI:170666.6:2001MAY17156 178 forwardTM Transmembrane 191 LI:170666.6:2001MAY17179 222 forwardTM Cytosolic 192 LI:197048.10:2001MAY171 336 forwardTM Non-Cytosolic 192 LI:197048.10:2001MAY17337 359 forwardTM Transmembrane 192 LI:197048.10:2001MAY17360 598 forwardTM Cytosolic 192 LI:197048.10:2001MAY17599 621 forwardTM Transmembrane 192 LI:197048.10:2001MAY17622 640 forwardTM Non-Cytosolic 192 LI:197048.10:2001MAY17641 663 forwardTM Transmembrane 192 LI:197048.10:2001MAY17664 714 forwardTM Cytosolic 192 LI:197048.10:2001MAY17715 737 forwardTM Transmembrane 192 LI:197048.10:2001MAY17738 751 forwardTM Non-Cytosolic 192 LI:197048.10:2001MAY17752 771 forwardTM Transmembrane 192 LI:197048.10:2001MAY17772 829 forwardTM Cytosolic 192 LI:197048.10:2001MAY171 324 forwardTM Cytosolic 192 LI:197048.10:2001MAY1732S 347 forwardTM Transmembrane 192 LI:197048.10:2001MAY17348 361 forwardTM Non-Cytosolic 192 LI:197048.10:2001MAY17362 384 forwardTM Transmembrane 192 LI:197048.10:2001MAY17385 488 forwardTM Cytosolic SEQ Template ID StartStopFrame Domain Topology D NO: Type 192 LI:197048.10:2001MAY17489 506forwardTM Transmembrane 192 LI:197048.10:2001MAY17507 509forwardTM Non-Cytosolic 192 LI:197048.10:2001MAY17510 529forwardTM Transmembrane 192 LI:197048.10:2001MAY17530 597forwardTM Cytosolic 192 LI:197048.10:2001MAY17598 620forwardTM Transmembrane 192 LI:197048.10:2001MAY17621 639forwardTM Non-Cytosolic 192 LI:197048.10:2001MAY17640 662forwardTM Transmembrane 192 LI:197048.10:2001MAY17663 797forwardTM Cytosolic 192 LI:197048.10:2001MAY17798 820forwardTM Transmembrane 192 LI:197048.10:2001MAY17821 828forwardTM Non-Cytosolic 192 LI:197048.10:2001MAY171 376forwardTM Non-Cytosolic 192 LI:197048.10:2001MAY17377 399forwardTM Transmembrane 192 LI:197048.10:2001MAY17400 436forwardTM Cytosolic 192 LI:197048.10:2001MAY17437 459forwardTM Transmembrane 192 LI:197048.10:2001MAY17460 488forwardTM Non-Cytosolic 192 LI:197048.10:2001MAY17489 511forwardTM Transmembrane 192 LI:197048.10:2001MAY17512 523forwardTM Cytosolic 192 LI:197048.10:2001MAY17524 546forwardTM Transmembrane 192 LI:197048.10:2001MAY17547 555forwardTM Non-Cytosolic 192 LI:197048.10:2001MAY17556 578forwardTM Transmembrane 192 LI:197048.10:2001MAY17579 597forwardTM Cytosolic 192 LI:197048.10:2001MAY17598 617forwardTM Transmembrane 192 LI:197048.10:2001MAY17618 828forwardTM Non-Cytosolic 193 LI:228655.5:2001MAY171 33 forwardTM Non-Cytosolic 1 , 193 LI:228655.5:2001MAY1734 56 forwardTM Transmembrane 193 LI:228655.5:2001MAY1757 76 forwardTM Cytosolic 193 LI:228655.5:2001MAY1777 94 forward' TM Transmembrane 193 LI:228655.5:2001MAY1795 108forwardTM Non-Cytosolic ~ 1 193 LI:228655.5:2001MAY17109 131forwardTM Transmembrane ~ 1 193 LI:228655.5:2001MAY17132 200forward. TM Cytosolic 193 LI:228655.5:2001MAY17201 223forwardTM Transmembrane 193 LI:228655.5:2001MAY17224 237forwardTM Non-Cytosolic 194 LI:229789.6:2001MAY171 367forwardTM Non-Cytosolic 194 LI:229789.6:2001MAY17368 390forwardTM Transmembrane 194 LI:229789.6:2001MAY17391 394forwardTM Cytosolic 195 LI:231500.8:2001MAY171 458forwardTM Non-Cytosolic 195 LI:231500.8:2001MAY17459 477forwardTM Transmembrane 195 LI:231500.8:2001MAY17478 481forwardTM Cytosolic 196 LI:253851.26:2001MAY171 6 forwardTM Cytosolic 196 LI:253851.26:2001MAY177 25 forwardTM Transmembrane I96 LI:253851.26:2001MAY1726 34 forwardTM Non-Cytosolic 196 LI:253851.26:2001MAY1735 57 forwardTM Transmembrane 196 LI:253851.26:2001MAY1758 414forwardTM Cytosolic 196 LI:253851.26:2001MAY17415 437forwardTM Transmembrane 196 LI:253851.26:2001MAY17438 477forwardTM Non-Cytosolic 196 LI:253851.26:2001MAY17478 497forwardTM Transmembrane 196 LI:253851.26:2001MAY17498 517forwardTM Cytosolic 196 LI:253851.26:2001MAY17518 537forwardTM Transmembrane 196 LI:253851.26:2001MAY17538 556forwardTM Non-Cytosolic 196 LI:253851.26:2001MAY17557 579forwardTM Transmembrane 196 LI:253851.26:2001MAY17580 748forwardTM Cytosolic 197 LI:373302.1:2001MAY171 61 forwardTM Non-Cytosolic 197 LI:373302.1:2001MAY1762 84 forwardTM Transmembrane 197 LI:373302.1:2001MAY1785 104forwardTM Cytosolic SEQ Template ID Start StopFrame Domain Topology D NO: Type 197 LI:373302.1:2001MAY17lOS 124forwardTM Transmembrane 197 LI:373302.1:2001MAY1712S 4S7forwardTM Non-Cytosolic 197 LI:373302.1:2001MAY171 110forwardTM Non-Cytosolic 197 LI:373302.1:2001MAY17111 133forwardTM Transmembrane 197 LI:373302.1:2001MAY17134 161forwardTM Cytosolic 197 LI:373302.1:2001MAY17162 184forwardTM Transmembrane 197 LI:373302.1:2001MAY1718S 214forwardTM Non-Cytosolic 197 LI:373302.1:2001MAY1721S 237forwardTM Transmembrane 197 LI:373302.1:2001MAY17238 39SforwardTM Cytosolic 197 LI:373302.1:2001MAY17396 418forwardTM Transmembrane 197 LI:373302.1:2001MAY17419 4S6forwardTM Non-Cytosolic 197 LI:373302.1:2001MAY171 98 forwardTM Cytosolic 197 LI:373302.1:2001MAY1799 121forwardTM Transmembrane 197 LI:373302.1:2001MAY17122 368forwardTM Non-Cytosolic 197 LI:373302.1:2001MAY17369 391forwardTM Transmembrane 197 LI:373302.1:2001MAY17392 411forwardTM Cytosolic 197 LI:373302.1:2001MAY17412 434forwardTM Transmembrane 197 LI:373302.1:2001MAY1743S 4S6forwardTM Non-Cytosolic 198 LI:40S707.12:2001MAY171 14 forwardTM Non-Cytosolic 198 LI:40S707.12:2001MAY171S 37 forwardTM Transmembrane 198 LI:40S707.12:2001MAY1738 128forwardTM Cytosolic 198 LI:40S707.12:2001MAY17129 146forwardTM Transmembrane 198 LI:40S707.12:2001MAY17147 149forwardTM Non-Cytosolic 198 LI:40S707.12:2001MAY171S0 172forwardTM Transmembrane 198 LI:40S707.12:2001MAY17173 438forwardTM Cytosolic 199 LI:411441.8:2001MAY171. 92 forwardTM Cytosolic ' 3 199 LI:411441.8:2001MAY1793 115forwardTM Transmembrane 199' L1:411441.8:2001MAY171'16 497' forwardTM Non-Cytosolic 200 LI:7S8193.3:2001MAY17'1 9 forwardTM Non-Cytosolic 200 LI:7S8193.3:2001MAY1710 32 forwardTM Transmembrane 200 LI:7S8193.3:2001MAY1733 S2 forwardTM Cytosolic 200 LI:7S8193.3:2001MAY17S3 7S forwardTM Transmembrane 200 LI:7S8193.3:2001MAY1776 99 forwardTM Non-Cytosolic 200 LI:758193.3:2001MAY17100 122forwardTM Transmembrane 200 LI:7S8193.3:2001MAY17123 214forwardTM Cytosolic 200 LI:7S8193.3:2001MAY1721S 237forwardTM Transmembrane 200 LI:7S8193.3:2001MAY17238 282forwardTM Non-Cytosolic 200 LI:7S8193.3:2001MAY17283 30SforwardTM Transmembrane 200 LI:7S8193.3:2001MAY17306 311forwardTM Cytosolic 200 LI:7S8193.3:2001MAY17312 334forwardTM Transmembrane 200 LI:7S8193.3:2001MAY1733S 343forwardTM Non-Cytosolic 200 LI:7S8193.3:2001MAY17344 366forwardTM Transmembrane 200 LI:7S8193.3:2001MAY17367 415forwardTM Cytosolic 200 LI:7S8193.3:2001MAY17416 43SforwardTM Transmembrane 200 LI:7S8193.3:2001MAY17436 476forwardTM Non-Cytosolic 200 LI:7S8193.3:2001MAY17477 499forwardTM Transmembrane 200 LI:7S8193.3:2001MAY17S00' SS2forwardTM Cytosolic 200 LI:7S8193.3:2001MAY17SS3 S7SforwardTM Transmembrane 200 LI:7S8193.3:2001MAY17S76 S84forwardTM Non-Cytosolic 200 LI:7S8193.3:2001MAY17S8S 607forwardTM Transmembrane 200 LI:7S8193.3:2001MAY17608 664forwardTM Cytosolic 200 LI:7S8193.3:2001MAY171 20 forwardTM Cytosolic 200 LI:7S8193.3:2001MAY1721 38 forwardTM Transmembrane 200 LI:7S8193.3:2001MAY1739 64 forwardTM Non-Cytosolic SEQ Template ID StartStopFrame Domain Topology D Type NO:

200 LI:758193.3:2001MAY1765 87 forwardTM Transmembrane 200 LI:758193.3:2001MAY1788 211 forwardTM Cytosolic 200 LI:758193.3:2001MAY17212 234 forwardTM Transmembrane 200 LI:758193.3:2001MAY17235 243 forwardTM Non-Cytosolic 200 LI:758193.3:2001MAY17244 261 forwardTM Transmembrane 200 LI:758193.3:2001MAY17262 277 forwardTM Cytosolic 200 LI:758193.3:2001MAY17278 300 forwardTM Transmembrane 200 LI:758193.3:2001MAY17301 476 forwardTM Non-Cytosolic 200 LI:758193.3:2001MAY17477 499 forwardTM Transmembrane 200 LI:758193.3:2001MAY17500 552 forwardTM. Cytosolic ~ 2 200 LI:758193.3:2001MAY17553 575 forwardTM Transmembrane 200 LI:758193.3:2001MAY17576 584 forwardTM Non-Cytosolic 200 LI:758193.3:2001MAY17585 607 forwardTM Transmembrane 200 LI:758193.3:2001MAY17608 664 forwardTM Cytosolic 200 LI:758193.3:2001MAY171 19 forwardTM Cytosolic 200 LI:758193.3:2001MAY1720 42 forwardTM Transmembrane 200 LI:758193.3:2001MAY1743 56 forwardTM Non-Cytosolic 200 LI:758193.3:2001MAY1757 79 forwardTM Transmembrane 200 LI:758193.3:2001MAYI780 115 forwardTM Cytosolic 200 LI:758193.3:2001MAY17116 138 forwardTM Transmembrane 200 LI:758193.3:2001MAY17I39 213 forwardTM Non-Cytosolic 200 LI:758193.3:2001MAY17214 236 forwardTM Transmembrane 200 LI:758193.3:2001MAY17237 278 forwardTM Cytosolic ~

200 LI:758193.3:2001MAY17279 301 forwardTM Transmembrane 200 LI:758193.3:2001MAY17302 360 forwardTM Non-Cytosolic 200 LI:758193.3:2001MAY17361 383 forwardTM Transmembrane 200 LI:758193.3:2001MAY17384 475 forwardTM Cytosolic 200 LI:758193.3:2001MAY17476 498 forwardTM Transmembrane 200 LI:758193.3:2001MAYI7499, 517 forwardTM Non-Cytosolic 200 LI:758193.3:2001MAY17518 540 forwardTM Transmembrane 200 LI:758193.3:2001MAY17541 664 forwardTM Cytosolic 201 LI:1028562.3:2001MAY171 6 forwardTM Cytosolic 201 LI:1028562.3:2001MAY177 24 forwardTM Transmembrane 201 LI:1028562.3:2001MAY1725 43 forwardTM Non-Cytosolic 201 LI:1028562.3:2001MAY1744 66 forwardTM Transmembrane 201 LI:1028562.3:2001MAY1767 69 forwardTM Cytosolic 202 LI:104650.7:2001MAY171 6 forwardTM Cytosolic 202 LI:104650.7:2001MAY177 29 forwardTM Transmembrane 202 LI:104650.7:2001MAY1730 38 forwardTM Non-Cytosolic 202 LI:104650.7:2001MAY1739 61 forwardTM Transmembrane 202 LI:104.650.7:2001MAY1762 72 forwardTM Cytosolic 202 LI:104650.7:2001MAY1773 95 forwardTM Transmembrane 202 LI:104650.7:2001MAY1796 265 forwardTM Non-Cytosolic 203 LI:1094557.4:2001MAY17I 57 forwardTM Non-Cytosolic 203 LI:1094557.4:2001MAY1758 80 forwardTM Transmembrane 203 LI:1094557.4:2001MAY1781 311 forwardTM Cytosolic 203 LI:1094557.4:2001MAY171 90 forwardTM Cytosolic 203 LI:1094557.4:2001MAY17' l forwardTM Transmembrane 203 LI:1094557.4:2001MAY17I 127 forwardTM Non-Cytosolic 203 LI:1094557.4:2001MAY17128 147 forwardTM Transmembrane 203 LI:1094557.4:2001MAY17148 310 forwardTM Cytosolic 204 LI:1143528.4:2001MAY171 302 forwardTM Non-Cytosolic 204 LI:1143528.4:2001MAY17303 325 forwardTM Transmembrane 204 LI:1143528.4:2001MAY17326 331 forwardTM Cytosolic SEQ Template ID StartStopFrame Domain Topolojy D NO: Type 204 LI:1143528.4:2001MAY171 298forwardTM Non-Cytosolic 204 LI:1143528.4:2001MAY17299 321forwardTM Transmembrane 204 LI:1143528.4:2001MAY17322 330forwardTM Cytosolic 205 LI:1172210.7:2001MAY171 582forwardTM Non-Cytosolic 205 LI:1172210.7:2001MAY17583 600forwardTM Transmembrane 205 LI:1172210.7:2001MAY17601 601forwardTM Cytosolic 206 LI:1178659.14:2001MAY171 694forwardTM Non-Cytosolic 206 LI:1178659.14:2001MAY17695 717forwardTM Transmembrane I

206 LI:1178659.14:2001MAY17718 779forwardTM Cytosolic 206 LI:1178659.14:2001MAY17780 802forwardTM Transmembrane 206 LI:1178659.14:2001MAY17803 811forwardTM Non-Cytosolic 206 LI:1178659.14:2001MAY17812 834forwardTM Transmembrane I

206 LI:1178659.14:200IMAY17835 835forwardTM Cytosolic 206 LI:1178659.14:2001MAY171 233forwardTM Cytosolic 206 LI:1178659.14:2001MAY17234 256forwardTM Transmembrane 206 LI:1178659.14:2001MAY17257 347forwardTM Non-Cytosolic 206 LI:1178659.14:2001MAY17348 370forwardTM Transmembrane 206 LI:1178659.14:2001MAY17371 689forwardTM ~ Cytosolic 206 LI:1178659.14:2001MAY17690 712forwardTM Transmembrane 206 LI:1178659.14:2001MAY17713 808forwardTM Non-Cytosolic 206 LI:l 178659.14:2001MAY17809 831forwardTM Transmembrane ~2 206 LI:1178659.14:ZOOIMAYI7832 835forwardTM Cytosolic 206 LI:1178659.14:2001MAY171 57 forwardTM Cytosolic 206 LI:1178659.14:2001MAY1758 80 forwardTM Transmembrane 206 LI:1178659.14:2001MAY1781 235forwardTM Non-Cytosolic 206 LI:1178659.14:2001MAY17236 258forwardTM Transmembrane . 3 206 LI:1178659.14:2001MAY17259 316forwardTM Cytosolic 206 LI:1178659.14:2001MAY17317 339forwardTM Transmembrane .

206 LI:1178659.14:2001MAY17340 370forwardTM Non-Cytosolic 206 LI:1178659.14:2001MAY17371 393forwardTM Transmembrane 3 , ;
' 206 LI:1178659.14:2001MAY17394 457forwardTM Cytosolic 206 LI:1178659.14:2001MAY17458 477forwardTM Transmembrane 206 LI:1178659.14:2001MAY17478 779forwardTM Non-Cytosolic 206 LI:1178659.14:2001MAY17780 802forwardTM Transmembrane 206 LI:1178659.14:2001MAY17803 808forwardTM Cytosolic 206 LI:1178659.14:2001MAY17809 831forwardTM Transmembrane 206 LI:1178659.14:2001MAY17832 835forwardTM Non-Cytosolic 207 LI:1983726.3:2001MAY171 95 forwardTM Cytosolic 207 LI:1983726.3:200IMAYI796 I18forwardTM Transmembrane 207 LI:1983726.3:2001MAY17119 151forwardTM Non-Cytosolic 207 LI:1983726.3:2001MAY17152 174forwardTM Transmembrane 207 LI:1983726.3:2001MAY17175 186forwardTM Cytosolic 207 LI:1983726.3:2001MAY17187 206forwardTM Transmembrane 207 LI:1983726.3:2001MAY17207 211forwardTM Non-Cytosolic 207 LI:1983726.3:2001MAYI7212 231forwardTM Transmembrane 207 LI:1983726.3:2001MAY17232 251forwardTM Cytosolic 207 LI:1983726.3:2001MAY17252 274forwardTM Transmembrane 207 LI:1983726.3:2001MAY17275 285forwardTM Non-Cytosolic 208 LI:2051495.3:2001MAY171 259forwardTM Non-Cytosolic 208 LI:2051495.3:2001MAY17260 279forwardTM Transmembrane I

208 LI:2051495.3:2001MAY17280 291forwardTM Cytosolic 208 LI:2051495.3:2001MAY17292 309forwardTM Transmembrane 208 LI:2051495.3:2001MAY17310 337forwardTM Non-Cytosolic 208 LI:2051495.3:200IMAY17338 360forwardTM Transmembrane I

SEQ D NO: Template ID StartStopFrame Domain Topology Type 208 LI:2051495.3:2001MAY17361 527 forwardTM Cytosolic 208 LI:2051495.3:2001MAY17528 550 forwardTM Transmembrane 208 LI:2051495.3:2001MAY17551 706 forwardTM Non-Cytosolic 208 LI:2051495.3:2001MAY171 320 forwardTM Non-Cytosolic 208 LI:2051495.3:2001MAY17321 343 forwardTM Transmembrane 208 LI:2051495.3:2001MAY17344 515 forwardTM Cytosolic 208 LI:2051495.3:2001MAY17516 538 forwardTM Transmembrane 208 LI:2051495.3:2001MAY17539 70S forwardTM Non-Cytosolic 208 . LI:20S1495.3:2001MAY171 336 forwardTM Non-Cytosolic 208 LI:2051495.3:2001MAY17337 359 forwardTM Transmembrane 208 LI:2051495.3:2001MAY17360 70S forwardTM Cytosolic 209 LI:2117629.1:2001MAY171 320 forwardTM Non-Cytosolic 209 LI:2117629.1:2001MAY17321 343 forwardTM Transmembrane 209 LI:2117629.1:2001MAY17344 355 forwardTM Cytosolic 209 LI:2117629.1:2001MAY17356 378 forwardTM Transmembrane 209 LI:2117629.1:2001MAY17379 397 forwardTM Non-Cytosolic 209 LI:2117629.1:2001MAY17398 416 forwardTM Transmembrane 209 LI:2117629.1:2001MAY17417 424 forwardTM Cytosolic 210 LI:2118007.3:2001MAY171 37 forwardTM Non-Cytosolic 210 LI:2118007.3:2001MAY1738 60 forwardTM Transmembrane 210 LI:2118007.3:2001MAY1761 203 forwardTM Cytosolic 210 LI:2118007.3:2001MAY17204 226 forwardTM Transmembrane 210 LI:2118007.3:2001MAY17227 338 forwardTM Non-Cytosolic 211 LI:2118292.9:2001MAY171 140 forwardTM Non-Cytosolic 211 LI:2118292.9:2001MAY17141 163 forwardTM Transmembrane 1 ' 211 LI:2118292.9:2001MAY17164 286 forwardTM, Cytosolic ' I

211 LI:2118292.9:2001MAY17287 306 forward.lTM Transmembrane 211 LI:2118292.9:2001MAY17307 344 forward, .TM Non-Cytosolic ' 1 211 LI:2118292.9:2001MAY17345 367 forwardTM Transmembrane 211 LI:2118292.9:2001MAY17368 520 forwardTM Cytosolic 1 ~

211 LI:2118292.9:2001MAY171 299 forwardTM Non-Cytosolic 21 1 LI:2118292.9:200IMAY17300 319 forwardTM Transmembrane 21 I LI:2118292.9:2001MAY17320 418 forwardTM Cytosolic 21 I LI:2118292.9:2001MAY17419 441 forwardTM Transmembrane 211 LI:2118292.9:2001MAY17442 478 forwardTM Non-Cytosolic 211 LI:2118292.9:2001MAY17479 501 forwardTM Transmembrane 211 LI:2118292.9:2001MAY17502 S20 forwardTM Cytosolic 211 LI:2118292.9:2001MAY171 292 forwardTM Cytosolic 211 LI:2118292.9:2001MAY17293 312 forwardTM Transmembrane 21 I LI:2118292.9:2001MAY17313 346 forwardTM Non-Cytosolic 211 LI:2118292.9:2001MAY17347 369 forwardTM Transmembrane 211 LI:2118292.9:2001MAY17370 452 forwardTM Cytosolic 21 I LI:2118292.9:2001MAY17453 475 forwardTM Transmembrane 211 LI:2118292.9:2001MAY17476 489 forwardTM Non-Cytosolic 211 LI:2118292.9:2001MAY17490 512 forwardTM Transmembrane 211 LI:2118292.9:2001MAY17513 519 forwardTM Cytosolic 212 LI:2118733.7:2001MAY171 48 forwardTM Non-Cytosolic 212 LI:2118733.7:2001MAY1749 71 forwardTM Transmembrane 212 LI:2118733.7:2001MAY1772 195 forwardTM Cytosolic 212 LI:2118733.7:2001MAY17I96 2I8 forwardTM Transmembrane 212 LI:2118733.7:2001MAY17219 222 forwardTM Non-Cytosolic I

212 LI:2118733.7:2001MAY17223 242 forwardTM Transmembrane 212 LI:2118733.7:2001MAY17243 292 forwardTM Cytosolic 212 LI:2118733.7:2001MAY17I 35 forward' TM Cytosolic SEQ Template ID StartStopFrame Domain Topology D Type NO:

212 LI:2118733.7:2001MAY1736 58 forwardTM Transmembrane 212 LI:2118733.7:2001MAY1759 110 forwardTM Non-Cytosolic 212 LI:2118733.7:ZOOIMAYI71I 133 forwardTM Transmembrane l 2 212 LI:2118733.7:2001MAY17134 153 forwardTM Cytosolic 212 LI:2118733.7:2001MAY17154 176 forward. TM Transmembrane 212 LI:2118733.7:2001MAY17177 195 forwardTM Non-Cytosolic 212 LI:2118733.7:2001MAY17196 218 forwardTM Transmembrane 212 LI:2118733.7:2001MAY17219 291 forwardTM Cytosolic 212 LI:2118733.7:2001MAY171 108 forwardTM Cytosolic 212 LI:2118733.7:2001MAY17109 131 forwardTM Transmembrane 212 LI:2118733.7:2001MAY17132 153 forwardTM Non-Cytosolic 212 LI:2118733.7:2001MAY17154 176 forwardTM Transmembrane 212 LI:2118733.7:2001MAY17177 199 forwardTM Cytosolic 2I2 LI:21I8733.7:2001MAY17200 222 forwardTM Transmembrane 212 LI:2118733.7:2001MAY17223 249 forwardTM Non-Cytosolic 212 LI:2118733.7:2001MAY17250 272 forwardTM Transmembrane 212 LI:2118733.7:200IMAY17273 29I forwardTM Cytosolic 213 LI:212702.3:2001MAY171 615 forwardTM Non-Cytosolic 213 LI:212702.3:2001MAY17616 638 forwardTM Transmembrane 213 LI:212702.3:2001MAY17639 854 forwardTM Cytosolic 213 LI:212702.3:2001MAY17855 874 forwardTM Transmembrane 213 LI:212702.3:2001MAY17875 902 forwardTM Non-Cytosolic 213 LI:212702.3:2001MAY17903 925 forwardTM Transmembrane 213 LI:2I2702.3:200IMAYI7926 995 forwardTM CytosoIic 213 LI:212702.3:2001MAY17996 1018forwardTM Transmembrane 213 LI:212702.3:2001MAY171019 1410forwardTM Non-Cytosolic 213 LI:212702.3:2001MAY171 19 forwardTM Non-Cytosolic 213 LI:212702.3:2001MAY1720 42 forwardTM Transmembrane 213 LI:212702.3:2001MAY1743 369 forwardTM Cytosolic 213 LI:212702.3:2001MAY17370 392 forwardTM Transmembrane 213 LI:212702.3:2001MAY17393 547 forwardTM Non-Cytosolic . 2 213 LI:212702.3:2001MAY17548 570 forwardTM Transmembrane 213 LI:212702.3:2001MAY17571 582 forwardTM Cytosolic 213 LI:212702.3:2001MAY17583' 605 forwardTM Transmembrane 213 LI:212702.3:2001MAY17606 614 forwardTM Non-Cytosolic 213 LI:212702.3:2001MAY17615 637 forwardTM Transmembrane 213 LI:212702.3:2001MAY17638 835 forwardTM Cytosolic 213 LI:212702.3:2001MAY17836 855 forwardTM Transmembrane 213 LI:212702.3:2001MAY17856 1410forwardTM Non-Cytosolic 213 LI:212702.3:2001MAY171 19 forwardTM Cytosolic 213 LI:212702.3:2001MAY1720 42 forwardTM Transmembrane 213 LI:212702.3:2001MAY1743 1409forwardTM Non-Cytosolic 214 LI:2207871.10:2001MAY171 74 forwardTM Cytosolic 214 LI:2207871.10:2001MAY1775 97 forwardTM Transmembrane 214 LI:2207871.10:2001MAY1798 101 forwardTM Non-Cytosolic 214 LI:2207871.10:2001MAY17102 121 forwardTM Transmembrane 214 LI:2207871.10:2001MAY17122 132 forwardTM Cytosolic 214 LI:2207871.10:2001MAY17133 155 forwardTM Transmembrane 214 LI:2207871.10:2001MAY17156 169 forwardTM Non-Cytosolic 214 LI:2207871.10:2001MAY17170 187 forwardTM Transmembrane 214 LI:2207871.10:2001MAY17188 193 forwardTM Cytosolic 214 LI:2207871.10:2001MAY17194 216 forwardTM Transmembrane 214 LI:2207871.10:2001MAY17217 629 forwardTM Non-Cytosolic 215 LI:2207876.5:2001MAY171 63 forwardTM Cytosolic SEQ Template ID Start StopFrame Domain Topology D NO: Type 216 LI:2208743.1:2001MAY171 115forwardTM Non-Cytosolic 216 LI:2208743.1:2001MAYI71I6 138forwardTM Transmembrane I

216 LI:2208743,1:2001MAY17139 226forwardTM Cytosolic 216 LI:2208743.1:2001MAY17227 249forwardTM Transmembrane I

216 LI:2208743.1:2001MAY17250 288forwardTM Non-Cytosolic 217 LI:2208744.1:2001MAY171 12 forwardTM Cytosolic 217 LI:2208744.1:2001MAY1713 35 forwardTM Transmembrane 217 LI:2208744.1:2001MAY1736 538forwardTM Non-Cytosolic 218 LI:230905.3:2001MAY171 252forwardTM Non-Cytosolic 218 LI:230905.3:2001MAY17253 275forwardTM Transmembrane 218 LI:230905.3:2001MAY17276 290forwardTM Cytosolic 218 LI:230905.3:2001MAY17291 313forwardTM Transmembrane 218 LI:230905.3:2001MAY17314 327forwardTM Non-Cytosolic 218 LI:230905.3:2001MAY17328 350forwardTM Transmembrane 218 LI:230905.3:2001MAY17351 373forwardTM Cytosolic 218 LI:230905.3:2001MAY171 4 forwardTM Cytosolic 218 LI:230905.3:2001MAY175 27 forwardTM Transmembrane 218 LI:230905.3:2001MAY1728 31 forwardTM Non-Cytosol.ic 218 LI:230905.3:2001MAY1732 54 forwardTM Transmembrane 218 LI:230905.3:2001MAY1755 248forwardTM Cytosolic 218 LI:230905.3:2001MAY17249 271forwardTM Transmembrane 218 LI:230905.3:2001MAY17272 285forwardTM Non-Cytosolic 218 LI:230905.3:2001MAY286 308forwardTM Transmembrane 218 LI:230905.3:2001MAY17309 372forwardTM Cytosolic 219 LI:235233.95:2001MAY171 19 forwardTM Cytosolic 219 LI:235233.95:2001MAY1720 42'forwardTM Transmembrane 219 LI:235233.95:2001MAY43 307forwardTM Non-Cytosolic 220 LI:235359.24:2001MAY171 I49forwardTM Cytosolic ' 3 220 LI:235359.24:2001MAYI7I50 172forwardTM Transmembrane 220 LI:235359.24:2001MAY17173 186forwardTM Non-Cytosolic Z20 LI:235359.24:2001MAY17187 206forwardTM Transmembrane 220 LI:235359.24:2001MAY17207 335forwardTM Cytosolic 221 LI:238365.6:200IMAY171 437forwardTM Non-Cytosolic 221 LI:238365.6:2001MAY17438 460forwardTM Transmembrane 221 LI:238365.6:2001MAYI7461 465forwardTM CytosoIic 222 LI:260259.23:2001MAY171 57 forwardTM Cytosolic 222 LI:260259.23:2001MAY171 57 forwardTM Cytosolic 222 LI:260259.23:2001MAY171 56 forwardTM Cytosolic 223 LI:321069.2:2001MAY171 181forwardTM Non-Cytosolic 223 LI:321069.2:2001MAY17182 204forwardTM Transmembrane 223 LI:321069.2:2001MAY17205 449forwardTM Cytosolic 223 LI:321069.2:2001MAY17450 469forwardTM Transmembrane 223 LI:321069.2:2001MAY17470 478forwardTM Non-Cytosolic 223 LI:321069.2:2001MAY17479 501forwardTM Transmembrane 223 LI:321069.2:2001MAY17502 507forwardTM Cytosolic 223 LI:321069.2:2001MAY17508 530forwardTM Transmembrane 223 LI:321069.2:2001MAY17531 631forwardTM Non-Cytosolic 223 LI:321069.2:2001MAY17632 654forwardTM Transmembrane 223 LI:321069.2:2001MAY17655 666forwardTM Cytosolic 223 LI:321069.2:2001MAY17667 689forwardTM Transmembrane 223 LI:321069.2:2001MAY17690 693forwardTM Non-Cytosolic 223 LI:321069.2:2001MAY694 713forwardTM Transmembrane 223 LI:321069.2:2001MAY17714 1071forwardTM Cytosolic 223 LI:321069.2:2001MAY171072 1094forwardTM Transmembrane SEQ D NO: Template ID Stan StopFrame Domain Topology Type 223 LI:321069.2:2001MAY171095 1103forwardTM Non-Cytosolic 223 LI:321069.2:2001MAY171104 1123forwardTM Transmembrane 223 LI:321069.2:2001MAY171124 1129forwardTM Cytosolic 223 LI:321069.2:2001MAY171130 1152forwardTM Transmembrane 223 LI:321069.2:2001MAY171153 1344forwardTM Non-Cytosolic 223 LI:321069.2:2001MAY171 630 forwardTM Non-Cytosolic 223 LI:321069.2:2001MAY17631 653 forwardTM Transmembrane 223 LI:321069.2:2001MAY17654 665 forwardTM Cytosolic 223 LI:321069.2:2001MAY17666 688 forward_ TM Transmembrane 223 LI:321069.2:2001MAY17689 702 forwardTM Non-Cytosolic 223 LI:321069.2:2001MAY17703 725 forwardTM Transmembrane 223 LI:321069.2:2001MAY17726 886 forwardTM Cytosolic 223 LI:321069.2:2001MAY17887 909 forwardTM Transmembrane 223 LI:321069.2:2001MAY17910 1343forwardTM Non-Cytosolic 223 LI:321069.2:2001MAY171 634 forwardTM Non-Cytosolic 223 LI:321069.2:2001MAY17635 653 forwardTM Transmembrane 223 LI:321069.2:2001MAY17654 664 forwardTM Cytosolic 223 LI:321069.2:2001MAY17665 687 forwardTM Transmembrane 223 LI:321069.2:2001MAY17688 806 forwardTM Non-Cytosolic 223 LI:321069.2:2001MAY17807 829 forwardTM Transmembrane 223 LI:321069.2:2001MAY17830 1078forwardTM Cytosolic 223 LI:321069.2:2001MAY171079 1101forwardTM Transmembrane 223 LI:321069.2:2001MAY171102 1127forwardTM Non-Cytosolic 223 LI:321069.2:2001MAY171128 1150forwardTM Transmembrane.

223 LI:321069.2:2001MAY171151 1343forwardTM Cytosolic 224 . LI:331499.8:2001MAY171 480 forwardTM Non-Cytosolic 224 LI:331499.8:2001MAY17481 503 forwardTM Transmembrane 224 LI:331499.8:ZOOIMAY17504 564 forwardTM Cytosolic 224 LI:331499.8:2001MAY17565 584 forwardTM Transmembrane 224 LI:331499.8:2001MAY17585 593 forwardTM Non-Cytosolic 224 LI:331499.8:2001MAY17594 613 forwardTM Transmembrane 224 LI:331499.8:2001MAY17614 614 forwardTM Cytosolic 224 LI:331499.8:2001MAY171 592 forwardTM Non-Cytosolic 224 LI:33I499.8:200IMAY17593 612 forwardTM Transmembrane 224 LI:331499.8:2001MAY17613 613 forwardTM Cytosolic 225 LI:332176.8:2001MAY171 124 forwardTM Non-Cytosolic 225 LI:332176.8:2001MAY17125 147 forwardTM Transmembrane 225 LI:332176.8:2001MAY17148 238 forwardTM Cytosolic 225 LI:332176.8:2001MAY17239 261 forwardTM Transmembrane 225 LI:332176.8:2001MAY17262 367 forwardTM Non-Cytosolic 225 LI:332176.8:2001MAY17368 390 forwardTM Transmembrane 225 LI:332176.8:2001MAY17391 457 forwardTM Cytosolic 226 LI:333952.7:2001MAY171 68 forwardTM Cytosolic 226 LI:333952.7:2001MAY1769 91 forwardTM Transmembrane I

226 LI:333952.7:2001MAY1792 105 forwardTM Non-Cytosolic 226 ~ LI:333952.7:2001MAY106 128 forwardTM Transmembrane 226 LI:333952.7:2001MAY17129 134 forwardTM Cytosolic I

226 LI:333952.7:2001MAY17135 157 . forwardTM Transmembrane 226 LI:333952.7:2001MAY17158 352 forwardTM Non-Cytosolic 227 LI:338428.2:2001MAY171 71 forwardTM Non-Cytosolic 227 LI:338428.2:2001MAY1772 94 forwardTM Transmembrane 227 LI:338428.2:200IMAY1795 127 forwardTM Cytosolic 228 LI:343869.2:2001MAY1 938 forwardTM Non-Cytosolic 228 LI:343869.2:2001MAY17939 961 forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D Type NO:

228 LI:343869.2:2001MAY17962 967 forwardTM Cytosolic 228 LI:343869.2:2001MAYI7968 990 forwardTM Transmembrane 228 LI:343869.2:2001MAY17991 1154forwardTM Non-Cytosolic 228 LI:343869.2:2001MAY171155 1172forwardTM Transmembrane 228 LI:343869.2:2001MAY171173 1183forwardTM Cytosolic 228 LI:343869.2:2001MAY171184 1206forwardTM Transmembrane 228 LI:343869.2:2001MAY171207 1237forwardTM Non-Cytosolic 228 LI:343869.2:2001MAY171238 1260forwardTM Transmembrane 228 LI:343869.2:2001MAY171261 1334forwardTM Cytosolic 228 LI:343869.2:2001MAY171335 1354forwardTM Transmembrane ~ 1 228 LI:343869.2:2001MAY171355 1363forwardTM Non-Cytosolic I

228 LI:343869.2:2001MAY171364 1383forwardTM Transmembrane 228 LI:343869.2:2001MAYI71384 1651forwardTM Cytosolic I

228 LI:343869.2:2001MAY171 957 forwardTM Non-Cytosolic 228 LI:343869.2:2001MAY17958 980 forwardTM Transmembrane 228 LI:343869.2:2001MAY17981 1126forwardTM Cytosolic 228 LI:343869.2:2001MAY171127 1149forwardTM Transmembrane 228 LI:343869.2:2001MAY171150 1183forwardTM Non-Cytosolic 228 LI:343869.2:2001MAY171184 1206forwardTM Transmembrane 228 LI:343869.2:2001MAY171207 1236forwardTM Cytosolic 228 LI:343869.2:2001MAY171237 1259forwardTM Transmembrane 228 LI:343869.2:2001MAY171260 1650forwardTM Non-Cytosolic 229 LI:363532.1:2001MAY171 77 forwardTM Non-Cytosolic 229 LI:363532.1:2001MAY1778 95 forwardTM Transmembrane, 229 LI:363532.1:2001MAYI796 189 forwardTM Cytosolic 229 LI:363532.1:2001MAY17190 209 forwardTM Transmembrane 229 LI:363532.1:2001MAY17210 234 forwardTM Non-Cytosolic 229 LI:363532.1:2001MAY17235 257 forwardTM Transmembrane 229 LI:363532.1:2001MAY17258 266 forwardTM Cytosolic ' 3 230 LI:398153.37:2001MAY171 139 forwardTM Cytosolic 230 LI:398153.37:2001MAY17140 162 forwardTM Transmembrane 230 LI:398153.37:2001MAY17163 287 forwardTM Non-Cytosolic 231 LI:4I6650.1:2001MAY171 26 forwardTM Cytosolic 231 LI:416650.1:2001MAY1727 49 forwardTM Transmembrane 231 LI:416650.1:2001MAY1750 231 forwardTM Non-Cytosolic 231 LI:416650.1:2001MAY171 30 forwardTM Cytosolic 231 LI:416650.1:2001MAY1731 53 forwardTM Transmembrane 231 LI:416650.1:2001MAY1754 230 forwardTM Non-Cytosolic 232 LI:444767.32:2001MAY17I 24 forwardTM Non-Cytosolic 232 LI:444767.32:2001MAY1725 47 forwardTM Transmembrane 232 LI:444767.32:2001MAY1748 192 forwardTM Cytosolic 232 LI:444767.32:2001MAY17193 215 forwardTM Transmembrane I

232 LI:444767.32:2001MAY17216 279 forwardTM Non-Cytosolic 232 LI:444767.32:2001MAY17280 302 forwardTM Transmembrane 232 LI:444767.32:2001MAY17303 440 forwardTM Cytosolic 232 LI:444767.32:2001MAY17441 463 forwardTM Transmembrane 232 LI:444767.32:2001MAY17464 596 forwardTM Non-Cytosolic 232 LI:444767.32:2001MAY171 12 forwardTM Cytosolic 232 LI:444767.32:2001MAY1713 32 forwardTM Transmembrane 232 LI:444767.32:2001MAY1733 519 forwardTM Non-Cytosolic 232 LI:444767.32:2001MAY17520 542 forwardTM Transmembrane 232 LI:444767.32:2001MAY17543 595 forwardTM Cytosolic 232 LI:444767.32:2001MAY1 12 forwardTM Cytosolic 232 LI:444767.32:2001MAY17I3 35 forwardTM Transmembrane SEQ Template ID Start StopFrame Domain Topology D Type NO:

232 LI:444767.32:2001MAY1736 595forwardTM Non-Cytosolic 233 LI:759073.1:2001MAY171 9 forwardTM Non-Cytosolic 233 LI:759073.1:2001MAY1710 32 forwardTM Transmembrane 233 LI:759073.1:2001MAY1733 210forwardTM Cytosolic 233 LI:759073.1:2001MAY17211 233forwardTM Transmembrane 233 LI:759073.1:2001MAY17234 252forwardTM Non-Cytosolic 233 LI:759073.1:2001MAY17253 270forwardTM Transmembrane 233 LI:759073.1:2001MAY17271 441forwardTM Cytosolic 233 LI:759073.1:2001MAY17442 464forwardTM Transmembrane I

233 LI:759073.1:2001MAY17465 574forwardTM Non-Cytosolic 233 LI:759073.1:2001MAY171 83 forwardTM Cytosolic 233 LI:7S9073.1:2001MAY1784 106forwardTM Transmembrane 233 LI:759073.1:ZOO1MAYI7107 129forwardTM Non-Cytosolic 233 LI:759073.1:2001MAY17130 152forwardTM Transmembrane 233 LI:759073.1:2001MAY17153 156forwardTM Cytosolic 233 LI:759073.1:2001MAY17157 179forwardTM Transmembrane 233 LI:759073.1:2001MAY17180 393forwardTM Non-Cytosolic 233 LI:759073.1:2001MAY17394 416forwardTM Transmembrane 233 LI:759073.1:2001MAY17417 427forwardTM Cytosolic 233 LI:759073.1:2001MAY17428 450forwardTM Transmembrane 233 LI:759073.1:2001MAY17451 574forwardTM Non-Cytosolic 233 LI:759073.1:2001MAY171 79 forwardTM Cytosolic 233 LI:759073.1:2001MAY1780 102forwardTM Transmembrane 233 LI:759073.1:2001MAY1T103 116forwardTM Non-Cytosolic 233 LI:759073.1:200IMAY17117 139forwardTM Transmembrane 233 LI:759073.1:2001MAY17~140 150forwardTM Cytosolic 233 LI:759073.1:2001MAY17151 170forwardTM Transmembrane 233 LI:759073.1:2001M'AY17171 573forwardTM Non-Cytosolic 3' 234 LI:759902.4:200IMAY17I 3 forwardTM Non-Cytosolic 234 LI:759902.4:2001MAY174 26 forwardTM Transmembrane 234 LI:759902.4:2001MAYI727 100forwardTM Cytosolic 235 LI:762268.1:2001MAY171 49 forwardTM Cytosolic 235 LI:762268.1:2001MAY1750 72 forwardTM Transmembrane 235 LI:762268.1:2001MAY1773 86 forwardTM Non-Cytosolic 235 LI:762268.1:2001MAY1787 109forwardTM Transmembrane 235 LI:762268.1:2001MAY17110 136forwardTM Cytosolic I

235 LI:762268.1:2001MAY17137 159forwardTM Transmembrane 235 LI:762268.1:2001MAY17160 S94forwardTM Non-Cytosolic ~ I

235 LI:762268.1:2001MAY171 16 forwardTM Cytosolic 235 LI:762268.1:2001MAY1717 39 forwardTM Transmembrane 235 LI:762268.1:2001MAY1740 48 forwardTM Non-Cytosolic 235 LI:762268.1:2001MAY1749 71 forwardTM Transmembrane 235 LI:762268.1:2001MAY1772 91 forwardTM Cytosolic 235 LI:762268.1:2001MAY1792 111forwardTM Transmembrane 235 LI:762268.1:2001MAY17112 125forwardTM Non-Cytosolic 235 LI:762268.1:2001MAY17126 148forwardTM Transmembrane 235 LI:762268.1:2001MAY17149 167forwardTM Cytosolic 235 LI:762268.1:2001MAY17168 190forwardTM Transmembrane 235 LI:762268.1:2001MAY17191 593forwardTM Non-Cytosolic 235 LI:762268.1:2001MAY171 45 forwardTM Non-Cytosolic 235 LI:762268.1:2001MAY1746 68 forwardTM Transmembrane 235 LI:762268.1:2001MAY1769 79 forwardTM Cytosolic 235 LI:762268.1:2001MAY1780 102forwardTM Transmembrane 235 LI:762268.1:2001MAY17I03 593forwardTM Non-Cytosolic TABLE

SEQ Template ID StartStopFrame Domain Topology D Type NO:

236 LI:8I3699.1:200IMAY171 394 forwardTM Cytosolic 236 LI:813699.1:2001MAY17395 417 forwardTM Transmembrane 236 LI:813699.1:2001MAY17418 457 forwardTM Non-Cytosolic 237 LI:024142.16:2001MAY171 49 forwardTM Non-Cytosolic 237 LI:024142.16:2001MAY1750 72 forwardTM Transmembrane 237 LI:024142.16:2001MAY1773 311 forwardTM Cytosolic 237 LI:024142.16:2001MAY17312 334 forwardTM Transmembrane 237 LI:024142.16:2001MAY17335 348 forwardTM Non-Cytosolic 237 LI:024142.16:2001MAY17349 371 forwardTM Transmembrane 237 LI:024142.16:2001MAY17372 377 forwardTM Cytosolic 237 LI:024142.I6:2001MAY17378 400 forwardTM Transmembrane I

237 LI:024142.16:2001MAY17401 1142forwardTM Non-Cytosolic 237 LI:024142.16:2001MAY171 279 forwardTM Cytosolic 237 LI:024142.16:2001MAY17280 299 forwardTM Transmembrane 237 LI:024142.16:2001MAY17300 313 forwardTM Non-Cytosolic 237 LI:024142.16:2001MAY17314 348 forwardTM Transmembrane 237 LI:024142.16:2001MAY17349'360 forwardTM Cytosolic 237 LI:024142.16:2001MAY17361 383 forwardTM Transmembrane 237 LI:024142.16:2001MAY17384 397 forwardTM Non-Cytosolic 237 LI:024142.16:2001MAY17398 420 forwardTM Transmembrane 237 LI:024142.16:2001MAY17421 536 forwardTM Cytosolic 237 LI:024142.16:2001MAY17537 559 forwardTM Transmembrane 237 LI:024142.16:2001MAY17560 586 forwardTM Non-Cytosolic 237 LI:024142.16:2001MAY17587 609 forwardTM Transmembrane 237 LI:024142.16:2001MAY17610 636 forwardTM Cytosolic 237 LI:024142.16:200IMAY17637 659 forwardTM ' Transmembrane . 2 237 LI:024142.16:2001MAY17660 1141forwardTM Non-Cytosolic . 2 237 LI:024142.16:ZOOIMAY17I 323 forwardTM Non-Cytosolic ' 3 237 LI:024142.16:2001MAY17324 346 forwardTM Transmembrane . 3 237 LI:024142.16:2001MAY17347 352 forwardTM Cytosolic 237 LI:024142.16:2001MAY17353 375 forwardTM Transmembrane 237 LI:024142.16:2001MAY17376 394 forwardTM Non-Cytosolic 237 LI:024142.16:2001MAY17395 414 forwardTM Transmembrane 237 LI:024142.16:2001MAY17415 570 forwardTM Cytosolic 237 LI:024142.16:2001MAY17571 593 forwardTM Transmembrane 237 LI:024142.16:2001MAY17594 1141forwardTM Non-Cytosolic 238 LI:1018424.4:2001MAY171 1194forwardTM Non-Cytosolic 238 LI:1018424.4:2001MAY1711951217forwardTM Transmembrane 238 LI:1018424.4:2001MAY1712181327forwardTM Cytosolic 239 LI:1085250.6:2001MAY171 840 forwardTM Non-Cytosolic 239 LI:I085250.6:2001MAY17841 863 forwardT'M Transmembrane 239 LI:1085250.6:2001MAY17864 929 forwardTM Cytosolic 239 LI:1085250.6:2001MAY17930 952 forwardTM Transmembrane 239 LI:1085250.6:2001MAY17953 955 forwardTM Non-Cytosolic I

239 LI:1085250.6:2001MAY17956 978 forwardTM Transmembrane 239 LI:1085250.6:2001MAYI7979 990 forwardTM Cytosolic 239 LI:1085250.6:2001MAY17991 1013forwardTM Transmembrane 239 LI:1085250.6:2001MAY1710141327forwardTM Non-Cytosolic 239 LI:1085250.6:2001MAY1713281350forwardTM Transmembrane 239 LI:I085250.6:2001MAY1713511369forwardTM Cytosolic 239 LI:1085250.6:2001MAY171 59 forwardTM Cytosolic 239 LI:1085250.6:2001MAY1760 82 forwardTM Transmembrane 239 LI:1085250.6:2001MAY83 515 forwardTM Non-Cytosolic 239 LI:1085250.6:2001MAY17516 538 forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D NO: Type 239 LI:1085250.6:2001MAY17539 558forwardTM Cytosolic 239 LI:1085250.6:2001MAY17559 578forwardTM Transmembrane 239 LI:1085250.6:2001MAY17579 597forwardTM Non-Cytosolic 239 LI:1085250.6:2001MAY17598 620forwardTM Transmembrane 239 LI:1085250.6:2001MAY17621 803forward~ TM Cytosolic 239 LI:1085250.6:2001MAY17804 826forwardTM Transmembrane 239 LI:1085250.6:2001MAY17827 835forwardTM Non-Cytosolic 239 LI:1085250.6:2001MAY17836 858forwardTM Transmembrane 239 LI:1085250.6:2001MAY17859 878forwardTM Cytosolic 239 LI:1085250.6:2001MAY17879 901forwardTM Transmembrane 239 LI:1085250.6:2001MAY17902 910forwardTM Non-Cytosolic 239 LI:1085250.6:2001MAY17911 933forwardTM Transmembrane 239 LI:1085250.6:2001MAY17934 986forwardTM Cytosolic 239 LI:1085250.6:2001MAY17987 1009forwardTM Transmembrane 239 LI:1085250.6:2001MAY17' 1211forwardTM Non-Cytosolic 239 LI:1085250.6:2001MAY171212 1234forwardTM Transmembrane 239 LI:1085250.6:2001MAY171235 1306forwardTM Cytosolic 239 LI:1085250.6:2001 1307 1329forwardTM Transmembrane 239 LI:1085250.6:2001MAY171330 1338forwardTM Non-Cytosolic 239 LI:1085250.6:2001MAY171339 1361forwardTM Transmembrane 239 LI:1085250.6:2001MAY171362 1368forwardTM Cytosolic . 2 239 LI:1085250.6:2001MAY171 546forwardTM Non-Cytosolic 239 LI:1085250.6:2001MAY17547 569forwardTM Transmembrane 239 LI:1085250.6:2001MAY17570 589forwardTM Cytosolic 239 LI:1085250.6:2001MAY17590 612forwardTM Transmembrane 239 LI:1085250.6:2001MAY17613. 911forwardTM Non-Cytosolic 239 LI:1085250.6:2001MAY17912 931-forwardTM Transmembrane 239 LI:1085250.6:2001MAY17932 1203forwardTM Cytosolic 239 LI:1085250.6:2001 1204 1226forwardTM Transmembrane 239 LI:1085250.6:2001MAY171227 1240forwardTM Non-Cytosolic 239 LI:1085250.6:2001MAY171241 1260forwardTM Transmembrane 239 LI:1085250.6:2001MAY171261 1319forwardTM Cytosolic 239 LI:1085250.6:2001MAY171320 1342forwardTM Transmembrane 239 LI:1085250.6:2001MAY171343 1368forwardTM Non-Cytosolic 240 LI:179233.63:2001MAY171 173forwardTM Cytosolic 240 LI:179233.63:2001MAY17174 196forwardTM Transmembrane 240 LI:179233.63:2001MAY17197 210forwardTM Non-Cytosolic 240 LI:179233.63:2001MAY17211 233forwardTM Transmembrane 240 LI:179233.63:2001 234 347forwardTM Cytosolic 241 LI:2207I25.3:2001 1 I2 forwardTM Cytosolic 241 LI:2207125.3:2001 13 35 forwardTM Transmembrane 241 LI:2207125.3:2001MAY1736 204forwardTM Non-Cytosolic 242 LI:235153.44:2001 1 753forwardTM Non-Cytosolic 242 LI:235153.44:2001MAY17754 776forwardTM Transmembrane 242 LI:235153.44:2001MAY17777 1029forwardTM Cytosolic 243 LI:007101.10:2001 I 528forwardTM Non-Cytosolic 243 LI:007101.10:2001MAY17529 551forwardTM Transmembrane 243 LI:007101.10:2001 552 694forwardTM Cytosolic 244 LI:008541.2:2001MAY171 79 forwardTM Cytosolic 244 LI:008541.2:2001 80 102forwardTM Transmembrane 244 LI:008541.2:2001MAY17103 568forwardTM Non-Cytosolic 245 LI:009658.13:2001MAY171 74 forwardTM Cytosolic 245 LI:009658.13:2001MAY1775 94 forwardTM Transmembrane 245 LI:009658.13:2001 95 1317forwardTM Non-Cytosolic SEQ Template ID StartStopFrame Domain Topology D Type NO:

245 LI:009658.13:2001MAY171318 1340forwardTM Transmembrane 245 LI:009658.13:2001MAY171341 1362forwardTM Cytosolic I

245 LI:009658.13:2001MAY171363 1385forwardTM Transmembrane 245 LI:009658.13:2001MAY171386 1423forwardTM Non-CytosoIic I

245 LI:009658.13:2001MAY171 927 forwardTM Non-Cytosolic 245 LI:009658.13:2001MAY17928 950 forwardTM Transmembrane 245 LI:009658.13:2001MAY17951 956 forwardTM Cytosolic 245 LI:009658.13:2001MAY17957 979 forwardTM Transmembrane 245 LI:009658.13:2001MAY17980 1321forwardTM Non-Cytosolic 245 LI:009658.13:2001MAY171322 1344forwardTM Transmembrane 245 LI:009658.13:2001MAY171345 1364forwardTM Cytosolic 245 LI:009658.13:2001MAY171365 1387forwardTM Transmembrane 245 LI:009658.13:2001MAY171388 1423forwardTM Non-Cytosolic 245 LI:009658.13:2001MAY171 706 forwardTM Non-Cytosolic 245 LI:009658.13:2001MAY17707 729 forwardTM Transmembrane 245 LI:009658.13:2001MAY17730 749 forwardTM Cytosolic 245 LI:009658.13:2001MAY17750 772 forwardTM Transmembrane 245 LI:009658.13:2001MAY17773 791 forwardTM Non-Cytosolic 245 LI:009658.13:2001MAY17792 811 forwardTM Transmembrane 245 LI:009658.13:2001MAY17812 934 forwardTM Cytosolic 245 LI:009658.13:2001MAY17935 957 forwardTM Transmembrane 245 LI:009658.13:2001MAY17958 971 forwardTM Non-Cytosolic 245 LI:009658.13:2001MAY17972 994 forwardTM Transmembrane 245 LI:009658.13:2001MAY17995 1319forwardTM Cytosolic 245 LI:009658.13:2001MAY171320 1342forwardTM Transmembrane 245 LI:009658.13:2001MAY171343 1356forwardTM Non-Cytosolic 245 LI:009658.13:2001MAY171357.1379forwardTM Transmembrane 245 LI:009658.13:2001MAY171380 1422forwardTM Cytosolic 246 LI:020012.14:2001MAY171 423 forwardTM Cytosolic 246 LI:020012.14:2001MAY17424 446 forwardTM Transmembrane 246 LI:020012.14:2001MAY17447 449 forwardTM Non-Cytosolic 246 LI:020012.14:2001MAY17450 469 forwardTM Transmembrane 246 LI:020012.14:2001MAY17470 884 forwardTM Cytosolic 246 LI:020012.14:200IMAY17885 907 forwardTM Transmembrane 246 LI:020012.14:2001MAY17908 955 forwardTM Non-Cytosolic 246 LI:020012.14:2001MAY17956 978 forwardTM Transmembrane 246 LI:020012.14:2001MAY17979 1013forwardTM Cytosolic 246 LI:020012.14:2001MAY171 582 forwardTM Non-Cytosolic 246 LI:020012.14:2001MAY17583 602 forwardTM Transmembrane 246 LI:020012.14:2001MAY17603 614 forwardTM Cytosolic 246 LI:020012.14:2001MAY17615 637 forwardTM Transmembrane 246 LI:020012.14:2001MAY17638 695 forwardTM Non-Cytosolic 246 LI:020012.14:2001MAY17696 718 forwardTM Transmembrane 246 LI:020012.14:2001MAY17719 724 forwardTM Cytosolic 246 LI:020012.14:2001MAY17725 747 forwardTM Transmembrane 246 LI:020012.14:2001MAY17748 761 forwardTM Non-Cytosolic 246 LI:020012.14:2001MAY17762 781 forwardTM Transmembrane 246 LI:020012.14:2001MAY17~ 953 forwardTM Cytosolic 246 LI:020012.14:2001MAY17954 976 forwardTM Transmembrane 246 LI:020012.14:2001MAY17977 1012forwardTM Non-Cytosolic 246 LI:020012.14:2001MAY17I 725 forwardTM Non-Cytosolic 246 LI:020012.14:2001MAY17726 748 forwardTM Transmembrane 246 LI:020012.14:2001MAY17749 760 forwardTM Cytosolic 246 LI:020012.14:2001MAY17761 780 forwardTM Transmembrane SEQ Template ID Start StopFrame Domain Topology D Type NO:

246 LI:020012.14:2001MAY17781 814forwardTM Non-Cytosolic 246 LI:020012.14:2001MAY17815 837forwardTM Transmembrane 246 LI:020012.14:2001MAY17838 849forwardTM Cytosolic 246 LI:020012.14:2001MAY17850 869forwardTM Transmembrane 246 LI:020012.14:2001MAY17870 883forwardTM Non-Cytosolic 246 LI:020012.14:2001MAY17884 906forwardTM Transmembrane 246 LI:020012.14:2001MAY17907 926forwardTM Cytosolic 246 LI:020012.14:2001MAY17927 946forwardTM Transmembrane 246 LI:020012.14:2001MAY17947 955forwardTM Non-Cytosolic 246 LI:020012.14:2001MAY17956 978forwardTM Transmembrane 246 LI:020012.14:2001MAY17979 1012forwardTM Cytosolic 247 LI:020691.1:2001MAY171 19 forwardTM Cytosolic 247 LI:020691.1:2001MAY1720 42 forwardTM Transmembrane 247 LI:020691.1:2001MAY1743 255forwardTM Non-Cytosolic 247 LI:020691.1:2001MAY171 12 forwardTM Cytosolic 247 LI:020691.1:2001MAY1713 35 forwardTM Transmembrane 247 LI:020691.1:2001MAY1736 255forwardTM Non-Cytosolic 248 LI:021188.12:2001MAY171 171forwardTM Non-Cytosolic 248 LI:021188.12:2001MAY17172 194forwardTM Transmembrane 248 LI:021188.12:2001MAY17195 377forwardTM Cytosolic 249 LI:021324.4:2001MAY171 53 forwardTM Cytosolic 249 LI:021324.4:2001MAY1754 76 forwardTM Transmembrane 249 LI:021324.4:2001MAY1777 90 forwardTM Non-Cytosolic 249 LI:021324.4:2001MAY1791 113forwardTM Transmembrane 249 LI:021324.4:2001MAY17114 227forwardTM Cytosolic 249 LI:021324.4:2001MAY17228 250forwardTM Transmembrane 249 LI:021324.4:2001MAY17251 710forwardTM Non-Cytosolic 250 LI:021834.15:200IMAY171 552forwardTM Non-Cytosolic 250 LI:021834.15:2001MAY17553 575forward'2TM Transmembrane 250 LI:021834.15:2001MAY17576 595forwardTM Cytosolic 250 LI:021834.15:2001MAY17596 618forwardTM Transmembrane 250 LI:021834.15:2001MAY17619 771forwardTM Non-Cytosolic 251 LI:024841.1:2001MAY171 752forwardTM Non-Cytosolic 251 LI:024841.1:2001MAY17753 775forwardTM Transmembrane 251 LI:024841.1:2001MAY17776 1017forwardTM Cytosolic 251 LI:024841.1:2001MAY171018 1040forwardTM Transmembrane 251 LI:024841.1:2001MAY171041 1054forwardTM Non-Cytosolic 251 LI:024841.1:2001MAY171055 1077forwardTM Transmembrane 251 LI:024841.1:2001MAY171078 1129forwardTM Cytosolic 251 LI:024841.1:2001MAY171 748forwardTM Non-Cytosolic 251 LI:024841.1:2001MAY17749 771forwardTM Transmembrane 251 LI:024841.1:2001MAY17772 1015forwardTM Cytosolic 251 LI:024841.1:2001MAY171016 1038forwardTM Transmembrana 251 LI:024841.1:2001MAY171039 1128forwardTM Non-Cytosolic 252 LI:025724.12:2001MAY171 446forwardTM Non-Cytosolic 252 LI:025724.12:2001MAY17447 469forwardTM Transmembrane 252 LI:025724.12:2001MAY17470 685forwardTM Cytosolic 252 LI:025724.12:2001MAY17686 703forwardTM Transmembrane 252 LI:025724.12:2001MAY17704 730forwardTM Non-Cytosolic 252 LI:025724.12:2001MAY17731 753forwardTM Transmembrane 252 LI:025724.12:2001MAY17754 895forwardTM Cytosolic 252 LI:025724.12:2001MAY17896 918forwardTM Transmembrane 252 LI:025724.12:2001MAY17919 984forwardTM Non-Cytosolic 252 LI:025724.12:2001MAY17985 1007forwardTM Transmembrane SEQ D NO: Template ID Start StopFrame Domain Topology Type 252 LI:025724.12:2001MAY171008 1018forwardTM Cytosolic 252 LI:025724.12:2001MAY171019 1041forwardTM Transmembrane 252 LI:025724.12:2001MAY171042 1074forwardTM Non-Cytosolic 252 LI:025724.12:2001MAY171075 1097forwardTM Transmembrane 252 LI:025724.12:2001MAY171098 1201forwardTM Cytosolic 252 LI:025724.12:2001MAY171 457 forwardTM Non-Cytosolic 252 LI:025724.12:2001MAY17458 480 forwardTM Transmembrane 252 LI:025724.12:2001MAY17481 695 forwardTM Cytosolic 252 LI:025724.12:2001MAY17696 718 forwardTM Transmembrane 252 ~ LI:025724.12:2001MAY17719 732 forwardTM Non-Cytosolic 252 LI:025724.12:2001MAY17~ 733 755 forwardTM Transmembrane 252 LI:025724.12:2001MAY17756 777 forwardTM Cytosolic 252 LI:025724.12:2001MAY17778 797 forwardTM Transmembrane 252 LI:025724.12:2001MAY17798 806 forwardTM Non-Cytosolic 252 LI:025724.12:2001MAY17807 829 forwardTM Transmembrane 252 LI:025724.12:2001MAY17830 921 forwardTM Cytosolic 252 LI:025724.12:2001MAY17922 939 forwardTM Transmembrane 252 LI:025724.12:2001MAY17940 1018forwardTM Non-Cytosolic 252 LI:025724.12:2001MAY171019 1041forwardTM Transmembrane 252 LI:025724.12:2001MAY171042 1133forwardTM Cytosolic 252 LI:025724.12:2001MAY171134 1156forwardTM Transmembrane 252 LI:025724.12:2001MAY171157 1165forwardTM Non-Cytosolic 252 LI:025724.12:2001MAY171166 1185forwardTM Transrnembrane 252 LI:025724.12:2001MAY171186 1201forwardTM Cytosolic 252 LI:025724.12:2001MAY171 729 forwardTM Non-Cytosolic 252 LI:025724.12:2001MAY17730 752 forwardTM Transmembrane 252 LI:025724.12:2001MAY17753 764 forwardTM Cytosolic 252 LI:025724.12:2001MAY17765 ,787forward~TM Transmembrane 252 LI:025724.12:2001MAY17788 - forwardTM Non-Cytosolic 252 LI:025724.12:2001MAY17807 829 forwardTM Transmembrane 252 LI:025724.12:2001MAY17830 873 forwardTM Cytosolic 252 LI:025724.12:2001MAY17874 896 forwardTM Transmembrane 252 LI:025724.12:2001MAY17897 910 forwardTM Non-Cytosolic 252 LI:025724.12:2001MAY17911 933 forwardTM Transmembrane 252 LI:025724.12:2001MAY17934 1042forwardTM Cytosolic 252 LI:025724.12:2001MAY171043 1065forwardTM Transmembrane 252 LI:025724.12:2001MAYJ71066 1200forwardTM Non-Cytosolic 253 LI:029328.2:2001MAY171 714 forwardTM Non-Cytosolic 253 LI:029328.2:2001MAY17715 737 forwardTM ' Transmembrane 253 LI:029328.2:2001MAY17738 1025forwardTM Cytosolic 253 LI:029328.2:2001MAY171026 1043forwardTM Transmembrane 253 LI:029328.2:2001MAY171044 1052forwardTM Non-Cytosolic 253 LI:029328.2:2001MAY171053 1075forwardTM Transmembrane 253 LI:029328.2:2001MAY171076 1179forwardTM Cytosolic 253 LI:029328.2:2001MAY171180 1202forwardTM Transmembrane 253 LI:029328.2:2001MAY171203 w forwardTM ~ Non-Cytosolic 253 LI:029328.2:2001MAY171284 1306forwardTM Transmembrane 253 LI:029328.2:2001MAY171307 1312forwardTM Cytosolic 253 LI:029328.2:2001MAY171313 1335forwardTM Transmembrane 253 LI:029328.2:2001MAY171336 2000forwardTM Non-Cytosolic 253 LI:029328.2:2001MAY171 301 forwardTM Non-Cytosolic 253 LI:029328.2:2001MAY17302 324 forwardTM Transmembrane 253 LI:029328.2:2001MAY17325 365 forwardTM Cytosolic 253 LI:029328.2:2001MAY17366 384 forwardTM Transmembrane SEQ D NO: Template ID StartStopFrame Domain Topolojy Type 253 LI:029328.2:2001MAY17385 1947forwardTM Non-Cytosolic 253 LI:029328.2:2001MAY171948 1970forwardTM Transmembrane 253 LI:029328.2:2001MAY171971 1999forwardTM Cytosolic 254 LI:032171.5:2001MAY171 459 forwardTM Non-Cytosolic 254 LI:032171.5:2001 460 477 forward'TM Transmembrane 254 LI:032171.5:2001MAY17478 481 forwardTM Cytosolic 254 LI:032171.5:2001MAY17482 504 forwardTM Transmembrane 254 LI:032171.5:2001MAY17505 518 forwardTM Non-Cytosolic 254 LI:032171.5:2001MAY519 541 forwardTM Transmembrane 254 LI:032171.5:2001MAY17542 553 forwardTM Cytosolic 254 LI:032171.5:2001MAY17554 576 forwardTM Transmembrane 254 LI:032171.5:2001MAY17577 626 forwardTM Non-Cytosolic 254 LI:032171.5:2001MAY17627 649 forwardTM Transmembrane 254 LI:032171.5:2001MAY17650 716 forwardTM Cytosolic 254 LI:032171.5:2001MAY171 625 forwardTM Non-Cytosolic 254 LI:032171.5:2001MAY17626 648 forwardTM Transmembrane 254 LI:032171.5:2001MAY17649 660 forwardTM Cytosolic 254 LI:032171.5:2001MAY17661 683 forwardTM Transmembrane 254 LI:032171.5:2001MAY17684 686 forwardTM Non-Cytosolic 254 LI:032171.5:2001MAY17687 709 forwardTM Transmembrane 254 LI:032171.5:2001MAY17710 715 forwardTM Cytosolic 255 LI:035055.1:2001MAY171 489 forwardTM Non-Cytosolic 255 LI:035055.1:2001MAY17490 512 forwardTM Transmembrane 255 LI:035055.1:2001MAY17513 584 forwardTM Cytosolic 255 LI:035055.1:2001MAY17585 607 forwardTM Transmembrane 255 LI:035055.1:2001MAY17608 619 forward. TM Non-Cytosolic ~ 2 255 LI:035055.1:2001MAY17620 642 forwardTM Transmembrane 255 LI:035055.1:2001MAY17643 673 forwardTM Cytosolic 255 LI:035055.1:2001MAY171 619 forwardTM Non-Cytosolic 255 LI:035055.1:2001MAYI7620 642 forwardTM Transmembrane 255 LI:035055.1:2001MAY17643 673 forwardTM Cytosolic 256 LI:036747.17:2001MAY171 269 forwardTM Cytosolic 256 LI:036747.17:2001MAY17270 292 forwardTM Transmembrane 256 LI:036747.17:2001MAYI7293 325 forwardTM Non-Cytosolic 256 LI:036747.17:2001MAY17326 348 forwardTM Transmembrane 256 LI:036747.17:2001MAY17349 427 forwardTM Cytosolic 256 LI:036747.17:2001MAY17428 450 forwardTM Transmembrane 256 LI:036747.17:2001MAY17451 464 forwardTM Non-Cytosolic 256 LI:036747.17:2001MAY17465 487 forwardTM Transmembrane 256 LI:036747.17:2001MAY17488 499 forwardTM Cytosolic 256 LI:036747.17:2001MAY17500 522 forwardTM Transmembrane 256 LI:036747.17:2001MAY17523 630 forwardTM Non-Cytosolic 256 LI:036747.17:2001MAY17631 653 forwardTM Transmembrane 256 LI:036747.17:2001MAY17654 665 forwardTM Cytosolic 256 LI:036747.17:2001MAY17666 687 forwardTM Transmembrane 256 LI:036747.17:2001MAY17688 762 forwardTM Non-Cytosolic 256 LI:036747.17:2001MAY17763 785 forwardTM Transmembrane 256 LI:036747.17:2001MAY17786 818 forwardTM Cytosolic 256 LI:036747.17:2001MAY171 269 forwardTM Non-Cytosolic 256 LI:036747.17:2001MAY17270 292 forwardTM Transmembrane 256 LI:036747.17:2001MAY17293 478 forward.2TM Cytosolic 256 LI:036747.17:2001MAY17479 501 forwardTM Transmembrane 256 LI:036747.17:2001MAY17502 515 forwardTM Non-Cytosolic 256 LI:036747.17:2001MAY17516 535 forwardTM Transmembrane SEQ Template ID Start StopFrame Domain Topology D NO: Type 256 LI:036747.17:2001MAY17536 624forwardTM Cytosolic 256 LI:036747.17:2001MAY17625 647forwardTM Transmembrane 256 LI:036747.17:2001MAY17648 666forwardTM Non-Cytosolic 256 LI:036747.17:2001MAY17667 689forwardTM Transmembrane 256 LI:036747.17:2001MAY17690 709forwardTM Cytosolic 256 LI:036747.17:2001MAY17710 732forwardTM Transmembrane 256 LI:036747.17:2001MAY17733 751forwardTM Non-Cytosolic 256 LI:036747.17:2001MAY17752 774forwardTM Transmembrane 256 LI:036747.17:2001MAY17775 785forwardTM Cytosolic 256 LI:036747.17:2001MAY17786 808forwardTM Transmembrane 256 LI:036747.17:2001MAY17809 817forwardTM Non-Cytosolic 256 LI:036747.17:2001MAY171 269forwardTM Non-Cytosolic 256 LI:036747.17:2001MAY17270 292forwardTM Transmembrane 256 LI:036747.17:2001MAY17293 399forwardTM Cytosolic 256 LI:036747.17:2001MAY17400 422forwardTM Transmembrane 256 LI:036747.17:2001MAY17423 499forwardTM Non-Cytosolic 256 LI:036747.17:2001MAY17500 522forwardTM Transmembrane 256 LI:036747.17:2001MAY17523 624forwardTM Cytosolic 256 LI:036747.17:2001MAY17625 642forwardTM Transmembrane 256 LI:036747.17:2001MAY17643 677forwardTM Non-Cytosolic 256 LI:036747.17:2001MAY17678 697forward. TM Transmembrane 256 LI:036747.17:2001MAY17698 709forwardTM Cytosolic 256 LI:036747.17:2001MAY17710 732forwardTM Transmembrane 256 LI:036747.17:2001MAY17733 751forwardTM Non-Cytosolic 256 LI:036747.17:2001MAY17752 774forwardTM Transmembrane 256 LI:036747.17:2001MAY17775 780forwardTM Cytosolic 256 LI:036747.17:2001MAY17781 803forwardTM Transmembrane 256 LI:036747.17:2001MAY17804 817forwardTM Non-Cytosolic 257 LI:044301.2:2001MAY171 965forwardTM Non-Cytosolic 257 LI:044301.2:2001MAY17966 988forwardTM Transmembrane 257 LI:044301.2:2001MAY17989 1000forwardTM Cytosolic 258 LI:061585.10:2001MAY171 672forwardTM Non-Cytosolic 258 LI:061585.10:2001MAY17673 695forwardTM Transmembrane 258 LI:061585.10:2001MAY17696 823forwardTM Cytosolic 258 LI:061585.10:2001MAY171 425forwardTM Non-Cytosolic 258 LI:061585.10:2001MAY17426 445forwardTM Transmembrane 258 LI:061585.10:2001MAY17446 451forwardTM Cytosolic 258 LI:061585.10:2001MAY17452 471forwardTM Transmembrane 258 LI:061585.10:2001MAY17472 680forwardTM Non-Cytosolic 258 LI:061585.10:2001MAY17681 700forwardTM Transmembrane 258 LI:061585.10:2001MAY17701 739forwardTM Cytosolic 258 LI:061585.10:2001MAYI7740 762forwardTM Transmembrane 258 LI:061585.10:2001MAY17763 823forwardTM Non-Cytosolic 258 LI:061585.10:2001MAY171 202forwardTM Cytosolic 258 LI:061585.10:2001MAY17203 225forwardTM Transmembrane 258 LI:061585.10:2001MAY17226 250forwardTM Non-Cytosolic 258 LI:061585.10:2001MAY17251 273forwardTM Transmembrane 258 LI:061585.10:2001MAY17274 277forwardTM Cytosolic 258 LI:061585.10:2001MAY17278 300forwardTM . Transmembrane 258 LI:061585.10:2001MAY17301 342forwardTM Non-Cytosolic 258 LI:061585.10:2001MAYI7343 365forwardTM Transmembrane 258 LI:061585.10:2001MAY17366 371forwardTM Cytosolic 258 LI:061585.10:2001MAY17372 394forwardTM Transmembrane 258 LI:061585.10:2001MAY17395 822forward'TM Non-Cytosolic SEQ Template ID StartStopFrame Domain Topology D Type NO:

259 LI:066742.21:2001MAY171 63 forwardTM Non-Cytosolic 259 LI:066742.21:2001MAY1764 86 forwardTM Transmembrane 259 LI:066742.21:2001MAY1787 318forwardTM Cytosolic 259 LI:066742.21:2001MAY17319 341forwardTM Transmembrane 259 LI:066742.21:2001MAY17342 355forward~ TM Non-Cytosolic 259 LI:066742.21:2001MAY17356 378forwardTM Transmembrane 259 LI:066742.21:2001MAY17379 430forwardTM Cytosolic 259 LI:066742.21:2001MAY17431 450forwardTM Transmembrane 259 LI:066742.21:2001MAY17451 1022forwardTM Non-Cytosolic 259 LI:066742.21:2001MAY171023 1045forwardTM Transmembrane 259 LI:066742.21:2001MAY171046 1068forwardTM Cytosolic 259 LI:066742.21:2001MAY171069 1091forwardTM Transmembrane 259 LI:066742.21:2001MAY171092 1408forwardTM Non-Cytosolic ' 1 259 LI:066742.21:2001MAY171409 1431forwardTM Transmembrane 259 LI:066742.21:2001MAY171432 1437forwardTM Cytosolic 259 LI:066742.21:2001MAY171438 1460forwardTM Transmembrane 259 LI:066742.21:2001MAY171461 1508forwardTM Non-Cytosolic 259 LI:066742.21:2001MAY171509 1531forwardTM Transmembrane 259 LI:066742.21:2001MAY171532 1542forwardTM Cytosolic 259 LI:066742.21:2001MAY171543 1562forwardTM Transmembrane 259 LI:066742.21:2001MAY171563 1583forwardTM Non-Cytosolic 259 LI:066742.21:2001MAY171 119forwardTM Cytosolic 259 LI:066742.21:2001MAY17120 142forwardTM Transmembrane 259 LI:066742.21:2001MAY17143 146forwardTM Non-Cytosolic, 259 LI:066742.21:2001MAY17147 169forwardTM Transmembrane 259 LI:066742.21:2001MAY17170 - forwardTM Cytosolic 259 LI:066742.21:2001MAY17352 374forwardTM Transmembrane 259 LI:066742.21:2001MAY17375 ' forwardTM Non-Cytosolic 259 LI:066742.21:2001MAY171203 1225forwardTM Transmembrane 259 LI:066742.21:2001MAY171226 1313forwardTM Cytosolic 259 LI:066742.21:2001MAY171314 1336forwardTM Transmembrane 259 LI:066742.21:2001MAY171337 1372forwardTM Non-Cytosolic 259 LI:066742.21:2001MAY171373 1395forwardTM Transmembrane 259 LI:066742.21:200IMAY171396 1582forwardTM Cytosolic 259 LI:066742.21:2001MAY171 16 forwardTM Cytosolic 259 LI:066742.21:2001MAY1717 39 forwardTM Transmembrane 259 LI:066742.21:2001MAY1740 53 forwardTM Non-Cytosolic 259 LI:066742.21:2001MAY1754 76 forwardTM Transmembrane 259 LI:066742.21:2001MAY1777 179forwardTM Cytosolic 259 LI:066742.21:2001MAY17180 202forwardTM Transmembrane 259 LI:066742.21:2001MAY17203 312forwardTM Non-Cytosolic 259 LI:066742.21:2001MAY17313 332forwardTM Transmembrane 259 LI:066742.21:2001MAY17333 351forwardTM Cytosolic 259 LI:066742.21:2001MAY17352 374forwardTM Transmembrane 259 LI:066742.21:2001MAY17375 378forwardTM Non-Cytosolic 259 LI:066742.21:2001MAY17379 401forwardTM Transmembrane 259 LI:066742.21:2001MAY17402 580forwardTM Cytosolic 259 LI:066742.21:2001MAY17581 598forwardTM Transmembrane 259 LI:066742.21:2001MAY17599 644forwardTM Non-Cytosolic 259 LI:066742.21:2001MAY17645 664forwardTM Transmembrane 259 LI:066742~21:2001MAY17665 717forwardTM Cytosolic 259 LI:066742.21:2001MAY17718 740forwardTM Transmembrane 259 LI:066742.21:2001MAY17741 759forwardTM Non-Cytosolic 259 LI:066742.21:2001MAY17760 782forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D Type NO:

259 LI:066742.21:2001MAY17783 1168forwardTM Cytosolic 259 LI:066742.21:2001MAY171169 1186forwardTM Transmembrane 259 LI:066742.21:2001MAY171187 1200forwardTM Non-Cytosolic 259 LI:066742.21:2001MAY171201 1223forwardTM Transmembrane 259 LI:066742.21:2001MAY171224 1409forwardTM Cytosolic 259 LI:066742.21:2001MAY171410 1432forwardTM Transmembrane 259 LI:066742.21:2001MAY171433 1507forwardTM Non-Cytosolic 259 LI:066742.21:2001MAY171508 1527forwardTM Transmembrane 259 LI:066742.21:2001MAY171528 1582forwardTM Cytosolic 260 LI:075492.206:2001MAY171 14 forwardTM Non-Cytosolic 260 LI:075492.206:2001MAY1715 37 forwardTM Transmembrane 260 LI:075492.206:2001MAY1738 206forwardTM Cytosolic 260 LI:075492.206:2001MAY17207 229forwardTM Transmembrane 260 LI:075492.206:2001MAY17230 476forwardTM Non-Cytosolic 260 LT:075492.206:2001MAY171 14 forwardTM Non-Cytosolic 260 LI:075492.206:2001MAY1715 34 forwardTM Transmembrane 260 LT:075492.206:2001MAY1735 46 forwardTM Cytosolic 260 LI:075492.206:2001MAY1747 69 forwardTM Transmembrane 260 LI:075492.206:2001MAY1770 476forwardTM Non-Cytosolic 260 LI:075492.206:2001MAY171 205forwardTM Cytosolic 260 LI:075492.206:2001MAY17206 223forwardTM Transmembrane 260 LI:075492.206:2001MAY17224 475forwardTM Non-Cytosolic 261 LI:090782.3:2001MAY171 131forwardTM Non-Cytosolic 26I LI:090782.3:200IMAY17I32 154forwardTM Transmembrane 261 LI:090782.3:2001MAY17155 339forwardTM Cytosolic 261 LI:090782.3:2001MAY17340 362forwardTM Transmembrane ' 1 261 LI:090782.3:2001MAY17363 792forwardTM Non-Cytosolic 261 LI:090782.3:2001MAY171 417forwardTM Non-Cytosolic 261 LI:090782.3:2001MAY17418 440forwardTM Transmembrane 261 LI:090782.3:2001MAY17441 451forwardTM Cytosolic 261 LI:090782.3:2001MAY17452 474forwardTM Transmembrane 261 LI:090782.3:2001MAY17475 792forwardTM Non-Cytosolic 262 LI:1031308.1:2001MAY171 670forwardTM Non-Cytosolic 262 LI:1031308.1:2001MAY17671 693forwardTM Transmembrane 262 LI:1031308.1:2001MAY17694 785forwardTM Cytosolic 262 LI:1031308.1:2001MAY17786 808forwardTM Transmembrane 262 LI:1031308.1:2001MAY17809 848forwardTM Non-Cytosolic 262 LI:1031308.1:2001MAY17849 866forwardTM Transmembrane 262 LI:1031308.1:2001MAY17867 880forwardTM Cytosolic 262 LI:1031308.1:2001MAY171 675forwardTM Non-Cytosolic 262 LI:1031308.1:2001MAY17676 698forwardTM Transmembrane 262 LI:1031308.1:2001MAY17699 879forwardTM Cytosolic 262 LI:1031308.1:2001MAY171 560forwardTM Non-Cytosolic 262 LI:1031308.1:2001MAY17561 583forwardTM Transmembrane 262 LI:1031308.1:2001MAY17584 633forwardTM Cytosolic 262 LI:1031308.1:2001MAY17634 656forwardTM Transmembrane ~ 3 262 LI:1031308.1:2001MAY17657 670forwardTM Non-Cytosolic 262 LI:1031308.1:2001MAY17671 693forwardTM Transmembrane 262 LI:1031308.1:2001MAY17694 879forwardTM Cytosolic 263 LI:1054377.1:2001MAY171 76 forwardTM Cytosolic 263 LI:1054377.1:2001MAY1777 99 forwardTM Transmembrane 263 LI:1054377.1:2001MAY17100 501forwardTM Non-Cytosolic 264 LI:1072074.10:2001MAY171 38 forwardTM Cytosolic 264 LI:1072074.10:2001MAY1739 58 forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D NO: Type 264 LI:1072074.10:2001MAY1759 1024forwardTM Non-Cytosolic 265 LI:1072889.15:2001MAY171 67 forwardTM Cytosolic 265 LI:1072889.15:2001MAY1768 87 forwardTM Transmembrane 265 LI:1072889.15:2001MAY1788 91 forwardTM Non-Cytosolic 265 LI:1072889.15:2001MAY1792 111forwardTM Transmembrane 265 LI:1072889.15:2001MAY17112 310forwardTM Cytosolic 265 LI:1072889.15:2001MAY17311 333forwardTM Transmembrane 265 LI:1072889.15:2001MAY17334 627forwardTM Non-Cytosolic 265 LI:1072889.15:2001MAY17628 650forwardTM Transmembrane 265 LI:1072889.15:2001MAY17651 662forwardTM Cytosolic 265 LI:1072889.15:2001MAY17663 685forwardTM Transmembrane 265 LI:1072889.15:2001MAY17686 694forwardTM Non-Cytosolic 265 LI:1072889.15:2001MAY171 19 forwardTM Cytosolic 265 LI:1072889.15:2001MAY1720 42 forwardTM Transmembrane 265 LI:1072889.15:2001MAY1743 51 forwardTM Non-Cytosolic 265 LI:1072889.15:2001MAY1752 74 forwardT1VI Transmembrane 265 LI:1072889.15:2001MAY1775 94 forwardTM Cytosolic 265 LI:1072889.15:2001MAY1795 117forwardTM Transmembrane 265 LI:1072889.15:2001MAY17118 139forwardTM Non-Cytosolic 265 LI:1072889.15:2001MAY17140 162forwardTM Transmembrane .

265 LI:1072889.15:2001MAY17163 272forwardTM Cytosolic 265 LI:1072889.15:2001MAY17273 295forwardTM Transmembrane 265 LI:1072889.15:2001MAY17296 520forwardTM Non-Cytosolic 265 LI:1072889.1'S:2001MAY17521 543forwardTM Transmembrane 265 LI:1072889.15:2001MAY17544 612forwardTM Cytosolic 265 LT:1072889.15:2001MAY17613 635forwardTM Transmembrane 265 LI:1072889.15:2001MAY17636 657forwardTM Non-Cytosolic . 2 265 LI:1072889:15:2001MAYi7' 680forwardTM Transmembrane ' 658 2 265 LI:1072889:15:2001MAY17681 694forwardTM Cytosolic 265 LI:1072889.15:2001MAY171 38 forwardTM Cytosolic 265 LI:1072889.15:2001MAY1739 61 forwardTM Transmembrane 265 LI:1072889.15:2001MAY1762 92 forwardTM Non-Cytosolic 265 LI:1072889.15:2001MAY1793 115forwardTM Transmembrane 265 LI:1072889.15:2001MAY17116 266forwardTM Cytosolic 265 LI:1072889.15:2001MAY17267 289forwardTM Transmembrane 265 LI:1072889.15:2001MAY17290 611forwardTM Non-Cytosolic 265 LI:1072889.15:2001MAY17612 634forwardTM Transmembrane 265 LI:1072889.15:2001MAY17635 654forwardTM Cytosolic 265 LI:1072889.15:2001MAY17655 677forwardTM Transmembrane 265 LI:1072889.15:2001MAY17678 694forwardTM Non-Cytosolic 266 LI:1077480.1:2001MAY171 11 forwardTM Cytosolic 266 LI:1077480.1:2001MAY1712 34 forwardTM Transmembrane 266 LI:1077480.1:2001MAY1735 53 forwardTM Non-Cytosolic 266 LI:1077480.1:2001MAY1754 76 forwardTM Transmembrane 266 LI:1077480.1:2001MAY1777 109forwardTM Cytosolic 266 LI:1077480.1:2001MAY17I10 132forwardTM Transmembrane 266 LI:1077480.1:2001MAY17133 176forwardTM Non-Cytosolic 266 LI:1077480.1:2001MAY17177 199forwardTM Transmembrane 266 LI:1077480.1:2001MAY17200 240forwardTM CytosoIic 266 LI:1077480.1:2001MAY17241 263forwardTM Transmembrane 266 LI:1077480.1:2001MAY17264 484forwardTM Non-Cytosolic 266 LI:1077480.1:2001MAY171 147forwardTM Cytosolic 266 LI:1077480.1:2001MAY17148 170forwardTM Transmembrane 266 LI:1077480.1:2001MAY17171 189forwardTM Non-Cytosolic SEQ Template ID StartStopFrame Domain Topology D Type NO:

266 LI:1077480.1:2001MAY17190 207 forwardTM Transmembrane 266 LI:1077480.1:2001MAY17208 251 forwardT'M Cytosolic 266 LI:1077480.1:2001MAY17252 274 forwardTM Transmembrane 266 LI:1077480.1:2001MAY17275 331 forwardTM Non-Cytosolic 266 LI:1077480.1:2001MAY17332 354 forwardTM Transmembrane 266 LI:1077480.1:2001MAY17355 365 forward, TM Cytosolic 266 LI:1077480.1:2001MAY17366 388 forwardTM Transmembrane 266 LI:1077480.1:2001MAY17389 484 forwardTM Non-Cytosolic 266 LI:1077480.1:2001MAY171 59 forwardTM Cytosolic 266 LI:1077480.1:2001MAY1760 82 forwardTM Transmembrane ' 3 266 LI:1077480.1:2001MAY1783 101 forwardTM Non-Cytosolic 266 LI:1077480.1:2001MAY17102 121 forwardTM Transmembrane 266 LI:1077480.1:2001MAY17122 132 forwardTM Cytosolic 266 LI:1077480.1:2001MAY17133 155 forwardTM Transmembrane 266 LI:1077480.1:2001MAY17156 241 forwardTM Non-Cytosolic 266 LI:1077480.1:2001MAY17242 264 forwardTM Transmembrane 266 LI:1077480.1:2001MAY17265 484 forwardTM Cytosolic 267 LI:1079555.1:2001MAY171 38 forwardTM Cytosolic 267 LI:1079555.1:2001MAY1739 61 forwardTM Transmembrane 267 LI:1079555.1:2001MAY1762 444 forwardTM Non-Cytosolic 268 LI:1084992.28:2001MAY171 68 forwardTM Cytosolic 268 LI:1084992.28:2001MAY1769 91 forwardTM Transmembrane 268 LI:1084992.28:2001MAY1792 263 forwardTM Non-Cytosolic 269 LI:1085472.5:2001MAY171 52 forwardTM Cytosolic ' . 1 269 LI:1085472.5:2001MAY1753 75 forwardTM Transmembrane 269 LI:1085472.5:2001MAY1776 ',1590forwardTM Non-Cytosolic 270 LI:1086800.7:2001MAY171 84 forwardTM Cytosolic 270 LI:1086800.7:2001MAY17~85 107 forwardTM Transmembrane 270 LI:1086800.7:2001MAY17' 140 forwardTM Non-Cytosolic , 108 1 270 LI:1086800.7:2001MAY17141 163 forwardTM Transmembrane 270 LI:1086800.7:2001MAY17164 431 forwardTM Cytosolic 270 LI:1086800.7:2001MAY17432 451 forwardTM Transmembrane 270 LI:1086800.7:2001MAY17452 479 forwardTM Non-Cytosolic 270 LI:1086800.7:2001MAY17480 502 forwardTM Transmembrane 270 LI:1086800.7:2001MAY17503 521 forwardTM Cytosolic 270 LI:1086800.7:2001MAY17522 541 forwardTM Transmembrane 270 LI:1086800.7:2001MAY17542 593 forwardTM Non-Cytosolic 270 LI:1086800.7:2001MAY17594 616 forwardTM Transmembrane 270 LI:1086800.7:2001MAY17617 622 forwardTM Cytosolic 270 LI:1086800.7:2001MAY17623 645 forwardTM Transmembrane 270 LI:1086800.7:2001MAY17646 686 forwardTM Non-Cytosolic 270 LI:1086800.7:2001MAY17687 709 forwardTM Transmembrane 270 LI:1086800.7:2001MAY17710 981 forwardTM Cytosolic 270 LI:1086800.7:2001MAY17982 1004forwardTM Transmembrane 270 LI:1086800.7:2001MAY1710051471forwardTM Non-Cytosolic 270 LI:1086800.7:2001MAY1714721489forwardTM Transmembrane 270 LI:1086800.7:2001MAY1714901578forwardTM Cytosolic 270 LI:1086800.7:2001MAY1715791601forwardTM Transmembrane 270 LI:1086800.7:2001MAY1716021641forwardTM Non-Cytosolic 270 LI:1086800.7:2001MAY1716421664forwardTM Transmembrane 270 LI:1086800.7:2001MAY1716651671forwardTM Cytosolic 270 LI:1086800.7:2001MAY17I 49 forwardTM Cytosolic 270 LI:1086800.7:2001MAY1750 72 forwardTM Transmembrane 270 LI:1086800.7:2001MAY1773 86 forwardTM Non-Cytosolic SEQ D NO: Template ID StartStopFrame Domain Topology Type 270 LI:1086800.7:2001MAY1787 109 forwardTM Transmembrane 270 LI:1086800.7:2001MAY17110 115 forwardTM Cytosolic 270 LI:1086800.7:2001MAY17116 138 forwardTM Transmembrane 270 LI:1086800.7:2001MAY17139 180 forwardTM Non-Cytosolic 270 LI:1086800.7:2001MAY17181 203 forwardTM Transmembrane 270 LI:1086800.7:2001MAY17204 238 forwardTM Cytosolic 270 LI:1086800.7:2001MAY17239 26I forwardTM Transmembrane 270 LI:1086800.7:2001MAY17262 275 forwardTM Non-Cytosolic 270 LI:1086800.7:2001MAY17276 298 forwardTM Transmembrane 270 LI:1086800.7:2001MAY17299 309 forwardTM Cytosolic 270 LI:1086800.7:2001MAY17310 332 forwardTM Transmembrane 270 LI:1086800.7:2001MAY17333 592 forwardTM Non-Cytosolic 270 LI:1086800.7:2001MAY17593 615 forwardTM Transmembrane 270 LI:1086800.7:2001MAY17616 868 forwardTM Cytosolic 270 LI:1086800.7:2001MAY17869 891 forwardTM Transmembrane 270 LI:I086800.7:2001MAY17892 905 forwardTM Non-Cytosolic 270 LI:1086800.7:2001MAY17906 928 forwardTM Transmembrane 270 LI:1086800.7:2001MAY17929 1036forwardTM Cytosolic 270 LI:1086800.7:2001MAY171037 1059forwardTM Transmembrane 270 LI:1086800.7:2001MAY171060 1670forwardTM Non-Cytosolic 270 LI:1086800.7:2001MAY171 46 forwardTM Cytosolic 270 LI:1086800.7:2001MAY1747 66 forwardTM Transmembrane 270 LI:1086800.7:2001MAY1767 80 forwardTM Non-Cytosolic 270 LI:1086800.7:2001MAY1781 103 forwardTM Transmembrane 270 LI:1086800.7:2001MAY17104 233 forwardTM Cytosolic 270 LI:1086800.7:2001MAY17234 256 forward' TM Transmembrane 270 LI:10868b0.7:2001MAY17257' 275 forwardTM Non-Cytosolic ~ 3 . 270 LI:1086800.7:2001MAY17~ 298 forward' ' TM Transmembrane 276' 3 270 LI:1086800.7:2001MAY17299 388 forwardTM Cytosolic 270 LI:1086800.7:2001MAY17389 411 forwardTM Transmembrane 270 LI:1086800.7:2001MAY17412 584 forwardTM Non-Cytosolic 270 LI:1086800.7:2001MAY17585 607 forwardTM Transmembrane 270 LI:1086800.7:2001MAY17608 775 forwardTM Cytosolic 270 LI:1086800.7:2001MAY17776 795 forwardTM Transmembrane 270 LI:1086800.7:2001MAY17796 1206forwardTM Non-Cytosolic 270 LI:1086800.7:2001MAY171207 1229forwardTM Transmembrane 270 LI:1086800.7:2001MAY171230 1262forwardTM Cytosolic 270 LI:1086800.7:2001MAY171263 1285forwardTM Transmembrane 270 LI:1086800.7:2001MAY171286 1294forwardTM Non-Cytosolic 270 LI:1086800.7:2001MAY171295 1314forwardTM Transmembrane 270 LI:1086800.7:2001MAY171315 1446forwardTM Cytosolic 270 LI:1086800.7:2001MAY171447 1469forwardTM Transmembrane 270 LI:1086800.7:2001MAY171470 1630forwardTM Non-Cytosolic 270 LI:1086800.7:2001MAY171631 1653forwardTM Transmembrane 270 LI:1086800.7:2001MAY171654 1670forwardTM Cytosolic 271 LI:1089871.9:2001MAY171 343 forwardTM Non-Cytosolic 271 LI:1089871.9:2001MAY17344 363 forwardTM Transmembrane 271 LI:1089871.9:2001MAY17364 369 forwardTM Cytosolic 271 LI:1089871.9:2001MAY17370 392 forwardTM Transmembrane 271 LI:1089871.9:2001MAY17393 1441forwardTM Non-Cytosolic 271 LI:I089871.9:ZOO1MAY171442 1464forwardTM Transmembrane 271 LI:1089871.9:2001MAY171465 1483forwardTM Cytosolic 271 LI:1089871.9:2001MAY171484 1503forwardTM Transmembrane 271 LI:1089871.9:2001MAY171504 1546forwardTM Non-Cytosolic SEQ Template ID Start StopFrame Domain Topology D Type NO:

271 LI:1089871.9:2001MAY171547 1569forwardTM Transmembrane I

271 LI:1089871.9:2001MAYI71570 1575forwardTM Cytosolic 271 LI:1089871.9:2001MAY171576 1598forwardTM Transmembrane 271 LI:1089871.9:2001MAY171599 1617forwardTM Non-Cytosolic 271 LI:I089871.9:2001MAY171618 1639forwardTM Transmembrane I

271 LI:1089871.9:2001MAY171640 1753forwardTM Cytosolic 1 ~

271 LI:1089871.9:2001MAY171754 1773forwardTM Transmembrane 271 LI:1089871.9:2001MAY171774 1928forwardTM Non-Cytosolic 271 LI:1089871.9:2001MAY171 1219forwardTM Non-Cytosolic 271 LI:1089871.9:2001MAY171220 1242forwardTM Transmembrane 271 LI:1089871.9:2001MAY171243 1408forwardTM Cytosolic 271 LI:1089871.9:2001MAY171409 1426forwardTM Transmembrane 271 LI:I089871.9:2001MAY171427 1430forwardTM Non-Cytosolic 271 LI:1089871.9:2001MAY171431 1448forwardTM Transmembrane 271 LI:1089871.9:2001MAY171449 1454forwardTM Cytosolic 271 LI:1089871.9:2001MAY171455 1477forwardTM Transmembrane 271 LI:1089871.9:2001MAY171478 1481forwardTM Non-Cytosolic 271 LI:1089871.9:2001MAY171482 1504forwardTM Transmembrane 271 LI:1089871.9:2001MAY171505 1579forwardTM Cytosolic 271 LI:1089871.9:2001MAY171580 1602forwardTM Transmembrane 271 LI:1089871.9:2001MAY171603 1673forwardTM Non-Cytosolic 271 LI:1089871.9:2001MAY171674 1693forwardTM Transmembrane 271 LI:1089871.9:2001MAY171694 1713forwardTM Cytosolic 271 LI:1089871.9:2001MAY171714 1736forwardTM Transmembrane 271 LI:I089871.9:2001MAY171737 1759forwardTM Non-Cytosolic 271 LI:1089871.9:2001MAY171760 1782forwardTM Transmembrane 271 LI:1089871.9:2001MAY171783 1836forwardTM Cytosolic 271 LI:1089871.9:2001MAY171837 1859forwardTM Transmembrane 271 LI:1089871.9:2001MAY171860 ' forwardTM Non-Cytosolic 271 LI:1089871.9:2001MAY171863 1885forwardTM Transmembrane 271 LI:1089871.9:2001MAY171886 1928forwardTM Cytosolic 271 LI:1089871.9:2001MAY171 1382forwardTM Non-Cytosolic 271 LI:1089871.9:2001MAY171383 1405forwardTM Transmembrane 271 LI:1089871.9:2001MAY171406 1425forwardTM Cytosolic 271 LI:1089871.9:2001MAY171426 1448forwardTM Transmembrane 271 LI:1089871.9:2001MAY171449 1471forwardTM Non-Cytosolic 271 LI:1089871.9:2001MAY171472 1494forwardTM Transmembrane 271 LI:1089871.9:2001MAY171495 1571forwardTM Cytosolic 271 LI:1089871.9:2001MAY171572 1594forwardTM Transmembrane 271 LI:108987I.9:2001MAY171595 1669forwardTM Non-Cytosolic 271 LI:1089871.9:2001MAY171670 1687forwardTM Transmembrane 271 LI:1089871.9:2001MAY171688 1706forwardTM Cytosolic 271 LI:1089871.9:2001MAY171707 1729forwardTM Transmembrane 271 LI:1089871.9:2001MAY171730 1748forwardTM ~ Non-Cytosolic 271 LI:1089871.9:2001MAY171749 1771forwardTM Transmembrane 271 LI:1089871.9:2001MAY171772 1849forwardTM Cytosolic 271 LI:1089871.9:2001MAY171850 1872forwardTM Transmembrane 271 LI:1089871.9:2001MAY171873 1881forwardTM Non-Cytosolic 271 LI:1089871.9:2001MAY171882 1904forwardTM Transmembrane 271 LI:108987I.9:2001MAY171905 1927forwardTM Cytosolic 272 LI:110297.6:2001MAY171 63 forwardTM Cytosolic 272 LI:110297.6:2001MAY1764 86 forwardTM Transmembrane 272 LI:110297.6:2001MAY1787 127forwardTM Non-Cytosolic 272 LI:110297.6:2001MAY17128 145forwardTM Transmembrane SEQ Template ID Start StopFrame Domain Topology D NO: Type 272 LI:110297.6:2001MAY17146 156forwardTM Cytosolic 272 LI:110297.6:2001MAY17157 179forwardTM Transmembrane 272 LI:110297.6:2001MAY17180 293forwardTM Non-Cytosolic 272 LI:110297.6:2001MAY17294 311forwardTM Transmembrane 272 LI:110297.6:2001MAY17312 587forward~ TM Cytosolic 272 LI:l I0297.6:2001MAY17588 610forwardTM Transmembrane 272 LI:110297.6:2001MAY17611 684forwardTM Non-Cytosolic 272 LI:110297.6:2001MAY17685 702forwardTM Transmembrane 272 LI:110297.6:2001MAY17703 737forwardTM Cytosolic 272 LI:110297.6:2001MAY17738 760forwardTM Transmembrane 272 LI:110297.6:2001MAY17761 769forwardTM Non-Cytosolic 272 LI:110297.6:2001MAY17770 792forwardTM Transmembrane 272 LI:110297.6:2001MAY17793 801forwardTM Cytosolic 272 LI:110297.6:2001MAY171 735forwardTM Non-Cytosolic 272 LI:110297.6:2001MAY17736 758forwardTM Transmembrane 272 LI:110297.6:2001MAY17759 769forwardTM Cytosolic 272 LI:110297.6:2001MAY17770 792forwardTM Transmembrane 272 LI:110297.6:2001MAY17793 801forwardTM Non-Cytosolic 272 LI:110297.6:2001MAY171 11 forwardTM Cytosolic 272 LI:110297.6:2001MAY1712 29 forwardTM Transmembrane 272 LI:110297.6:2001MAY1730 604forwardTM Non-Cytosolic 272 LI:110297.6:2001MAY17605 627forwardTM Transmembrane 272 LI:110297.6:2001MAY17628 738forwardTM Cytosolic 272 LI:110297:6:2001MAY17739 761forwardTM Transmembrane 272 LI:110297.6:2001MAY17762 775forward,3TM Non-Cytosolic 272 LI:110297.6:2001MAY17776 798forwardTM Transmembrane 272 LI:110297.6:2001MAY17799 800forwardv3TM Cytosolic 273 LI:1143463.8:2001MAY171 1373forwardTM Non-Cytosolic f 273 LI:1143463.8:2001MAY171374 1396forwardTM Transmembrane 273 LI:1143463.8:2001MAY171397 1555forwardTM Cytosolic 273 LI:I 143463.8:2001MAY171556 1578forwardTM Transmembrane 273 LI:1143463.8:2001MAY171579 1648forwardTM Non-Cytosolic 273 LI:1143463.8:2001MAY171649 1668forwardTM Transmembrane 273 LI:1143463.8:2001MAY171669 1712forwardTM Cytosolic 273 LI:1143463.8:2001MAY171713 1735forwardTM Transmembrane 273 LI:1143463.8:2001MAY171736 1744forwardTM Non-Cytosolic 273 LI:1143463.8:2001MAY171745 1764forwardTM Transmembrane 273 LI:1143463.8:2001MAY171765 1835forwardTM Cytosolic 273 LI:I 143463.8:2001MAY171836 1858forwardTM Transmembrane 273 LI:1143463.8:2001MAY171859 1872forwardTM Non-Cytosolic 273 LI:1143463.8':2001MAY171873 1892forwardTM Transmembrane 273 LI:1143463.8:2001MAY171893 1912forwardTM Cytosolic 273 LI:1143463.8:2001MAY171913 1935forwardTM Transmembrane 273 LI:1143463.8:2001MAY171936 1946forwardTM Non-Cytosolic 273 LI:1 143463.8:2001MAY171 12 forwardTM Cytosolic 273 LI:1143463.8:2001MAY1713 3S forwardTM Transmembrane 273 LI:1 143463.8:2001MAY1736 721forwardTM Non-Cytosolic 273 LI:1143463.8:2001MAY17722 739forwardTM Transmembrane 273 LI:1143463.8:2001MAY17740 751forwardTM Cytosolic 273 LI:I 143463.8:2001MAY17752 774forwardTM Transmembrane 2 ~

273 LI:1143463.8:2001MAY17775 777forwardTM Non-Cytosolic 273 LI:1143463.8:2001MAY17778 797forwardTM Transmembrane 273 LI:1 143463.8:2001MAY17798 837forwardTM Cytosolic 273 LI:1 143463.8:ZOOIMAYI7838 860forwardTM Transmembrane TABLE

SEQ D NO: Template ID StartStopFrame Domain Topology Type 273 LI:1143463.8:2001MAY17861 1641forwardTM Non-Cytosolic 273 LI:1143463.8:2001MAY171642 1664forwardTM Transmembrane 273 LI:1143463.8:2001MAY171665 1690forwardTM Cytosolic 273 LI:1143463.8:2001MAY171691 1710forwardTM Transmembrane 273 LI:1143463.8:2001MAY171711 1738forwardTM Non-Cytosolic 273 LI:1143463.8:2001MAY171739 1761forwardTM Transmembrane 273 LI:1143463.8:2001MAY171762 1835forwardTM Cytosolic 273 LI:1143463.8:2001MAY171836 1858forwardTM Transmembrane 273 LI:1143463.8:2001MAY171859 1877forwardTM Non-Cytosolic 273 LI:1143463.8:2001MAY171878 1900forwardTM Transmembrane 2 ~

273 LI:1143463.8:2001MAY171901 1946forwardTM Cytosolic 273 LI:1143463.8:2001MAY171 1257forwardTM Non-Cytosolic 273 LI:1143463.8:2001MAY171258 1280forwardTM Transmembrane 273 LI:1143463.8:2001MAY171281 1381forwardTM Cytosolic 273 LI:1143463.8:2001MAY171382 1404forwardTM Transmembrane 273 LI:1143463.8:2001MAY171405 1744forwardTM Non-Cytosolic 273 LI:1143463.8:2001MAY171745 1767forwardTM Transmembrane 273 LI:1143463.8:2001MAY171768 1816forwardTM Cytosolic 273 LI:1143463.8:2001MAYI71817 1839forwardTM Transmembrane 273 LI:1143463.8:2001MAY171840 1848forwardTM Non-Cytosolic 273 LI:1143463.8:2001MAY171849 1871forwardTM Transmembrane 273 LI:1143463.8:2001MAY171872 1877forwardTM Cytosolic 273 LI:1143463.8:2001MAY171878 1897forwardTM Transmembrane 273 LI:I I43463.8:2001MAY171898 1911forwardTM Non-Cytosolic 273 LI:1143463.8:2001MAY171912 1931forwardTM Transmembrane 273 LI:1143463.8:2001MAY171932 1946forwardTM Cytosolic 3 ' 274 LI:1144466.1:2001MAY171 708 forwardTM Non-Cytosolic 274 LI:1144'466.1:200IMAY17709 728 forwardTM Transmembrane 274 LI:1144466.1:2001MAY17729 741 forwardTM Cytosolic 274 LI:1144466.1:2001MAY171 707 forwardTM Non-Cytosolic 274 LI:1144466.1:2001MAY17708 727 forwardTM Transmembrane 274 LI:1144466.1:2001MAY17728 740 forwardTM Cytosolic 275 LI:1170624.2:2001MAY171 354 forwardTM Cytosolic 275 LI:1170624.2:2001MAY17355 377 forwardTM Transmembrane 275 LI:1170624.2:2001MAY17378 378 forwardTM Non-Cytosolic 275 LI:1170624.2:2001MAYI71 356 forwardTM Non-Cytosolic 275 LI:1170624.2:2001MAY17357 374 forwardTM Transmembrane 275 LI:1170624.2:2001MAY17375 378 forwardTM Cytosolic 276 LI:1171602.39:2001MAY171 133 forwardTM Non-Cytosolic 276 LI:1171602.39:2001MAY17134 156 forwardTM Transmembrane 276 LI:I 171602.39:2001MAY17157 234 forwardTM Cytosolic 276 LI:1171602.39:2001MAY171 4 forwardTM Cytosolic 276 LI:1171602.39:2001MAY175 22 forwardTM Transmembrane 276 LI:1171602.39:2001MAY1723 36 forwardTM Non-Cytosolic 276 LI:I 171602.39:2001MAY1737 59 forwardTM Transmembrane 276 LI:1171602.39:2001MAY1760 234 forwardTM Cytosolic 277 LI:1182361.3:2001MAY171 33 forwardTM Cytosolic 277 LI:1182361.3:2001MAY1734 56 forwardTM Transmembrane 277 LI:I 18236I.3:2001MAY1757 245 forwardTM Non-Cytosolic 278 LI:1188194.15:2001MAY171 542 forwardTM Non-Cytosolic 278 LI:I 188194.15:2001MAY17543 565 forwardTM Transmembrane 278 LI:1188194.15:2001MAY17566 585 forwardTM Cytosolic 278 LI:1 188194.15:2001MAY17586 608 forwardTM Transmembrane 278 LI:1 188194.I5:2001MAY17609 640 forwardTM Non-Cytosolic SEQ D NO: Template ID StartStopFrame Domain Topology Type 278 LI:1188194.15:2001MAY17641 659forwardTM Transmembrane 278 LI:1188194.15:2001MAY17660 662forwardTM Cytosolic 278 LI:1188194.15:2001MAY171 538forwardTM Non-Cytosolic 278 LI:1188194.15:2001MAY17539 561forwardTM Transmembrane 278 LI:1188194.15:2001MAY17562 634forwardTM Cytosolic 278 LI:1188194.15:2001MAY17635 657forwardTM Transmembrane 278 LI:1188194.15:2001MAY17658 662forwardTM Non-Cytosolic 279 LI:1189195.7:2001MAY171 426forwardTM Non-Cytosolic 279 LI:1189195.7:2001MAY17427 445forwardTM Transmembrane 279 LI:1189195.7:2001MAY17446 457forwardTM Cytosolic 279 LI:1189195.7:2001MAY17458 480forwardTM Transmembrane 279 LI:1189195.7:2001MAY17481 521forwardTM Non-Cytosolic 279 LI:1189195.7:2001MAY17522 539forwardTM Transmembrane 279 LI:1189195.7:2001MAY17540 567forwardTM Cytosolic 279 LI:1189195.7:2001MAY17568 590forwardTM Transmembrane 279 LI:1189195.7:2001MAY17591 661forwardTM Non-Cytosolic 279 LI:1189195.7:2001MAY171 283forwardTM Non-Cytosolic 279 LI:1189195.7:2001MAY17284 306forwardTM Transmembrane 279 LI:1189195.7:2001MAY17307 380forwardTM Cytosolic 279 LI:1189195.7:2001MAY17381 403forwardTM Transmembrane .

279 LI:l 189195.7:2001MAY17404 422forwardTM Non-Cytosolic 279 LI:1189195.7:2001MAY17423 445forwardTM Transmembrane 279 LI:1189195.7:2001MAY17446 457forwardTM Cytosolic 279 LI:1189195.7:2001MAY17458 480forwardTM Transmembrane 279 LI:1189195.7:2001MAY17481 489forwardTM Non-Cytosolic 279 LI:1189195.7:2001MAY17490 ' forwardTM' Transmembrane 279 LI:1189195.7:2001MAY17510 521forwardTM ~ Cytosolic 279 LI:1189195.7:2001MAY17522 539forwardTM Transmemlirane 279 LI:1189195.7:2001MAY17540 573forwardTM Non-Cytosolic !

279 LI:1189195.7:2001MAY17574 596forwardTM Transmembrane 279 LI:1189195.7:2001MAY17597 602forwardTM Cytosolic 279 LI:1189195.7:2001MAY17603 625forwardTM Transmembrane 279 LI:1189195.7:2001MAY17626 661forwardTM Non-Cytosolic 279 LI:1189195.7:2001MAY171 67 forwardTM Cytosolic 279 LI:1189195.7:2001MAY1768 90 forwardTM Transmembrane 279 LI:l 189195.7:2001MAY1791 109forwardTM Non-Cytosolic 279 LI:1189195.7:2001MAY17110 132forwardTM Transmembrane 279 LI:1189195.7:2001MAY17133 270forwardTM Cytosolic 279 LI:1189195.7:2001MAY17271 293forwardTM Transmembrane 279 LI:1189195.7:2001MAY17294 359forwardTM Non-Cytosolic 279 LI:1189195.7:2001MAY17360 382forwardTM Transmembrane 279 LI:1189195.7:2001MAY17383 388forwardTM Cytosolic 279 LI:1189195.7:2001MAY17389 411forwardTM Transmembrane 279 LI:1189195.7:2001MAY17412 458forwardTM Non-Cytosolic 279 LI:1189195.7:2001MAY17459 481forwardTM Transmembrane 279 LI:1189195.7:2001MAY17482 517forwardTM Cytosolic 279 LI:1189195.7:2001MAY17518 537forwardTM Transmembrane 279 LI:1189195.7:2001MAY17538 660forwardTM Non-Cytosolic 280 LI:1190092.13:2001MAY171 127forwardTM Non-Cytosolic ' 280 LI:1190092.13:2001MAY17128 150forwardTM Transmembrane 280 LI:1190092.13:2001MAY17151 162forwardTM Cytosolic 280 LI:1190092.13:2001MAY171 162forwardTM Cytosolic 281 LI:1190318.4:2001MAY171 328forwardTM Non-Cytosolic 281 LI:1190318.4:2001MAY17329 351forwardTM Transmembrane SEQ D Template ID StartStopFrame Domain Topology NO: Type 281 LI:1190318.4:2001MAY17352 375 forwardTM Cytosolic 282 LI:144233.1:2001MAY171 20 forwardTM Cytosolic 282 LI:144233.1:2001MAY1721 43 forwardTM Transmembrane 282 LI:144233.1:200IMAYI744 241 forwardTM Non-Cytosolic 283 LI:154608.1:2001MAY1 246 forwardTM Non-Cytosolic 283 LI:154608.1:2001MAY17247 269 forwardTM Transmembrane 283 LI:154608.1:2001MAY17270 307 forwardTM Cytosolic 283 LI:154608.1:2001MAY171 40 forwardTM Cytosolic 283 LI:154608.1:2001MAY1741 63 forwardTM Transmembrane 283 ' LI:154608.1:2001MAY1764 I96 forwardTM Non-CytosoIic 283 LI:154608.1:2001MAY17197 219 forwardTM Transmembrane 283 LI:154608.1:2001MAY17220 307 forwardTM Cytosolic 283 LI:154608.1:2001MAY171 203 forwardTM Non-Cytosolic 283 LI:154608.1:2001MAY17204 226 forwardTM Transmembrane 283 LI:154608.1:2001MAY17227 245 forwardTM Cytosolic 283 LI:154608.I:2001MAY17246 268 forwardTM Transmembrane 283 LI:154608.1:2001MAY17269 306 forwardTM Non-Cytosolic 284 LI:170101.1:2001MAY17I 99 forwardTM Cytosolic 284 LI:170101.1:2001MAY17100 122 forwardTM Transmembrane 284 LI:170101.1:2001MAY17123 386 forwardTM Non-Cytosolic 284 LI:170101.1:2001MAY171 35 forwardTM Non-Cytosolic 284 LI:17010I.1:2001MAY1736 58 forwardTM Transmembrane 284 LI:170101.I:2001MAY1759 99 forwardTM Cytosolic 284 ,LI:170101.1:2001MAY17100 122 forwardTM Transmembrane 284 LI:170101.1:2001MAY17123 136 forwardTM Non-Cytosolic 284 LI:170101.1:2001MAY17.137 1.56forwardTM Transmembrane 284 LI:170101.1:2001MAY17~ 386 forwardTM Cytosolic 284 LI:170IOL1:2001MAY171 81 forwardTM Cytosolic 284 LI:170101.1:2001MAY17:82 101 forwardTM Transmembrane 284 LI:170101.1:2001MAY17102 110 forwardTM Non-Cytosolic 284 LI:170101.1:2001MAY17111 133 forwardTM Transmembrane 284 LI:170101.1:2001MAY17134 139 forwardTM Cytosolic 284 LI:170101.1:2001MAY17140 157 forwardTM Transmembrane 284 LI:170101.I:200IMAY17158 386 forwardTM Non-Cytosolic 285 LI:180043.1:2001MAY171 4 forwardTM Cytosolic 285 LI:180043.1:2001MAY175 27 forwardTM Transmembrane 285 LI:180043.1:2001MAY1728 46 forwardTM Non-Cytosolic 285 LI:180043.1:200IMAY1747 69 forwardTM Transmembrane 285 LI:180043.I:200IMAYI770 238 forwardTM Cytosolic I

285 LI:180043.1:200IMAY17239 261 forwardTM Transmembrane 285 LI:180043.1:2001MAY17262 373 forwardTM Non-Cytosolic 285 LI:180043.1:2001MAYI71 208 forwardTM Non-Cytosolic 285 LI:180043.1:2001MAY17209 228 forwardTM Transmembrane 285 LI:180043.1:2001MAY17229 373 forwardTM Cytosolic 286 LI:193050.1:2001MAY171 142 forwardTM Non-Cytosolic 286 LI:193050.1:2001MAY17143 162 forwardTM Transmembrane 286 LI:193050.1:2001MAY17163 339 forwardTM Cytosolic 286 LI:193050.1:2001MAY17340 358 forwardTM Transmembrane 286 LI:193050.1:2001MAY17359 777 forwardTM Non-Cytosolic 286 LI:193050.1:2001MAY171 182 forwardTM Non-Cytosolic 286 LI:193050.1:2001MAY17183 205 forwardTM Transmembrane 286 LI:193050.1:200IMAYI7206 247 forwardTM Cytosolic 286 LI:193050.1:2001MAY17248 2T0 forwardTM Transmembrane 286 LI:193050.1:2001MAYI7271 329 forwardTM Non-Cytosolic TABLE

SEQ Template ID Start StopFrame Domain Topology D Type NO:

286 LI:193050.I:2001MAYI7330 352forwardTM Transmembrane 286 LI:193050.1:2001MAY17353 482forwardTM Cytosolic 286 LI:193050.1:2001MAY17483 505forwardTM Transmembrane 286 LI:193050.1:2001MAY17S06 536forwardTM Non-Cytosolic 286 LI:193050.1:2001MAY17537 559forwardTM Transmembrane 286 LI:193050.1:2001MAY17560 684forwardTM Cytosolic 286 LI:193050.1:2001MAY17685 704forwardTM Transmembrane 286 LI:193050.1:2001MAY17705 734forwardTM Non-Cytosolic 286 LI:193050.1:2001MAY17735 757forwardTM Transmembrane 286 LI:193050.1:2001MAY17758 777forwardTM Cytosolic 286 LI:193050.1:2001MAY171 144forwardTM Cytosolic 286 LI:193050.1:2001MAY17145 167forwardTM Transmembrane 286 LI:193050.1:2001MAY17168 181forwardTM , Non-Cytosolic 286 LI:193050.1:2001MAY17182 204forwardTM Transmembrane 286 LI:193050.I:2001MAY17205 255forwardTM Cytosolic 286 LI:193050.1:2001MAY17256 278forwardTM Transmembrane 286 LI:193050.1:2001MAY17279 327forwardTM Non-Cytosolic 286 LI:193050.1:2001MAY17328 350forwardTM Transmembrane 286 LI:193050.1:2001MAY17351 419forwardTM Cytosolic 286 LI:193050.1:2001MAY17420 439forwardTM Transmembrane 286 LI:193050.1:2001MAY17440 776forwardTM Non-Cytosolic 287 LI:197477.31:2001MAY171 447forwardTM Non-Cytosolic 287 LI:197477.31:2001MAY17448 470forwardTM Transmembrane 287 LI:197477.31:2001MAY17471 500forwardTM Cytosolic 287 LI:197477.31:2001MAY17501 523forwardTM Transmembrane 287 LI:197477.31:2001MAY17524 ,532forwardTM Non-Cytosolic 287 LI:197477.31:2001MAY17533 550forwardTM Transmembrane 1 .

287 LI:I97477.31:2001MAY17'551 655forwardTM Cytosolic 288 LI:199639.I2:2001MAY171 266forwardTM Non-Cytosolic 288 LI:199639.12:2001MAY17267 289forwardTM Transmembrane 288 LI:199639.12:2001MAY17290 334forwardTM Cytosolic 288 LI:199639.12:2001MAY1733S 3S7forwardTM Transmembrane 288 LI:199639.12:2001MAY17358 360forwardTM Non-Cytosolic 288 LI:199639.12:2001MAY17361 383forwardTM Transmembrane 288 LI:199639.12:2001MAY17384 509forwardTM Cytosolic 288 LI:199639.12:2001MAY17S10 532forwardTM Transmembrane 288 LI:199639.12:2001MAY17533 556forwardTM Non-Cytosolic I

288 LI:199639.12:2001MAY17557 579forwardTM Transmembrane 288 LI:199639.12:2001MAY17S80 585forwardTM Cytosolic 288 LI:199639.12:2001MAY17586 608forwardTM Transmembrane 288 LI:199639.I2:200IMAYI7609 798forwardTM Non-Cytosolic 288 LI:199639.12:2001MAY171 252forwardTM Cytosolic 288 LI:199639.12:2001MAY17253 275forwardTM Transmembrane 288 LI:199639.12:2001MAY17276 798forwardTM Non-Cytosolic 289 LI:200058.6:2001MAY171 101forwardTM Cytosolic I

289 LI:200058.6:2001MAY17102 124forwardTM Transmembrane 289 LI:200058.6:2001MAY17125 546forwardTM Non-Cytosolic 289 LI:200058.6:2001MAY171 402forwardTM Non-Cytosolic 289 LI:200058.6:2001MAYI7403 422forwardTM Transmembrane 289 LI:200058.6:200IMAYI7423 434forwardTM Cytosolic 289 LI:200058.6:2001MAY17435 454forwardTM Transmembrane 289 LI:200058.6:2001MAY17455 468forwardTM Non-Cytosolic 289 LI:200058.6:2001MAY17469 491forwardTM Transmembrane 289 LI:200058.6:2001MAY17492 546forwardTM Cytosolic SEQ Template ID Start StopFrame Domain Topology D Type NO:

290 LI:201374.23:2001MAY171 177forwardTM Non-Cytosolic 290 LI:201374.23:2001MAY17178 200forwardTM Transmembrane 290 LI:201374.23:2001MAY17201 202forwardTM Cytosolic 290 LI:201374.23:2001MAY171 58 forwardTM Cytosolic 290 LI:201374.23:2001MAY1759 81 forwardTM Transmembrane 290 LI:201374.23:2001MAY1782 201forwardTM Non-Cytosolic 291 LI:201824.1:2001MAY171 488forwardTM Non-Cytosolic 291 LI:201824.1:2001MAY17489 511forwardTM Transmembrane 291 LI:201824.1:2001MAY17512 713forwardTM Cytosolic 291 LI:201824.1:2001MAY17714 736forwardTM Transmembrane 291 LI:201824.1:2001MAY17737 804forwardTM Non-Cytosolic 291 LI:201824.1:2001MAY17805 824forwardTM Transmembrane 291 LI:201824.1:2001MAY17825 836forwardTM Cytosolic 291 LI:201824.1:2001MAY17837 856forwardTM Transmembrane 291 LI:201824.1:2001MAY17857 870forwardTM Non-Cytosolic 291 LI:201824.1:2001MAY17871 893forwardTM Transmembrane 291 LI:201824.1:2001MAY17894 1218forwardTM Cytosolic 291 LI:201824.1:2001MAY17' 12191249forwardTM Transmembrane 291 LI:201824.1:2001MAY171250 1253forwardTM Non-Cytosolic 291 LI:201824.1:2001MAY171 143forwardTM Cytosolic 291 LI:201824.1:2001MAY17144 166forwardTM Transmembrane 291 LI:201824.1:2001MAY17167 199forwardTM Non-Cytosolic 291 LI:201824.1:2001MAY17200 219forwardTM Transmembrane 291 LI:201824.1:2001MAY17220 231forwardTM Cytosolic 291 LI:201824.1:2001MAY17232 254forwardTM Transmembrane ' 3 291 LI:201824.1:2001MAY17' 255 500forwardTM Non-Cytosolic ' 3 291 LI:201824.1:2001MAY17501 523forwardTM Transmembrane 29I LI:20I824.1:2001MAY17''524 529forwardTM Cytosolic ' . 3 291 LI:201824.1:2001MAY17'530 549forwardTM Transmembrane 291 LI:201824.1:2001MAY17550 575forwardTM Non-Cytosolic 291 LI:201824.1:2001MAY17576 598forwardTM Transmembrane 291 LI:201824.1:2001MAY17599 692forwardTM Cytosolic 291 LI:201824.1:2001MAY17693 715forwardTM Transmembrane 291 LI:201824.1:2001MAY17716 729forwardTM Non-Cytosolic 291 LI:201824.1:2001MAY17730 752forwardTM Transmembrane 291 LI:201824.1:2001MAY17753 860forwardTM Cytosolic 291 LI:201824.1:2001MAY17861 883forwardTM Transmembrane 291 LI:201824.1:2001MAY17884 1226forwardTM Non-Cytosolic 291 LI:201824.1:2001MAY171227 1249forwardTM Transmembrane 291 LI:201824.1:2001MAY171250 1253forwardTM Cytosolic 292 LI:201989.11:2001MAY171 406forwardTM Non-Cytosolic I

292 LI:201989.11:2001MAY17407 429forwardTM Transmembrane 292 LI:201989.11:2001MAY17430 443forwardTM Cytosolic 292 LI:201989.11:2001MAY171 400forwardTM Non-Cytosolic 292 LI:201989.11:200IMAYI740I 423forwardTM Transmembrane 292 LI:201989.11:2001MAY17424 442forwardTM Cytosolic 293 LI:2035159.1:2001MAY171 52 forwardTM Cytosolic 293 LI:2035159.1:2001MAY1753 72 forwardTM Transmembrane 293 LI:2035159.1:2001MAY1773 242forwardTM Non-Cytosolic 293 LI:2035159.I:2001MAYI71 216forwardTM Cytosolic 293 LI:2035159.1:2001MAY17217 236forwardTM Transmembrane 293 LI:2035159.1:2001MAY17237 242forwardTM Non-Cytosolic 294 LI:204818.10:2001MAY171 364forwardTM Non-Cytosolic 294 LI:204818.10:2001MAY17365 387forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D NO: Type 294 LI:2048I8.10:2001MAYI7388 482 forwardTM Cytosolic 294 LI:204818.10:2001MAY171 229 forwardTM Non-Cytosolic 294 LI:204818.10:2001MAY17230 252 forwardTM Transmembrane 294 LI:204818.10:2001MAY17253 365 forwardTM Cytosolic 294 LI:2048I8.10:2001MAY17366 388 forward. TM Transmembrane 294 LI:204818.10:2001MAY17389 481 forwardTM Non-Cytosolic 295 LI:2048337.1:2001MAY171 611 forwardTM Non-Cytosolic 295 LI:2048337.1:2001MAY17612 634 forwardTM Transmembrane 295 LI:2048337.1:2001MAY17635 658 forwardTM Cytosolic 295 LI:2048337.1:2001MAY17659 681 forwardTM Transmembrane 295 LI:2048337.1:2001MAY17682 709 forwardTM Non-Cytosolic 296 LI:2049697.4:2001MAYI7I 390 forwardTM Non-Cytosolic 296 LI:2049697.4:2001MAY17391 413 forwardTM Transmembrane 296 LI:2049697.4:2001MAY17414 698 forwardTM Cytosolic 297 LI:2050808.19:2001MAY171 105 forwardTM Non-Cytosolic 2 ~

297 LI:2050808.19:2001MAY17106 128 forward2TM Transmembrane 297 LI:2050808.19:2001MAY17129 134 forwardTM Cytosolic 297 LI:2050808.19:2001MAY17135 157 forwardTM Transmembrane 297 LI:2050808.19:2001MAY17158 176 forwardTM Non-Cytosolic 297 LI:2050808.19:2001MAY17177 199 forwardTM Transmembrane 297 LI:2050808.19:2001MAY17200 412 forwardTM Cytosolic 298 LI:209773.25:2001MAY171 4 forwardTM Cytosolic 298 LI:209773.25:2001MAY175 27 forwardTM Transmembrane 298 LI:209773.25:2001MAY1728. 363 forwardTM Non-Cytosolic , 1 298 LI:209773.25:2001MAY171 6 forwardTM Cytosolic 298 LI:209773.25:2001MAY177 .29~forwardTM Transmembrane 298 LI:209773.25:2001.MAY1.730 362 forwardTM Non-Cytosolic 3 .

299 LI:2117881.32:2001MAY171 177 forwardTM Non-Cytosolic ' 1 299 LI:2117881.32:2001MAY17178 200 forwardTM Transmembrane . 1 299 LI:2117881.32:2001MAY17201 386 forwardTM Cytasolic 299 LI:2117881.32:2001MAY17387 406 forwardTM Transmembrane 299 LI:2117881.32:2001MAY17407 422 forwardTM Non-Cytosolic 299 LI:2117881.32:2001MAY171 288 forwardTM Cytosolic 299 LI:2117881.32:2001MAY17289 311 forwardTM Transmembrane 299 LI:2117881.32:2001MAY17312 325 forwardTM Non-Cytosolic 299 LI:21 I7881.32:2001MAYI7326 348 forwardTM Transmembrane 299 LI:2117881.32:2001MAY17349 422 forwardTM Cytosolic 299 LI:2117881.32:2001MAY171 384 forwardTM Non-Cytosolic 299 LI:211788I.32:2001MAY17385 404 forwardTM Transmembrane 299 LI:2117881.32:2001MAY17405 422 forwardTM Cytosolic 300 LI:2118140.9:2001MAY171 446 forwardTM Non-Cytosolic 300 LI:2118140.9:2001MAY17447 469 forwardTM Transmembrane 300 LI:2118140.9:200IMAY17470 SIO forwardTM Cytosolic 300 LI:2118140.9:2001MAY17511 533 forwardTM Transmembrane 300 LI:2118140.9:2001MAY17534 566 forwardTM Non-Cytosolic 300 LI:2118140.9:2001MAY171 179 forwardTM Non-Cytosolic 300 LI:2118140.9:2001MAY17180 202 forwardTM Transmembrane 300 LI:2118140.9:2001MAY17203 411 forwardTM Cytosolic 300 LI:2118140.9:2001MAY17412 434 forwardTM Transmembrane 300 LI:2118140.9:2001MAY17435 443 forwardTM Non-Cytosolic 300 LI:21 I 8140.9:2001MAY17444 466 forwardTM Transmembrane 300 LI:2118140.9:2001MAY17467 565 forwardTM Cytosolic 300 LI:2118140.9:2001MAY171 201 forwardTM Cytosolic 300 LI:2118140.9:2001MAY17202 219 forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D Type NO:

300 LI:2118140.9:2001MAY17220 233 forwardTM Non-Cytosolic 300 LI:2118140.9:2001MAY17234 2S6 forwardTM Transmembrane 300 LI:2118140.9:2001MAY172S7 296 forwardTM Cytosolic 300 LI:2118140.9:2001MAY17297 319 forwardTM Transmembrane 300 LI:2118140.9:2001MAY17320 442 forwardTM Non-Cytosolic 300 LI:2118140.9:2001MAY17443 46S forwardTM Transmembrane 300 LI:2118140.9:2001MAY17466 S6S forwardTM Cytosolic 301 LI:2118151.15:2001MAY171 45 forwardTM Cytosolic 301 LI:21181S1.1S:2001MAY1746 68 forwardTM Transmembrane 301 LI:21181S1.1S:2001MAY1769 82 forwardTM Non-Cytosolic 301 LI:21181S1.1S:2001MAY1783 102 forwardTM Transmembrane 301 LI:21181S1.1S:2001MAY17103 360 forwardTM Cytosolic 301 LI:21181S1.1S:2001MAY17361 383 forwardTM Transmembrane 301 LI:21181S1.1S:2001MAY17384 409 forwardTM Non-Cytosolic 301 LI:21181S1.1S:2001MAY17410 429 forwardTM Transmembrane 301 LI:21181S1.1S:2001MAY17430 441 forwardTM Cytosolic 301 LI:21181S1.1S:2001MAY17442 464 forwardTM Transmembrane 301 LI:21181S1.1S:2001MAY1746S 467 forwardTM Non-Cytosolic 301 LI:21181S1.1S:2001MAY17468 490 forwardTM Transmembrane 301 LI:21181S1.1S:2001MAY17491 S09 forwardTM Cytosolic 30I LI:21181S1.I5:2001MAY17S10 529 forwardTM . Transmembrane 301 LI:21181S1.1S:2001MAY17530 S43 forwardTM Non-Cytosolic 301 LI:21181S1.1S:2001MAY17S44 S66 forwardTM Transmembrane 301 LI:21181S1.1S:2001MAY17567 7SS forwardTM Cytosolic 301 LI:21181S1.1S:2001MAY17756 778 forwardTM Transmembrane 301 LI:21181S1.1S:2001MAY17779 2202forwardTM Non-Cytosolic ', 2 301 LI:21181S1.1S:2001MAY17,22032225forward,2TM Transmembrane ' 301 LI:21181S1.1S:2001MAY17~22262231forward'2TM Cytosolic 301 LI:21181S1.1S:2001MAY1722322254forwardTM Transmembrane 301 LI:21181S1.1S:2001MAY1722SS2268forwardTM Non-Cytosolic 301 LI:21181S1.1S:2001MAY1722692291forwardTM Transmembrane 301 LI:21181S1.1S:2001MAY1722922293forwardTM Cytosolic 302 LI:2118324.9:2001MAY171 338 forwardTM Non-Cytosolic 302 LI:2118324.9:2001MAY17339 361 forwardTM Transmembrane 302 LI:2118324.9:2001MAYI7362 380 forwardTM Cytosolic I

302 LI:2118324.9:2001MAY17381 403 forwardTM Transmembrane 302 LI:2118324.9:2001MAY17404 412 forwardTM Non-Cytosolic 302 LI:2118324.9:2001MAY17413 43S forwardTM Transmembrane 302 LI:2118324.9:2001MAY17436 S80 forwardTM Cytosolic 302 LI:2118324.9:2001MAY17S81 603 forwardTM Transmembrane 302 LI:2118324.9:2001MAY17604 612 forwardTM Non-Cytosolic 302 LI:2118324.9:2001MAY17613 63S forwardTM Transmembrane 302 LI:2118324.9:2001MAY17636 836 forwardTM Cytosolic 302 LI:2118324.9:2001MAY17837 8SS forwardTM Transmembrane 302 LI:2118324.9:2001MAY178S6'1153forwardTM Non-Cytosolic 302 LI:2118324.9:2001MAY1711541176forwardTM Transmembrane 302 LI:2118324.9:2001MAY1711771200forwardTM Cytosolic 302 LI:2118324.9:2001MAY1712011223forwardTM Transmembrane 302 LI:2118324.9:2001MAY1712241242forwardTM Non-Cytosolic 302 LI:2118324.9:2001MAY1712431265forwardTM Transmembrane 302 LI:2118324.9:2001MAY1712661518forwardTM Cytosolic 302 LI:2118324.9:2001MAY17IS191541forwardTM Transmembrane 302 LI:2118324.9:2001MAY1715421578forwardTM Non-Cytosolic 302 LI:2118324.9:2001MAY171 4 ~ forwardTM Cytosolic SEQ Template ID StartStopFrame Domain Topology D NO: Type 302 LI:2118324.9:2001MAY175 27 forwardTM Transmembrane 302 LI:2118324.9:2001MAY1728 334forwardTM Non-Cytosolic 302 LI:2118324.9:2001MAY17335 357forwardTM Transmembrane 302 LI:2118324.9:2001MAY17358 392forwardTM Cytosolic 302 LI:2118324.9:2001MAY17393 415forwardTM Transmembrane 302 LI:2118324.9:2001MAY17416 491forwardTM Non-Cytosolic 302 LI:2118324.9:2001MAY17492 514forwardTM Transmembrane 302 LT:2118324.9:2001MAY17515 534forwardTM Cytosolic 302 LI:2118324.9:2001MAY17535 557forwardTM Transmembrane 302 LI:2118324.9:2001MAY17558 585forwardTM Non-Cytosolic 302 LI:2118324.9:2001MAY17586 608forwardTM Transmembrane 302 LI:2118324.9:2001MAY17609 614forwardTM Cytosolic 302 LI:2118324.9:2001MAY17615 637forwardTM Ti'ansmembrane 302 LI:2118324.9:2001MAY17638 1154forwardTM Non-Cytosolic 302 LI:2118324.9:2001MAY171155 1177forwardTM Transmembrane 302 LI:2118324.9:2001MAY171178 1224forwardTM Cytosolic 302 LI:2118324.9:2001MAY171225 1247forwardTM Transmembrane 302 LI:2118324.9:2001MAY17.1248 1578forwardTM Non-Cytosolic 302 LI:2118324.9:2001MAY171 152forwardTM Cytosolic 302 LI:2118324.9:2001MAY17153 175forwardTM Transmembrane 302 LI:2118324.9:2001MAY17176 206forwardTM Non-Cytosolic 302 LI:2118324.9:2001MAY17207 229forwardTM Transmembrane 302 LI:2118324.9:2001MAY17230 334forwardTM Cytosolic 302 LI:2118324.9:2001MAY17~ 357forwardTM Transmembrane 302 LI:2118324.9:2001MAY17358 410forwardTM Non-Cytosolic 302 'LI:2118324.9:2001MAY17. 433forwardTM Transmembrane ' 411' 3 302 LI:2118324.9:2001MAY17' 535forwardTM Cytosolic ' . 3.

302 LI:2118324.9:2001MAYI7'S36 S58forwardTM Transmembrane ' 3 302 LI:2118324.9:2001MAY17.559 592forwardTM Non-Cytosolic 302 LI:2118324.9:2001MAY17593 615forwardTM Transmembrane 302 LI:2118324.9:2001MAY17616 838forwardTM Cytosolic 302 LI:2118324.9:2001MAY17839 861forwardTM Transmembrane 302 LI:2118324.9:2001MAY17862 890forwardTM Non-Cytosolic 302 LI:2118324.9:2001MAY17891 910forwardTIvI Transmembrane 302 LI:2118324.9:2001MAY17911 1094forwardTM Cytosolic 302 LI:2118324.9:2001MAY171095 1117forwardTM Transmembrane 302 LI:2118324.9:2001MAY171118 I forwardTM Non-Cytosolic 302 LI:2118324.9:2001MAY171142 1164forwardTM Transmembrane 302 LI:2118324.9:2001MAY171165 1225forwardTM Cytosolic 302 LI:2118324.9:2001MAY171226 1248forwardTM Transmembrane 302 LI:2118324.9:2001MAY171249 1267forwardTM Non-Cytosolic 302 LI:2118324.9:2001MAY171268 1290forwardTM Transmembrane 302 LI:2118324.9:2001MAY171291 1512forwardTM Cytosolic 302 LI:2118324.9:2001MAY171513 1535forwardTM Transmembrane 302 LI:2118324.9:2001MAY171536 1577forwardTM Non-Cytosolic 303 LI:2118368.12:2001MAYI71 50 forwardTM Non-Cytosolic 303 LI:2118368.12:2001MAY1751 73 forwardTM Transmembrane 303 LI:2118368.12:2001MAY1774 84 forwardTM Cytosolic 303 LI:2118368.12:2001MAY1785 107forwardTM Transmembrane 303 LI:2118368.12:2001MAY17108 121forwardTM Non-Cytosolic 303 LI:2118368.12:2001MAY17122 144forwardTM Transmembrane 303 LI:2118368.12:2001MAY17145 171forwardTM Cytosolic 303 LI:2118368.12:2001MAY17172 194forwardTM Transmembrane 303 LI:2118368.12:2001MAY17195 452forwardTM Non-Cytosolic SEQ Template ID StartStopFrame Domain Topology D Type NO:

303 LI:2118368.12:2001MAY171 53 forwardTM Cytosolic 303 LI:2118368.12:2001MAY1754 76 forwardTM Transmembrane 303 LI:2118368.12:2001MAY1777 452forwardTM Non-Cytosolic 304 LI:2119448.5:2001MAY171 220forwardTM Cytosolic 304 LI:2119448.5:2001MAY17221 243forwardTM Transmembrane 304 LI:2119448.5:2001MAY17244 262forwardTM Non-Cytosolic 304 LI:2119448.5:2001MAY17263 285forwardTM Transmembrane 304 LI:2119448.5:2001MAY17286 393forwardTM Cytosolic 304 LI:2119448.5:2001MAY17394 416forwardTM Transmembrane 304 LI:2119448.5:2001MAY17417 1120forwardTM Non-Cytosolic ' 3 305 LI:212023.7:2001MAY171 69 forwardTM Cytosolic 305 LI:212023.7:2001MAY1770 92 forwardTM Transmembrane 305 LI:212023.7:2001MAY1793 106forwardTM Non-Cytosolic 305 LI:212023.7:2001MAY17107 129forwardTM Transmembrane 305 LI:212023.7:2001MAY17130 140forwardTM Cytosolic 305 LI:212023.7:2001MAY17141 158forwardTM Transmembrane 305 LT:212023.7:2001MAY17159 172forwardTM Non-Cytosolic 305 LI:212023.7:2001MAY17173 195forwardTM Transmembrane 305 LI:212023.7:2001MAY17196 491forwardTM Cytosolic 306 LT:2120556.1:2001MAY171 99 forwardTM Cytosolic 306 LI:2120556.1:2001MAY17100 122forwardTM Transmembrane 306 LI:2120556.1:2001MAY17123 386forwardTM Non-Cytosolic 307 LI:2121577.3:2001MAY171 73 forwardTM Cytosolic 308 LI:2123395.11:2001MAY171 364.forwardTM Non-Cytosolic 308 LI:2123395.11:2001MAY17365 387forwardTM Transmembrane 308 LI:2123395.11:2001MAY17388 457forwardTM Cytosolic 308 LI:2123395.11:2001MAY17458 480forwardTM Transmembrane 308 LI:2123395.11:2001MAY17481 588forwardTM Non-Cytosolic 308 LI:2123395.11:2001MAY17589 611forwardTM Transmembrane 308 LI:2123395.11:2001MAY17612 707forwardTM Cytosolic 308 LI:2123395.11:2001MAY17708 730forwardTM Transmembrane 308 LI:2123395.11:2001MAY17731 775forwardTM Non-Cytosolic 308 LI:2123395.11:2001MAY17776 798forwardTM Transmembrane 308 LI:2123395.11:2001MAY17799 883forwardTM Cytosolic 308 LI:2123395.11:2001MAY171 535forwardTM Non-Cytosolic 308 LI:2123395.11:2001MAY17536 558forwardTM Transmembrane 308 LI:2123395.11:2001MAY17559 578forwardTM Cytosolic 308 LI:2123395.11:2001MAY17579 601forwardTM Transmembrane 308 LI:2123395.11:2001MAY17602 665forwardTM Non-Cytosolic 308 LI:2123395.11:2001MAY17666 688forwardTM Transmembrane 308 LI:2123395.11:2001MAY17689 707forwardTM Cytosolic 308 LI:2123395.11:2001MAY17708 730forwardTM Transmembrane 308 LI:2123395.11:2001MAY17731 749forwardTM Non-Cytosolic 308 LI:2123395.11:2001MAY17750 772forwardTM Transmembrane 308 LI:2123395.11:2001MAY17773 882forwardTM Cytosolic 308 LI:2123395.11:2001MAY171 369forwardTM Non-Cytosolic 308 LI:2123395.11:2001MAY17370 392forwardTM Transmembrane 308 LI:2123395.11:2001MAY17393 437forwardTM Cytosolic 308 LI:2123395.11:2001MAY17438 460forwardTM Transmembrane 308 LI:2123395.11:2001MAY17461 882forwardTM Non-Cytosolic 309 LI:2123452.9:2001MAY171 462forwardTM Non-Cytosolic 309 LI:2123452.9:2001MAY17463 485forwardTM Transmembrane 309 LI:2123452.9:2001MAY17486 497forwardTM Cytosolic 309 LI:2123452.9:2001MAY17498 520forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D NO: Type 309 LI:2123452.9:2001MAY17521 534 forwardTM Non-Cytosolic 309 LI:2123452.9:2001MAY17535 552 forwardTM Transmembrane 309 LI:2123452.9:2001MAY17553 556 forwardTM Cytosolic 309 LI:2123452.9:2001MAY17557 574 forwardTM Transmembrane 309 LI:2123452.9:2001MAY17575 583 forwardTM Non-Cytosolic 309 LI:2123452.9:2001MAY17584 606 forwardTM Transmembrane 309 LI:2123452.9:2001MAY17607 686 forwardTM Cytosolic 309 LI:2123452.9:2001MAY171 468 forwardTM Non-Cytosolic 309 LI:2123452.9:2001MAY17469 491 forwardTM Transmembrane 309 LI:2123452.9:2001MAY17492 551 forwardTM Cytosolic 309 LI:2123452.9:ZOOIMAYI7552 574 forwardTM Transmembrane 309 LI:2123452.9:2001MAY17575 583 forwardTM Non-Cytosolic 309 LI:2123452.9:2001MAY17584 606 forwardTM Transmembrane 309 LI:2123452.9:2001MAY17607 657 forwardTM Cytosolic 309 LI:2123452.9:2001MAY17658 680 forwardTM Transmembrane 309 LI:2123452.9:2001MAY17681 686 forwardTM Non-Cytosolic 309 LI:2123452.9:2001MAY171 389 forwardTM Non-Cytosolic 309 LI:2123452.9:2001MAY17390 408 forwardTM Transmembrane 309 LI:2123452.9:2001MAY17409 428 forwardTM Cytosolic 309 LI:2123452.9:200IMAY17429 448 forwardTM Transmembrane 309 LI:2123452.9:2001MAY17449 457 forwardTM Non-Cytosolic 309 LI:2123452.9:2001MAY17458 480 forwardTM Transmembrane 309 LI:2123452.9:2001MAY17481 484 forwardTM Cytosolic 309 LI:2123452.9:2001MAY17485 507 forwardTM Transmembrane 309 LI:2123452.9:2001MAY17508 685 forwardTM Non-Cytosolic 310 LI:2164109.1:2001MAY171 20 forwardTM Cytosolic 310 LI:2164109.1:2001MAY1721 43 forwardTM Transmembrane 310 LI:2164109.1:2001MAY1744 127 forwardTM . Non-Cytosolic 310 LI:2I64109.1:2001MAY17128 150 forwardTM . Transmembrane I

310 LI:2164109.1:2001MAY17151 154 forwardTM Cytosolic 310 LI:2164109.1:2001MAY171 12 forwardTM Cytosolic 310 LI:2164109.1:2001MAY1713 35 forwardTM Transmembrane 310 LI:2164109.1:2001MAY1736 153 forwardTM Non-Cytosolic 311. LI:2168320.1:2001MAY171 9 forwardTM Non-Cytosolic 311 LI2168320.1:2001MAY1710 32 forwardTM Transmembrane 311 LI:2168320.1:2001MAY1733 38 forwardTM Cytosolic 311 LI:2168320.1:2001MAY1739 61 forwardTM Transmembrane 311 LI:2168320.1:2001MAY1762 123 forwardTM Non-Cytosolic 311 LI:2168320.1:2001MAY17124 146 forwardTM Transmembrane 311 LI:2168320.1:2001MAY17147 172 forwardTM Cytosolic 311 LI:2168320.1:2001MAY171 9 forwardTM Non-Cytosolic 311 LI:2168320.1:2001MAY1710 32 forwardTM Transmembrane 311 LI:2168320.1:2001MAY1733 172 forwardTM Cytosolic 312 LI:2173577.1:2001MAY171 30 forwardTM Non-Cytosolic 312 LI:2173577.1:2001MAY1731 53 forward'TM Transmembrane 312 LI:2173577.1:2001MAY1754 65 forwardTM Cytosolic 312 LI:2173577.1:2001MAY1766 88 forwardTM Transmembrane , 1 312 LI:2173577.1:2001MAY1789 92 forwardTM Non-Cytosolic 312 LI:2173577.1:2001MAY1793 115 forwardTM Transmembrane 312 LI:2173577.1:2001MAY17116 194 forwardTM Cytosolic 312 LI:2173577.1:2001MAY17I 37 forwardTM Cytosolic 312 LI:2173577.1:2001MAY1738 57 forwardTM Transmembrane 312 LI:2173577.1:2001MAY1758 66 forwardTM Non-Cytosolic 312 LI:2173577.1:2001MAY1767 89 forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D NO: Type 312 LI:2173577.1:2001MAY1790 193forwardTM Cytosolic 312 LI:2173577.1:2001MAY171 43 forwardTM Cytosolic 312 LI:2173577.1:2001MAY1744 66 forwardTM Transmembrane 312 LI:2173577.1:2001MAY1767 75 forwardTM Non-Cytosolic 312 LI:2173577.1:2001MAY1776 98 forwardTM Transmembrane 312 LI:2173577.1:2001MAY1799 193forwardTM Cytosolic ' 3 313 LI:2179256.1:2001MAY171 41 forwardTM Cytosolic 313 LI:2179256.1:2001MAY1742 64 forwardTM Transmembrane 313 LI:2179256.1:2001MAY1765 210forwardTM Non-Cytosolic 314 LI:2180388.1:2001MAY171 118forwardTM Non-Cytosolic 314 LI:2180388.1:2001MAY17119 141forwardTM Transmembrane 314 LI:2180388.1:2001MAY17142 215forwardTM Cytosolic 315 LI:2199713.8:2001MAY171 553forwardTM Non-Cytosolic 315 LI:2199713.8:2001MAY17554 571forwardTM Transmembrane 315 LI:2199713.8:2001MAY17572 590forwardTM Cytosolic 316 LI:2200587.2:2001MAY171 4 forwardTM Cytosolic 316 LI:2200587.2:2001MAY175 27 forwardTM Transmembrane 316 LI:2200587.2:2001MAY1728 36 forwardTM Non-Cytosolic 316 LI:2200587.2:2001MAY1737 56 forwardTM Transmembrane 316 LI:2200587.2:2001MAY1757 62 forwardTM Cytosolic 316 LI:2200587.2:2001MAY1763 85 forwardTM Transmembrane 316 LI:2200587.2:2001MAY1786 88 forwardTM Non-Cytosolic 316 LI:2200587.2:2001MAY1789 111forwardTM Transmembrane 316 LI:2200587.2:2001MAY17112 119forwardTM Cytosolic 316 LI:2200587.2:2001MAY17120 142forwardTM Transmembrane 316 LI:2200587.2:2001MAY17143 146.forwardTM Non-Cytosolic '316 LI:2200587.2:2001MAY17147 169forwardTM: Transmembrane 316 LI:2200587.2:2001MAY17170 176forward' TM Cytosolic 1' 316 LI:2200587.2:2001MAY171 22 forwardTM Non-Cytosolic 316 LI:2200587.2:2001MAY1723 45 forwardTM Transmembrane 316 LI:2200587.2:2001MAY1746 53 forwardTM Cytosolic 316 LI:2200587.2:2001MAY1754 76 forwardTM Transmembrane 316 LI:2200587.2:2001MAY1777 90 forwardTM Non-Cytosolic 316 LI:2200587.2:2001MAY1791 113forwardTM Transmembrane 316 LI:2200587.2:2001MAY17114 125forwardTM Cytosolic 316 LI:2200587.2:2001MAY17126 148forwardTM Transmembrane 316 LI:2200587.2:2001MAY17149 176forwardTM Non-Cytosolic 316 LI:2200587.2:2001MAY171 14 forwardTM Non-Cytosolic 316 LI:2200587.2:2001MAY1715 37 forwardTM Transmembrane 316 LI:2200587.2:2001MAY1738 43 forwardTM Cytosolic 316 LI:2200587.2:2001MAY1744 63 forwardTM Transmembrane 316 LI:2200587.2:2001MAY1764 72 forwardTM Non-Cytosolic 316 LI:2200587.2:2001MAY1773' 95 forwardTM Transmembrane 316 LI:2200587.2:2001MAY1796 101forwardTM Cytosolic 316 LI:2200587.2:2001MAY17102 124forwardTM Transmembrane 316 LI:2200587.2:2001MAY17125 143forwardTM Non-Cytosolic 316 LI:2200587.2:2001MAY17144 166forwardTM Transmembrane 316 LI:2200587.2:2001MAY17167 176forwardTM Cytosolic 317 LI:2200761.12:2001MAY171 3 forwardTM Non-Cytosolic 317 LI:2200761.12:2001MAY174 26 forwardTM Transmembrane 317 LI:2200761.12:2001MAY1727 343forwardTM Cytosolic 317 LI:2200761.12:2001MAY17344 366forwardTM Transmembrane 317 LI:2200761.12:2001MAY17367 374forwardTM Non-Cytosolic 317 LI:2200761.12:2001MAY171 346forward~TM Non-Cytosolic SEQ D NO: Template ID Stan StopFrame Domain Topology Type 317 LI:2200761.12:2001MAY17347 369 forwardTM Transmembrane 317 LI:2200761.12:2001MAY17370 374 forwardTM Cytosolic 317 LI:2200761.12:2001MAY17I 299 forwardTM Non-Cytosolic 317 LI:2200761.12:2001MAY17300 322 forwardTM Transmembrane 317 LI:2200761.12:2001MAY17323 342 forward. TM Cytosolic 317 LI:2200761.12:2001MAY17343 365 forwardTM Transmembrane 317 LI:2200761.12:2001MAY17366 373 forwardTM Non-Cytosolic 318 LI:2203624.1:2001MAY171 139 forwardTM Cytosolic 318 LI:2203624.1:2001MAY17140 156 forwardTM Transmembrane 318 LI:2203624.1:2001MAY17157 226 forwardTM Non-Cytosolic 318 LI:2203624.1:2001MAY17227 249 forwardTM Transmembrane 318 LI:2203624.1:2001MAY17250 376 forwardTM Cytosolic 319 LI:220495.9:2001MAY171 40 forwardTM Non-Cytosolic 319 LI:220495.9:2001MAY174I 63 forwardTM Transmembrane 319 LI:220495.9:2001MAY1764 163 forwardTM Cytosolic 319 LI:220495.9:2001MAY17164 183 forwardTM Transmembrane 319 LI:220495.9:2001MAY17184 192 forwardTM Non-Cytosolic 319 LI:220495.9:2001MAY17193 210 forwardTM Transmembrane 319 LI:220495.9:2001MAY17211 247 forwardTM Cytosolic 319 LI:220495.9:2001MAY17248 270 forwardTM Transmembrane .

319 LI:220495.9:2001MAY17271 284 forwardTM Non-Cytosolic 319 LI:220495.9:2001MAY17285 307 forwardTM Transmembrane 319 LI:220495.9:2001MAY17308 451 forwardTM Cytosolic . 2 319 LI:220495.9:2001MAY17452 474 forwardTM Transmembrane 319 LI:220495.9:2001MAY17475 931 forwardTM Non-Cytosolic 319 LI:220495.9:2001MAY17.932 954 forward. TM Transmembrane 319 LI:220495.9:2001MAY17,955 973 forwardTM Cytosolic ' 319 LI:220495.9:2001MAY17974 996 forwardTM Transmembrane.

319 LI:220495.9:2001MAY17997 1034forwardTM . Non-Cytosolic 319 LI:220495.9:2001MAY171 25 forwardTM Non-Cytosolic 319 LI:220495.9:2001MAY1726 48 forwardTM Transmembrane 319 LI:220495.9:2001MAY1749 453 forwardTM Cytosolic 319 LI:220495.9:2001MAY17454 472 forwardTM Transmembrane 319 LI:220495.9:2001MAY17473 491 forwardTM Non-Cytosolic 319 LI:220495.9:2001MAY17492 514 forwardTM Transmembrane 319 LI:220495.9:2001MAY17515 574 forwardTM Cytosolic 319 LI:220495.9:2001MAY17575 597 forwardTM Transmembrane 319 LI:220495.9:2001MAY17598 606 forwardTM Non-Cytosolic 319 LI:220495.9:2001MAY17607 629 forwardTM Transmembrane 319 LI:220495.9:2001MAY17630 931 forwardTM Cytosolic 319 LI:220495.9:2001MAY17932 954 forwardTM Transmembrane 319 LI:220495.9:2001MAY17955 1033forwardTM Non-Cytosolic 320 LI:2205532.1:2001MAY171 28 forwardTM Non-Cytosolic 320 LI:2205532.1:2001MAY1729 51 forwardTM Transmembrane 320 . LI:2205532.1:2001MAY1752 70 forwardTM Cytosolic 320 LI:2205532.1:2001MAY177I 90 forwardTM Transmembrane I

320 LI:2205532.1:2001MAY1791 99 forwardTM Non-Cytosolic 320 LI:2205532.1:2001MAY17100 122 forwardTM Transmembrane 320 LI:2205532.1:2001MAY17123 155 forwardTM Cytosolic 320 LI:2205532.1:2001MAY17156 178 forwardTM Transmembrane 320 LI:2205532.1:2001MAY17179 210 forwardTM Non-Cytosolic 320 LI:2205532.1:2001MAY17211 230 forwardTM Transmembrane 320 LI:2205532.1:2001MAY17231 250 forwardTM Cytosolic 320 LI:2205532.1:2001MAY17251 273 forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D NO: Type 320 LI:2205532.1:2001MAY17274 367forwardTM Non-Cytosolic 320 LI:2205532.1:2001MAY17368 390forwardTM Transmembrane 320 LI:2205532.1:2001MAY17391 407forwardTM Cytosolic 320 LI:2205532.1:2001MAY171 30 forwardTM Cytosolic 320 LI:2205532.1:2001MAY1731 53 forward.2TM Transmembrane 320 LI:2205532.1:2001MAY1754 96 forwardTM Non-Cytosolic 320 LI:2205532.1:2001MAY1797 119forwardTM Transmembrane 320 LI:2205532.1:2001MAY17120 243forwardTM Cytosolic 320 LI:2205532.1:2001MAY17244 266forwardTM Transmembrane 320 LI:2205532.1:2001MAY17267 275forwardTM Non-Cytosolic 320 LI:2205532.I:2001MAYI7276 293forwardTM Transmembrane 320 LI:2205532.1:2001MAY17294 406forwardTM Cytosolic 320 LI:2205532.1:2001MAY171 35 forwardTM Cytosolic 320 LI:2205532.1:2001MAY1736 58 forwardTM Transmembrane 320 LI:2205532.1:2001MAY1759 82 forwardTM Non-Cytosolic 320 LI:2205532.1:2001MAY1783 102forwardTM Transmembrane 320 LI:2205532.1:2001MAY17103 106forwardTM Cytosolic 320 LI:2205532.1:2001MAY17107 129forwardTM Transmembrane 320 LI:2205532.1:2001MAY17130 148forwardTM Non-Cytosolic 320 LI:2205532.1:2001MAY17149 171forwardTM Transmembrane 320 'LI:2205532.1:2001MAY17172 244forwardTM Cytosolic 320 LI:2205532.1:2001MAY17245 267forwardTM Transmembrane 320 LI:2205532.1:2001MAY17268 406forwardTM Non-Cytosolic 321 LI:2206277.1:2001MAY171 246forwardTM Cytosolic 321 LI:2206277.1:2001MAY17247 269forwardTM Transmembrane 321 LI:2206277.1:2001MAY17270 283forwardTM Non-Cytosolic~
w 1 321 LI:2206277.1:2001MAY17' 306forwardTM Transmembrane w 284 1 321 LI:2206277.1:2001MAY17~ 367forwardTM Cytosolic ' 307 1 322 LI:2207765.8:2001MAY171 6 forwardTM Cytosolic 322 LI:2207765.8:2001MAY177 29 forwardT'M Transmembrane 322 LI:2207765.8:2001MAY1730 384forwardTM Non-Cytosolic 323 LI:2208404.4:2001MAY171 44 forwardTM Non-Cytosolic 323 LI:2208404.4:2001MAY1745 64 forwardTM Transmembrane 323 LI:2208404.4:2001MAY1765 114forwardTM Cytosolic 324 LI:2208715.3:2001MAY171 237forwardTM Cytosolic 325 LI:2208766.2:2001MAY171 28 forwardTM Non-Cytosolic 325 LI:2208766.2:2001MAY1729 48 forwardTM Transmembrane 325 LI:2208766.2:2001MAY1749 272forwardTM Cytosolic 325 LI:2208766.2:2001MAY17273 295forwardT'M Transmembrane 325 LI:2208766.2:2001MAY17296 309forwardTM Non-Cytosolic 325 LI:2208766.2:2001MAY17310 332forwardTM Transmembrane X25 LI:2208766.2:2001MAY17333 369forwardTM Cytosolic 325 LI:2208766.2:2001MAY17370 387forwardTM Transmembrane 325 LI:2208766.2:2001MAY17388 396forwardTM Non-Cytosolic 325 LI:2208766.2:2001MAY17397 419forwardTM Transmembrane 325 LI:2208766.2:2001MAY17420 535forwardTM Cytosolic 325 LI:2208766.2:2001MAY17536 558forwardTM Transmembrane 325 LI:2208766.2:2001MAY17559 577forwardTM Non-Cytosolic 325 LI:2208766.2:2001MAY17578 597forwardTM Transmembrane 325 LI:2208766.2:2001MAYI7598 731forwardTM Cytosolic 325 LI:2208766.2:2001MAY17732 751forwardTM Transmembrane 325 LI:2208766.2:2001MAY17752 779forwardTM Non-Cytosolic 325 LI:2208766.2:2001MAY17780 802forwardTM Transmembrane 325 LI:2208766.2:2001MAY17803 835forwardTM Cytosolic SEQ Template ID StartStopFrame Domain Topology D NO: Type 325 LI:2208766.2:2001MAY171 43 forwardTM Non-Cytosolic 325 LI:2208766.2:2001MAY1744 66 forwardTM Transmembrane 325 LI:2208766.2:2001MAY1767 78 forwardTM Cytosolic 325 LI:2208766.2:2001MAY1779 101forwardTM Transmembrane 325 LI:2208766.2:2001MAY17102 197forwardTM Non-Cytosolic 325 LI:2208766.2:2001MAY17198 220forwardTM Transmembrane 325 LI:2208766.2:2001MAY17221 272forwardTM Cytosolic 325 LI:2208766.2:2001MAY17273 295forwardTM Transmembrane 325 LT:2208766.2:2001MAY17296 309forwardTM Non-Cytosolic 325 LI:2208766.2:2001MAY17310 332forwardTM Transmembrane 325 LI:2208766.2:2001MAY17333 518forwardTM Cytosolic 325 LI:2208766.2:2001MAY17519 541forwardTM Transmembrane 325 LI:2208766.2:2001MAY17542 550forwardTM Non-Cytosolic 325 LI:2208766.2:2001MAY17551 573forwardTM Transmembrane 325 LI:2208766.2:2001MAY17574 690forwardTM Cytosolic 325 LI:2208766.2:2001MAY17691 713forwardTM Transmembrane 325 LI:2208766.2:2001MAY17714 727forwardTM Non-Cytosolic 325 LI:2208766.2:2001MAY17728 750forwardTM Transmembrane 325 LI:2208766.2:2001MAY17751 834forwardTM Cytosolic 325 LI:2208766.2:2001MAY171 267forwardTM Non-Cytosolic 325 LI:2208766.2:2001MAY17268 290forwardTM Transmembrane 325 LI:2208766.2:2001MAY17291 296forwardTM Cytosolic 325 LI:2208766.2:2001MAY17297 319forwardTM Transmembrane 325 LI:2208766.2:2001MAY17320 834forwardTM Non-Cytosolic .
3 .

326 LI:2209636.3:2001MAY171 154forwardTM Cytosolic 326 LI:2209636.3:2001MAY17155 177forwardTM Transmembrane 326 LI:2209636.3:2001MAY17178 207forwardTM Non-Cytosolic 326 LI:2209636.3:2001MAY17208' 230forwardTM Transmembrane ' 1 326 LI:2209636.3:2001MAY17231 375forwardTM Cytosolic 326 LI:2209636.3:2001MAY17376 395forwardTM Transmembrane 326 LI:2209636.3:2001MAY17396 443forwardTM Non-Cytosolic 326 LI:2209636.3:2001MAY17444 466forwardTM Transmembrane 326 LI:2209636.3:2001MAY17467 472forwardTM Cytosolic 326 LI:2209636.3:2001MAY17473 495forwardTM Transmembrane 326 LI:2209636.3:2001MAY17496 498forwardTM Non-Cytosolic 326 LI:2209636.3:2001MAY17499 521forwardTM Transmembrane 326 LI:2209636.3:2001MAY17522 527forwardTM Cytosolic 326 LI:2209636.3:2001MAY17528 550forwardTM Transmembrane 326 LI:2209636.3:2001MAY17551 616forwardTM Non-Cytosolic 326 LI:2209636.3:2001MAY171 20 forwardTM . Cytosolic 326 LI:2209636.3:2001MAY1721 43 forwardTM Transmembrane 326 LI:2209636.3:2001MAY1744 196forwardTM Non-Cytosolic 326 LI:2209636.3:2001MAY17197 219forwardTM Transmembrane 326 LI:2209636.3:2001MAY17220 319forwardTM Cytosolic 326 LI:2209636.3:2001MAY17320 342forwardTM Transmembrane 326 LI:2209636.3:2001MAY17343 425forwardTM Non-Cytosolic 326 LI:2209636.3:2001MAY17426 448forwardTM Transmembrane 326 LI:2209636.3:2001MAY17449 467forwardTM Cytosolic 326 LI:2209636.3:2001MAY17468 490forwardTM Transmembrane 326 LI:2209636.3:2001MAY17491 499forwardTM Non-Cytosolic 326 LI:2209636.3:2001MAY17500 522forwardTM Transmembrane 326 LI:2209636.3:2001MAY17523 616forwardTM Cytosolic 327 LI:221864.68:2001MAY171 183forwardTM Cytosolic 328 LI:229267.1:2001MAY171 294forwardTM Non-Cytosolic SEQ Template ID Start StopFrame Domain Topology D NO: Type 328 LI:229267.1:2001MAY17295 317forwardTM Transmembrane 328 LI:229267.1:2001MAY17318 570forwardTM Cytosolic 328 LI:229267.1:2001MAY17571 593forwardTM Transmembrane 328 LI:229267.1:2001MAY17594 927forwardTM Non-Cytosolic 329 LI:229648.2:2001MAY171 539forwardTM Non-Cytosolic 329 LI:229648.2:2001MAY17540 562forwardTM Transmembrane 329 LI:229648.2:2001MAY17563 751forwardTM Cytosolic 329 LI:229648.2:2001MAY17752 774forwardTM Transmembrane 329 LI:229648.2:2001MAY17775 779forwardTM Non-Cytosolic 329 LI:229648.2:2001MAY17780 802forwardTM Transmembrane ~ 2 329 LI:229648.2:2001MAY17803 814forwardTM Cytosolic 329 LI:229648.2:2001MAY17815 837forwardTM Transmembrane 329 LI:229648.2:2001MAY17838 846forwardTM Non-Cytosolic 329 LI:229648.2:2001MAY17847 869forwardTM Transmembrane 329 LI:229648.2:2001MAY17870 891forwardTM Cytosolic 329 LI:229648.2:2001MAY171 657forwardTM Non-Cytosolic 329 LI:229648.2:2001MAY17658 680forwardTM Transmembrane 329 LI:229648.2:2001MAY17681 755forwardTM Cytosolic 329 LI:229648.2:2001MAY17756 778forwardTM Transmembrane 329 LI:229648.2:2001MAY17779 833forwardTM Non-Cytosolic 329 LI:229648.2:2001MAY17834 856forwardTM Transmembrane 329 LI:229648.2:2001MAY17857 891forwardTM Cytosolic 330 LI:231016.1:2001MAY171 14 forwardTM Non-Cytosolic 330 LI:231016.1:2001MAY17~. 37 forwardTM Transmembrane 330 LI:231016.1:2001MAY1738 57 forwardTM Cytosolic 330 LI:231016.1:2001MAY17~ 58 80 forwardTM Transmembrane 330 LI:231016.1:2001MAY1781 84 forwardTM Non-Cytosolic 330 LI:231016.1:2001MAY17' 85 107forwardTM Transmembrane 330 LI:231016.1:2001MAY17108 201forwardTM Cytosolic 330 LI:231016.1:2001MAY17202 224forwardTM Transmembrane 330 LI:231016.1:2001MAY17225 360forwardTM Non-Cytosolic 331 LI:231140.5:2001MAY171 146forwardTM Non-Cytosolic 331 LI:231140.5:2001MAY17147 169forwardTM Transmembrane 331 LI:231140.5:2001MAY17170 223forwardTM Cytosolic 331 LI:231140.5:2001MAY17224 246forwardTM Transmembrane 331 LI:231140.5:2001MAY17247 250forwardTM Non-Cytosolic 331 LI:231140.5:2001MAY171 127forwardTM Cytosolic 331 LI:231140.5:2001MAY17128 150forwardTM Transmembrane 331 LI:231140.5:2001MAY17151 159forwardTM Non-Cytosolic 331 LI:231140.5:2001MAY17160 178forwardTM Transmembrane 331 LI:231140.5:2001MAY17179 249forwardTM Cytosolic 332 LI:231695.14:2001MAY171 I48forwardTM Non-Cytosolic 332 LI:231695.14:2001MAY17149 171forwardTM Transmembrane 332 LI:231695.14:2001MAY17172 212forwardTM Cytosolic 333 LI:232846.24:2001MAY171 1167forwardTM Non-Cytosolic 333 LI:232846.24:2001MAY171168 1187forwardTM Transmembrane 333 LI:232846.24:2001MAY171188 1193forwardTM Cytosolic 333 LI:232846.24:2001MAY171194 1216forwardTM Transmembrane 333 LI:232846.24:2001MAY171217 1848forwardTM Non-Cytosolic 333 LI:232846.24:2001MAY171 1311forwardTM Non-Cytosolic 333 LI:232846.24:2001MAY171312 1334forwardTM Transmembrane 333 LI:232846.24:2001MAY171335 1449forwardTM Cytosolic 333 LI:232846.24:2001MAY171450 1472forwardTM Transmembrane 333 LI:232846.24:2001MAY171473 1848forwardTM Non-Cytosolic SEQ Template ID StartStopFrame Domain Topology D NO: Type 333 LI:232846.24:2001MAY171 906forwardTM Non-Cytosolic 333 LI:232846.24:2001MAY17907 929forwardTM Transmembrane 333 LI:232846.24:2001MAY17930 1166forwardTM Cytosolic 333 LI:232846.24:2001MAY171167 1189forwardTM Transmembrane 333 LI:232846.24:2001MAY171190 1848forwardTM Non-Cytosolic ~ 3 334 LI:233411.11:2001MAY171 1003forwardTM Non-Cytosolic 334 LI:233411.11:2001MAY171004 1026forwardTM Transmembrane 334 LI:233411.11:2001MAY171027 lOSSforwardTM Cytosolic 334 LI:233411.11:2001MAY171056 1078forwardTM Transmembrane 334 LI:233411.11:2001MAY171079 1092forwardTM Non-Cytosolic . 334 LI:233411.11:2001MAY171093 1115forwardTM Transmembrane 334 LI:233411.11:2001MAY171116 1236forwardTM Cytosolic 334 LI:233411.11:2001MAY171 261forwardTM Non-Cytosolic 334 LI:233411.11:2001MAY17262 284forwardTM Transmembrane 334 LI:233411.11:2001MAY17285 360forwardTM Cytosolic 334 LI:233411.11:2001MAY17361 383forwardTM Transmembrane 334 LI:233411.11:2001MAY17384 1236forwardTM Non-Cytosolic ~ 2 334 LI:233411.11:2001MAY171 345forwardTM Non-Cytosolic 334 LI:233411.11:2001MAY17346 368forwardTM Transmembrane 334 LI:233411.11:2001MAY17369 374forwardTM CytosoIic 334 LI:233411.11:2001MAY17375 397forwardTM Transmembrane 334 LI:233411.11:2001MAY17398 887forwardTM Non-Cytosolic 334 LI:233411.11:2001MAY17888 910forwardTM Transmembrane 334 LI:233411.11:2001MAY17911 922forwardTM Cytosolic 334 LI:233411.11:2001MAY17923 945forwardTM Transmembrane 334 LI:233411.11:2001MAY17946 959forvdardTM Non-Cytosolic 334 LI:233411.11:2001MAY17960 982forwardTM Transmembrane ' 3 334 LI:233411.11:2001MAY17983 1050forwardTM Cytosolic 334 LI:233411.11:2001MAY17lOSl 1073forwardTM Transmembrane ~ 3 334 LI:233411.11:2001MAY171074 1092forwardTM Non-Cytosolic 334 LI:233411.11:2001MAY171093 1115forwardTM Transmembrane 334 LI:233411.11:2001MAY171116 1126forwardTM Cytosolic 334 LI:233411.11:2001MAY171127 1149forwardTM Transmembrane 334 LI:233411.11:2001MAY171150 1203forwardTM Non-Cytosolic 334 LI:233411.11:2001MAY171204 1223forwardTM Transmembrane 334 LI:233411.11:2001MAY171224 1235forwardTM Cytosolic 335 LI:233545.13:2001MAY171 506forwardTM Non-Cytosolic 335 LI:233545.13:2001MAY17S07 529forwardTM Transmembrane 335 LI:233545.13:2001MAY17530 630forwardTM Cytosolic 336 LI:234671.101:2001MAY171 103forwardTM Cytosolic 336 LI:234671.101:2001MAY17104 126forwardTM Transmembrane 336 LI:234671.101:2001MAY17127 418forwardTM Non-Cytosolic 336 LI:234671.101:2001MAY171 288forwardTM Non-Cytosolic 336 LI:234671.101:2001MAY17289 311forwardTM Transmembrane 336 LI:234671.101:2001MAY17312 323forwardTM Cytosolic 336 LI:234671.101:2001MAY17324 343forwardTM Transmembrane 336 LI:234671.101:2001344 352forwardTM Non-Cytosolic 336 LI:234671.101:2001MAYI73S3 37SforwardTM Transmembrane 336 LI:234671.101:2001MAY17376 418forwardTM Cytosolic 337 LI:236098.14:2001MAY171 34 forwardTM Cytosolic 337 LI:236098.14:2001MAY1735 57 forwardTM Transmembrane 337 LI:236098.14:2001MAY1758 71 forwardTM Non-Cytosolic I

337 LI:236098.14:2001MAY1772 91 forwardTM Transmembrane 337 LI:236098.14:2001MAY1792 97 forwardTM Cytosolic I

SEQ Template ID StartStopFrame Domain Topology D Type NO:

337 LI:236098.14:2001MAY1798 117 forwardTM Transmembrane 337 LI:236098.14:2001MAY17118 127 forwardTM Non-Cytosolic 337 LI:236098.14:2001MAY17128 150 forwardTM Transmembrane 337 LI:236098.14:2001MAY17151 520 forwardTM Cytosolic 337 LI:236098.14:2001MAY17521 543 forwardTM Transmembrane 337 LI:236098.14:2001MAY17544 562 forwardTM Non-Cytosolic 337 LI:236098.14:2001MAY17563 585 forwardTM Transmembrane 337 LI:236098.14:2001MAY17586' S91 forwardTM Cytosolic 337 LI:236098.14:2001MAY17592 614 forwardTM Transmembrane 337 LI:236098.14:2001MAY17615 628 forwardTM Non-Cytosolic 337 LI:236098.14:2001MAY17629 651 forwardTM Transmembrane 337 LI:236098.14:2001MAY17652 858 forwardTM Cytosolic 337 LI:236098.14:2001MAY17859 881 forwardTM Transmembrane 337 LI:236098.14:2001MAY17882 900 forwardTM Non-Cytosolic 337 LI:236098.14:2001MAY17901 923 forwardTM Transmembrane 337 LI:236098.14:2001MAY17924 976 forwardTM Cytosolic 337 LI:236098.14:2001MAY17977 999 forwardTM Transmembrane 337 LI:236098.14:2001MAY171000 1008forwardTM Non-Cytosolic 337 LI:236098.14:2001MAY171009 1031forwardTM Transmembrane 337 LI:236098.14:2001MAY171032 1051forwardTM Cytosolic 337 LI:236098.14:2001MAY171052 1074forwardTM Transmembrane 337 LI:236098.14:2001MAY171075 1088forwardTM Non-Cytosolic 337 LI:236098.14:2001MAY171089 1111forwardTM Transmembrane 337 LI:236098.14:2001MAY171112 1124forward, TM Cytosolic 337 LI:236098.14:2001MAY17. 19 forwardTM Cytosolic 337 LI:236098.14:2001MAY1720 39 forwardTM Transmembrane , 2 337 LI:236098.14:2001MAY1740 65 forwardTM Non-Cytosolic ~ 2 337 LI:236098.14:2001MAY1766 88 forward. TM Transmembrane 337 LI:236098.14:2001MAY1789 133 forwardTM Cytosolic 337 LI:236098.14:2001MAY17134 156 forwardTM Transmembrane 337 LI:236098.14:2001MAY17157 170 forwardTM Non-Cytosolic 337 LI:236098.14:2001MAY17171 188 forwardTM Transmembrane 337 LI:236098.14:2001MAY17189 215 forwardTM Cytosolic 337 LI:236098.14:'2001MAY17216 235 forwardTM Transmembrane 337 LI:236098.14:2001MAY17236 244 forwardTM Non-Cytosolic 337 LI:236098.14:2001MAY17245 267 forwardTM Transmembrane 337 LI:236098.14:2001MAY17268 518 forwardTM Cytosolic 337 LI:236098.14:2001MAY17519 541 forwardTM Transmembrane 337 LI:236098.14:2001MAY17542 550 forwardTM Non-Cytosolic 337 LI:236098.14:2001MAY17551 573 forwardTM Transmembrane 337 LI:236098.14:2001MAY17574 593 forwardTM Cytosolic 337 LI:236098.14:2001MAY17594 616 forwardTM Transmembrane 337 LI:236098.14:2001MAY17617 635 forwardTM Non-Cytosolic 337 LI:236098.14:2001MAY17636 658 forwardTM Transmembrane 337 LI:236098.14:2001MAY17659 799 forwardTM Cytosolic 337 LI:236098.14:2001MAY17800 822 forwardTM Transmembrane 337 LI:236098.14:2001MAY17823 1124forwardTM Non-Cytosolic 337 LI:236098.14:2001MAY171 66 forwardTM Cytosolic 337 LI:236098.14:2001MAY1767 89 forwardTM Transmembrane 337 LI:236098.14:2001MAY1790 159 forwardTM Non-Cytosolic 337 LI:236098.14:2001MAY17160 182 forwardTM Transmembrane 337 LI:236098.14:2001MAY17183 245 forwardTM Cytosolic 337 LI:236098.14:2001 246 268 forwardTM Transmembrane 337 LI:236098.14:2001MAY17269 389 forward'TM Non-Cytosolic SEQ Template ID Start StopFrame Domain Topology D NO: Type 337 LI:236098.14:2001MAY17390 412forwardTM Transmembrane 337 LI:236098.14:2001MAY17413 S28forwardTM Cytosolic 337 LI:236098.14:2001MAY17529 551forwardTM Transmembrane 337 LI:236098.14:2001MAY17552 565forwardTM Non-Cytosolic 337 LI:236098.14:2001MAY17566 583forward~ TM Transmembrane 337 LI:236098.14:2001MAY17584 587forwardTM Cytosolic 337 LI:236098.14:2001MAY17588 610forwardTM Transmembrane 337 LI:236098.14:2001MAY17611 1124forwardTM Non-Cytosolic 338 LI:236196.15:2001MAY171 267forwardTM Cytosolic 338 LI:236196.15:2001MAY17268 287forwardTM Transmembrane 338 LI:236196.15:2001MAY17288 301forwardTM Non-Cytosolic 338 LI:236196.15:2001MAY17302 324forwardTM Transmembrane 338 LI:236196.15:2001MAY17325 328forwardTM Cytosolic 338 LI:236196.15:2001MAY17329 348forwardTM Transmembrane 338 LI:236196.15:2001MAY17349 S00forwardTM Non-Cytosolic 338 LI:236196.15:2001MAY17501 S23forwardTM Transmembrane I

338 LI:236196.15:2001MAY17524 589forwardTM Cytosolic 338 LI:236196.15:2001MAY17590 612forwardTM Transmembrane 338 LI:236196.15:2001MAY17613 613forwardTM Non-Cytosolic 338 LI:236196.15:2001MAY171 201forwardTM Cytosolic 338 LI:236196.15:2001MAY17202 224forwardTM Transmembrane 338 LI:236196.15:2001MAY17225 261forwardTM Non-Cytosolic 338 LI:236196.15:2001MAY17262 281forwardTM Transmembrane 338 LI:236196.15:2001MAY17282 300,forwardTM Cytosolic 338 LI:236196.15:2001MAY17301 323forwardTM Transmembrane 338 LI:236196.15:2001MAY17~ 324 502forwardTM Non-Cytosolic 2 .

338 LI:236196.15:2001MAY17503 525forwardTM Transmembrane 338, LI:236196.15:2001MAY17526 545' forwardTM Cytosolic 338 LI:236I96.15:2001MAY175'46 568forwardTM Transmembrane 338 LI:236196.15:2001MAY17569 613forwardTM Non-Cytosolic 338 LI:236196.15:2001MAY171 266forwardTM Cytosolic 338 LI:236196.15:2001MAY17267 284forwardTM Transmembrane 338 LI:236196.15:2001MAY17285 293forwardTM Non-Cytosolic 338 LI:236196.15:2001MAY17294 316forwardTM Transmembrane 338 LI:236196.15:2001MAY17317 483forwardTM Cytosolic 338 LI:236196.15:2001MAY17484 506forwardTM Transmembrane 338 LI:236196.15:2001MAY17507 558forwardTM Non-Cytosolic 338 LI:236196.15:2001MAYI7559 581forwardTM Transmembrane 338 LI:236196.15:2001MAY17582 613forwardTM Cytosolic 339 LI:237086.1:2001MAY171 320forwardTM Non-Cytosolic 339 LI:237086.1:2001MAY17321 343forwardTM Transmembrane 339 LI:237086.1:2001MAY17344 379forwardTM Cytosolic 339 LI:237086.1:2001MAYI71 182forwardTM Non-Cytosolic 339 LI:237086.1:2001MAY17183 205forwardTM Transmembrane 339 LI:237086.1:2001MAY17206 358forwardTM Cytosolic 339 LI:237086.1:200IMAYI7359 378forwardTM Transmembrane 339 LI:237086.1:2001MAY17379 379forwardTM Non-Cytosolic 340 LI:238585.30:2001MAY171 108forwardTM Cytosolic 340 LI:238585.30:2001MAY17109 131forwardTM Transmembrane 340 LI:238585.30:2001MAYI7132 134forwardTM Non-Cytosolic 340 LI:238585.30:2001MAY17135 157forwardTM Transmembrane 340 LI:238585.30:2001MAY17158 183forwardTM Cytosolic 340 LI:238585.30:2001MAY171 41 forwardTM Non-Cytosolic 340 LI:238585.30:2001MAY1742 64 forwardTM Transmembrane SEQ Template ID Start StopFrame Domain Topology D NO: Type 340 LI:238585.30:2001MAY1765 102forwardTM Cytosolic 340 LI:238585.30:2001MAY17103 12SforwardTM Transmembrane 340 LI:238585.30:2001MAY17126 139forwardTM Non-Cytosolic 340 LI:238585.30:2001MAY17140 162forwardTM Transmembrane 340 LI:238585.30:2001MAY17163 183forwardTM Cytosolic 341 LI:238672.6:200IMAY171 228forwardTM Non-Cytosolic 341 LI:238672.6:2001MAY17229 251forwardTM Transmembrane 341 LI:238672.6:2001MAY17252 279forwardTM Cytosolic 341 LI:238672.6:2001MAY17280 301forwardTM Transmembrane 341 LI:238672.6:2001MAY17302 320forwardTM Non-Cytosolic 341 LI:238672.6:2001MAY17321 343forwardTM Transmembrane 341 LI:238672.6:2001MAY17344 373forwardTM Cytosolic 342 LI:239579.9:2001MAY171 685forwardTM Non-Cytosolic 342 LI:239579.9:2001MAY17686 708forwardTM Transmembrane 342 LI:239579.9:2001MAY17709 736forwardTM Cytosolic 342 LI:239579.9:2001MAY171 62 forwardTM Cytosolic 342 LI:239579.9:2001MAY1763 85 forwardTM Transmembrane 342 LI:239579.9:2001MAY1786 491forwardTM Non-Cytosolic 342 LI:239579.9:2001MAY17492 514forwardTM Transmembrane 342 LI:239579.9:2001MAY17S1S 687forwardTM Cytosolic 342 LI:239579.9:2001MAYI7688 710forwardTM Transmembrane 342 LI:239579.9:2001MAY17711 736forwardTM Non-Cytosolic 342 LI:239579.9:2001MAY171 489forwardTM Non-Cytosolic 342 LI:239579.9:2001MAY17490 512forwardTM Transmembrane 342 LI:239579.9:2001MAY17513 531forwardTM Cytosolic 342 LI:239579.9:2001MAY17S32 S54forwardTM Transmembrane ' 3 342 LI:239S79.9:2001MAY17555 568forward3TM Non-Cytosolic 342 LI:239579.9:2001MAY17S69 591forwardTM Transmembrane 342 LI:239579.9:2001MAY17592 685forwardTM Cytosolic 342 LI:239579.9:2001MAY17686 708forwardTM Transmembrane 342 LI:239579.9:2001MAY17709 735forwardTM Non-Cytosolic 343 LI:239720.1:2001MAY171 986forwardTM Non-Cytosolic 343 LI:239720.1:2001MAY17987 1009forwardTM Transmembrane 343 LI:239720.1:2001MAY171010 1210forwardTM Cytosolic 344 LI:240037.6:2001MAY171 306forwardTM Non-Cytosolic 344 LI:240037.6:ZOO1MAYI7307 329forwardTM Transmembrane 344 LI:240037.6:2001MAY17330 346forwardTM Cytosolic 345 LI:243900.7:2001MAY171 289forwardTM Cytosolic 34S LI:243900.7:2001MAY17290 309forwardTM Transmembrane 345 LI:243900.7:2001MAY17310 313forwardTM Non-Cytosolic 345 LI:243900.7:2001MAY17314 336forwardTM Transmembrane 345 LI:243900.7:2001MAY17337 401forwardTM Cytosolic 345 LI:243900.7:2001MAY171 308forwardTM Non-Cytosolic 345 LI:243900.7:2001MAY17309 331forwardTM Transmembrane 345 LI:243900.7:2001MAY17332 400forwardTM Cytosolic 346 LI:244378.1:2001MAY171 57 forwardTM Non-Cytosolic 346 LI:244378.1:2001MAY1758 75 forwardTM Transmembrane 346 LI:244378.1:2001MAY1776 87 forwardTM Cytosolic 346 LI:244378.1:2001MAY1788 110forwardTM Transmembrane 346 LI:244378.1:2001MAY17111 119forwardTM Non-Cytosolic 346 LI:244378.1:2001MAY17120 142forwardTM Transmembrane . 1 346 LI:244378.1:2001MAY17I43 160forwardTM Cytosolic I

346 LI:244378.1:2001MAY17161 178forwardTM Transmembrane 346 LI:244378.1:2001MAY17179 826forwardTM Non-Cytosolic I

TABLE

SEQ D NO: Template ID Start StopFrame Domain Topology Type 346 LI:244378.1:2001MAY171 47 forwardTM Non-Cytosolic 346 LI:244378.1:2001MAY1748 70 forwardTM Transmembrane 346 LI:244378.1:2001MAY1771 101forwardTM Cytosolic 346 LI:244378.1:2001MAY17102 124forwardTM Transmembrane 346 LI:244378.1:2001MAY17125 258forwardTM Non-Cytosolic 346 LI:244378.1:2001MAY17259 278forwardTM Transmembrane 346 LI:244378.1:2001MAY17279 538forwardTM Cytosolic 346 LI:244378.1:2001MAY17539 561forwardTM Transmembrane 346 LI:244378.1:2001MAY17562 826forwardTM Non-Cytosolic 346 LI:244378.1:2001MAY171 31 forwardTM Non-Cytosolic 346 LI:244378.1:2001MAY1732 54 forwardTM Transmembrane 346 LI:244378.1:2001MAY1755 85 forwardTM Cytosolic 346 LI:244378.1:2001MAY1786 105forwardTM Transmembrane 346 LI:244378.1:2001MAY17106 825forwardTM Non-Cytosolic 347 LI:245500.3:2001MAY171 107forwardTM Cytosolic 347 LI:245500.3:2001MAY17108 130forwardTM Transmembrane 347 LI:245500.3:2001MAY17131 144forwardTM Non-Cytosolic 347 LI:245500.3:2001MAY17145 167forwardTM Transmembrane 347 LI:245500.3:2001MAY17168 232forwardTM Cytosolic 347 LI:245500.3:2001MAY17233 255forwardTM Transmembrane 347 LI:245500.3:2001MAY17256 267forwardTM Non-Cytosolic 347 LI:245500.3:2001MAY17268 290forwardTM Transmembrane 347 LI:245500.3:2001MAY17291 340forwardTM Cytosolic 347 LI:245500.3:2001MAY17341 363forwardTM Transmembrane 347 LI:245500.3:2001MAY17364 372forwardTM Non-Cytosolic 347 LI:245500.3:2001MAY17373 395forwardTM Transmembrane 347 LI:245500.3:2001MAY17396 414forwardTM Cytosolic 347 LI:245500.3:2001MAY17415 437forwardTM Transmembrane 347 LI:245500.3:2001MAY17438 935forwardTM Non-Cytosolic 347 LI:245500.3:2001MAY17936 958forwardTM Transmembrane 347 LI:245500.3:200IMAY17959 1018forwardTM Cytosolic I

347 LI:245500.3:2001MAY171019 1041forwardTM Transmembrane 347 LI:245500.3:2001MAY171042 1052forwardTM Non-Cytosolic 347 LI:245500.3:2001MAY171 19 forwardTM Cytosolic 347 LI:245500.3:2001MAY1720 39 forwardTM Transmembrane 347 LI:245500.3:2001MAY1740 48 forwardTM Non-Cytosolic 347 LI:245500.3:2001MAY1749 71 forwardTM Transmembrane 347 LI:245500.3:2001MAY1772 116forwardTM Cytosolic 347 LI:245500.3:2001MAY17117 136forwardTM Transmembrane 347 LI:245500.3:2001MAY17137 145forwardTM Non-Cytosolic 347 LI:245500.3:2001MAY17146 168forwardTM Transmembrane 347 LI:245500.3:2001MAY17169 243forwardTM Cytosolic 347 LI:245500.3:2001MAY17244 266forwardTM Transmembrane 347 LI:245500.3:2001MAY17267 337forwardTM Non-Cytosolic 347 LI:245500.3:2001MAY17338 360forwardTM Transmembrane 347 LI:245500.3:2001MAY17361 366forwardTM Cytosolic 347 LI:245500.3:2001MAY17367 389forwardTM Transmembrane 347 LI:245500.3:200IMAY17390 392forwardTM Non-Cytosotic 347 LI:245500.3:2001MAY17393 410forwardTM Transmembrane 347 LI:245500.3:2001MAY17411 439forwardTM Cytosolic 347 LI:245500.3:2001MAY17440 459forwardTM Transmembrane 347 LI:245500.3:2001MAY17460 491forwardTM Non-Cytosolic 347 LI:245500.3:2001MAY492 514forwardTM Transmembrane 347 LI:245500.3:2001MAY515 677forwardTM Cytosolic SEQ D NO: Template ID Start StopFrame Domain Topology Type 347 LI:245500.3:2001MAY17678 700forwardTM Transmembrane 347 LI:245500.3:2001MAY17701 727forwardTM Non-Cytosolic 347 LI:245500.3:2001MAY17728 750forwardTM Transmembrane 347 LI:245500.3:2001MAY17751 761forwardTM Cytosolic 347 LI:245500.3:2001MAY17762 784forwardTM Transmembrane 347 LI:245500.3:2001MAY17785 803forwardTM Non-Cytosolic 347 LI:Z45500.3:ZOO1MAYI7804 826forwardTM Transmembrane 347 LI:245500.3:2001MAY17827 939forwardTM Cytosolic 347 LI:245500.3:2001MAY17940 959forwardTM Transmembrane 347 LI:245500.3:2001MAY17960 1052forwardTM Non-Cytosolic ~

347 LI:245500.3:2001MAY17I 295forwardTM Non-Cytosolic 347 LI:245500.3:2001MAY17296 3I8forwardTM Transmembrane 347 LI:245500.3:2001MAY17319 329forwardTM Cytosolic 347 LI:245500.3:200IMAY17330 352forwardTM Transmembrane 347 LI:245500.3:2001MAY17353 386forwardTM Non-Cytosolic 347 LI:245S00.3:2001MAY17387 409forwardTM . Transmembrane 347 LI:245500.3:2001MAY17410 429forwardTM Cytosolic 347 LI:245500.3:2001MAY17430 452forwardTM Transmembrane 347 LI:245S00.3:2001MAY17453 1052forwardTM Non-Cytosolic 348 LI:245982.24:2001MAY171 748forwardTM Non-Cytosolic 348 LI:245982.24:2001MAY17749 77IforwardTM Transmembrane 348 LI:245982.24:2001MAY17772 788forwardTM Cytosolic 349 LI:246054.1:2001MAY171 214forwardTM Non-Cytosolic 349 LI:246054.1:2001MAY17215 237forwardTM Transmembrane~.

349 LI:246054.1:2001MAY17238 243forwardTM Cytosolic 349 LI:246054.1:2001MAYi7244 266forwardTM Transmembrane 349 LI:246054.1:2001MAY17267 509forwardTM Non=Cytosolic 349 LI:246054.I:2001MAY17510 532forwardTM Transmembrane 349 LI:246054.1:2001MAY533 627forwardTM Cytosolic 349 LI:246054.1:2001MAY171 257forwardTM Non-Cytosolic 349 LI:246054.1:2001MAY17258 280forwardTM Transmembrane 349 LI:246054.1:2001MAY17281 306forwardTM Cytosolic 349 LI:246054.1:2001MAY17307 329forwardTM Transmembrane 349 LI:246054.1:2001MAY17330 627forwardTM Non-Cytosolic 349 LI:246054.1:2001MAY171 506forwardTM Non-Cytosolic 349 LI:246054.1:2001MAY17507 529forwardTM Transmembrane 349 LI:246054.1:2001MAY17530 597forwardTM Cytosolic 349 LI:246054.1:2001MAY598 620forwardTM Transmembrane 349 LI:246054.1:2001MAY17621 627forwardTM Non-Cytosolic 350 LI:256051.229:2001MAY171 229forwardTM Non-Cytosolic 350 LI:256051.229:2001MAY17230 ' forwardTM Transmembrane 350 LI:256051.229:200IMAY17253 257forwardTM Cytosolic 3S0 LI:256051.229:2001MAY171 225forwardTM Cytosolic 350 LI:256051.229:2001MAY17226 248forwardTM Transmembrane 350 LI:256051.229:2001MAY17249 256forwardTM Non-Cytosolic 351 LI:260629.7:2001MAY171 4 forwardTM Cytosolic 351 LI:260629.7:2001MAY175 27 forwardTM Transmembrane 351 LI:260629.7:2001MAY1728 48 forwardTM Non-Cytosolic 351 LI:260629.7:200IMAY17I I4 forwardTM Non-Cytosolic 351 LI:260629.7:200IMAY171S 32 forwardTM Transmembrane 351 LI:260629.7:2001MAY33 48 forwardTM Cytosolic 352 LI:272723.1:2001MAY171 116forwardTM Non-Cytosolic 3S2 LI:272723.1:2001MAY17117 139forwardTM Transmembrane 352 LI:272723.1:2001MAY17140 2SSforwardTM Cytosolic 185 ' SEQ D Template ID Start StopFrame Domain Topology NO: Type 352 LI:272723.1:2001MAY17256 278forwardTM Transmembrane 352 LI:272723.1:2001MAY17279 287forwardTM Non-Cytosolic 353 LI:272766.1:2001MAY171 270forwardTM Non-Cytosolic 353 LI:272766.1:2001MAY17271 293forwardTM Transmembrane 353 LI:272766.1:2001MAY17294 318forwardTM Cytosolic 354 LI:275726.1:2001MAY171 197forwardTM Cytosolic 355 LI:276815.1:2001MAY171 20 forwardTM Cytosolic 355 LI:276815.1:2001MAY1721 43 forwardTM Transmembrane 355 LI:276815.1:2001MAY1744 199forwardTM Non-Cytosolic 355 LI:276815.1:2001MAY171 20 forwardTM Cytosolic 355 LI:276815.1:2001MAY1721 43 forwardTM Transmembrane 355 LI:276815.1:2001MAY1744 198forwardTM Non-Cytosolic 356 LI:283562.5:2001MAY171 289forwardTM Cytosolic 356 LI:283562.5:2001MAY17290 312forwardTM Transmembrane 356 LI:283562.5:2001MAY17313 1092forwardTM Non-Cytosolic 356 LI:283562.5:2001MAY171093 1115forwardTM Transmembrane 356 LI:283562.5:2001MAY171116 1125forwardTM Cytosolic 356 LI:283562.5:2001MAY171 1091forwardTM Non-Cytosolic 356 LI:283562.5:2001MAY171092 1114forwardTM Transmembrane 356 LI:283562.5:2001MAY171115 1124forwardTM Cytosolic 357 LI:289066.15:2001MAY171 175forwardTM Cytosolic 357 LI:289066.15:2001MAY17176 198forwardTM Transmembrane 357 LI:289066.15:2001MAY17199 925forwardTM Non-Cytosolic 357 , LI:289066.15:2001MAY17926 948forwardTM Transmembrane 357 LI:289066.15:2001MAY17949 968forwardTM Cytosolic 357 ~ LI:289066.15:2001MAY17969 991forwardTM Transmembrane.

357 LI:289066.15:2001MAY17992 1022forwardTM Non-Cytosolic 357 LI:289066.15:2001MAY171023 1045forwardTM Transmembrane 357 LI:289066.15:2001MAY171046 1083forwardTM Cytosolic 357 LI:289066.15:2001MAY171 12 forwardTM Cytosolic 357 LI:289066.15:2001MAY1713 30 forwardTM Transmembrane 357 LI:289066.15:2001MAY1731 39 forwardTM Non-Cytosolic 357 LI:289066.15:2001MAY1740 59 forwardTM Transmembrane 357 LI:289066.15:2001MAY1760 189forwardTM Cytosolic 357 LI:289066.15:2001MAY17190 212forwardTM Transmembrane 357 LI:289066.15:2001MAY17213 226forwardTM Non-Cytosolic 357 LI:289066.15:2001MAY17227 249forwardTM Transmembrane 357 LI:289066.15:2001MAY17250 303forwardTM Cytosolic 357 LI:289066.15:2001MAY17304 326forwardTM Transmembrane 357 LI:289066.15:2001MAY17327 932forwardTM Non-Cytosolic 357 LI:289066.15:2001MAY17933 955forwardTM Transmembrane 357 LI:289066.15:2001MAY17956 975forwardTM Cytosolic 357 LI:289066.15:2001MAY17976 998forwardTM Transmembrane 357 LI:289066.15:2001MAY17999 1026forwardTM Non-Cytosolic 357 LI:289066.15:2001MAY171027 1049forwardTM Transmembrane 357 LI:289066.15:2001MAY171050 1083forwardTM Cytosolic 357 LI:289066.15:2001MAY171 90 forwardTM Cytosolic 357 LI:289066.15:2001MAY1791 113forwardTM Transmembrane 357 LI:289066.15:2001MAY17114 174forwardTM Non-Cytosolic 357 LI:289066.15:2001MAY17175 197forwardTM Transmembrane 357 LI:289066.15:2001MAY17198 220forwardTM Cytosolic 357 LI:289066.15:2001MAY17221 243forwardTM Transmembrane 357 LI:289066.15:2001MAY17244 833forwardTM Non-Cytosolic 357 LI:289066.15:2001MAY17834 856forwardTM Transmembrane SEQ D NO: Template ID Start StopFrame Domain Topolojy Type 357 LI:289066.15:2001MAY17857 975forwardTM Cytosolic 357 LI:289066.15:2001MAY17976 998forwardTM Transmembrane 357 LI:289066.15:2001MAY17999 1017forwardTM Non-Cytosolic 357 LI:289066.15:2001MAY171018 1040forwardTM Transmembrane 357 LI:289066.15:2001MAY171041 1083forwardTM Cytosolic 358 LI:331040.17:2001MAY171 207forwardTM Non-Cytosolic 358 LI:331040.17:2001MAY17208 230forwardTM Transmembrane 358 LI:331040.17:2001MAY17231 314forward' TM Cytosolic 358 LI:331040.17:2001MAY171 239forwardTM Non-Cytosolic 358 LI:331040.17:2001MAY17240 262forwardTM Transmembrane 358 LI:331040.17:2001MAY17263 282forwardTM Cytosolic 358 LI:331040.17:2001MAY17283 305forwardTM Transmembrane 358 LI:331040.17:2001MAY17306 313forwardTM Non-Cytosolic 3S9 LI:332414.5:2001MAY171 534forwardTM Non-Cytosolic 359 LI:332414.5:2001MAY17535 557forwardTM Transmembrane 359 LI:332414.5:2001MAY17558 574forwardTM Cytosolic 359 LI:332414.5:2001MAY171 167forwardTM Cytosolic 359 LI:332414.5:2001MAY17168 190forwardTM Transmembrane 359 LI:332414.5:2001MAY17191 574forwardTM Non-Cytosolic 359 LI:332414.5:2001MAY171 534forwardTM Non-Cytosolic 3S9 LI:332414.5:2001MAY17S35 S57forwardTM Transmembrane 359 LI:332414.5:2001MAY17558 573forwardTM Cytosolic 360 LI:332730.16:2001MAYI71 427forwardTM Cytosolic I

360 LI:332730.1.6:2001MAY17428 450forwardTM Transmembrane 360 LI:332730.16:2001MAY17451 963forwardTM Non-Cytosolic 360 LI:332730.16:2001MAY17964 986forwardTM Transmembrane 360 LI:332730.16:2001MAY17987 1176forwardTM Cytosolic 360 ' LI332730.1'6:2001MAY171177 1199forwardTM Transmembrane 360 LI:332730.16:2001MAY171200 1218forwardTM Non-Cytosolic 360 LI:332730.16:2001MAY171219 1241forwardTM Transmembrane 360 LI:332730.16:2001MAY171242 1328forwardTM Cytosolic 360 LI:332730.16:2001MAY171329 1351forwardTM Transmembrane 360 LI:332730.16:2001MAY171352 1383forwardTM Non-Cytosolic 360 LI:332730.16:2001MAY171384 1406forwardTM Transmembrane 360 LI:332730.16:2001MAY171407 1438forwardTM Cytosolic 360 LI:332730.16:2001MAY171439 1461forwardTM Transmembrane 360 LI:332730.16:2001MAY171462 1465forwardTM Non-Cytosolic 360 LI:332730.16:2001MAY171466 1485forwardTM Transmembrane 360 LI:332730.16:2001MAY171486 1516forwardTM Cytosolic 360 LI:332730.16:2001MAY171517 1539forwardTM Transmembrane 360 LI:332730.16:2001MAY171540 1738forwardTM Non-Cytosolic 360 LI:332730.16:2001MAY171 951forwardTM Non-Cytosolic 360 LI:332730.16:2001MAY17952 974forwardTM Transmembrane 360 LI:332730.16:2001MAY17975 1175forwardTM Cytosolic 360 LI:332730.16:2001MAY171176 1198forwardTM Transmembrane 360 LI:332730.16:2001MAY171199 1217forwardTM Non-Cytosolic 360 LI:332730.16:2001MAY171218 1240forwardTM Transmembrane 360 LI:332730.16:2001MAY171241 1531forwardTM Cytosolic 360 LI:332730.16:2001MAY171532 1554forwardTM Transmembrane 360 LI:332730.16:2001MAY171555 1618forwardTM Non-Cytosolic 360 LI:332730.16:2001MAY171619 1638forwardTM Transmembrane 360 LI:332730.16:2001MAY171639 1649forwardTM Cytosolic 360 LI:332730.16:2001MAY171650 1672forwardTM Transmembrane 360 LI:332730.16:2001MAY171673 1706forwardTM Non-Cytosolic SEQ Template ID Start StopFrame Domain Topology D NO: Type 360 LI:332730.16:2001MAY171707 1724forwardTM Transmembrane 360 LI:332730.16:2001MAY171725 1738forwardTM Cytosolic 360 LI:332730.16:2001MAY171 952forwardTM Non-Cytosolic 360 LI:332730.16:2001MAY1753 975forwardTM Transmembrane 360 LI:332730.16:2001MAY17976 11'20forward' TM Cytosolic 360 LI:332730.16:2001MAY171121 1143forwardTM Transmembrane 360 LI:332730.16:2001MAY171144 1146forwardTM Non-Cytosolic 360 LI:332730.16:2001MAY171147 1169forwardTM Transmembrane 360 LI:332730.16:2001MAY171170 1175forwardTM Cytosolic 360 LI:332730.16:2001MAY171176 1198forwardTM Transmembrane 360 LI:332730.16:2001MAY171199 1217forwardTM Non-Cytosolic 360 LI:332730.16:2001MAY171218 1240forwardTM Transmembrane 360 LI:332730.16:2001MAY171241 1447forwardTM Cytosolic 360 LI:332730.16:2001MAY171448 1470forwardTM Transmembrane 360 LI:332730.16:2001MAY171471 1479forwardTM Non-Cytosolic 360 LI:332730.16:2001MAY171480 1499forwardTM Transmembrane 360 LI:332730.16:2001MAY171500 1519forwardTM Cytosolic 360 LI:332730.16:2001MAY171520 1542forwardTM Transmembrane 360 LI:332730.16:2001MAY171543 1738forwardTM Non-Cytosolic 361 LI:333849.21:2001MAY171 188forwardTM Cytosolic 362 LI:337038.15:2001MAY171 660forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY17661 683forwardTM Transmembrane 362 LI:337038.15:2001MAY17684 793forwardTM Cytosolic 362 LI:337038.15:2001MAY17794 816forwardTM Transmembrane ~ 1 362 LI:337038~15:2001MAY17817 928forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY17'929 951forwardTM Transmembrane 362 LI:337038.15:2001MAY1~7952 957forwardTM Cytosolic 362 LI:337038.15:2001MAY17958 980forwardTM Transmembrane 362 LI:337038.15:2001MAY17981 989forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY17990 1009forwardTM Transmembrane 362 LI:337038.15:2001MAY171010 1029forwardTM Cytosolic 362 LI:337038.15:2001MAY171030 1052forwardTM Transmembrane 362 LI:337038.15:2001MAY171053 1119forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY171120 1142forwardTM Transmembrane 362 LI:337038.15:2001MAY171143 1174forwardTM Cytosolic 362 LI:337038.15:2001MAY171175 1197forwardTM Transmembrane 362 LI:337038.15:2001MAY171198 1211forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY171212 1231forwardTM Transmembrane 362 LI:337038.15:2001MAY171232 1357forwardTM Cytosolic I

362 LI:337038.15:2001MAY171358 1380forwardTM Transmembrane 362 LI:337038.15:2001MAY171381 1394forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY171395 1417forwardTM Transmembrane 362 LI:337038.15:2001MAY171418 1429forwardTM Cytosolic 362 LI:337038.15:2001MAY171430 1452forwardTM Transmembrane 362 LI:337038.15:2001MAY171453 1515forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY171516 1538forwardTM Transmembrane 362 LI:337038.15:2001MAY171539 1550forwardTM Cytosolic 362 LI:337038.15:2001MAY171551 1573forwardTM Transmembrane 362 LI:337038.15:2001MAY171574 1582forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY171583 1601forwardTM Transmembrane 362 LI:337038.15:2001MAY171602 1656forwardTM Cytosolic 362 LI:337038.15:2001MAY171657 1679forwardTM Transmembrane 362 LI:337038.15:2001MAY171680 1698forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY171699 1721forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D NO: Type 362 LI:337038.15:2001MAY171722 1749forwardTM Cytosolic 362 LI:337038.15:2001MAY171 660 forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY17661 683 forwardTM Transmembrane 362 LI:337038.15:2001MAY17684 703 forwardTM Cytosolic 362 LI:337038.15:2001MAY17704 721 forwardTM Transmembrane 362 LI:337038.15:2001MAY17722 735 forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY17736 758 forwardTM Transmembrane 362 LI:337038.15:2001MAY17759 764 forwardTM Cytosolic 362 LI:337038.15:2001MAY17765 785 forwardTM Transmembrane 362 LI:337038.15:2001MAY17786 804 forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY17805 827 forwardTM Transmembrane 362 LI:337038.15:2001MAY17828 839 forwardTM Cytosolic 362 LI:337038.15:2001MAY17840 862 forwardTM Transmembrane 362 LI:337038.15:2001MAY17863 935 forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY17936 953 forwardTM Transmembrane 362 LI:337038.15:2001MAY17954 959 forwardTM Cytosolic 362 LI:337038.15:2001MAY17960 982 forwardTM Transmembrane 362 LI:337038.15:2001MAY17983 1027forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY171028 1050forwardT'M Transmembrane 362 LI:337038.15:2001MAY171051 1095forwardTM Cytosolic 362 LI:337038.15:2001MAY171096 1118forwardTM Transmembrane 362 LI:337038.15:2001MAY171119 1132forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY171133 1152forwardTM Transmembrane 362 LI:337038.15:2001MAY17..1153 1325forwardTM Cytosolic 362 LI:337038.15:2001MAY171326 1345forwardTM Transmembrane 362 LI:337038.15:2001MAY171346 1359forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY171360.1382forwardTM Transmembrane 362 LI:337038.15:2001MAY171383 1401forwardTM Cytosolic 362 LI:337038.15:2001MAY171402 1424forwardTM Transmembrane 362 LI:337038.I5:200IMAY171425 1438forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY171439 1461forwardTM Transmembrane 362 LI:337038.15:2001MAY171462 1467forwardTM Cytosolic 362 LI:337038.15:2001MAY171468 1487forwardTM Transmembrane 362 LI:337038.15:2001MAY171488 1491forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY171492 1509forwardTM Transmembrane 362 LI:337038.15:2001MAY171510 1515forwardTM Cytosolic 362 LI:337038.15:2001MAY171516 1538forwardTM Transmembrane 362 LI:337038.15:2001MAY171539 1552forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY171553 1575forwardTM Transmembrane 362 LI:337038.15:2001MAY171576 1610forwardTM Cytosolic 362 LI:337038.15:2001MAY171611 1633forwardTM Transmembrane 362 LI:337038.I5:2001MAYI71634 1749forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY171 206 forwardTM Cytosolic 362 LI:337038.15:2001MAY17207 229 forwardTM Transmembrane 362 LI:337038.15:2001MAY17230 764 forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY17765 787 forwardTM Transmembrane 362 LI:337038.15:2001MAY17788 942 forwardTM Cytosolic 362 LI:337038.15:2001MAY17943 965 forwardTM Transmembrane 362 LI:337038.15:2001MAY17966 1030forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY171031 1050forwardTM Transmembrane 362 LI:337038.15;2001MAY171051 1172forwardTM Cytosolic 362 LI:337038.15;2001MAY171173 1192forwardTM Transmembrane 362 LI:337038.15:2001MAY171193 1242forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY171243 1265forwardTM Transmembrane SEQ Template ID Start StopFrame Domain Topology D NO: Type 362 LI:337038.15:2001MAY171266 1393forwardTM Cytosolic 362 LI:337038.15:2001MAY171394 1416forwardTM Transmembrane 362 LI:337038.15:2001MAY171417 1430forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY171431 1453forwardTM Transmembrane 362 LI:337038.15:2001MAY171454 1472forwardTM Cytosolic 362 LI:337038.15:2001MAY171473 1495forwardTM Transmembrane 362 LI:337038.15:2001MAY171496 1516forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY171517 1539forwardTM Transmembrane 362 LI:337038.15:2001MAY171540 1551forwardTM Cytosolic 362 LI:337038.15:2001MAY171552 1574forwardTM Transmembrane 362 LI:337038.15:2001MAY171575 1607forwardTM Non-Cytosolic 362 LI:337038.15:2001MAY171608 1630forwardTM Transmembrane 362 LI:337038.15:2001MAY171631 1749forwardTM Cytosolic 363 LI:337606.6:2001MAY171 73 forwardTM Cytosolic 363 LI:337606.6:2001MAY1774 96 forwardTM Transmembrane 363 LI:337606.6:2001MAY1797 210forwardTM Non-Cytosolic 363 LI:337606.6:2001MAY171 168forwardTM Cytosolic 363 LI:337606.6:2001MAY17169 191forwardTM Transmembrane 363 LI:337606.6:2001MAY17192 209forwardTM Non-Cytosolic 364 LI:338032.10:2001MAY171 4 forwardTM Non-Cytosolic 364 LI:338032.10:2001MAY175 27 forwardTM Transmembrane 364 LI:338032.10:2001MAY1728 131forwardTM Cytosolic 365 LI:339265.16:2001MAY171 1231forwardTM Non-Cytosolic 365 LI:339265.16:2001MAY171232 1254forwardTM Transmembrane 365 LI:339265.16:2001MAY1T1255 1274forwardTM Cytosolic 365 LI:339265.16:2001MAY1'7~1 224forwardTM Non-Cytosolic ~ 3 365 LI:339265.16:2001MAY17225 247forwardTM Transmembrane ~ 3 365 LI:339265.16:2001MAY17248 341forwardTM Cytosolic 365 LI:339265.16:2001MAY17342 364forwardTM Transmembrane 365 LI:339265.16:2001MAY17365 1274forwardTM Non-Cytosolic 366 LI:344646.4:2001MAYI71 452forwardTM Non-Cytosolic 366 LI:344646.4:2001MAY17453 475forwardTM Transmembrane 366 LI:344646.4:2001MAY17476 598forwardTM Cytosolic 366 LI:344646.4:2001MAY171 104forwardTM Cytosolic 366 LI:344646.4:2001MAY17105 127forwardTM Transmembrane 366 LI:344646.4:2001MAY17128 141forwardTM Non-Cytosolic 366 LI:344646.4:2001MAY17142 164forwardTM Transmembrane 366 LI:344646.4:2001MAY17165 250forwardTM Cytosolic 366 LI:344646.4:2001MAY17251 273forwardTM Transmembrane 366 LI:344646.4:2001MAY17274 S98forwardTM Non-Cytosolic 366 LI:344646.4:2001MAY171 289forwardTM Cytosolic 366 LI:344646.4:2001MAY17290 312forwardTM Transmembrane 366 LI:344646.4:2001MAY17313 345forwardTM Non-Cytosolic 366 LI:344646.4:2001MAY17346 365forwardTM Transmembrane 366 LI:344646.4:2001MAY17366 523forwardTM Cytosolic 366 LI:344646.4:2001MAY17524 546forwardTM Transmembrane 366 LI:344646.4:2001MAY17547 598forwardTM Non-Cytosolic 367 LI:347393.7:2001MAY17I 384forwardTM Non-CytosoIic 367 LI:347393.7:2001MAY17385 407forwardTM Transmembrane 367 LI:347393.7:2001MAY17408 449forwardTM Cytosolic 368 LI:348107.36:2001MAY17I 140forwardTM Non-Cytosolic 368 LI:348107.36:2001MAY17141 163forwardTM Transmembrane 368 LI:348107.36:2001MAY17164 166forwardTM Cytosolic 369 LI:351120.6:2001MAY171 196forwardTM Non-Cytosolic SEQ Template ID Start StopFrame Domain Topology D Type NO:

369 LI:351120.6:2001MAY17197 219forwardTM Transmembrane 369 LI:351120.6:2001MAY17220 303forwardTM Cytosolic 369 LI:351120.6:2001MAY17304 326forwardTM Transmembrane 369 LI:351120.6:2001MAY17327 357forwardTM Non-Cytosolic 369 LI:351120.6:2001MAY17358 380forwardTM Transmembrane 369 LI:351120.6:2001MAY17381 392forwardTM Cytosolic 369. LI:351120.6:2001MAY17393 415forwardTM Transmembrane 369 LI:351120.6:2001MAY17416 458forwardTM Non-Cytosolic 369 LI:351120.6:2001MAY17459 481forwardTM Transmembrane 369 LI:351120.6:2001MAY17482 554forwardTM Cytosolic 369 LI:351120.6:2001MAY17555 577forwardTM Transmembrane 369 LI:351120.6:200IMAYI7578 586forwardTM Non-Cytosolic 369 LI:351120.6:2001MAY17587 609forwardTM Transmembrane 369 LI:351120.6:2001MAY17610 737forwardTM Cytosolic 369 LI:351120.6:2001MAY17738 760forwardTM Transmembrane 369 LI:351120.6:2001MAY17761 1098forwardTM Non-Cytosolic 369 LI:351120.6:2001MAY171 270forwardTM Non-Cytosolic 369 LI:351120.6:2001MAY17271 290forwardTM Transmembrane 369 LI:351120.6:2001MAY17291 344forwardTM Cytosolic 369 LI:351120.6:2001MAY17345 367forwardTM Transmembrane 369 LI:351120.6:2001MAY17368 381forwardTM Non-Cytosolic 369 LI:351120.6:2001MAY17382 404forwardTM Transmembrane 369 LI:351120.6:2001MAY17405 416forwardTM Cytosolic 369 LI:351120.6:2001MAY, 417 434forwardTM Transmembrane 17 = 2 369 LI:351120.6:2001MAY17435 448forward, TM Non-Cytosolic 369 LI:351120.6:2001MAY17449 4T1forwardTM Transmembrane 369 LI:351120.6:2001MAY17472 491forwardTM Cytosolic 369 LI:351120.6:2001MAY17492 511forwardTM Transmembrane 369 LI:351120.6:2001MAY17512 525forwardTM Non-Cytosolic 369 LI:351120.6:2001MAY17526 548forwardTM Transmembrane 369 LI:351120.6:2001MAY17549 641forwardTM Cytosolic 369 LI:351120.6:2001MAY17642 664forwardTM Transmembrane 369 LI:351120.6:2001MAY17665 698forwardTM Non-Cytosolic 369 LI:351120.6:2001MAY17699 721forwardTM Transmembrane 369 LI:351120.6:2001MAY17722 737forwardTM Cytosolic 369 LI:351120.6:2001MAY17738 760forwardTM~ Transmembrane 369 LI:351120.6:2001MAY17761 1098forwardTM Non-Cytosolic 369 LI:351120.6:2001MAY171 87 forwardTM Cytosolic 369 LI:351120.6:2001MAY1788 107forwardTM Transmembrane 369 LI:351120.6:2001MAY17108 121forwardTM Non-Cytosolic 369 LI:351120.6:2001MAY17122 14IforwardTM Transmembrane 369 LI:351120.6:2001MAY17142 309forwardTM Cytosolic 369 LI:351120.6:2001MAY17310 329forwardTM Transmembrane 369 LI:351120.6:2001MAY17330 357forwardTM Non-Cytosolic 369 LI:351120.6:2001MAY17358 380forwardTM Transmembrane 369 LI:351120.6:2001MAY17381 392forwardTM Cytosolic 369 LI:35I120.6:2001MAY17393 415forwardTM Transmembrane 369 LI:351120.6:2001MAY17416 1097forwardTM Non-Cytosolic 370 LI:358762.41:2001MAY171 177forwardTM Non-Cytosolic 370 LI:358762.41:2001MAY17178 200forwardTM Transmembrane 370 LI:358762.41:2001MAY17201 206forwardTM Cytosolic 370 LI:358762.41:2001MAY17207 229forwardTM Transmembrane 370 LI:358762.41:2001MAY17230 561forwardTM Non-Cytosolic 370 LI:358762.41:2001MAY171 160forwardTM Cytosolic SEQ Template ID StartStopFrame Domain Topology D NO: Type 370 LI:358762.41:2001MAY17161 183forwardTM Transmembrane 370 LI:358762.41:2001MAY17184 216forwardTM Non-Cytosolic 370 LI:358762.41:2001MAY17217 239forwardTM Transmembrane 370 LT:358762.41:2001MAY17240 441forwardTM Cytosolic 370 LI:358762.41:2001MAY17442 464forwardTM Transmembrane 370 LI:358762.41:2001MAY17465 561forwardTM Non-Cytosolic 370 LI:358762.41:2001MAY171 14 forwardTM Non-Cytosolic 370 LI:358762.41:2001MAY1715 37 forwardTM Transmembrane 370 LI:358762.41:2001MAY1738 172forwardTM Cytosolic 370 LI:358762.41:2001MAY17173 195forwardTM Transmembrane 370 LI:358762.41:2001MAY17196 209forwardTM Non-Cytosolic 370 LI:358762.41:2001MAY17210 229forwardTM Transmembrane 370 LI:358762.41:2001MAY17230 433forwardTM Cytosolic 370 LI:358762.41:2001MAY17434 453forwardTM Transmembrane 370 LI:358762.41:2001MAY17454 472forwardTM Non-Cytosolic 370 LI:358762.41:2001MAY17473 495forwardTM Transmembrane 370 LI:358762.41:2001MAY17496 560forwardTM Cytosolic 371 LI:363003.48:2001MAY171 192forwardTM Non-Cytosolic 371 LI:363003.48:2001MAY17193 215forwardTM Transmembrane 371 LI:363003.48:2001MAY17216 256forwardTM Cytosolic 371 LI:363003.48:2001MAY17257 279forwardTM Transmembrane 371 LI:363003.48:2001MAY17280 288forwardTM Non-Cytosolic 371 LI:363003.48:2001MAY17289 311forwardTM Transmembrane 371 LI:363003.48:2001MAY17312 323forwardTM Cytosolic 371 LI:363003.48:2001MAY17324 346.forwardTM Transmembrane 371 LI:363003.48:2001MAY17347 347:forward~ TM Non-Cytosolic 372 LI:370899.6:2001MAY171 S23forwardTM Non-Cytosolic 372 LI:370899.6:2001MAY17524 S46forwardTM Transmembrane 372 LI:370899.6:2001MAY17547 579forward, TM Cytosolic 1 .

372 LI:370899.6:2001MAY17580 602forwardTM Transmembrane 372 LI:370899.6:2001MAY17603 621forwardTM Non-Cytosolic 372 LI:370899.6:2001MAY17622 644forwardTM Transmembrane 372 LI:370899.6:2001MAY17645 664forwardTM Cytosolic 372 LI:370899.6:2001MAY17665 687forwardTM Transmembrane 372 LI:370899.6:2001MAY17688 1216forwardTM Non-Cytosolic 372 LI:370899.6:2001MAY171 553forwardTM Non-Cytosolic 372 LI:370899.6:2001MAY17554 S76forwardTM Transmembrane 372 LI:370899.6:2001MAY17577 617forwardTM Cytosolic 372 LI:370899.6:2001MAY17618 640forwardTM Transmembrane 372 LI:370899.6:2001MAY17641 659forwardTM Non-Cytosolic 372 LI:370899.6:2001MAY17660 682forwardTM Transmembrane 372 LI:370899.6:2001MAY17683 711forwardTM Cytosolic 372 LI:370899.6:2001MAY17712 734forwardTM Transmembrane 372 LI:370899.6:2001MAY17735 1216forwardTM Non-Cytosolic 372 LI:370899.6:2001MAY171 522forwardTM Non-Cytosolic 372 LI:370899.6:2001MAY17523 545forwardTM Transmembrane 372 LI:370899.6:2001MAY17546 714forwardTM Cytosolic 372 LI:370899.6:2001MAY17715 737forwardTM Transmembrane 372 LI:370899.6:2001MAY17738 1215forwardTM Non-Cytosolic 373 LI:376470.1:2001MAY171 126forwardTM Cytosolic 373 LI:376470.1:2001MAY17127 149forwardTM Transmembrane ' 3 373 LI:376470.1:2001MAY17150 180forwardTM Non-Cytosolic 374 LI:400961.18:2001MAY171 303forwardTM Non-Cytosolic 374 LI:400961.18:2001MAY17304 326forwardTM Transmembrane SEQ Template ID Start StopFrame Domain Topology D NO: Type 374 LI:400961.18:2001MAY17327 489forwardTM Cytosolic 374 LI:400961.18:2001MAYI7490 512forwardTM Transmembrane 374 LI:400961.18:2001MAY17513 607forwardTM Non-Cytosolic 374 LI:400961.18:2001MAY171 186forwardTM Non-Cytosolic 374 LI:400961.18:2001MAY17187 206forwardTM Transmembrane 374 LI:400961.18:2001MAY17207 210forwardTM Cytosolic 374 LI:400961.18:2001MAY17211 233forwardTM Transmembrane 374 LI:400961.18:2001MAY17234 606forwardTM Non-Cytosolic 375 LI:404482.20:2001MAY171 421forwardTM Non-Cytosolic 375 LI:404482.20:2001MAYI7422 444forwardTM Transmembrane 3.75 LI:404482.20:200IMAYI7445 653forwardTM Cytosolic 375 LI:404482.20:2001MAY17654 676forwardTM Transmembrane 375 LI:404482.20:2001MAY17677 719forwardTM Non-Cytosolic 37S LI:404482.20:2001MAY17720 742forwardTM Transmembrane I

375 LI:404482.20:2001MAY17743 1018forwardTM Cytosolic . 1 375 LI:404482.20:2001MAY171019 1038forwardTM Transmembrane 375 LI:404482.20:2001MAYI72039 1052forwardTM Non-Cytosolic 375 LI:404482.20:2001MAY172053 1075forwardTM Transmembrane 375 LI:404482.20:200IMAY172076 1081forwardTM Cytosolic 37S LI:404482.20:2001MAY171082 1100forwardTM Transmembrane 375 LI:404482.20:2001MAY171101 1201forwardTM Non-Cytosolic 375 LI:404482.20:2001MAY171 250forwardTM Cytosolic 375 LI:404482.20:2001MAY17251 273forwardTM Transmembrane 375 LI:404482.20:2001MAY17274 1041forwardTM Non-Cytosolic 375 LI:404482.20:2001MAY171042 1061forwardTM Transmembrane 375 LI:404482.20:2001MAY171062 1201forwardTM Cytosolic 375 LI:404482.20:2001MAY171 930forwardTM Non-Cytosolic 375 LI:404482.Z0:200IMAYI7931 953forwardTM Transmembrane 375 LI:404482.20:2001MAY17954 1016forwardTM Cytosolic 375 LI:404482.20:2001MAY171017 1039forwardTM Transmembrane 375 LI:404482.20:2001MAY171040 1048forwardTM Non-Cytosolic 375 LI:404482.20:2001MAY171049 1071forwardTM Transmembrane 375 LI:404482.20:2001MAY171072 1102forwardTM Cytosolic 375 LI:404482.20:2001MAY171103 1125forwardTM Transmembrane 375 LI:404482.20:2001MAY171126 1200forwardTM Non-Cytosolic 376 LI:405985.1:2001MAY171 364forwardTM Non-Cytosolic 376 LI:405985.1:200IMAY17365 387forwardTM Transmembrane 376 LI:405985.1:2001MAY17388 424forwardTM Cytosolic 376 LI:405985.1:2001MAY171 64 forwardTM Cytosolic 376 LI:405985.1:2001MAY1765 87 forwardTM Transmembrane 376 LI:405985.1:2001MAY1788 424forwardTM Non-Cytosolic 377 LI:406389.1:2001MAY171 37 forwardTM Cytosolic 377 LI:406389.1:2001MAYI738 60 forwardTM Transmembrane 377 LI:406389.1:2001MAY1761 160forwardTM Non-Cytosolic 377 LI:406389.1:2001MAY17161 183forwardTM Transmembrane 377 LI:406389.1:2001MAY17184 199forwardTM Cytosolic 377 LI:406389.1:2001MAY17200 222forwardTM Transmembrane 377 LI:406389.1:2001MAY17223 622forwardTM Non-Cytosolic 378 LI:406833.1:2001MAY171 448forwardTM Non-Cytosolic 378 LI:406833.1:2001MAY17449 471forwardTM Transmembrane 378 LI:406833.I:2002MAYI7472 500forwardTM Cytosolic 378 LI:406833.1:2001MAY17501 523forwardTM Transmembrane 378 LI:406833.1:2001MAY17524 975forwardTM Non-Cytosolic 378 LI:406833.1:2001MAY171 902forward~ TM Non-Cytosolic SEQ Template ID Start StopFrame Domain Topology D Type NO:

378 LI:406833.1:2001MAY17903 925forwardTM Transmembrane 378 LI:406833.1:2001MAY17926 945forwardTM Cytosolic 378 LI:406833.1:2001MAY17946 968forwardTM Transmembrane 378 LI:406833.1:2001MAY17969 975forwardTM Non-Cytosolic 378 LI:406833.1:2001MAY171 9'01forward' TM Non-Cytosolic 378 LI:406833.1:2001MAY17902 924forwardTM Transmembrane 378 LI:406833.1:2001MAY17925 943forwardTM Cytosolic 378 LI:406833.1:2001MAY17944 961forwardTM Transmembrane 378 LI:406833.1:2001MAY17962 975forwardTM Non-Cytosolic 379 LI:407921.3:2001MAY171 1805forwardTM Non-Cytosolic 379 LI:407921.3:2001MAY171806 1828forwardTM Transmembrane 379 LI:407921.3:2001MAY171829 1863forwardTM Cytosolic 380 LI:409078.54:2001MAY171 28 forwardTM Non-Cytosolic 380 LI:409078.54:2001MAY1729 51 forwardTM Transmembrane 380 LI:409078.54:2001MAY1752 80 forwardTM Cytosolic 380 LI:409078.54:2001MAY1781 103forwardTM Transmembrane 380 LI:409078.54:2001MAY17104 1242forwardTM Non-Cytosolic 381 LI:423601.6:2001MAY171 314forwardTM Non-Cytosolic 381 LI:423601.6:2001MAY17315 337forwardTM Transmembrane 381 LI:423601.6:2001MAY17338 345forwardTM Cytosolic 381 LI:423601.6:2001MAY17346 364forwardTM Transmembrane 381 LI:423601.6:2001MAY17365 378forwardTM Non-Cytosolic 381 LI:423601.6:2001MAY17379 401forwardTM Transmembrane 381 LI:423601.6:2001MAY17402 414forwardTM Cytosolic 382 LI:425024.5:2001MAY171 173forward. . . Non-Cytosolic 382 LI:425024.5:2001MAY17174 196forwardTM Transmembrane 382 LI:425024.5:2001MAY17197 215forwardTM Cytosolic 382 LI:425024.5:2001MAY17216 238forwardTM ' Transmembrane 382 LI:425024.5:2001MAY17239 242forwardTM Non-Cytosolic 382 LI:425024.5:2001MAY17243 260forwardTM Transmembrane 382 LI:425024.5:2001MAY1726I 266forwardTM Cytosolic 382 LI:425024.5:2001MAY17267 289forwardTM Transmembrane 382 LI:425024.5:2001MAY17290 583forwardTM Non-Cytosolic 383 LI:427909.29:2001MAY171 252forwardTM Non-Cytosolic 383 LI:427909.29:2001MAY17253 275forwardTM Transmembrane ~ 1 383 LI:427909.29:2001MAY17276 463forwardTM Cytosolic 383 LI:427909.29:2001MAY17464 483forwardTM Transmembrane 383 LI:427909.29:2001MAY17484 545forwardTM Non-Cytosolic 383 LI:427909.29:2001MAY17546 568forwardTM Transmembrane 383 LI:427909.29:2001MAY17569 580forwardTM Cytosolic 383 LI:427909.29:2001MAY17581 603forwardTM Transmembrane 383 LI:427909.29:2001MAY17604 617forwardTM Non-Cytosolic 383 LI:427909.29:2001MAY17618 637forwardTM Transmembrane 383 LI:427909.29:2001MAY17638 657forwardTM Cytosolic 383 LI:427909.29:2001MAY17658 680forwardTM Transmembrane 383 LI:427909.29:2001MAY17681 725forwardTM Non-Cytosolic 383 LI:427909.29:2001MAY17726 748forwardTM Transmembrane 383 LI:427909.29:2001MAY17749 780forwardTM Cytosolic 383 LI:427909.29:2001MAY17781 803forwardTM Transmembrane 383 LI:427909.29:2001MAY17804 858forwardTM Non-Cytosolic 383 LI:427909.29:2001MAY17859 881forwardTM Transmembrane 383 LI:427909.29:2001MAY17882 1201forwardTM Cytosolic 383 LI:427909.29:2001MAY171202 1224forwardTM Transmembrane 383 LI:427909.29:2001MAY171225 1255forwardTM Non-Cytosolic SEQ D NO: Template ID StartStopFrame Domain Topology Type 383 LI:427909.29:2001MAY171 283 forwardTM Non-Cytosolic 383 LI:427909.29:2001MAY17284 306 forwardTM Transmembrane 383 LI:427909.29:2001MAY17307 318 forwardTM Cytosolic 383 LI:427909.29:2001MAY17319 341 forwardTM Transmembrane 383 LI:427909.29:2001MAY17342 460 forwardTM Non-Cytosolic 383 LI:427909.29:2001MAY17461 483 forwardTM Transmembrane 383 LI:427909.29:2001MAY17484 582 forwardTM Cytosolic 383 LI:427909.29:2001MAY17583 605 forwardTM Transmembrane 383 LI:427909.29:2001MAY17606 624 forwardTM Non-Cytosolic 383 LI:427909.29:2001MAY17625 642 forwardTM Transmembrane 383 LI:427909.29:2001MAY17643 662 forwardTM Cytosolic 383 LI:427909.29:2001MAY17663 685 forwardTM Transmembrane 383 LI:427909.29:2001MAY17686 688 forwardTM Non-Cytosolic 383 LI:427909.29:2001MAY17689 711 forwardTM Transmembrane 383 LI:427909.29:2001MAY17712 729 forwardTM Cytosolic 383 LI:427909.29:2001MAY17730 752 forwardTM Transmembrane 383 LI:427909.29:2001MAY17753 780 forwardTM Non-Cytosolic 383 LI:427909.29:2001MAY17781 803 forwardTM Transmembrane 383 LI:427909.29:2001MAY17804 929 forwardTM Cytosolic 383 LI:427909.29:2001MAY17930 949 forwardTM Transmembrane 383' LI:427909.29:2001MAY17950 1254forwardTM Non-Cytosolic 383 LI:427909.29:2001MAY171 319 forwardTM Cytosolic 383 LI:427909.29:2001MAY17320 339 forwardTM Transmembrane 383 , LI:427909.29:2001MAY17340 622 forwardTM Non-Cytosolia 383 LI:427909.29:2001MAY17623 640 forwardTM Transmembrane 383 LI:427909.29:2001MAY17641 675 'forwardTM Cytosolic 383 LI:427909.29:2001MAY17676 698 forwardTM Transmembrane 383 LI:427909.29:2001MAY17699 728 forwardTM Non-Cytosolic 383 LI:427909.29:2001MAY17729 751 forwardTM Transmembrane 383 LI:427909.29:2001MAY17752 833 forwardTM Cytosolic 383 LI:427909.29:2001MAY17834 856 forwardTM Transmembrane 383 LI:427909.29:2001MAY17857 1254forwardTM Non-Cytosolic 384 LI:428198.20:2001MAY171 171 forwardTM Cytosolic 384 LI:428198.20:2001MAY17172 194 forwardTM Transmembrane 384 LI:428198.20:2001MAY17195 820 forwardTM Non-Cytosolic 384 LI:428198.20:2001MAY17821 840 forward. TM Transmembrane 384 LI:428198.20:2001MAY17841 860 forwardTM Cytosolic 384 LI:428198.20:2001MAY17861 883 forwardTM Transmembrane 384 LI:428198.20:2001MAY17884 892 forwardTM Non-Cytosolic 384 LI:428198.20:2001MAY17893 915 forwardTM Transmembrane 384 LI:428198.20:2001MAY17916 958 forwardTM Cytosolic 384 LI:428198.20:2001MAY171 910 forwardTM Non-Cytosolic 384 LI:428198.20:2001MAY17911 933 forwardTM Transmembrane 384 LI:428198.20:2001MAY17934 958 forwardTM Cytosolic 385 LI:429738.6:2001MAY171 19 forwardTM Cytosolic 385 LI:429738.6:2001MAY1720 42 forwardTM Transmembrane 385 LI:429738.6:2001MAY1743 45 forwardTM Non-Cytosolic 385 LI:429738.6:2001MAY1746 63 forwardTM Transmembrane 385 LI:429738.6:2001MAY1764 343 forwardTM Cytosolic 38S LI:429738.6:2001MAY17344 366 forwardTM Transmembrane 38S LI:429738.6:200IMAY17367 380 forwardTM Non-Cytosolic 38S LI:429738.6:2001MAY17381 403 forwardTM Transmembrane 385 LI:429738.6:2001MAY17404 416 forwardTM Cytosolic 385 LI:429738.6:2001MAY171 19 forwardTM Non-Cytosolic SEQ D NO: Template ID Start StopFrame Domain Topology Type 385 LI:429738.6:2001MAY1720 42 forwardTM Transmembrane 385 LI:429738.6:2001MAY1743 336forwardTM Cytosolic 385 LI:429738.6:2001MAY17337 359forwardTM Transmembrane 385 LI:429738.6:2001MAY17360 363forwardTM Non-Cytosolic 385 LI:429738.6:2001MAY17364 386forwardTM Transmembrane 385 LI:429738.6:2001MAY17387 392forwardTM Cytosolic 385 LI:429738.6:2001MAY17393 415forwardTM Transmembrane 385 LI:429738.6:2001MAY17416 416forwardTM Non-Cytosolic 385 LI:429738.6:2001MAY171 19 forwardTM Cytosolic 385 LI:429738.6:2001MAY1720 42 forwardTM Transmembrane 385 LI:429738.6:2001MAY1743 333forwardTM Non-Cytosolic 385 LI:429738.6:2001MAY17334 356forwardTM Transmembrane 385 LI:429738.6:2001MAY17357 360forwardTM Cytosolic 385 LI:429738.6:2001MAY17361 383forwardTM Transmembrane 385 LI:429738.6:2001MAY17384 387forwardTM Non-Cytosolic 385 LI:429738.6:2001MAY17388 410forwardTM Transmembrane 385 LI:429738.6:2001MAY17411 415forwardTM Cytosolic 386 LI:449437.1:2001MAY171 73 forwardTM Cytosolic 386 LI:449437.1:2001MAY1774 96 forwardTM Transmembrane 386 LI:449437.1:2001MAY1797 115forwardTM Non-Cytosolic 386 LI:449437.1:2001MAY17116 133forwardTM Transmembrane 386 LI:449437.1:2001MAY17134 237forwardTM Cytosolic 386 LI:449437.1:2001MAY17238 260forwardTM Transmembrane 386. LI:449437.1:2001MAY17261 279forwardTM Non-Cytosolic:

. 387. LI:459269.25:2001MAY17.1 326forwardTM Non-Cytosolic . 2 387 LI:459269.25:2001MAY17327 349forwardTM Transmembrane 387 LI:459269.25:2001MAY17.,350 640forwardTM Cytosolic , 2 388 LI:464206.1:2001MAY171 80 forwardTM Cytosolic 388 LI:464206.1:2001MAY17, 81 103forwardTM Transmembrane 2 .

388 LI:464206.1:2001MAY17104 942forwardTM Non-Cytosolic 388 LI:464206.1:2001MAY171 694forwardTM Non-Cytosolic 388 LI:464206.1:2001MAY17695 717forwardTM Transmembrane 388 LI:464206.1:2001MAY17718 723forwardTM Cytosolic 388 LI:464206.1:2001MAY17724 746forwardTM Transmembrane 388 LI:464206.1:2001MAY17747 942forwardTM Non-Cytosolic 389 LI:465821.2:2001MAY171 446forwardTM Non-Cytosolic 389 LI:465821.2:2001MAY17447 466forwardTM Transmembrane 389 LI:465821.2:2001MAY17467 477forwardTM Cytosolic 389 LI:465821.2:2001MAY17478 500forwardTM Transmembrane 389 LI:465821.2:2001MAY17501 654forwardTM Non-Cytosolic 389 LI:465821.2:2001MAY171 439forwardTM Non-Cytosolic 389 LI:465821.2:2001MAY17440 459forwardTM Transmembrane 389 LI:465821.2:2001MAY17460 470forwardTM Cytosolic 389 LI:465821.2:2001MAY17471 493forwardTM Transmembrane 389 LI:465821.2:2001MAY17494 653forwardTM Non-Cytosolic 389 LI:465821.2:2001MAY171 469forwardTM Non-Cytosolic 389 LI:465821.2:2001MAY17470 492forwardTM Transmembrane 389 LI:465821.2:2001MAY17493 653forwardTM Cytosolic 390 LI:474414.28:2001MAY171 349forwardTM Non-Cytosolic 390 LI:474414.28:2001MAY17350 372forwardTM Transmembrane 390 LI:474414.28:2001MAY17373 391forwardTM Cytosolic 390 LI:474414.28:2001MAY17392 414forwardTM Transmembrane 390 LI:474414.28:2001MAY17415 1028forwardTM Non-Cytosolic 390 LI:474414.28:2001MAY171029 1051forwardTM Transmembrane SEQ Template ID Start StopFrame Domain Topology D NO: Type 390 LI:474414.28:2001MAY171052 1133forwardTM Cytosolic 390 LI:474414.28:2001MAY171134 1156forwardTM Transmembrane 390 LI:474414.28:2001MAY171157 1405forwardTM Non-Cytosolic 390 LI:474414.28:2001MAY171 12 forwardTM Cytosolic 390 LI:474414.28:2001MAY1713 35 forwardTM Transmembrane 390 LI:474414.28:2001MAYI736 44 forwardTM Non-Cytosolic 390 LI:474414.28:2001MAY1745 67 forwardTM Transmembrane 390 LI:474414.28:2001MAY1768 437forwardTM Cytosolic 390 LI:474414.28:2001MAY17438 457forwardTM Transmembrane 390 LI:474414.28:2001MAY17458 466forwardTM Non-Cytosolic 390 LI:474414.28:2001MAY17467 489forwardTM Transmembrane 390 LI:474414.28:2001MAY17490 501forwardTM Cytosolic 390 LI:474414.28:2001MAY17502 521forwardTM Transmembrane 390 LI:474414.28:2001MAY17522 1405forwardTM Non-Cytosolic 390 LI:474414.28:2001MAY171 302forwardTM Non-Cytosolic 390 LI:474414.28:2001MAY17303 325forwardTM Transmembrane 390 LI:474414.28:2001MAY17326 345forwardTM Cytosolic 390 LI:474414.28:2001MAY17346 368forwardTM Transmembrane 390 LI:474414.28:2001MAY17369 394forwardTM Non-Cytosolic 390 LI:474414.28:2001MAY17395 417forwardTM Transmembrane 390 LI:474414.28:2001MAY17418 437forwardTM Cytosolic 390 LI:474414.28:2001MAY17438 455forwardTM Transmembrane 390 LI:474414.28:2001MAY17456 467forwardTM Non-Cytosolic 390 LI:474414.28:2001MAY17468 490forwardTM Transmembrane 390 LI:474414.28:2001MAY17. 491 496forwardTM Cytosolic . . 3 390 LI:474414.28:2001MAY1?497 514forwardTM Transmembrane 390 LI:474414.28:2001MAY17515 629forwardTM Non-Cytosolic 390 LI:4744I4.28:2001MAY17630 652forwardTM Transmembrane 390 LI:474414.28:2001MAY17653 920forwardTM Cytosolic 3 .

390 LI:474414.28:2001MAY17921 943forwardTM Transmembrane 390 LI:474414.28:2001MAY17944 1027forwardTM Non-Cytosolic 390 LI:474414.28:2001MAY171028 1050forwardTM Transmembrane 390 LI:474414.28:2001MAY171051 1259forwardTM Cytosolic 390 LI:474414.28:2001MAY171260 1282forwardTM Transmembrane 390 LI:474414.28:2001MAY171283 1296forwardTM Non-Cytosolic 390 LI:474414.28:2001MAY171297 1316forwardTM Transmembrane 390 LI:474414.28:2001MAY171317 1405forwardTM Cytosolic 391 LI:474435.14:2001MAY171 137forwardTM Non-Cytosolic 391 LI:474435.14:2001MAY17138 160forwardTM Transmembrane 391 LI:474435.14:2001MAY17161 180forwardTM Cytosolic 391 LI:474435.14:2001MAY17181 203forwardTM Transmembrane 391 LI:474435.14:2001MAY17204 472forwardTM Non-Cytosolic 391 LI:474435.14:2001MAY17473 495forwardTM Transmembrane 391 LI:474435.14:2001MAY17496 542forwardTM Cytosolic 391 LI:474435.14:2001MAY17543 565forwardTM Transmembrane 391 LI:474435.14:2001MAY17566 1160forwardTM Non-Cytosolic 392 LI:474458.11:2001MAY171 3 forwardTM Non-Cytosolic 392 LI:474458.11:2001MAY174 21 forwardTM Transmembrane 392 LI:474458.11:2001MAY1722 203forwardTM Cytosolic 392 LI:474458.11:2001MAY17204 226forwardTM Transmembrane I

392 LI:474458.11:2001MAY17227 249forwardTM Non-Cytosolic 392 LI:474458.11:2001MAY17250 269forwardTM Transmembrane 392 LI:474458.11:2001MAY17270 275forwardTM Cytosolic 392 LI:474458.11:2001MAY17276 298forwardTM Transmembrane SEQ Template ID StartStopFrame Domain Topology D Type NO:

392 LI:474458.11:2001MAY17299 567 forwardTM Non-Cytosolic 392 LI:474458.11:2001MAY17568 590 forwardTM Transmembrane 392 LI:474458.11:2001MAY17591 617 forwardTM ~ Cytosolic 392 LI:474458.11:2001MAY17618 640 forwardTM Transmembrane 392 LI:474458.11:2001MAY17641 854 forwardTM Non-Cytosolic 392 LI:474458.11:2001MAY171 572 forwardTM Non-Cytosolic 392 LI:474458.11:2001MAY17573 595 forwardTM Transmembrane 392 LI:474458.11:2001MAY17596 606 forwardTM Cytosolic 392 LI:474458.11:2001MAY17607 629 forwardTM Transmembrane 392 LI:474458.11:2001MAY17630 854 forwardTM Non-Cytosolic 392 LI:474458.11:2001MAY171 116 forwardTM Cytosolic 392 LI:474458.1I:2001MAY17117 139 forwardTM Transmembrane 392 LI:474458.11:2001MAY17140 185 forwardTM Non-Cytosolic 392 LI:474458.11:2001MAY17186 208 forwardTM Transmembrane 392 LI:474458.11:2001MAY17209 214 forwardTM Cytosolic 392 LI:474458.11:2001MAY17215 234 forwardTM Transmembrane 392 LI:474458.11:2001MAYI7235 248 forwardTM Non-Cytosolic 392 LI:474458.11:2001MAY17249 268 forwardTM Transmembrane 392 LI:474458.11:2001MAY17269 304 forwardTM Cytosolic 392 LI:474458.11:2001MAY17305 327 forwardTM Transmembrane 392 LI:474458.11:2001MAY17328 336 forwardTM Non-Cytosolic 392 LI:474458.11:2001MAY17337 359 forwardTM Transmembrane 392 LI:474458.11:2001MAY17360 415 forwardTM Cytosolic 392 LI:474458.11:200IMAYI7416 433 forwardTM Transmembrane 392 LI:474458.11:2001MAY17, . forwardTM Non-Cytosolic 392 LI:474458.11:2001MAY17568 590 forwardTM Transmembrane 392 LI:474458.11:2001MAY17591 752 forwardTM Cytosolic 392 LI:474458.11:2001MAY17753 775 forwardTM Transmembrane ' 3 392 LI:474458.11:2001MAY17776 819 forwardTM Non-Cytosolic 392 LI:474458.11:2001MAY17820 842 forwardTM Transmembrane 392 LI:474458.11:2001MAY17843 854 forwardTM Cytosolic 393 LI:477I27.18:2001MAY171 659 forwardTM Non-Cytosolic 393 LI:477127.18:2001MAY17660 682 forwardTM Transmembrane 393 LI:477127.18:2001MAY17683 752 forwardTM Cytosolic 393 LI:477127.18:2001MAY17753 775 forwardTM Transmembrane 393 LI:477127.18:2001MAY17776 1102forwardTM Non-Cytosolic 393 LI:477127.18:2001MAY171 664 forwardTM Non-Cytosolic 393 LI:477127.18:2001MAY17665 687 forwardTM Transmembrane 393 LI:477127.18:2001MAY17688 750 forwardTM Cytosolic 393 LI:477127.18:2001MAY17751 773 forwardTM Transmembrane 393 LI:477127.18:2001MAY17774 1102forwardTM Non-Cytosolic 393 LI:477127.18:2001MAY171 135 forwardTM Cytosolic 393 LI:477127.18:2001MAY17136 158 forwardTM Transmembrane 393 LI:477127.18:2001MAY17159 1102forwardTM Non-Cytosolic 394 LI:480375.55:2001MAY171 740 forwardTM Non-Cytosolic 394 LI:480375.55:2001MAY17741 763 forwardTM Transmembrane 394 LI:480375.55:2001MAY17764 805 forwardTM Cytosolic 395 LI:480467.24:2001MAY171 146 forwardTM Cytosolic 395 LI:480467.24:2001MAY17147 164 . forwardTM Transmembrane 395 LI:480467.24:2001MAY17165 191 forwardTM Non-Cytosolic 395 LI:480467.24:2001MAY17192 214 forwardTM Transmembrane 395 LI:480467.24:2001MAY17215 220 forwardTM Cytosolic 395 LI:480467.24:2001MAY17221 238 forwardTM Transmembrane 395 LI:480467.24:2001MAY17239 325 forwardTM Non-Cytosolic SEQ Template ID Start StopFrame Domain Topology D Type N0:

395 LI:480467.24:2001MAY17326 343forwardTM Transmembrane 395 LI:480467.24:2001MAY17344 457forwardTM Cytosolic 396 LI:480587.1:2001MAY171 95 forwardTM Cytosolic 396 LI:480587.1:2001MAY1796 118forwardTM Transmembrane 396 LI:480587.1:2001MAY17119 157forwardTM Non-Cytosolic 396 LI:480587.1:2001MAY17158 175forwardTM Transmembrane 396 LI:480587.1:2001MAY17176 238forwardTM Cytosolic 396 LI:480587.1:2001MAY17239 261forwardTM Transmembrane 396 LI:480587.1:2001MAY17262 273forwardTM Non-Cytosolic 396 LI:480587.1:2001MAY17274 296forwardTM Transmembrane 396 LI:480587.1:2001MAY17297 308forwardTM Cytosolic 396 LI:480587.1:2001MAY17309 331forwardTM Transmembrane 396 LI:480587.1:2001MAY17332 886forwardTM Non-Cytosolic 396 LI:480587.1:2001MAY17887 909forwardTM Transmembrane 396 LI:480587.1:2001MAYi7910 942forwardTM Cytosolic 396 LI:480587.1:2001MAY17943 965forwardTM Transmembrane 396 LI:480587.1:2001MAY17966 1035forwardTM Non-Cytosolic 396 LI:480587.1:2001MAY171036 1058forwardTM Transmembrane 396 LI:480587.1:2001MAY171059 1070forwardTM Cytosolic 396 LI:480587.1:2001MAY171071 1093forwardTM Transmembrane 396 LI:480587.1:2001MAY171094 1097forwardTM Non-Cytosolic 396 LI:480587.1:2001MAY171098 1120forwardTM Transmembrane 396 LI:480587.1:2001MAY171121 1236forwardTM Cytosolic 396 LI:480587.1:2001MAY171 275forwardTM Cytosolic 396 LI:480587.1:2001MAY17276 298forwardTM Transmembrane 396 LI:480587.1:2001MAY17299 307forwardTM Non-Cytosolic 396 LI:480587.1:2001MAY17308 330forwardTM Transmembrane 396 LI:480587.1:2001MAY17331 424forwardTM Cytosolic 396 LI:480587.1:2001MAY17425 447forwardTM Transmembrane 396 LI:480587.1:2001MAY17448 938forwardTM Non-Cytosolic 396 LI:480587.1:2001MAY17939 961forwardTM Transmembrane 396 LI:480587.1:2001MAY17962 1073forwardTM Cytosolic 396 LI:480587.1:2001MAY171074 1096forwardTM Transmembrane 396 LI:480587.1:2001MAY171097 1235forwardTM Non-Cytosolic 397 LI:480798.13:2001MAY171 392forwardTM Non-Cytosolic 397 LI:480798.13:2001MAY17393 410forwardTM Transmembrane 397 . LI:480798.13:2001MAY17411 557forwardTM Cytosolic 397 LI:480798.13:2001MAY17558 580forwardTM Transmembrane 397 LI:480798.13:2001MAY17581 678forwardTM Non-Cytosolic 397 LI:480798.13:2001MAY17679 701forwardTM Transmembrane 397 LI:480798.13:2001MAY17702 741forwardTM Cytosolic 397 LI:480798.13:2001MAY171 362forwardTM Non-Cytosolic 397 LI:480798.13:2001MAY17363 380forwardTM Transmembrane 397 LI:480798.13:2001MAY17381 386forwardTM Cytosolic 397 LI:480798.13:2001MAY17387 409forwardTM Transmembrane 397 LI:480798.13:2001MAY17410 418forwardTM Non-Cytosolic 397 LI:480798.13:2001MAY17419 441forwardTM Transmembrane 397 LI:480798.13:2001MAY17442 670forwardTM Cytosolic 397 LI:480798.13:2001MAY17671 693forwardTM Transmembrane 397 LI:480798.13:2001MAY17694 741forwardTM Non-Cytosolic 397 LI:480798.13:2001MAY171 360forwardTM Non-Cytosolic 397 LI:480798.13:2001MAY17361 380forwardTM Transmembrane 397 LI:480798.13:2001MAY17381 391forwardTM Cytosolic 397 LI:480798.13:2001MAY17392 411forward' TM Transmembrane SEQ Template ID StartStopFrame Domain Topology D NO: Type 397 LI:480798.13:2001MAY17412 420 forwardTM Non-Cytosolic 397 LI:480798.13:2001MAY17421 443 forwardTM Transmembrane 397 LI:480798.13:2001MAY17444 476 forwardTM Cytosolic 397 LI:480798.13:2001MAY17477 499 forwardTM Transmembrane 397 LI:480798.13:2001MAY17500 5'59forward~ TM Non-Cytosolic 397 LI:480798.13:200.1MAY17560 579 forwardTM Transmembrane ~ 3 397 LI:480798.13:2001MAY17580 637 forwardTM Cytosolic 397 LI:480798.13:2001MAY17638 656 forwardTM Transmembrane 397 LI:480798.13:2001MAY17657 670 forwardTM Non-Cytosolic 397 LI:480798.13:2001MAY17671 693 forwardTM Transmembrane 397 LI:480798.13:2001MAY17694 740 forwardTM Cytosolic 398 LI:481203.14:2001MAY171 160 forwardTM Cytosolic 39$ LI:48I203.14:200IMAYI7161 183 forwardTM Transmembrane 398 LI:481203.14:2001MAY17184 1084forwardTM Non-Cytosolic 399 LI:481237.11:2001MAY171 711 forwardTM Non-Cytosolic 399 LI:481237.11:2001MAY17712 731 forwardTM Transmembrane 399 LI:481237.11:2001MAY17732 811 forwardTM Cytosolic 399 LI:481237.11:2001MAY17812 831 forwardTM Transmembrane 399 LI:481237.11:2001MAY17832 844 forwardTM Non-Cytosolic 400 LI:481368.12:2001MAY171 15 forwardTM Cytosolic 400 LI:481368.12:2001MAY1716 38 forwardTM Transmembrane 400 LI:481368.12:2001MAY1739 956 forwardTM Non-Cytosolic 401 LI:482301.8:2001MAY171 358 forwardTM Non-Cytosolic 401 LI:482301.8:2001MAY17359 381 forwardTM Transmembrane ~

401 LI:482301.8:2001MAY17382 409 forwardTM Cytosolic 401 LI:482301.8:2001MAY17410 . forwardTM Transmembrane ~ 432 1 ~

401 LI:482301.8:2001MAY17. 589 foxwardTM . Non-Cytosolic 401 LI:482301.8:2001MAY17. 609 forwardTM Transmembrane 590 1_ 401 LI:482301.8:2001MAY17, 626 forwardTM Cytosolic ;

401 LI:482301.8:2001MAY171 361 forwardTM Non-CytosoIic 401 LI:482301.8:2001MAY17362 384 forwardTM Transmembrane 401 LI:482301.8:2001MAY17385 536 forwardTM Cytosolic 401 LI:482301.8:2001MAY17537 559 forwardTM Transmembrane 401 LI:482301.8:2001MAY17560 597 forwardTM Non-Cytosolic 401 LI:482301.8:2001MAY17598 620 forwardTM Transmembrane 401 LI:482301.8:2001MAYI7621 625 forwardTM Cytosolic 401 LI:482301.8:2001MAY171 153 forwardTM ~ Non-Cytosolic 401 LI:482301.8:2001MAY17154 176 forwardTM Transmembrane 401 LI:482301.8:2001MAYI7177 333 forwardTM Cytosolic 401 LI:482301.8:2001MAY17334 356 forwardTM Transmembrane 401 LI:482301.8:2001MAY17357 360 forwardTM Non-Cytosolic 401 LI:482301.8:2001MAY17361 383 forwardTM Transmembrane 401 LI:482301.8:2001MAY17384 387 forwardTM Cytosolic 401 LI:482301.8:2001MAY17388 410 forwardTM . Transmembrane 40I LI:482301.8:ZOOIMAYI7411 625 forwardTM Non-Cytosolic 402 LI:482482.29:2001MAY171 168 forwardTM Cytosolic 402 LI:482482.29:2001MAY17169 191 forwardTM Transmembrane 402 LI:482482.29:2001MAY17192 386 forwardTM Non-Cytosolic 402 LI:482482.29:2001MAY171 119 forwardTM Cytosolic.

402 LI:482482.29:2001MAY17120 142 forwardTM Transmembrane 402 LI:482482.29:2001MAY17143 385 forwardTM Non-Cytosolic 403 LI:758877.26:2001MAY171 201 forwardTM Non-Cytosolic 403 LI:758877.26:2001MAY17202 224 forwardTM Transmembrane 403 LI:758877.26:2001MAY17225 265 forwardTM Cytosolic SEQ Template ID Start StopFrame Domain Topology D NO: Type 403 LI:758877.26:2001MAY17266 288forwardTM Transmembrane 403 LI:758877.26:2001MAY17289 711forwardTM Non-Cytosolic 403 LI:758877.26:2001MAY171 205forwardTM Cytosolic 403 LI:758877.26:2001MAY17206 228forwardTM Transmembrane 403 LI:758877.26:2001MAY17229 263forwardTM Non-Cytosolic 403 LI:758877.26:2001MAY17264 286forwardTM Transmembrane 403 LI:758877.26:2001MAY17287 290forwardTM Cytosolic 403 LI:758877.26:2001MAY17291 313forwardTM Transmembrane 403 LI:758877.26:2001MAY17314 32'7forwardTM Non-Cytosolic 403 LI:758877.26:2001MAY17328 350forwardTM Transmembrane 403 LI:758877.26:2001MAY17351 485forwardTM Cytosolic 403 LI:758877.26:2001MAY17486 508forwardTM Transmembrane 403 LI:758877.26:2001MAY17509 586forwardTM Non-Cytosolic 403 LI:758877.26:200IMAY17587 609forwardTM Transmembrane 403 LI:758877.26:2001MAY17610 711forwardTM Cytosolic 403 LI:758877.26:2001MAY171 490forwardTM Non-Cytosolic 403 LI:758877.26:2001MAY17491 513forwardTM Transmembrane 403 LI:758877.26:2001MAY17514 571forwardTM Cytosolic 403 LI:758877.26:2001MAY17572 594forwardTM Transmembrane 403 LI:758877.26:2001MAY17595 640forwardTM Non-Cytosolic 403 LI:758877.26:200IMAY17641 663forwardTM Transmembrane 403 LI;758877.26:2001MAY17664 710forwardTM Cytosolic 404 LI;791042.1:2001MAY171 455forwardTM Non-Cytosolic 404 LI:791042.1:2001MAY17456 478forward1'M Transmembrane 404 LI:791042.1:2001MAY17479 497forwardTM Cytosolic 404 LI:791042.1:2001MAY17' 498-520-forwardTM Transmembrane~

404 LI:791042.1:2001MAY17521 550forwardTM Non-Cytosolic 405 LI:808999.26:2001MAY171 1475forwardTM Non-Cytosolic 405 LI:808999.26:2001MAY171476 1498forwardTM. Transmembrane 405 LI:808999.26:2001MAY171499 1523forwardTM Cytosolic 405 LI:808999.26:2001MAY171524 1546forwardTM Transmembrane 405 LI:808999.26:2001MAY171547 1565forwardTM Non-Cytosolic 405 LI:808999.26:2001MAY171566 1588forwardTM Transmembrane 405 LT:808999.26:2001MAY171589 1846forwardTM Cytosolic 406 LI:815715.I0:2001MAY171 355forwardTM Non-Cytosolic 406 LI:815715.10:2001MAY17356 378forwardTM Transmembrane 406 LI:815715.10:2001MAY17379 387forwardTM . Cytosolic 406 LI:815715.10:2001MAY171 14 forwardTM Non-Cytosolic 406 LI:815715.10:2001MAY1715 37 forwardTM Transmembrane 406 LI:815715.10:2001MAY1738 305forwardTM Cytosolic 406 LI:815715.10:2001MAY17306 328forwardTM Transmembrane 406 LI:815715.10:2001MAYI7329 337forwardTM Non-Cytosolic 406 LI:815715.10:2001MAY17338 360forwardTM Transmembrane 406 LI:815715.10:2001MAY17361 366forwardTM Cytosolic 406 LT:815715.10:2001MAY17367 384forwardTM Transmembrane 406 LI:815715.10:2001MAY17385 386forwardTM Non-Cytosolic 406 LI:815715.10:2001MAY171 92 forwardTM Cytosolic 406 LI:815715.10:2001MAY1793 115forwardTM Transmembrane 406 LI:815715.10:2001MAY17I16 358forwardTM Non-Cytosolic 406 LI:815715.10:2001MAY17359 381forwardTM Transmembrane 406 LI:815715.10:2001MAY17382 386forwardTM Cytosolic 407 LI:902980.16:2001MAY171 448forwardTM Non-Cytosolic 407 LI:902980.16:2001MAY17449 471forwardTM Transmembrane 407 LI:902980.16:2001MAY17472 553forwardTM Cytosolic SEQ Template ID Start StopFrame Domain Topology D NO: Type 407 LI:902980.16:2001MAY17554 576forwardTM Transmembrane 407 LI:902980.16:2001MAY17577 585forwardTM Non-Cytosolic 407 LI:902980.16:2001MAY17586 608forwardTM Transmembrane 407 LI:902980.16:2001MAY17609 655forwardTM Cytosolic 407 LI:902980.16:2001MAY17656 678forwardTM Transmembrane 407 LI:902980.16:2001MAY17679 1196forwardTM Non-Cytosolic 407 LI:902980.16:2001MAY171 415forwardTM Non-Cytosolic 407 LI:902980.16:2001MAY17416 438forwardTM Transmembrane 407 LI:902980.16:2001MAY17439 559forwardTM Cytosolic 407 LI:902980.16:2001MAY17560 582forwardTM Transmembrane 407 LI:902980.16:2001MAY17583 596forwardTM Non-Cytosolic 407 LI:902980.16:2001MAY17597 619forwardTM Transmembrane 407 LI:902980.16:2001MAY17620 639forwardTM Cytosolic 407 LI:902980.16:2001MAY17640 662forwardTM Transmembrane 407 LI:902980.16:2001MAY17663 699forwardTM Non-Cytosolic 407 LI:902980.16:2001MAY17700 721forwardTM Transmembrane 407 LI:902980.16:2001MAY17722 816forwardTM Cytosolic 407 LI:902980.16:2001MAY17817 834forwardTM Transmembrane 407 LI:902980.16:2001MAY17835 853forwardTM Non-Cytosolic 407 LI:902980.16:2001MAY17854 876forwardTM Transmembrane 407 LI:902980.16:2001MAY17877 882forwardTM Cytosolic 407 LI:902980.16:2001MAY17883 905forwardTM Transmembrane 407 LI:902980.16:2001MAY17906 1196forwardTM Non-Cytosolic 407 LI:902980.16:2001MAY171 558forwardTM Non-Cytosolic 407 LI:902980.16:2001MAY17559 581forwardTM Transmembrane 407 LI:902980.16:2001MAY17582 655forwardTM Cytosolic 407 LI:902980.16:2001MAY17656 678forwardTM Transmembrane 407 LI:902980.16:2001MAY17679 840forwardTM Non-Cytosolic 407 LI:902980.16:2001MAY17841 863forwardTM Transmembrane 407 LI:902980.16:2001MAY17864 869forwardTM Cytosolic 407 LI:902980.16:2001MAY17870 892forwardTM Transmembrane 407 LI:902980.16:2001MAY17893 1002forwardTM Non-Cytosolic 407 LI:902980.16:2001MAY171003 1025forwardTM Transmembrane 407 LI:902980.16:2001MAY171026 1044forwardTM Cytosolic 407 LI:902980.16:2001MAY171045 1067forwardTM Transmembrane 407 LI:902980.16:2001MAY171068 1196forwardTM Non-Cytosolic 408 LI:903196.25:ZOO1MAY171 829forwardTM Non-Cytosolic 408 LI:903196.25:2001MAY17830 852forwardTM Transmembrane 408 LI:903196.25:2001MAY17853 864forwardTM Cytosolic 408 LI:903196.25:2001MAY17865 884forwardTM Transmembrane 408 LI:903196.25:2001MAY17885 920forwardTM Non-Cytosolic 408 LI:903196.25:2001MAY17921 943forwardTM Transmembrane 408 LI:903196.25:2001MAY17944 1224forwardTM Cytosolic 409 LI:903914.10:2001MAY171 415forwardTM Non-Cytosolic 409 LI:903914.10:2001MAY17416 435forwardTM Transmembrane 409 LI:903914.10:2001MAY17436 664forwardTM Cytosolic 409 LI:903914.10:2001MAY17665 687forwardTM Transmembrane 409 LI:903914.10:2001MAY17688 701forwardTM Non-Cytosolic 409 LI:903914.10:2001MAY17702 724forwardTM Transmembrane 409 LI:903914.10:2001MAY17725 743forwardTM Cytosolic 409 LI:903914.10:2001MAY17744 766forwardTM Transmembrane 409 LI:903914.10:2001MAY17767 1664forwardTM Non-Cytosolic 409 LI:903914.10:2001MAY171 668forwardTM Non-Cytosolic 409 LI:903914.10:2001MAY17669 691forwardTM Transmembrane SEQ Template ID Start StopFrame Domain Topology D NO: Type 409 LI:903914.10:2001MAY17692 841forwardTM Cytosolic 409 LI:903914.10:2001MAYI7842 864forwardTM Transmembrane 409 LI:903914.10:2001MAY17865 1579forwardTM Non-Cytosolic 409 LI:903914.10:2001MAY171580 1602forwardTM Transmembrane 409 LI:903914.10:2001MAY171603 1663forwardTM Cytosolic 410 LG:006764.2:2001JUN221 139forwardTM Cytosolic 410 LG:006764.2:2001JUN22140 162forwardTM Transmembrane 410 LG:006764.2:2001JUN22163 181forwardTM Non-Cytosolic 410 LG:006764.2:2001JUN22182 204forwardTM Transmembrane 410 LG:006764.2:2001JUN22205 479forwardTM Cytosolic ~ 1 410 LG:006764.2:2001JUN22480 502forwardTM Transmembrane 410 LG:006764.2:2001JUN22503 511forwardTM Non-Cytosolic 410 LG:006764.2:2001JUN22512 534forwardTM Transmembrane 410 LG:006764.2:2001JUN22535 539forwardTM Cytosolic 410 LG:006764.2:2001JUN221 441forwardTM Non-Cytosolic 410 LG:006764.2:2001JUN22442 464forwardTM Transmembrane 410 LG:006764.2:2001JUN22465 484forwardTM Cytosolic 410 LG:006764.2:2001JUN22485 507forwardTM Transmembrane 410 LG:006764.2:2001JUN22508 S38forwardTM Non-Cytosolic 410 LG:006764.2:2001JUN221 86 forwardTM Non-Cytosolic 410 LG:006764.2:2001JUN2287 109forwardTM Transmembrane 4I0 LG:006764.2:2001JUN22110 142forwardTM Cytosolic 410 LG:006764.2:2001JUN22143 165forwardTM Transmembrane 410 LG:006764.2:2001JUN22166 184forwardTM Non-Cytosolic 410 LG:006764.2:2001JUN22185 207forwardTM Transmembrane 410 LG:006764.2:2001JUN22208 472forward, TM Cytosolic 410 LG:006764.2:2001JUN22473 495forwardTM Transmembrane 410 LG:006764.2:2001JUN22496 509forwardTM Non-Cytosolic 410 LG:006764.2:2001JUN22510 532forwardTM Transmembrane 410 LG:006764.2:2001JUN22533 538forwardTM Cytosolic 411 LG:OI4704.8:2001JUN221 30 forwardTM Non-Cytosolic 411 LG:014704.8:2001JUN2231 53 forwardTM Transmembrane 411 LG:014704.8:2001JUN2254 72 forwardTM Cytosolic 411 LG:014704.8:2001JUN2273 95 forwardTM Transmembrane 411 LG:014704.8:2001JUN2296 467forwardTM Non-Cytosolic 411 LG:014704.8:2001JUN22468 485forwardTM Transmembrane 411 LG:014704.8:2001JUN22486 517forwardTM Cytosolic 411 LG:014704.8:2001JUN22518 540forwardTM Transmembrane 411 LG:014704.8:2001JUN22541 568forwardTM Non-Cytosolic 411 LG:014704.8:200IJUN22569 591forwardTM Transmembrane 411 LG:014704.8:2001JUN22592 647forwardTM Cytosolic 411 LG:014704.8:2001JUN221 505forwardTM Non-Cytosolic 411 LG:014704.8:2001JUN22506 523forwardTM Transmembrane 411 LG:014704.8:2001JUN22524 560forwardTM Cytosolic 411 LG:014704.8:2001JUN22561 583forwardTM Transmembrane 41I LG:014704.8:2001JUN2Z584 646forwardTM Non-Cytosolic 411 LG:014704.8:2001JUN221 133forwardTM Cytosolic 411 LG:014704.8:2001JUN22134 151forwardTM Transmembrane 411 LG:014704.8:2001JUN22152 165forwardTM Non-Cytosolic 411 LG:014704.8:2001JUN22166 184forwardTM Transmembrane 411 LG:014704.8:2001JUN22185 196forwardTM Cytosolic 411 LG:014704.8:2001JUN22197 219forwardTM Transmembrane 411 LG:014704.8:2001JUN22220 233forwardTM Non-Cytosolic 411 LG:014704.8:2001JUN22234 256forwardTM Transmembrane SEQ Template ID Start StopFrame Domain Topology D Type NO:

411 LG:014704.8:2001JUN22257 305forwardTM Cytosolic 411 LG:014704.8:2001JUN22306 328forwardTM Transmembrane 411 LG:014704.8:2001JUN22329 350forwardTM Non-Cytosolic 411 LG:014704.8:2001JUN22351 373forwardTM Transmembrane 411 LG:014704.8:2001JUN22374 393forwardTM Cytosolic 411 LG:014704.8:2001JUN22394 413forwardTM Transmembrane 411 LG:014704.8:2001JLTN22414 467forwardTM Non-Cykosolic 411 LG:014704.8:2001JUN22468 485forwardTM Transmembrane 4I1 LG:014704.8:2001JUN22486 491forwardTM Cytosolic 411 LG:014704.8:2001JUN22492 514forwardTM Transmembrane 411 LG:014704.8:200IJUN22515 564forwardTM Non-Cytosolic 411 LG:014704.8:2002JUN22565 584forwardTM Transmembrane 411 LG:014704.8:2001JIJN22585 646forwardTM Cytosolic 412 LG:1447607.7:2001JUN221 72 forwardTM Cytosolic 412 LG:1447607.7:2001JUN2273 95 forwardTM Transmembrane I

412 LG:1447607.7:2001JUN2296 336forwardTM Non-Cytosolic 412 LG:I447607.7:200IJUN22337 359forwardTM Transmembrane 412 LG:1447607.7:2001JUN22360 406forwardTM Cytosolic 412 LG:1447607.7:2001JUN22407 429forwardTM Transmembrane 412 LG:1447607.7:2001JUN22430 760forwardTM Non-Cytosolic 412 LG:1447607.7:2001JUN221 20 forwardTM Cytosolic 412 LG:1447607.7:2001JUN2221 43 forwardTM Transmembrane 412 LG:1447607.7:2001JUN2244 72 forwardTM Non-Cytosolic 4I2 LG:1447607.7:2001JUN2273 92 forwardTM, Transmembrane 412 LG:1447607.7:2001JUN2293 276forwardTM Cytosolic 412 LG:1447607.7:2001JUN22277 299forwardTM Transmembrane 412 LG:1447607.7:2001JUN22300 323forwardTM Non-Cytosolic 412 LG:1447607.7:2001JUN22324 346forwardTM Transmembrane 412 LG:1447607.7:2001JUN22347 407forwardTM Cytosolic 412 LG:1447607.7:2001JUN22408 430forwardTM Transmembrane 412 LG:1447607.7:2001JUN22431 449forwardTM Non-Cytosolic 412 LG:1447607.7:2001JUN22450 472forwardTM Transmembrane 412 LG:1447607.7:2001JUN22473 694forwardTM Cytosolic 412 LG:1447607.7:2001JUN22695 717forwardTM Transmembrane ~ 2 412 LG:1447607.7:2001JUN22718 759forwardTM Non-Cytosolic 412 LG:1447607.7:2001JUN221 19 forwardTM Cytosolic 412 LG:1447607.7:2001JUN2220 39 forwardTM Transmembrane 412 LG:1447607.7:2001JUN2240 334forwardTM Non-Cytosolic 412 LG:1447607.7:2001JUN22335 357forwardTM Transmembrane 412 LG:1447607.7:2001JUN22358 381forwardTM Cytosolic 412 LG:1447607.7:ZOO1JUN22382 404forwardTM Transmembrane 412 LG:1447607.7:2001JUN22405 423forwardTM Non-Cytosolic 412 LG:1447607.7:2001JUN22424 446forwardTM Transmembrane 412 LG:1447607.7:2001JUN22447 699forwardTM Cytosolic 412 LG:1447607.7:2001JUN22700 722forwardTM Transmembrane .412 LG:1447607.7:2001JUN22723 759forwardTM Non-Cytosolic 413 LG:1455032.3:2001JUN221 151forwardTM Cytosolic 413 LG:1455032.3:2001JUN22152 174forwardTM Transmembrane 413 LG:1455032.3:2001JUN22175 244forwardTM Non-Cytosolic 413 LG:1455032.3:2001JUN22245 264forwardTM Transmembrane 413 LG:1455032.3:2001JUN22265 396forwardTM Cytosolic 413 LG:1455032.3:2001JUN221 134forwardTM Cytosolic 413 LG:1455032.3:2001JUN22135 157forwardTM Transmembrane 413 LG:1455032.3:2001JUN22158 166forwardTM Non-Cytosolic SEQ D NO: Template ID Start StopFrame Domain Topology Type 413 LG:1455032.3:2001JUN22167 184forwardTM Transmembrane 413 LG:1455032.3:2001JUN22185 396forwardTM Cytosolic 413 LG:1455032.3:2001JUN221 164forwardTM Cytosolic 413 LG:1455032.3:2001JUN22165 187forwardTM Transmembrane 413 LG:1455032.3:2001JUN22188 274forwardTM Non-Cytosolic 413 LG:1455032.3:2001JUN22275 297forwardTM Transmembrane 413 LG:1455032.3:2001JUN22298 395forwardTM Cytosolic 414 LG:1501898.18:2001JUN221 6 forwardTM Cytosolic 414 LG:1501898.18:2001JUN227 29 forwardTM Transmembrane 414 LG:1501898.18:2001JUN2230 357forwardTM Non-Cytosolic 415 LG:1502692.5:2001JUN221 178forwardTM Non-Cytosolic 415 LG:1502692.5:2001JUN22179 201forwardTM Transmembrane 415 LG:1502692.5:2001JUN22202 213forwardTM Cytosolic 415 LG:1502692.5:2001JUN22214 236forwardTM Transmembrane 415 LG:1502692.5:2001JUN22237 255forwardTM Non-Cytosolic 415 LG:1502692.5:2001JUN22~ 256 273forwardTM Transmembrane 415 LG:1502692.5:2001JUN22274 327forwardTM Cytosolic 415 LG:1502692.5:2001JUN22328 347forwardTM Transmembrane 415 LG:1502692.5:2001JUN22348 359forwardTM Non-Cytosolic 415 LG:1502692.5:2001JUN221 129forwardTM Cytosolic 415 LG:1502692.5:2001JUN22130 152forwardTM Transmembrane 415 LG:1502692.5:2001JUN22153 224forwardTM Non-Cytosolic 415 LG:1502692.5:2001JUN22225 247forwardTM Transmembrane 41.5 LG:1502692.5:2001JUN22248 258forwardTM Cytosolic 415 LG:1502692.5:2001JUN22259 276forwardTM Transmembrane 415 ' LG:1502692.5:2001JUN22277 330forwardTM Non-Cytosolic 415 LG:1502692.5:2001JUN22331 350forwardTM Transmembrane 415 LG:1502692.5:2001JUN22351 359forwardTM Cytosolic 415 LG:1502692.5:2001JUN221 44 forwardTM Cytosolic 415 LG:1502692.5:2001JUN2245 67 forwardTM Transmembrane 415 LG:1502692.5:2001JUN2268 166forwardTM Non-Cytosolic 415 LG:1502692.5:2001JUN22167 189forwardTM Transmembrane 415 LG:1502692.5:2001JUN22190 209forwardTM Cytosolic 415 LG:1502692.5:2001JUN22210 232forwardTM Transmembrane 415 LG:1502692.5:2001JUN22233 358forwardTM Non-Cytosolic 416 LG:208949.8:2001JUN221 177forwardTM Cytosolic 416 LG:208949.8:2001JUN22178 200forwardTM Transmembrane 416 LG:208949.8:2001JUN22201 219forwardTM Non-Cytosolic 416 LG:208949.8:2001JUN22220 237forwardTM Transmembrane 416 LG:208949.8:2001JUN22238 253forwardTM Cytosolic 416 LG:208949.8:2001JUN221 161forwardTM Cytosolic 416 LG:208949.8:2001JUN22162 184forwardTM Transmembrane 416 LG:208949.8:2001JUN22185 253forwardTM Non-Cytosolic 416 LG:208949.8:2001JUN221 223forwardTM Cytosolic 416 LG:208949.8:2001JUN22224 246forwardTM Transmembrane 416 LG:208949.8:2001.1UN22247 252forwardTlvl Non-Cytosolic 417 LG:240501.10:2001JUN221 112forwardTM Cytosolic 417 LG:240501.10:2001113 135forwardTM Transmembrane 417 LG:240501.10:2001JUN22136 138forwardTM Non-Cytosolic I

417 LG:240501.10:2001JUN22139 161forwardTM Transmembrane 417 LG:240501.10:2001JUN22162 167forwardTM Cytosolic 417 LG:240501.10:2001JUN22168 185forwardTM Transmembrane I

417 LG:240501.10:2001JUN22186 215forwardTM Non-Cytosolic 417 LG:240501.10:2001JUN22216 235forward'TM Transmembrane DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

NOTE : Pour les tomes additionels, veuillez contacter 1e Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME
NOTE POUR LE TOME / VOLUME NOTE:

Claims (28)

What is claimed is:

1. An isolated polynucleotide selected from the group consisting of:
a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of NO:1-567, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least about 90% identical to a polynucleotide sequence selected from the group consisting of NO:1-567, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d).

2. An isolated polynucleotide of claim 1, comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-567.

3. An isolated polynucleotide comprising at least about 60 contiguous nucleotides of a polynucleotide of claim 1.

4. A composition for the detection of expression of secretory polynucleotides comprising at least one of the polynucleotides of claim 1 and a detectable label.

5. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 1, the method comprising:
a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

6. A method for detecting a target polynucleotide in a sample, said target polynucleotide comprising a sequence of a polynucleotide of claim 1, the method comprising:
a) hybridizing the sample with a probe comprising at least about 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

7. A method of claim 5, wherein the probe comprises at least about 30 contiguous nucleotides.

8. A method of claim 5, wherein the probe comprises at least about 60 contiguous nucleotides.

9. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 1.

10. A cell transformed with a recombinant polynucleotide of claim 9.

11. A transgenic organism comprising a recombinant polynucleotide of claim 9.

12. A method for producing a secretory polypeptide, the method comprising:
a) culturing a cell under conditions suitable for expression of the secretory polypeptide, wherein said cell is transformed with a recombinant polynucleotide of claim 9, and b) recovering the secretory polypeptide so expressed.

13. A purified secretory polypeptide (SPTM) encoded by at least one of the polynucleotides of claim 2.

14. An isolated antibody which specifically binds to a secretory polypeptide of claim 13.

15. A method of identifying a test compound which specifically binds to the secretory polypeptide of claim 13, the method comprising:
a) providing a test compound;
b) combining the secretory polypeptide with the test compound for a sufficient time and under suitable conditions for binding; and c) detecting binding of the secretory polypeptide to the test compound, thereby identifying the test compound which specifically binds the secretory polypeptide.

16. A microarray wherein at least one element of the microarray is a polynucleotide of claim

17. A method for generating a transcript image of a sample which contains polynucleotides, the method comprising:
a) labeling the polynucleotides of the sample, b) contacting the elements of the microarray of claim 16 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and c) quantifying the expression of the polynucleotides in the sample.

18. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence of claim 1, the method comprising:
a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

19. A method for assessing toxicity of a test compound, said method comprising:
a) treating a biological sample containing nucleic acids with the test compound;
b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least about 20 contiguous nucleotides of a polynucleotide of claim 1 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 1 or fragment thereof;
c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

20. An array comprising different nucleotide molecules affixed in distinct physical locations on a solid substrate, wherein at least one of said nucleotide molecules comprises a first oligonucleotide or polynucleotide sequence specifically hybridizable with at least about 30 contiguous nucleotides of a target polynucleotide, said target polynucleotide having a sequence of claim 1.

21. An array of claim 20, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least about 30 contiguous nucleotides of said target polynucleotide.

22. An array of claim 20, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least about 60 contiguous nucleotides of said target polynucleotide

23. An array of claim 20, which is a microarray.

24. An array of claim 20, further comprising said, target polynucleotide hybridized to said first oligonucleotide or polynucleotide.

25. An array of claim 20, wherein a linker joins at least one of said nucleotide molecules to said solid substrate.

26. An array of claim 20, wherein each distinct physical location on the substrate contains multiple nucleotide molecules having the same sequence, and each distinct physical location on the substrate contains nucleotide molecules having a sequence which differs from the sequence of nucleotide molecules at another physical location on the substrate.

27. An isolated polypeptide selected from the soup consisting of:
a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:568-1146, b) a naturally occurring polypeptide comprising an amino acid sequence at least about 90%
identical to an amino acid sequence selected from the group consisting of SEQ
ID N0:568-1146, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID N0:568-1146, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID N0:568-1146.

28. An isolated polypeptide of claim 27, comprising a polypeptide sequence selected from the group consisting of SEQ ID N0:568-1146.